Pharmaceutical co-crystal compositions

ABSTRACT

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

INCORPORATION BY REFERENCE

This application claims the benefit of U.S. Provisional PatentApplication No. 60/451,213 filed on Feb. 28, 2003; U.S. ProvisionalPatent Application No. 60/463,962, filed on Apr. 18, 2003; and U.S.Provisional Application No. 60/487,064, filed on Jul. 11, 2003 each ofwhich incorporated herein by reference in its entirety. This applicationis also a continuation-in-part of PCT/US03/27772, filed on Sep. 4, 2003which is a continuation-in-part of U.S. patent application Ser. No.10/378,956, filed Mar. 3, 2003, which claims the benefit of U.S.Provisional Application No. 60/360,768, filed Mar. 1, 2002; saidPCT/US03/27772 also claims the benefit of U.S. Provisional PatentApplication No. 60/451,213 filed on Feb. 28, 2003; U.S. ProvisionalPatent Application No. 60/463,962, filed on Apr. 18, 2003; and U.S.Provisional Application No. 60/487,064, filed on Jul. 11, 2003. Thisapplication is also a continuation-in-part of U.S. patent applicationSer. No. 10/601,092, filed Jun. 20, 2003. Each of these applications ishereby incorporated by reference in their entireties, including allfigures, tables and formulae.

FIELD OF THE INVENTION

The present invention relates to co-crystal API-containing compositions,pharmaceutical compositions comprising such APIs, and methods forpreparing the same.

BACKGROUND OF THE INVENTION

Active pharmaceutical ingredients (API or APIs (plural)) inpharmaceutical compositions can be prepared in a variety of differentforms. Such APIs can be prepared so as to have a variety of differentchemical forms including chemical derivatives or salts. Such APIs canalso be prepared to have different physical forms. For example, the APIsmay be amorphous, may have different crystalline polymorphs, or mayexist in different solvation or hydration states. By varying the form ofan API, it is possible to vary the physical properties thereof. Forexample, crystalline polymorphs typically have different solubilitiesfrom one another, such that a more thermodynamically stable polymorph isless soluble than a less thermodynamically stable polymorph.Pharmaceutical polymorphs can also differ in properties such asshelf-life, bioavailability, morphology, vapour pressure, density,colour, and compressibility. Accordingly, variation of the crystallinestate of an API is one of many ways in which to modulate the physicalproperties thereof.

It would be advantageous to have new forms of these APIs that haveimproved properties, in particular, as oral formulations. Specifically,it is desirable to identify improved forms of APIs that exhibitsignificantly improved properties including increased aqueous solubilityand stability. Further, it is desirable to improve the processability,or preparation of pharmaceutical formulations. For example, needle-likecrystal forms or habits of APIs can cause aggregation, even incompositions where the API is mixed with other substances, such that anon-uniform mixture is obtained. It is also desirable to increase thedissolution rate of API-containing pharmaceutical compositions in water,increase the bioavailability of orally-administered compositions, andprovide a more rapid onset to therapeutic effect. It is also desirableto have a form of the API which, when administered to a subject, reachesa peak plasma level faster, has a longer lasting therapeutic plasmaconcentration, and higher overall exposure when compared to equivalentamounts of the API in its presently-known form.

SUMMARY OF THE INVENTION

It has now been found that new co-crystalline forms of APIs can beobtained which improve the properties of APIs as compared to such APIsin a non-co-crystalline state (free acid, free base, zwitter ions,salts, etc.).

Accordingly, in a first aspect, the present invention provides aco-crystal pharmaceutical composition comprising an API compound and aco-crystal former, such that the API and co-crystal former are capableof co-crystallizing from a solid or solution phase under crystallizationconditions.

Another aspect of the present invention provides a process for theproduction of a pharmaceutical composition, which process comprises:

(1) providing an API which has at least one functional group selectedfrom ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone,nitrate ester, phosphate ester, thiophosphate ester, ester, thioester,sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid,sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiaryamine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo,organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclicring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamicacid, imidazole, and pyridine;

(2) providing a co-crystal former which has at least one functionalgroup selected from ether, thioether, alcohol, thiol, aldehyde, ketone,thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester,thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinicacid, sulfonic acid, amide, primary amine, secondary amine, ammonia,tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile,diazo, organohalide, nitro, s-heterocyclic ring, thiophene,n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide,peroxide, hydroxamic acid, imidazole, and pyridine;

(3) grinding, heating or contacting in solution the API with theco-crystal former under crystallization conditions;

(4) isolating co-crystals formed thereby; and

(5) incorporating the co-crystals into a pharmaceutical composition.

A further aspect of the present invention provides a process for theproduction of a pharmaceutical composition, which comprises:

(1) grinding, heating or contacting in solution an API compound with aco-crystal former, under crystallization conditions, so as to form asolid phase;

(2) isolating co-crystals comprising the API and the co-crystal former;and

(3) incorporating the co-crystals into a pharmaceutical composition.

In a further aspect, the present invention provides a process for theproduction of a pharmaceutical composition, which comprises:

(1) providing (i) an API or a plurality of different APIs, and (ii) aco-crystal former or a plurality of different co-crystal formers,wherein at least one of the APIs and the co-crystal formers is providedas a plurality thereof;

(2) isolating co-crystals comprising the API and the co-crystal former;and

(3) incorporating the co-crystals into a pharmaceutical composition.

Solubility Modulation

In a further aspect, the present invention provides a process formodulating the solubility of an API, which process comprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Dissolution Modulation

In a further aspect, the present invention provides a process formodulating the dissolution of an API, whereby the aqueous dissolutionrate or the dissolution rate in simulated gastric fluid or in simulatedintestinal fluid, or in a solvent or plurality of solvents is increasedor decreased, which process comprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

In one embodiment, the dissolution of the API is increased.

Bioavailability Modulation

In a further aspect, the present invention provides a process formodulating the bioavailability of an API, whereby the AUC is increased,the time to T_(max) is reduced, the length of time the concentration ofthe API is above ½ T_(max) is increased, or C_(max) is increased, whichprocess comprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Dose Response Modulation

In a further aspect the present invention provides a process forimproving the linearity of a dose response of an API, which processcomprises:

(1) grinding, heating, or contacting in solution an API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Increased Stability

In a still further aspect the present invention provides a process forimproving the stability of a pharmaceutical salt, which processcomprises:

(1) grinding, heating or contacting in solution the pharmaceutical saltwith a co-crystal former under crystallization conditions, so as to forma co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Difficult to Salt or Unsaltable Compounds

In a still further aspect the present invention provides a process formaking co-crystals of difficult to salt or unsaltable APIs, whichprocess comprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Decreasing Hygroscopicity

In a still further aspect the present invention provides a method fordecreasing the hygroscopicity of an API, which method comprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Crystallizing Amorphous Compounds

In a still further embodiment aspect the present invention provides aprocess for crystallizing an amorphous compound, which processcomprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Decreasing Form Diversity

In a still further embodiment aspect the present invention provides aprocess for reducing the form diversity of an API, which processcomprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Morphology Modulation

In a still further embodiment aspect the present invention provides aprocess for modifying the morphology of an API, which process comprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

In a further aspect, the present invention provides a co-crystalcomposition comprising a co-crystal, wherein said co-crystal comprisesan API compound and a co-crystal former. In further embodiments theco-crystal has an improved property as compared to the free form(including a free acid, free base, zwitter ion, hydrate, solvate, etc.)or a salt (which includes salt hydrates and solvates). In furtherembodiments, the improved property is selected from the group consistingof: increased solubility, increased dissolution, increasedbioavailability, increased dose response, decreased hygroscopicity, acrystalline form of a normally amorphous compound, a crystalline form ofa difficult to salt or unsaltable compound, decreased form diversity,more desired morphology, or other property described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 PXRD pattern for a co-crystal of carbamazepine and saccharin(Form I).

FIG. 2 DSC thermogram for a co-crystal of carbamazepine and saccharin(Form I).

FIG. 3 PXRD pattern for a co-crystal of carbamazepine and nicotinamide(Form I).

FIG. 4 DSC thermogram for a co-crystal of carbamazepine and nicotinamide(Form I).

FIG. 5 PXRD pattern for a co-crystal of carbamazepine and trimesic acid(Form I).

FIG. 6 PXRD pattern for a co-crystal of topiramate and 18-crown-6.

FIG. 7 DSC thermogram for a co-crystal of topiramate and 18-crown-6.

FIG. 8 PXRD pattern for a co-crystal of olanzapine and nicotinamide(Form I).

FIG. 9 DSC thermogram for a co-crystal of olanzapine and nicotinamide(Form I).

FIG. 10 PXRD pattern for a co-crystal of celecoxib and 18-crown-6.

FIG. 11 DSC thermogram for a co-crystal of celecoxib and 18-crown-6.

FIG. 12 PXRD pattern for a co-crystal of itraconazole and succinic acid.

FIG. 13 DSC thermogram for a co-crystal of itraconazole and succinicacid.

FIG. 14 PXRD pattern for a co-crystal of itraconazole and fumaric acid.

FIG. 15 DSC thermogram for a co-crystal of itraconazole and fumaricacid.

FIG. 16 PXRD pattern for a co-crystal of itraconazole and tartaric acid

FIG. 17 DSC thermogram for a co-crystal of itraconazole and tartaricacid.

FIG. 18 PXRD pattern for a co-crystal of itraconazole and malic acid.

FIG. 19 DSC thermogram for a co-crystal of itraconazole and malic acid.

FIG. 20 PXRD pattern for a co-crystal of itraconazoleHCl and tartaricacid.

FIG. 21 DSC thermogram for a co-crystal of itraconazoleHCl and tartaricacid.

FIG. 22 PXRD pattern for a co-crystal of modafinil and malonic acid.

FIG. 23 PXRD pattern for a co-crystal of modafinil and benzamide.

FIG. 24 PXRD pattern for a co-crystal of modafinil and mandelic acid.

FIG. 25 PXRD pattern for a co-crystal of modafinil and glycolic acid.

FIG. 26 PXRD pattern for a co-crystal of modafinil and fumaric acid.

FIG. 27 Dissolution profile for a co-crystal of celecoxib:nicotinamidevs. celecoxib free acid.

FIG. 28 Dissolution profile for co-crystals of itraconazole:succinicacid, itraconazle:tartaric acid and itraconazole:malic acid vs.itraconazole free base.

FIG. 29 Hygroscopicity profile for a co-crystal ofcelecoxib:nicotinamide vs. celecoxib sodium.

FIG. 30 PXRD pattern for a co-crystal of olanzapine and nicotinamide(Form II).

FIG. 31 PXRD pattern for a co-crystal of olanzapine and nicotinamide(Form III).

FIG. 32A-D Packing diagrams and crystal structure of olanzapine andnicotinamide (Form III). FIG. 32A depicts the molecular structure of theolanzapine-nicotinamide-H₂O-IPOAc crystal. In FIG. 32C, the olanzapinemolecules occupy the spaces shown and are hydrogen bonded to the watermolecules. The arrangement of the olanzapine molecules is similar tothat observed from the methanol solvate and the published structures forthe hydrates; the water molecules bridge the olanzapine moietiesresulting in hydrogen-bonded zigzag sheets (see FIG. 32D).

FIG. 33 DSC thermogram for a co-crystal of 5-fluorouracil and urea.

FIG. 34 TGA thermogram for a co-crystal of 5-fluorouracil and urea.

FIG. 35 Raman spectrum for a co-crystal of 5-fluorouracil and urea.

FIG. 36 PXRD pattern for a co-crystal of 5-fluorouracil and urea.

FIG. 37 PXRD pattern for a co-crystal of hydrochlorothiazide andnicotinic acid.

FIG. 38 PXRD pattern for a co-crystal of hydrochlorothiazide and18-crown-6.

FIG. 39 PXRD pattern for a co-crystal of hydrochlorothiazide andpiperazine.

FIG. 40 DSC thermogram for a co-crystal of modafinil and malonic acid.

FIG. 41 TGA thermogram for a co-crystal of modafinil and malonic acid.

FIG. 42 Raman spectrum for a co-crystal of modafinil and malonic acid.

FIG. 43 PXRD pattern for a co-crystal of modafinil and maleic acid.

FIG. 44A-B An acetaminophen 1-D polymeric chain and a co-crystal ofacetaminophen and 4,4′-bipyridine, respectively.

FIG. 45A-B Pure phenyloin and a co-crystal with phenyloin and pyridone,respectively.

FIG. 46A-D Pure aspirin and the corresponding crystal structure areshown in FIGS. 46A and 46B, respectively. FIGS. 46C and 46D show thesupramolecular entity containing the synthon and correspondingco-crystal of aspirin and 4,4′-bipyridine, respectively.

FIG. 47A-D Pure ibuprofen and the corresponding crystal structure areshown in FIGS. 7A and 7B, respectively. FIGS. 7C and 7D show thesupramolecular entity containing the synthon and correspondingco-crystal of ibuprofen and 4,4′-bipyridine, respectively.

FIG. 48A-D Pure flurbiprofen and the corresponding crystal structure areshown in FIGS. 48A and 48B, respectively. FIGS. 5C and 5D show thesupramolecular synthon and corresponding co-crystal of flurbiprofen and4,4′-bipyridine, respectively.

FIG. 49A-B The supramolecular entity containing the synthon and thecorresponding co-crystal structure of flurbiprofen andtrans-1,2-bis(4-pyridyl)ethylene, respectively.

FIG. 50A-B The crystal structure of pure carbamazepine and theco-crystal structure of carbamazepine and p-phthalaldehyde,respectively.

FIG. 51 The co-crystal structure of carbamazepine and nicotinamide (FormII).

FIG. 52 The co-crystal structure of carbamazepine and saccharin (FormII).

FIG. 53A-C The chemical structures of ibuprofen, flurbiprofen, andaspirin, respectively.

FIG. 54A-B The crystal structure of carbamazepine and the co-crystalstructure of carbamazepine and 2,6-pyridinedicarboxylic acid,respectively.

FIG. 55A-B The crystal structure of carbamazepine and the co-crystalstructure of carbamazepine and 5-nitroisophthalic acid, respectively.

FIG. 56A-B The crystal structure of carbamazepine and the co-crystalstructure of carbamazepine and 1,3,5,7-adamantanetetracarboxylic acid,respectively.

FIG. 57A-B The crystal structure of carbamazepine and the co-crystalstructure of carbamazepine and benzoquinone, respectively.

FIG. 58A-B The crystal structure of carbamazepine and the co-crystalstructure of carbamazepine and trimesic acid (Form II), respectively.

FIG. 59 PXRD diffractogram for a co-crystal of celecoxib andnicotinamide.

FIG. 60 DSC thermogram for a co-crystal of celecoxib and nicotinamide.

FIG. 61 TGA thermogram for a co-crystal of celecoxib and nicotinamide.

FIG. 62 Raman spectrum for a co-crystal of celecoxib and nicotinamide.

FIG. 63 Hydrogen-bonding motifs observed in co-crystals.

DETAILED DESCRIPTION OF THE INVENTION

The term “co-crystal” as used herein means a crystalline materialcomprised of two or more unique solids at room temperature, eachcontaining distinctive physical characteristics, such as structure,melting point and heats of fusion, with the exception that, ifspecifically stated, the API may be a liquid at room temperature. Theco-crystals of the present invention comprise a co-crystal formerH-bonded to an API. The co-crystal former may be H-bonded directly tothe API or may be H-bonded to an additional molecule which is bound tothe API. The additional molecule may be H-bonded to the API or boundionically or covalently to the API. The additional molecule could alsobe a different API. Solvates of API compounds that do not furthercomprise a co-crystal former are not co-crystals according to thepresent invention. The co-crystals may however, include one or moresolvate molecules in the crystalline lattice. That is, solvates ofco-crystals, or a co-crystal further comprising a solvent or compoundthat is a liquid at room temperature, is included in the presentinvention, but crystalline material comprised of only one solid and oneor more liquids (at room temperature) are not included in the presentinvention, with the previously noted exception of specifically statedliquid APIs. The co-crystals may also be a co-crystal between aco-crystal former and a salt of an API, but the API and the co-crystalformer of the present invention are constructed or bonded togetherthrough hydrogen bonds. Other modes of molecular recognition may also bepresent including, pi-stacking, guest-host complexation and van derWaals interactions. Of the interactions listed above, hydrogen-bondingis the dominant interaction in the formation of the co-crystal, (and arequired interaction according to the present invention) whereby anon-covalent bond is formed between a hydrogen bond donor of one of themoieties and a hydrogen bond acceptor of the other. Hydrogen bonding canresult in several different intermolecular configurations. For example,hydrogen bonds can result in the formation of dimers, linear chains, orcyclic structures. These configurations can further include extended(two-dimensional) hydrogen bond networks and isolated triads (FIG. 63).An alternative embodiment provides for a co-crystal wherein theco-crystal former is a second API. In another embodiment, the co-crystalformer is not an API. In another embodiment the co-crystal comprises twoco-crystal formers. For purposes of the present invention, the chemicaland physical properties of an API in the form of a co-crystal may becompared to a reference compound that is the same API in a differentform. The reference compound may be specified as a free form, or morespecifically, a free acid, free base, or zwitter ion; a salt, or morespecifically for example, an inorganic base addition salt such assodium, potassium, lithium, calcium, magnesium, ammonium, aluminum saltsor organic base addition salts, or an inorganic acid addition salts suchas HBr, HCl, sulfuric, nitric, or phosphoric acid addition salts or anorganic acid addition salt such as acetic, proprionic, pyruvic, malanic,succinic, malic, maleic, fumaric, tartaric, citric, benzoic,methanesulfonic, ethanesulforic, stearic or lactic acid addition salt;an anhydrate or hydrate of a free form or salt, or more specifically,for example, a hemihydrate, monohydrate, dihydrate, trihydrate,quadrahydrate, pentahydrate; or a solvate of a free form or salt. Forexample, the reference compound for an API in salt form co-crystallizedwith a co-crystal former can be the API salt form. Similarly, thereference compound for a free acid API co-crystallized with a co-crystalformer can be the free acid API. The reference compound may also bespecified as crystalline or amorphous.

According to the present invention, the co-crystals can include an acidaddition salt or base addition salt of an API. Acid addition saltsinclude, but are not limited to, inorganic acids such as hydrochloricacid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid,and organic acids such as acetic acid, propionic acid, hexanoic acid,heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid,lactic acid, malonic acid, succinic acid, malic acid, maleic acid,fumaric acid, tartatic acid, citric acid, benzoic acid,o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, madelic acid,methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid,2-hydroxyethanesulfonic acid, benzenesulfonic acid,p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,p-toluenesulfonic acid, camphorsulfonic acid,4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid,4,4′-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionicacid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuricacid, gluconic acid, glutaric acid, hydroxynaphthoic acid, salicylicacid, stearic acid, and muconic acid. Base addition salts include, butare not limited to, inorganic bases such as sodium, potassium, lithium,ammonium, calcium and magnesium salts, and organic bases such asprimary, secondary and tertiary amines (e.g. isopropylamine, trimethylamine, diethyl amine, tri(iso-propyl)amine, tri(n-propyl) amine,ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine,histidine, caffeine, procaine, hydrabamine, choline, betaine,ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines,piperazine, piperidine, morpholine, and N-ethylpiperidine).

The ratio of API to co-crystal former may be stoichiometric ornon-stoichiometric according to the present invention. For example, 1:1,1:1.5 and 1:2 ratios of API:co-crystal former are acceptable.

It has surprisingly been found that when an API and a selectedco-crystal former are allowed to form co-crystals, the resultingco-crystals give rise to improved properties of the API, as compared tothe API in a free form (including free acids, free bases, and zwitterions, hydrates, solvates, etc.), or an acid or base salt thereofparticularly with respect to: solubility, dissolution, bioavailability,stability, Cmax, Tmax, processability, longer lasting therapeutic plasmaconcentration, hygroscopicity, crystallization of amorphous compounds,decrease in form diversity (including polymorphism and crystal habit),change in morphology or crystal habit, etc. For example, a co-crystalform of an API is particularly advantageous where the original API isinsoluble or sparingly soluble in water. Additionally, the co-crystalproperties conferred upon the API are also useful because thebioavailability of the API can be improved and the plasma concentrationand/or serum concentration of the API can be improved. This isparticularly advantageous for orally-administrable formulations.Moreover, the dose response of the API can be improved, for example byincreasing the maximum attainable response and/or increasing the potencyof the API by increasing the biological activity per dosing equivalent.

Accordingly, in a first aspect, the present invention provides apharmaceutical composition comprising a co-crystal of an API and aco-crystal former, such that the API and co-crystal former are capableof co-crystallizing from a solution phase under crystallizationconditions or from the solid-state, for example, through grinding orheating. In another aspect, the API has at least one functional groupselected from ether, thioether, alcohol, thiol, aldehyde, ketone,thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester,thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinicacid, sulfonic acid, amide, primary amine, secondary amine, ammonia,tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile,diazo, organohalide, nitro, s-heterocyclic ring, thiophene,n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide,peroxide, hydroxamic acid, imidazole, and pyridine and a co-crystalformer which has at least one functional group selected from ether,thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester,phosphate ester, thiophosphate ester, ester, thioester, sulfate ester,carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide,primary amine, secondary amine, ammonia, tertiary amine, sp2 amine,thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro,s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole,o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid,imidazole, and pyridine, or a functional group in a Table herein, suchthat the API and co-crystal former are capable of co-crystallizing froma solution phase under crystallization conditions.

The co-crystals of the present invention are formed where the API andco-crystal former are bonded together through hydrogen bonds. Othernon-covalent interactions, including pi-stacking and van der Waalsinteractions, may also be present.

In one embodiment, the co-crystal former is selected from the co-crystalformers of Table I and Table II. In other embodiments, the co-crystalformer of Table I is specified as a Class 1, Class 2, or Class 3co-crystal former (see column labeled “class” Table I). In anotherembodiment, the difference in pK_(a) value of the co-crystal former andthe API is less than 2. In other embodiments, the difference in pK_(a)values of the co-crystal former and API is less than 3, less than 4,less than 5, between 2 and 3, between 3 and −4, or between 4 and 5.Table I lists multiple pK_(a) values for co-crystal formers havingmultiple functionalities. It is readily apparent to one skilled in theart the particular functional group corresponding to a particular pK_(a)value.

In another embodiment the particular functional group of a co-crystalformer interacting with the API is specified (see for example Table I,columns labeled “Functionality” and “Molecular Structure” and the columnof Table II labeled “Co-Crystal Former Functional Group”). In a furtherembodiment the functional group of the API interacting with theco-crystal former functional group is specified (see, for example,Tables II and III).

In another embodiment, the co-crystal comprises more than one co-crystalformer. For example, two, three, four, five, or more co-crystal formerscan be incorporated in a co-crystal with an API. Co-crystals whichcomprise two or more co-crystal formers and an API are bound togethervia hydrogen bonds. In one embodiment, incorporated co-crystal formersare hydrogen bonded to the API molecules. In another embodiment,co-crystal formers are hydrogen bonded to either the API molecules orthe incorporated co-crystal formers.

In a further embodiment, several co-crystal formers can be contained ina single compartment, or kit, for ease in screening an API for potentialco-crystal species. The co-crystal kit can comprise 5, 10, 15, 20, 25,30, 40, 50, 60, 70, 80, 90, 100, or more of the co-crystal formers inTables I and II. The co-crystal formers are in solid form and in anarray of individual reaction vials such that individual co-crystalformers can be tested with one or more APIs by one or morecrystallization methods or multiple co-crystal formers can be easilytested against one or more compounds by one or more crystallizationmethods. The crystallization methods include, but are not limited to,melt recrystallization, grinding, milling, standing, co-crystalformation from solution by evaporation, thermally driven crystallizationfrom solution, co-crystal formation from solution by addition ofanti-solvent, co-crystal formation from solution by vapor-diffusion,co-crystal formation from solution by drown-out, co-crystal formationfrom solution by any combination of the above mentioned techniques,co-crystal formation by co-sublimation, co-crystal formation bysublimation using a Knudsen cell apparatus, co-crystal formation bystanding the desired components of the co-crystal in the presence ofsolvent vapor, co-crystal formation by slurry conversion of the desiredcomponents of the co-crystal in a solvent or mixtures of solvents, orco-crystal formation by any combination of the above techniques in thepresence of additives, nucleates, crystallization enhancers,precipitants, chemical stabilizers, or anti-oxidants. Theco-crystallization kits can be used alone or as part of largercrystallization experiments. For example, kits can be constructed assingle co-crystal former single well kits, single co-crystal formermulti-well kits, multi-co-crystal former single well kits, ormulti-co-crystal former multi-well kits.

In a further embodiment, the API is selected from an API of Table IV orelsewhere herein. For pharmaceuticals listed in Table IV, co-crystalscan comprise such APIs in free form (i.e. free acid, free base, zwitterion), salts, solvates, hydrates, or the like. For APIs in Table IVlisted as salts, solvates, hydrates, and the like, the API can either beof the form listed in Table IV or its corresponding free form, or ofanother form that is not listed. Table IV includes the CAS number,chemical name, or a PCT or patent reference (each incorporated herein intheir entireties). In further embodiments, the functional group of theparticular API interacting with the co-crystal former is specified. Aspecific functional group of a co-crystal former, a specific co-crystalformer, or a specified functional group or a specific co-crystal formerinteracting with the particular API may also be specified. It is notedthat for Table II, the co-crystal former, and optionally the specificfunctionality, and each of the listed corresponding interacting groupsare included as individual species of the present invention. Thus, eachspecific combination of a co-crystal former and one of the interactinggroups in the same row may be specified as a species of the presentinvention. The same is true for other combinations as discussed in theTables and elsewhere herein.

In each process according to the invention, there is a need to contactthe API with the co-crystal former. This may involve grinding the twosolids together or melting one or both components and allowing them torecrystallize. This may also involve either solubilizing the API andadding the co-crystal former, or solubilizing the co-crystal former andadding the API. Crystallization conditions are applied to the API andco-crystal former. This may entail altering a property of the solution,such as pH or temperature and may require concentration of the solute,usually by removal of the solvent, typically by drying the solution.Solvent removal results in the concentration of both API and co-crystalformer increasing over time so as to facilitate crystallization. Oncethe solid phase comprising any crystals is formed, this may be tested asdescribed herein.

The co-crystals obtained as a result of such process steps may bereadily incorporated into a pharmaceutical composition by conventionalmeans. Pharmaceutical compositions in general are discussed in furtherdetail below and may further comprise a pharmaceutically-acceptablediluent, excipient or carrier.

In a further aspect, the present invention provides a process for theproduction of a pharmaceutical composition, which process comprises:

(1) providing an API which has at least one functional group selectedfrom ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone,nitrate ester, phosphate ester, thiophosphate ester, ester, thioester,sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid,sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiaryamine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo,organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclicring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamicacid, imidazole, and pyridine or of Table II or III;

(2) providing a co-crystal former which has at least one functionalgroup selected from ether, thioether, alcohol, thiol, aldehyde, ketone,thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester,thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinicacid, sulfonic acid, amide, primary amine, secondary amine, ammonia,tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo,organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclicring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamicacid, imidazole, and pyridine or of Table I, II, or III;

(3) grinding, heating or contacting in solution the API with theco-crystal former under crystallization conditions;

(4) isolating co-crystals formed thereby; and

(5) incorporating the co-crystals into a pharmaceutical composition.

In a still further aspect the present invention provides a process forthe production of a pharmaceutical composition, which comprises:

(1) grinding, heating or contacting in solution an API with a co-crystalformer, under crystallization conditions, so as to form a solid phase;

(2) isolating co-crystals comprising the API and the co-crystal former;and

(3) incorporating the co-crystals into a pharmaceutical composition.

Assaying the solid phase for the presence of co-crystals of the API andthe co-crystal former may be carried out by conventional methods knownin the art. For example, it is convenient and routine to use powderX-ray diffraction techniques to assess the presence of co-crystals. Thismay be affected by comparing the spectra of the API, the crystal formerand putative co-crystals in order to establish whether or not trueco-crystals had been formed. Other techniques, used in an analogousfashion, include differential scanning calorimetry (DSC),thermogravimetric analysis (TGA) and Raman spectroscopy. Single crystalX-ray diffraction is especially useful in identifying co-crystalstructures.In a further aspect, the present invention therefore provides a processof screening for co-crystal compounds, which comprises:

(1) providing (i) an API compound, and (ii) a co-crystal former; and

(2) screening for co-crystals of APIs with co-crystal formers bysubjecting each combination of API and co-crystal former to a stepcomprising:

(a) grinding, heating or contacting in solution the API with theco-crystal former under crystallization conditions so as to form a solidphase; and

(b) isolating co-crystals comprising the API and the co-crystal former.

An alternative embodiment is drawn to a process of screening forco-crystal compounds, which comprises:

(1) providing (i) an API or a plurality of different APIs, and (ii) aco-crystal former or a plurality of different co-crystal formers,wherein at least one of the API and the co-crystal former is provided asa plurality thereof; and

(2) screening for co-crystals of APIs with co-crystal formers bysubjecting each combination of API and co-crystal former to a stepcomprising

(a) grinding, heating or contacting in solution the API with theco-crystal former under crystallization conditions so as to form a solidphase; and

(b) isolating co-crystals comprising the API and the co-crystal former.

Solubility Modulation

In a further aspect, the present invention provides a process formodulating the solubility of an API, which process comprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

In one embodiment, the solubility of the API is modulated such that theaqueous solubility is increased. Solubility of APIs may be measured byany conventional means such as chromatography (e.g., HPLC) orspectroscopic determination of the amount of API in a saturated solutionof the API, such as UV-spectroscopy, IR-spectroscopy, Ramanspectroscopy, quantitative mass spectroscopy, or gas chromatography.

In another aspect of the invention, the API may have low aqueoussolubility. Typically, low aqueous solubility in the present applicationrefers to a compound having a solubility in water which is less than orequal to 10 mg/mL, when measured at 37 degrees C., and preferably lessthan or equal to 5 mg/mL or 1 mg/mL. Low aqueous solubility can furtherbe specifically defined as less than or equal to 900, 800, 700, 600,500, 400, 300, 200 150 100, 90, 80, 70, 60, 50, 40, 30, 20micrograms/mL, or further 10, 5 or 1 micrograms/mL, or further 900, 800,700, 600, 500, 400, 300, 200 150, 100 90, 80, 70, 60, 50, 40, 30, 20, or10 ng/mL, or less than 10 ng/mL when measured at 37 degrees C. Aqueoussolubility can also be specified as less than 500, 400, 300, 200, 150,100, 75, 50 or 25 mg/mL. As embodiments of the present invention,solubility can be increased 2, 3, 4, 5, 7, 10, 15, 20, 25, 50, 75, 100,200, 300, 500, 750, 1000, 5000, or 10,000 times by making a co-crystalof the reference form (e.g., crystalline or amorphous free acid, freebase or zwitter ion, hydrate or solvate), or a salt thereof. Furtheraqueous solubility can be measured in simulated gastric fluid (SGF) orsimulated intestinal fluid (SIF) rather than water. SGF (non-diluted) ofthe present invention is made by combining 1 g/L Triton X-100 and 2 g/LNaCl in water and adjusting the pH with 20 mM HCl to obtain a solutionwith a final pH=1.7 (SIF is 0.68% monobasic potassium phosphate, 1%pancreatin, and sodium hydroxide where the pH of the final solution is7.5). The pH of the solvent used may also be specified as 1, 1.1, 1.2,1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7,2.8, 2.9, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10,10.5, 11, 11.5, or 12, or any pH in between successive values.

Examples of embodiments includes: co-crystal compositions with anaqueous solubility, at 37 degrees C. and a pH of 7.0, that is increasedat least 5 fold over the reference form, co-crystal compositions with asolubility in SGF that is increased at least 5 fold over the referenceform, co-crystal compositions with a solubility in SIF that is increasedat least 5 fold over the reference form.

Dissolution Modulation

In another aspect of the present invention, the dissolution profile ofthe API is modulated whereby the aqueous dissolution rate or thedissolution rate in simulated gastric fluid or in simulated intestinalfluid, or in a solvent or plurality of solvents is increased.Dissolution rate is the rate at which API solids dissolve in adissolution medium. For APIs whose absorption rates are faster than thedissolution rates (e.g., steroids), the rate-limiting step in theabsorption process is often the dissolution rate. Because of a limitedresidence time at the absorption site, APIs that are not dissolvedbefore they are removed from intestinal absorption site are considereduseless. Therefore, the rate of dissolution has a major impact on theperformance of APIs that are poorly soluble. Because of this factor, thedissolution rate of APIs in solid dosage forms is an important, routine,quality control parameter used in the API manufacturing process.Dissolution rate=K S(C _(s) −C)where K is dissolution rate constant, S is the surface area, C_(s) isthe apparent solubility, and C is the concentration of API in thedissolution medium.For rapid API absorption, C_(s)−C is approximately equal to C_(s)

The dissolution rate of APIs may be measured by conventional means knownin the art.

The increase in the dissolution rate of a co-crystal, as compared to thereference form (e.g., free form or salt), may be specified, such as by10, 20, 30, 40, 50, 60, 70, 80, 90, or 100%, or by 2, 3, 4, 5, 6, 7, 8,9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, 300,350, 400, 500, 1000, 10,000, or 100,000 fold greater than the referenceform (e.g., free form or salt form) in the same solution. Conditionsunder which the dissolution rate is measured is the same as discussedabove The increase in dissolution may be further specified by the timethe composition remains supersaturated before reaching equilibriumsolubility.

Examples of above embodiments include: co-crystal compositions with adissolution rate in aqueous solution, at 37 degrees C. and a pH of 7.0,that is increased at least 5 fold over the reference form, co-crystalcompositions with a dissolution rate in SGF that is increased at least 5fold over the reference form, co-crystal compositions with a dissolutionrate in SIF that is increased at least 5 fold over the reference form.

Bioavailability Modulation

The methods of the present invention are used to make a pharmaceuticalAPI formulation with greater solubility, dissolution, andbioavailability. Bioavailability can be improved via an increase in AUC,reduced time to T_(max), (the time to reach peak blood serum levels), orincreased C_(max). The present invention can result in higher plasmaconcentrations of API when compared to the neutral form or salt alone(reference form).

AUC is the area under the plot of plasma concentration of API (notlogarithm of the concentration) against time after API administration.The area is conveniently determined by the “trapezoidal rule”: The datapoints are connected by straight line segments, perpendiculars areerected from the abscissa to each data point, and the sum of the areasof the triangles and trapezoids so constructed is computed. When thelast measured concentration (C_(n), at time t_(n)) is not zero, the AUCfrom t_(n) to infinite time is estimated by C_(n)/k_(el).

The AUC is of particular use in estimating bioavailability of APIs, andin estimating total clearance of APIs (Cl_(T)). Following singleintravenous doses, AUC=D/Cl_(T), for single compartment systems obeyingfirst-order elimination kinetics, where D is the dose; alternatively,AUC=C₀/k_(el), where k_(el) is the API elimination rate constant. Withroutes other than the intravenous, for such systems, AUC=F·D/Cl_(T),where F is the absolute bioavailability of the API.

Thus, in a further aspect, the present invention provides a process formodulating the bioavailability of an API when administered in its normaland effective dose range as a co-crystal, whereby the AUC is increased,the time to T_(max) is reduced, or C_(max) is increased, as compared toa reference form, which process comprises:

(1) grinding, heating or contacting in solution the API with aco-crystal former under crystallization conditions, so as to form aco-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Examples of the above embodiments include: co-crystal compositions witha time to T_(max) that is reduced by at least 10% as compared to thereference form, co-crystal compositions with a time to T_(max) that isreduced by at least 20% over the reference form, co-crystal compositionswith a time to T_(max) that is reduced by at least 40% over thereference form, co-crystal compositions with a time to T_(max) that isreduced by at least 50% over the reference form, co-crystal compositionswith a T_(max) that is reduced by at least 60% over the reference form,co-crystal compositions with a T_(max) that is reduced by at least 70%over the reference form, co-crystal compositions with a T_(max) that isreduced by at least 80% over the reference form, co-crystal compositionswith a T_(max) that is reduced by at least 90% over the reference form,co-crystal compositions with a C_(max) that is increased by at least 20%over the reference form, co-crystal compositions with a C_(max) that isincreased by at least 30% over the reference form, co-crystalcompositions with a C_(max) that is increased by at least 40% over thereference form, co-crystal compositions with a C_(max) that is increasedby at least 50% over the reference form, co-crystal compositions with aC_(max) that is increased by at least 60% over the reference form,co-crystal compositions with a C_(max) that is increased by at least 70%over the reference form, co-crystal compositions with a C_(max) that isincreased by at least 80% over the reference form, co-crystalcompositions with a Cmax that is increased by at least 2 fold, 3 fold, 5fold, 7.5 fold, 10 fold, 25 fold, 50 fold or 100 fold, co-crystalcompositions with an AUC that is increased by at least 10% over thereference form, co-crystal compositions with an AUC that is increased byat least 20% over the reference form, co-crystal compositions with anAUC that is increased by at least 30% over the reference form,co-crystal compositions with an AUC that is increased by at least 40%over the reference form, co-crystal compositions with an AUC that isincreased by at least 50% over the reference form, co-crystalcompositions with an AUC that is increased by at least 60% over thereference form, co-crystal compositions with an AUC that is increased byat least 70% over the reference form, co-crystal compositions with anAUC that is increased by at least 80% over the reference form orco-crystal compositions with an AUC that is increased by at least 2fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, or 10fold. Other examples include wherein the reference form is crystalline,wherein the reference form is amorphous, wherein the reference form isan anhydrous crystalline sodium salt, or wherein the reference form isan anhydrous crystalline HCl salt.

Dose Response Modulation

In a further aspect the present invention provides a process forimproving the dose response of an API, which process comprises:

(1) contacting in solution an API with a co-crystal former undercrystallization conditions, so as to form a co-crystal of the API andthe co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

Dose response is the quantitative relationship between the magnitude ofresponse and the dose inducing the response and may be measured byconventional means known in the art. The curve relating effect (as thedependent variable) to dose (as the independent variable) for anAPI-cell system is the “dose-response curve”. Typically, thedose-response curve is the measured response to an API plotted againstthe dose of the API (mg/kg) given. The dose response curve can also be acurve of AUC against the dose of the API given.

In an embodiment of the present invention, a co-crystal of the presentinvention has an increased dose response curve or a more linear doseresponse curve than the corresponding reference compound.

Increased Stability

In a still further aspect the present invention provides a process forimproving the stability of an API (as compared to a reference form suchas its free form or a salt thereof), which process comprises:

(1) grinding, heating or contacting in solution the pharmaceutical saltwith a co-crystal former under crystallization conditions, so as to forma co-crystal of the API and the co-crystal former; and

(2) isolating co-crystals comprising the API and the co-crystal former.

In a preferred embodiment, the compositions of the present invention,including the API or active pharmaceutical ingredient (API) andformulations comprising the API, are suitably stable for pharmaceuticaluse. Preferably, the API or formulations thereof of the presentinvention are stable such that when stored at 30 degrees C. for 2 years,less than 0.2% of any one degradant is formed. The term degradant refersherein to product(s) of a single type of chemical reaction. For example,if a hydrolysis event occurs that cleaves a molecule into two products,for the purpose of the present invention, it would be considered asingle degradant. More preferably, when stored at 40 degrees C. for 2years, less than 0.2% of any one degradant is formed. Alternatively,when stored at 30 degrees C. for 3 months, less than 0.2% or 0.15%, or0.1% of any one degradant is formed, or when stored at 40 degrees C. for3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant isformed. Further alternatively, when stored at 60 degrees C. for 4 weeks,less than 0.2% or 0.15%, or 0.1% of any one degradant is formed. Therelative humidity (RH) may be specified as ambient (RH), 75% (RH), or asany single integer between 1 to 99%.

Difficult to Salt or Unsaltable Compounds

In a still further aspect the present invention provides a process formaking co-crystals of unsaltable or difficult to salt APIs which processcomprises:

-   (1) grinding, heating or contacting in solution an API with a    co-crystal former under crystallization conditions, so as to form a    co-crystal of the API and the co-crystal former; and-   (2) isolating co-crystals comprising the API and the co-crystal    former.

Difficult to salt compounds include bases with a pKa<3 or acids with apKa>10. Zwitter ions are also difficult to salt or unsaltable compoundsaccording to the present invention.

Decreasing Hygroscopicity

In a still further aspect, the present invention provides a method fordecreasing the hygroscopicity of an API, which method comprises:

-   (1) grinding, heating or contacting in solution the API with a    co-crystal former under crystallization conditions, so as to form a    co-crystal of the API and the co-crystal former; and-   (2) isolating co-crystals comprising the API and the co-crystal    former.

An aspect of the present invention provides a pharmaceutical compositioncomprising a co-crystal of an API that is less hygroscopic thanamorphous or crystalline, free form or salt (including metal salts suchas sodium, potassium, lithium, calcium, magnesium) or another referencecompound. Hygroscopicity can be assessed by dynamic vapor sorptionanalysis, in which 5-50 mg of the compound is suspended from a Cahnmicrobalance. The compound being analyzed should be placed in anon-hygroscopic pan and its weight should be measured relative to anempty pan composed of identical material and having nearly identicalsize, shape, and weight. Ideally, platinum pans should be used. The pansshould be suspended in a chamber through which a gas, such as air ornitrogen, having a controlled and known percent relative humidity (% RH)is flowed until equilibrium criteria are met. Typical equilibriumcriteria include weight changes of less than 0.01% over 3 minutes atconstant humidity and temperature. The relative humidity should bemeasured for samples dried under dry nitrogen to constant weight (<0.01%change in 3 minutes) at 40 degrees C. unless doing so would de-solvateor otherwise convert the material to an amorphous compound. In oneaspect, the hygroscopicity of a dried compound can be assessed byincreasing the RH from 5 to 95% in increments of 5% RH and thendecreasing the RH from 95 to 5% in 5% increments to generate a moisturesorption isotherm. The sample weight should be allowed to equilibratebetween each change in % RH. If the compound deliquesces or becomesamorphous above 75% RH, but below 95% RH, the experiment should berepeated with a fresh sample and the relative humidity range for thecycling should be narrowed to 5-75% RH or 10-75% RH, instead of 5-95%RH. If the sample cannot be dried prior to testing due to lack of formstability, than the sample should be studied using two complete humiditycycles of either 10-75% RH or 5-95% RH, and the results of the secondcycle should be used if there is significant weight loss at the end ofthe first cycle.

Hygroscopicity can be defined using various parameters. For purposes ofthe present invention, a non-hygroscopic molecule should not gain orlose more than 1.0%, or more preferably, 0.5% weight at 25 degrees C.when cycled between 10 and 75% RH (relative humidity at 25 degrees C.).The non-hygroscopic molecule more preferably should not gain or losemore than 1.0%, or more preferably, 0.5% weight when cycled between 5and 95% RH at 25 degrees C., or more than 0.25% of its weight between 10and 75% RH. Most preferably, a non-hygroscopic molecule will not gain orlose more than 0.25% of its weight when cycled between 5 and 95% RH.

Alternatively, for purposes of the present invention, hygroscopicity canbe defined using the parameters of Callaghan et al., “Equilibriummoisture content of pharmaceutical excipients”, in Api Dev. Ind. Pharm.,Vol. 8, pp. 335-369 (1982). Callaghan et al. classified the degree ofhygroscopicity into four classes.

-   Class 1: Non-hygroscopic Essentially no moisture increases occur at    relative humidities below 90%.-   Class 2: Slightly hygroscopic Essentially no moisture increases    occur at relative humidities below 80%.-   Class 3: Moderately hygroscopic Moisture content does not increase    more than 5% after storage for 1 week at relative humidities below    60%.-   Class 4: Very hygroscopic Moisture content increase may occur at    relative humidities as low as 40 to 50%.

Alternatively, for purposes of the present invention, hygroscopicity canbe defined using the parameters of the European Pharmacopoeia TechnicalGuide (1999, p. 86) which has defined hygrospocity, based on the staticmethod, after storage at 25 degrees C. for 24 hours at 80% RH:

Slightly hygroscopic: Increase in mass is less than 2 percent m/m andequal to or greater than 0.2 percent m/m.

Hygroscopic: Increase in mass is less than 15 percent m/m and equal toor greater than 0.2 percent m/m.

Very Hygroscopic: Increase in mass is equal to or greater than 15percent m/m.

Deliquescent: Sufficient water is absorbed to form a liquid.

Co-crystals of the present invention can be set forth as being in Class1, Class 2, or Class 3, or as being Slightly hygroscopic, Hygroscopic,or Very Hygroscopic. Co-crystals of the present invention can also beset forth based on their ability to reduce hygroscopicity. Thus,preferred co-crystals of the present invention are less hygroscopic thana reference compound. The reference compound can be specified as the APIin free form (free acid, free base, hydrate, solvate, etc.) or salt(e.g., especially metal salts such as sodium, potassium, lithium,calcium, or magnesium). Further included in the present invention areco-crystals that do not gain or lose more than 1.0% weight at 25 degreesC. when cycled between 10 and 75% RH, wherein the reference compoundgains or loses more than 1.0% weight under the same conditions. Furtherincluded in the present invention are co-crystals that do not gain orlose more than 0.5% weight at 25 degrees C. when cycled between 10 and75% RH, wherein the reference compound gains or loses more than 0.5% ormore than 1.0% weight under the same conditions. Further included in thepresent invention are co-crystals that do not gain or lose more than1.0% weight at 25 degrees C. when cycled between 5 and 95% RH, whereinthe reference compound gains or loses more than 1.0% weight under thesame conditions. Further included in the present invention areco-crystals that do not gain or lose more than 0.5% weight at 25 degreesC. when cycled between 5 and 95% RH, wherein the reference compoundgains or loses more than 0.5% or more than 1.0% weight under the sameconditions. Further included in the present invention are co-crystalsthat do not gain or lose more than 0.25% weight at 25 degrees C. whencycled between 5 and 95% RH, wherein the reference compound gains orloses more than 0.5% or more than 1.0% weight under the same conditions.

Further included in the present invention are co-crystals that have ahygroscopicity (according to Callaghan et al.) that is at least oneclass lower than the reference compound or at least two classes lowerthan the reference compound. Included are a Class 1 co-crystal of aClass 2 reference compound, a Class 2 co-crystal of a Class 3 referencecompound, a Class 3 co-crystal of a Class 4 reference compound, a Class1 co-crystal of a Class 3 reference compound, a Class 1 co-crystal of aClass 4 reference compound, or a Class 2 co-crystal of a Class 4reference compound.

Further included in the present invention are co-crystals that have ahygroscopicity (according to the European Pharmacopoeia Technical Guide)that is at least one class lower than the reference compound or at leasttwo classes lower than the reference compound. Non-limiting examplesinclude; a slightly hygroscopic co-crystal of a hygroscopic referencecompound, a hygroscopic co-crystal of a very hygroscopic referencecompound, a very hygroscopic co-crystal of a deliquescent referencecompound, a slightly hygroscopic co-crystal of a very hygroscopicreference compound, a slightly hygroscopic co-crystal of a deliquescentreference compound, and a hygroscopic co-crystal of a deliquescentreference compound.

Crystallizing Amorphous Compounds

In a further aspect, the present invention provides a process forcrystallizing an amorphous compound, which process comprises:

-   (1) grinding, heating or contacting in solution the API with a    co-crystal former under crystallization conditions, so as to form a    co-crystal of the API and the co-crystal former; and-   (2) isolating co-crystals comprising the API and the co-crystal    former.    An amorphous compound includes compounds that do not crystallize    using routine methods in the art.    Decreasing Form Diversity

In a still further embodiment aspect the present invention provides aprocess for reducing the form diversity of an API, which processcomprises:

-   (1) grinding, heating or contacting in solution the API with a    co-crystal former under crystallization conditions, so as to form a    co-crystal of the API and the co-crystal former; and-   (2) isolating co-crystals comprising the API and the co-crystal    former.    For purposes of the present invention, the number of forms of a    co-crystal is compared to the number of forms of a reference    compound (e.g. the free form or a salt of the API) that can be made    using routine methods in the art.    Morphology Modulation

In a still further aspect the present invention provides a process formodifying the morphology of an API, which process comprises:

-   (1) grinding, heating or contacting in solution the API with a    co-crystal former under crystallization conditions, so as to form a    co-crystal of the API and the co-crystal former; and-   (2) isolating co-crystals comprising the API and the co-crystal    former.

In an embodiment the co-crystal comprises or consists of a co-crystalformer and a pharmaceutical wherein the interaction between the two,e.g., H-bonding, occurs between a functional group of Table III of anAPI with a corresponding interacting group of Table III. In a furtherembodiment, the co-crystal comprises a co-crystal former of Table I orII and an API with a corresponding interacting group of Table III. In afurther embodiment the co-crystal comprises an API from Table IV and aco-crystal former with a functional group of Table III. In a furtherembodiment, the co-crystal is from Table I or II. In an aspect of theinvention, only co-crystals having an H-bond acceptor on the firstmolecule and an H-bond donor on the second molecule, where the first andsecond molecules are either co-crystal former and API respectively orAPI and co-crystal former respectively, are included in the presentinvention. Table IV includes the CAS number, chemical name or a PCT orpatent reference (each incorporated herein in their entireties). Thus,whether a particular API contains an H-bond donor, acceptor or both isreadily apparent.

In another embodiment, the co-crystal former and API each have only oneH-bond donor/acceptor. In another aspect, the molecular weight of theAPI is less than 2000, 1500, 1000, 750, 500, 350, 200, or 150 Daltons.In another embodiment, the molecular weight of the API is between100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900,900-1000, 1000-1200, 1200-1400, 1400-1600, 1600-1800, or 1800-2000. APIswith the above molecular weights may also be specifically excluded fromthe present invention.

In another embodiment, peptides, proteins, nucleic acids or otherbiological APIs are excluded from the present invention. In anotherembodiment, all non-pharmaceutically acceptable co-crystal formers areexcluded from the present invention. In another embodiment,organometalic APIs are excluded from the present invention. In anotherembodiment, a co-crystal former comprising any one or more of thefunctional groups of Table III may be specifically excluded from thepresent invention. In another embodiment, any one or more of theco-crystal formers of Table I or II may be specifically excluded fromthe present invention. Any APIs currently known in the art may also bespecifically excluded from the present invention. For example,carbanazepine, itraconazole, nabumetone, fluoxetine, acetaminophen andtheophylline can each be specifically excluded from the presentinvention. In another embodiment, the API is not a salt, is not anon-metal salt, or is not a metal salt, e.g., sodium, potassium,lithium, calcium or magnesium. In another embodiment, the API is a salt,is a non-metal salt, or is a metal salt, e.g., sodium, potassium,lithium, calcium, magnesium. In one embodiment, the API does not containa halogen. In one embodiment, the API does contain a halogen.

In another embodiment, any one or more of the APIs of Table IV may bespecifically excluded from the present invention. Any APIs currentlyknown in the art may also be specifically excluded from the presentinvention. For example, nabumetone:2,3-naphthalenediol, fluoxetineHCl:benzoic acid, fluoxetine HCl:succinic acid,acetaminophen:piperazine, acetaminophen:theophylline,theophylline:salicylic acid, theophylline:p-hydroxybenzoic acid,theophylline:sorbic acid, theophylline:1-hydroxy-2-naphthoic acid,theophylline:glycolic acid, theophylline:2,5-dihydroxybenzoic acid,theophylline:chloroacetic acid, bis(diphenylhydantoin):9-ethyladenineacetylacetone solvate, bis(diphenylhydantoin):9-ethyladenine2,4-pentanedione solvate, 5,5-diphenylbarbituric acid:9-ethyladenine,bis(diphenylhydantoin):9-ethyladenine, 4-aminobenzoicacid:4-aminobenzonitrile, sulfadimidine:salicylic acid,8-hydroxyquinolinium 4-nitrobenzoate:4-nitrobenzoic acid,sulfaproxyline:caffeine, retro-inverso-isopropyl(2R,3S)-4-cyclohexyl-2-hydroxy-3-(N-((2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl)-L-histidylamino)butyrate:cinnamicacid monohydrate, benzoic acid:isonicotinamide,3-(2-N′,N′-(dimethylhydrazino)-4-thiazolylmethylthio)-N″-sulfamoylpropionamidine:maleicacid, diglycine hydrochloride (C₂H₅NO₂:C₂H₆NO₂ ⁺Cl⁻), octadecanoicacid:3-pyridinecarboxamide,cis-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamidehydrochloride:oxalic acid,trans-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-ylium)-N-phenylpropanamideoxalate:oxalic acid dihydrate,bis(1-(3-((4-(2-isopropoxyphenyl)-1-piperazinyl)methyl)benzoyl)piperidine)succinate:succinic acid, bis(p-cyanophenyl)imidazolylmethane:succinicacid, cis-1-((4-(1-imidazolylmethyl)cyclohexyl)methyl)imidazole:succinicacid,(+)-2-(5,6-dimethoxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline:(+)-dibenzoyl-D-tartaricacid, raclopride:tartaric acid,2,6-diamino-9-ethylpurine:5,5-diethylbarbituric acid,5,5-diethylbarbituric acid:bis(2-aminopyridine), 5,5-diethylbarbituricacid:acetamide, 5,5-diethylbarbituric acid:KI₃, 5,5-diethylbarbituricacid:urea, bis(barbital):hexamethylphosphoramide, 5,5-diethylbarbituricacid:imidazole, barbital: 1-methylimidazole, 5,5-diethylbarbituricacid:N-methyl-2-pyridone,2,4-diamino-5-(3,4,5-trimethoxybenzyl)-pyrimidine:5,5-diethylbarbituricacid, bis(barbital):caffeine, bis(barbital): 1-methylimidazole,bis(beta-cyclodextrin):bis(barbital) hydrate,tetrakis(beta-cyclodextrin):tetrakis(barbital),9-ethyladenine:5,5-diethylbarbituric acid,barbital:N′-(p-cyanophenyl)-N-(p-iodophenyl)melamine,barbital:2-amino-4-(m-bromophenylamino)-6-chloro-1,3,5-triazine,5,5-diethylbarbituric acid:N,N′-diphenylmelamine, 5,5-diethylbarbituricacid:N,N′-bis(p-chlorophenyl)melamine,N,N′-bis(p-bromophenyl)melamine:5,5-diethylbarbituric acid,5,5-diethylbarbituric acid:N,N′-bis(p-iodophenyl)melamine,5,5-diethylbarbituric acid:N,N′-bis(p-tolyl)melamine,5,5-diethylbarbituric acid:N,N′-bis(m-tolyl)melamine,5,5-diethylbarbituric acid:N,N′-bis(m-chlorophenyl)melamine,N,N′-Bis(m-methylphenyl)melamine:barbital,N,N′-bis(m-chlorophenyl)melamine:barbital tetrahydrofuran solvate,5,5-diethylbarbituric acid:N,N′-bis(t-butyl)melamine,5,5-diethylbarbituric acid:N,N′-di(t-butyl)melamine, 6,6′-diquinolylether:5,5-diethylbarbituric acid,5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid,N,N′-bis(4-carboxymethylphenyl)melamine:barbital ethanol solvate,N,N′-bis(4-t-butylphenyl)melamine:barbital,tris(5,17-N,N′-bis(4-amino-6-(butylamino)-1,3,5-triazin-2-yl)diamino-11,23-dinitro-25,26,27,28-tetrapropoxycalix(4)arene):hexakis(diethylbarbituricacid) toluene solvate, N,N′-bis(m-fluorophenyl)melamine:barbital,N,N′-bis(m-bromophenyl)melamine:barbital acetone solvate,N,N′-bis(m-iodophenyl)melamine:barbital acetonitrile solvate,N,N′-bis(m-trifluoromethylphenyl)melamine:barbital acetonitrile solvate,aminopyrine:barbital, N,N′-bis(4-fluorophenyl)melamine:barbital,N,N′-bis(4-trifluoromethylphenyl)melamine:barbital,2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine:barbital,hydroxybutyrate:hydroxyvalerate, 2-aminopyrimidine:succinic acid,1,3-bis(((6-methylpyrid-2-yl)amino)carbonyl)benzene:glutaric acid,5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid,bis(dithiobiuret-S,S′)nickel(II):diuracil, platinum3,3′-dihydroxymethyl-2,2′-bipyridine dichloride:AgF_(3 CSO) ₃,4,4′-bipyridyl:isophthalic acid,4,4′-bipyridyl:1,4-naphthalenedicarboxylic acid,4,4′-bipyridyl:1,3,5-cyclohexane-tricarboxylic acid,4,4′-bipyridyl:tricaballylic acid, urotropin:azelaic acid, insulin:C8-HI(octanoyl-N^(e)-LysB29-human insulin), isonicotinamide:cinnamic acid,isonicotinamide:3-hydroxybenzoic acid,isonicotinamide:3-N,N-dimethylaminobenzoic acid,isonicotinamide:3,5-bis(trifluoromethyl)-benzoic acid,isonicotinamide:d,1-mandelic acid, isonicotinamide:chloroacetic acid,isonicotinamide:fumaric acid monoethyl ester,isonicotinamide:12-bromododecanoic acid, isonicotinamide:fumaric acid,isonicotinamide:succinic acid, isonicotinamide:4-ketopimelic acid,isonicotinamide:thiodiglycolic acid, 1,3,5-cyclohexane-tricarboxylicacid:hexamethyltetramine, 1,3,5-cyclohexane-tricarboxylicacid:4,7-phenanthroline, 4,7-phenanthroline:oxalic acid,4,7-phenanthroline:terephthalic acid, 4,7-phenanthroline:1,3,5-cyclohexane-tricarboxylic acid, 4,7-phenanthroline:1,4-naphthalenedicarboxylic acid, pyrazine:methanoic acid,pyrazine:ethanoic acid, pyrazine:propanoic acid, pyrazine:butanoic acid,pyrazine:pentanoic acid, pyrazine:hexanoic acid, pyrazine:heptanoicacid, pyrazine:octanoic acid, pyrazine:nonanoic acid, pyrazine:decanoicacid, diammine-(deoxy-quanyl-quanyl-N⁷,N⁷)-platinum:tris(glycine)hydrate, 2-aminopyrimidine:p-phenylenediacetic acid,bis(2-aminopyrimidin-1-ium)fumarate:fumaric acid,2-aminopyrimidine:indole-3-acetic acid,2-aminopyrimidine:N-methylpyrrole-2-carboxylic acid,2-aminopyrimidine:thiophen-2-carboxylic acid,2-aminopyrimidine:(+)-camphoric acid, 2,4,6-Trinitrobenzoic acid:2-aminopyrimidine, 2-aminopyrimidine:4-aminobenzoic acid,2-aminopyrimidine:bis(phenoxyacetic acid),2-aminopyrimidine:(2,4-dichlorophenoxy)acetic acid,2-aminopyrimidine:(3,4-dichlorophenoxy)acetic acid,2-aminopyrimidine:indole-2-carboxylic acid,2-aminopyrimidine:terephthalic acid,2-aminopyrimidine:bis(2-nitrobenzoic acid),2-aminopyrimidine:bis(2-aminobenzoic acid),2-aminopyrimidine:3-aminobenzoic acid, 2-hexeneoic acid:isonicotinamide,4-nitrobenzoic acid:isonicotinamide, 3,5-dinitrobenzoicacid:isonicotinamide:4-methylbenzoic acid,2-amino-5-nitropyrimidine:2-amino-3-nitropyridine, 3,5-dinitrobenzoicacid:4-chlorobenzamide, 3-dimethylaminobenzoic acid:4-chlorobenzamide,fumaric acid:4-chlorobenzamide, oxine:4-nitrobenzoic acid,oxine:3,5-dinitrobenzoic acid, oxine:3,5-dinitrosalicylic acid,3-[2-(N′,N′-dimethylhydrazino)-4-thiazolylmethylthio]-N²-sulfamoylpropionamidine:maleicacid, 5-fluorouracil:9-ethylhypoxanthine, 5-fluorouracil:cytosinedihydrate, 5-fluorouracil:theophylline monohydrate, stearicacid:nicotinamide,cis-1-{[4-(1-imidazolylmethyl)cyclohexyl]methyl}imidazole:succinic acid,CGS18320B:succinic acid, sulfaproxyline:caffeine, 4-aminobenzoicacid:4-aminobenzonitrile, 3,5-dinitrobenzoicacid:isonicotinamide:3-methylbenzoic acid, 3,5-dinitrobenzoicacid:isonicotinamide:4-(dimethylamino)benzoic acid, 3,5-dinitrobenzoicacid:isonicotinamide:4-hydroxy-3-methoxycinnamic acid,isonicotinamide:oxalic acid, isonicotinamide:malonic acid,isonicotinamide:succinic acid, isonicotinamide:glutaric acid,isonicotinamide:adipic acid, benzoic acid:isonicotinamide,mazapertine:succinate, betaine:dichloronitrophenol,betainepyridine:dichloronitrophenol, betainepyridine:pentachlorophenol,4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:methyl2,4-dihydroxybenzoate,4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxypropiophenone,4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxyacetophenone,squaric acid:4,4′-dipyridylacetylene, squaric acid:1,2-bis(4-pyridyl)ethylene, chloranilic acid:1,4-bis[(4-pyridyl)ethynyl]benzene, 4,4′-bipyridine:phthalic acid,4,4′-dipyridylacetylene:phthalic acid,bis(pentamethylcyclopentadienyl)iron:bromanilic acid,bis(pentamethylcyclopentadienyl)iron:chloranilic acid,bis(pentamethylcyclopentadienyl)iron:cyananilic acid,pyrazinotetrathiafulvalene:chloranilic acid, phenol:pentafluorophenol,co-crystals of itraconazole, and co-crystals of topiramate arespecifically excluded from the present invention.

Excipients employed in pharmaceutical compositions of the presentinvention can be solids, semi-solids, liquids or combinations thereof.Preferably, excipients are solids. Compositions of the inventioncontaining excipients can be prepared by any known technique of pharmacythat comprises admixing an excipient with an API or therapeutic agent. Apharmaceutical composition of the invention contains a desired amount ofAPI per dose unit and, if intended for oral administration, can be inthe form, for example, of a tablet, a caplet, a pill, a hard or softcapsule, a lozenge, a cachet, a dispensable powder, granules, asuspension, an elixir, a dispersion, a liquid, or any other formreasonably adapted for such administration. If intended for parenteraladministration, it can be in the form, for example, of a suspension ortransdermal patch. If intended for rectal administration, it can be inthe form, for example, of a suppository. Presently preferred are oraldosage forms that are discrete dose units each containing apredetermined amount of the API, such as tablets or capsules.

In another embodiment, APIs with an inappropriate pH for transdermalpatches can be co-crystallized with an appropriate co-crystal former,thereby adjusting its pH to an appropriate level for use as atransdermal patch. In another embodiment, an APIs pH level can beoptimized for use in a transdermal patch via co-crystallization with anappropriate co-crystal former.

Non-limiting examples follow of excipients that can be used to preparepharmaceutical compositions of the invention.

Pharmaceutical compositions of the invention optionally comprise one ormore pharmaceutically acceptable carriers or diluents as excipients.Suitable carriers or diluents illustratively include, but are notlimited to, either individually or in combination, lactose, includinganhydrous lactose and lactose monohydrate; starches, including directlycompressible starch and hydrolyzed starches (e.g., Celutab™ and Emdex™);mannitol; sorbitol; xylitol; dextrose (e.g., Cerelose™ 2000) anddextrose monohydrate; dibasic calcium phosphate dihydrate; sucrose-baseddiluents; confectioner's sugar; monobasic calcium sulfate monohydrate;calcium sulfate dihydrate; granular calcium lactate trihydrate;dextrates; inositol; hydrolyzed cereal solids; amylose; cellulosesincluding microcrystalline cellulose, food grade sources of alpha- andamorphous cellulose (e.g., RexcelJ), powdered cellulose,hydroxypropylcellulose (HPC) and hydroxypropylmethylcellulose (HPMC);calcium carbonate; glycine; bentonite; block co-polymers;polyvinylpyrrolidone; and the like. Such carriers or diluents, ifpresent, constitute in total about 5% to about 99%, preferably about 10%to about 85%, and more preferably about 20% to about 80%, of the totalweight of the composition. The carrier, carriers, diluent, or diluentsselected preferably exhibit suitable flow properties and, where tabletsare desired, compressibility.

Lactose, mannitol, dibasic sodium phosphate, and microcrystallinecellulose (particularly Avicel PH microcrystalline cellulose such asAvicel PH 101), either individually or in combination, are preferreddiluents. These diluents are chemically compatible with many co-crystalsdescribed herein. The use of extragranular microcrystalline cellulose(that is, microcrystalline cellulose added to a granulated composition)can be used to improve hardness (for tablets) and/or disintegrationtime. Lactose, especially lactose monohydrate, is particularlypreferred. Lactose typically provides compositions having suitablerelease rates of co-crystals, stability, pre-compression flowability,and/or drying properties at a relatively low diluent cost. It provides ahigh density substrate that aids densification during granulation (wherewet granulation is employed) and therefore improves blend flowproperties and tablet properties.

Pharmaceutical compositions of the invention optionally comprise one ormore pharmaceutically acceptable disintegrants as excipients,particularly for tablet formulations. Suitable disintegrants include,but are not limited to, either individually or in combination, starches,including sodium starch glycolate (e.g., Explotab™ of PenWest) andpregelatinized corn starches (e.g., National™ 1551 of National Starchand Chemical Company, National™ 1550, and Colorcon™ 1500), clays (e.g.,Veegum™ HV of R.T. Vanderbilt), celluloses such as purified cellulose,microcrystalline cellulose, methylcellulose, carboxymethylcellulose andsodium carboxymethylcellulose, croscarmellose sodium (e.g., Ac-Di-Sol™of FMC), alginates, crospovidone, and gums such as agar, guar, locustbean, karaya, pectin and tragacanth gums.

Disintegrants may be added at any suitable step during the preparationof the composition, particularly prior to granulation or during alubrication step prior to compression. Such disintegrants, if present,constitute in total about 0.2% to about 30%, preferably about 0.2% toabout 10%, and more preferably about 0.2% to about 5%, of the totalweight of the composition.

Croscarmellose sodium is a preferred disintegrant for tablet or capsuledisintegration, and, if present, preferably constitutes about 0.2% toabout 10%, more preferably about 0.2% to about 7%, and still morepreferably about 0.2% to about 5%, of the total weight of thecomposition. Croscarmellose sodium confers superior intragranulardisintegration capabilities to granulated pharmaceutical compositions ofthe present invention.

Pharmaceutical compositions of the invention optionally comprise one ormore pharmaceutically acceptable binding agents or adhesives asexcipients, particularly for tablet formulations. Such binding agentsand adhesives preferably impart sufficient cohesion to the powder beingtableted to allow for normal processing operations such as sizing,lubrication, compression and packaging, but still allow the tablet todisintegrate and the composition to be absorbed upon ingestion. Suchbinding agents may also prevent or inhibit crystallization orrecrystallization of a co-crsytal of the present invention once the salthas been dissolved in a solution. Suitable binding agents and adhesivesinclude, but are not limited to, either individually or in combination,acacia; tragacanth; sucrose; gelatin; glucose; starches such as, but notlimited to, pregelatinized starches (e.g., National™ 1511 and National™1500); celluloses such as, but not limited to, methylcellulose andcarmellose sodium (e.g., Tylose™); alginic acid and salts of alginicacid; magnesium aluminum silicate; PEG; guar gum; polysaccharide acids;bentonites; povidone, for example povidone K-15, K-30 and K-29/32;polymethacrylates; HPMC; hydroxypropylcellulose (e.g., Klucel™ ofAqualon); and ethylcellulose (e.g., Ethocel™ of the Dow ChemicalCompany). Such binding agents and/or adhesives, if present, constitutein total about 0.5% to about 25%, preferably about 0.75% to about 15%,and more preferably about 1% to about 10%, of the total weight of thepharmaceutical composition.

Many of the binding agents are polymers comprising amide, ester, ether,alcohol or ketone groups and, as such, are preferably included inpharmaceutical compositions of the present invention.Polyvinylpyrrolidones such as povidone K-30 are especially preferred.Polymeric binding agents can have varying molecular weight, degrees ofcrosslinking, and grades of polymer. Polymeric binding agents can alsobe copolymers, such as block co-polymers that contain mixtures ofethylene oxide and propylene oxide units. Variation in these units'ratios in a given polymer affects properties and performance. Examplesof block co-polymers with varying compositions of block units arePoloxamer 188 and Poloxamer 237 (BASF Corporation).

Pharmaceutical compositions of the invention optionally comprise one ormore pharmaceutically acceptable wetting agents as excipients. Suchwetting agents are preferably selected to maintain the co-crystal inclose association with water, a condition that is believed to improvebioavailability of the composition. Such wetting agents can also beuseful in solubilizing or increasing the solubility of co-crystals.

Non-limiting examples of surfactants that can be used as wetting agentsin pharmaceutical compositions of the invention include quaternaryammonium compounds, for example benzalkonium chloride, benzethoniumchloride and cetylpyridinium chloride, dioctyl sodium sulfosuccinate,polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol10, and degrees Ctoxynol 9, poloxamers (polyoxyethylene andpolyoxypropylene block copolymers), polyoxyethylene fatty acidglycerides and oils, for example polyoxyethylene (8) caprylic/capricmono- and diglycerides (e.g., Labrasol™ of Gattefosse), polyoxyethylene(35) castor oil and polyoxyethylene (40) hydrogenated castor oil;polyoxyethylene alkyl ethers, for example polyoxyethylene (20)cetostearyl ether, polyoxyethylene fatty acid esters, for examplepolyoxyethylene (40) stearate, polyoxyethylene sorbitan esters, forexample polysorbate 20 and polysorbate 80 (e.g., Tween™ 80 of ICI),propylene glycol fatty acid esters, for example propylene glycol laurate(e.g., Lauroglycol™ of Gattefosse), sodium lauryl sulfate, fatty acidsand salts thereof, for example oleic acid, sodium oleate andtriethanolamine oleate, glyceryl fatty acid esters, for example glycerylmonostearate, sorbitan esters, for example sorbitan monolaurate,sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate,tyloxapol, and mixtures thereof. Such wetting agents, if present,constitute in total about 0.25% to about 15%, preferably about 0.4% toabout 10%, and more preferably about 0.5% to about 5%, of the totalweight of the pharmaceutical composition.

Wetting agents that are anionic surfactants are preferred. Sodium laurylsulfate is a particularly preferred wetting agent. Sodium laurylsulfate, if present, constitutes about 0.25% to about 7%, morepreferably about 0.4% to about 4%, and still more preferably about 0.5%to about 2%, of the total weight of the pharmaceutical composition.

Pharmaceutical compositions of the invention optionally comprise one ormore pharmaceutically acceptable lubricants (including anti-adherentsand/or glidants) as excipients. Suitable lubricants include, but are notlimited to, either individually or in combination, glyceryl behapate(e.g., Compritol™ 888 of Gattefosse); stearic acid and salts thereof,including magnesium, calcium and sodium stearates; hydrogenatedvegetable oils (e.g., Sterotex™ of Abitec); colloidal silica; talc;waxes; boric acid; sodium benzoate; sodium acetate; sodium fumarate;sodium chloride; DL-leucine; PEG (e.g., Carbowax™ 4000 and Carbowax™6000 of the Dow Chemical Company); sodium oleate; sodium lauryl sulfate;and magnesium lauryl sulfate. Such lubricants, if present, constitute intotal about 0.1% to about 10%, preferably about 0.2% to about 8%, andmore preferably about 0.25% to about 5%, of the total weight of thepharmaceutical composition.

Magnesium stearate is a preferred lubricant used, for example, to reducefriction between the equipment and granulated mixture during compressionof tablet formulations.

Suitable anti-adherents include, but are not limited to, talc,cornstarch, DL-leucine, sodium lauryl sulfate and metallic stearates.Talc is a preferred anti-adherent or glidant used, for example, toreduce formulation sticking to equipment surfaces and also to reducestatic in the blend. Talc, if present, constitutes about 0.1% to about10%, more preferably about 0.25% to about 5%, and still more preferablyabout 0.5% to about 2%, of the total weight of the pharmaceuticalcomposition.

Glidants can be used to promote powder flow of a solid formulation.Suitable glidants include, but are not limited to, colloidal silicondioxide, starch, talc, tribasic calcium phosphate, powdered celluloseand magnesium trisilicate. Colloidal silicon dioxide is particularlypreferred.

Other excipients such as colorants, flavors and sweeteners are known inthe pharmaceutical art and can be used in pharmaceutical compositions ofthe present invention. Tablets can be coated, for example with anenteric coating, or uncoated. Compositions of the invention can furthercomprise, for example, buffering agents.

Optionally, one or more effervescent agents can be used as disintegrantsand/or to enhance organoleptic properties of pharmaceutical compositionsof the invention. When present in pharmaceutical compositions of theinvention to promote dosage form disintegration, one or moreeffervescent agents are preferably present in a total amount of about30% to about 75%, and preferably about 45% to about 70%, for exampleabout 60%, by weight of the pharmaceutical composition.

According to a particularly preferred embodiment of the invention, aneffervescent agent, present in a solid dosage form in an amount lessthan that effective to promote disintegration of the dosage form,provides improved dispersion of the API in an aqueous medium. Withoutbeing bound by theory, it is believed that the effervescent agent iseffective to accelerate dispersion of the API from the dosage form inthe gastrointestinal tract, thereby further enhancing absorption andrapid onset of therapeutic effect. When present in a pharmaceuticalcomposition of the invention to promote intragastrointestinal dispersionbut not to enhance disintegration, an effervescent agent is preferablypresent in an amount of about 1% to about 20%, more preferably about2.5% to about 15%, and still more preferably about 5% to about 10%, byweight of the pharmaceutical composition.

An “effervescent agent” herein is an agent comprising one or morecompounds which, acting together or individually, evolve a gas oncontact with water. The gas evolved is generally oxygen or, mostcommonly, carbon dioxide. Preferred effervescent agents comprise an acidand a base that react in the presence of water to generate carbondioxide gas. Preferably, the base comprises an alkali metal or alkalineearth metal carbonate or bicarbonate and the acid comprises an aliphaticcarboxylic acid.

Non-limiting examples of suitable bases as components of effervescentagents useful in the invention include carbonate salts (e.g., calciumcarbonate), bicarbonate salts (e.g., sodium bicarbonate),sesquicarbonate salts, and mixtures thereof. Calcium carbonate is apreferred base.

Non-limiting examples of suitable acids as components of effervescentagents and/or solid organic acids useful in the invention include citricacid, tartaric acid (as D-, L-, or D/L-tartaric acid), malic acid (asD-, L-, or DL-malic acid), maleic acid, fumaric acid, adipic acid,succinic acid, acid anhydrides of such acids, acid salts of such acids,and mixtures thereof. Citric acid is a preferred acid.

In a preferred embodiment of the invention, where the effervescent agentcomprises an acid and a base, the weight ratio of the acid to the baseis about 1:100 to about 100:1, more preferably about 1:50 to about 50:1,and still more preferably about 1:10 to about 10:1. In a furtherpreferred embodiment of the invention, where the effervescent agentcomprises an acid and a base, the ratio of the acid to the base isapproximately stoichiometric.

Excipients which solubilize APIs typically have both hydrophilic andhydrophobic regions, or are preferably amphiphilic or have amphiphilicregions. One type of amphiphilic or partially-amphiphilic excipientcomprises an amphiphilic polymer or is an amphiphilic polymer. Aspecific amphiphilic polymer is a polyalkylene glycol, which is commonlycomprised of ethylene glycol and/or propylene glycol subunits. Suchpolyalkylene glycols can be esterified at their termini by a carboxylicacid, ester, acid anhyride or other suitable moiety. Examples of suchexcipients include poloxamers (symmetric block copolymers of ethyleneglycol and propylene glycol; e.g., poloxamer 237), polyalkyeneglycolated esters of tocopherol (including esters formed from a di- ormulti-functional carboxylic acid; e.g., d-alpha-tocopherol polyethyleneglycol-1000 succinate), and macrogolglycerides (formed by alcoholysis ofan oil and esterification of a polyalkylene glycol to produce a mixtureof mono-, di- and tri-glycerides and mono- and di-esters; e.g., stearoylmacrogol-32 glycerides). Such pharmaceutical compositions areadvantageously administered orally.

Pharmaceutical compositions of the present invention can comprise about10% to about 50%, about 25% to about 50%, about 30% to about 45%, orabout 30% to about 35% by weight of a co-crystal; about 10% to about50%, about 25% to about 50%, about 30% to about 45%, or about 30% toabout 35% by weight of an excipient which inhibits crystallization inaqueous solution, in simulated gastric fluid, or in simulated intestinalfluid; and about 5% to about 50%, about 10% to about 40%, about 15% toabout 35%, or about 30% to about 35% by weight of a binding agent. Inone example, the weight ratio of the co-crystal to the excipient whichinhibits crystallization to binding agent is about 1 to 1 to 1.

Solid dosage forms of the invention can be prepared by any suitableprocess, not limited to processes described herein.

An illustrative process comprises (a) a step of blending an API of theinvention with one or more excipients to form a blend, and (b) a step oftableting or encapsulating the blend to form tablets or capsules,respectively.

In a preferred process, solid dosage forms are prepared by a processcomprising (a) a step of blending a co-crystal of the invention with oneor more excipients to form a blend, (b) a step of granulating the blendto form a granulate, and (c) a step of tableting or encapsulating theblend to form tablets or capsules respectively. Step (b) can beaccomplished by any dry or wet granulation technique known in the art,but is preferably a dry granulation step. A salt of the presentinvention is advantageously granulated to form particles of about 1micrometer to about 100 micrometer, about 5 micrometer to about 50micrometer, or about 10 micrometer to about 25 micrometer. One or morediluents, one or more disintegrants and one or more binding agents arepreferably added, for example in the blending step, a wetting agent canoptionally be added, for example in the granulating step, and one ormore disintegrants are preferably added after granulating but beforetableting or encapsulating. A lubricant is preferably added beforetableting. Blending and granulating can be performed independently underlow or high shear. A process is preferably selected that forms agranulate that is uniform in API content, that readily disintegrates,that flows with sufficient ease so that weight variation can be reliablycontrolled during capsule filling or tableting, and that is dense enoughin bulk so that a batch can be processed in the selected equipment andindividual doses fit into the specified capsules or tablet dies.

In an alternative embodiment, solid dosage forms are prepared by aprocess that includes a spray drying step, wherein an API is suspendedwith one or more excipients in one or more sprayable liquids, preferablya non-protic (e.g., non-aqueous or non-alcoholic) sprayable liquid, andthen is rapidly spray dried over a current of warm air.

A granulate or spray dried powder resulting from any of the aboveillustrative processes can be compressed or molded to prepare tablets orencapsulated to prepare capsules. Conventional tableting andencapsulation techniques known in the art can be employed. Where coatedtablets are desired, conventional coating techniques are suitable.

Excipients for tablet compositions of the invention are preferablyselected to provide a disintegration time of less than about 30 minutes,preferably about 25 minutes or less, more preferably about 20 minutes orless, and still more preferably about 15 minutes or less, in a standarddisintegration assay.

Pharmaceutically acceptable co-crystals can be administered bycontrolled- or delayed-release means. Controlled-release pharmaceuticalproducts have a common goal of improving drug therapy over that achievedby their non-controlled release counterparts. Ideally, the use of anoptimally designed controlled-release preparation in medical treatmentis characterized by a minimum of drug substance being employed to cureor control the condition in a minimum amount of time. Advantages ofcontrolled-release formulations include: 1) extended activity of thedrug; 2) reduced dosage frequency; 3) increased patient compliance; 4)usage of less total drug; 5) reduction in local or systemic sideeffects; 6) minimization of drug accumulation; 7) reduction in bloodlevel fluctuations; 8) improvement in efficacy of treatment; 9)reduction of potentiation or loss of drug activity; and 10) improvementin speed of control of diseases or conditions. Kim, Cherng-ju,Controlled Release Dosage Form Design, 2 (Technomic Publishing,Lancaster, Pa.: 2000).

Conventional dosage forms generally provide rapid or immediate drugrelease from the formulation. Depending on the pharmacology andpharmacokinetics of the drug, use of conventional dosage forms can leadto wide fluctuations in the concentrations of the drug in a patient'sblood and other tissues. These fluctuations can impact a number ofparameters, such as dose frequency, onset of action, duration ofefficacy, maintenance of therapeutic blood levels, toxicity, sideeffects, and the like. Advantageously, controlled-release formulationscan be used to control a drug's onset of action, duration of action,plasma levels within the therapeutic window, and peak blood levels. Inparticular, controlled- or extended-release dosage forms or formulationscan be used to ensure that the maximum effectiveness of a drug isachieved while minimizing potential adverse effects and safety concerns,which can occur both from under dosing a drug (i.e., going below theminimum therapeutic levels) as well as exceeding the toxicity level forthe drug.

Most controlled-release formulations are designed to initially releasean amount of drug (active ingredient) that promptly produces the desiredtherapeutic effect, and gradually and continually release other amountsof drug to maintain this level of therapeutic or prophylactic effectover an extended period of time. In order to maintain this constantlevel of drug in the body, the drug must be released from the dosageform at a rate that will replace the amount of drug being metabolizedand excreted from the body. Controlled-release of an active ingredientcan be stimulated by various conditions including, but not limited to,pH, ionic strength, osmotic pressure, temperature, enzymes, water, andother physiological conditions or compounds.

A variety of known controlled- or extended-release dosage forms,formulations, and devices can be adapted for use with the co-crystalsand compositions of the invention. Examples include, but are not limitedto, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809;3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548;5,073,543; 5,639,476; 5,354,556; 5,733,566; and 6,365,185 B1; each ofwhich is incorporated herein by reference. These dosage forms can beused to provide slow or controlled-release of one or more activeingredients using, for example, hydroxypropylmethyl cellulose, otherpolymer matrices, gels, permeable membranes, osmotic systems (such asOROS®) (Alza Corporation, Mountain View, Calif. USA)), multilayercoatings, microparticles, liposomes, or microspheres or a combinationthereof to provide the desired release profile in varying proportions.Additionally, ion exchange materials can be used to prepare immobilized,adsorbed co-crystals and thus effect controlled delivery of the drug.Examples of specific anion exchangers include, but are not limited to,Duolite® A568 and Duolite® AP143 (Rohm & Haas, Spring House, Pa. USA).

One embodiment of the invention encompasses a unit dosage form whichcomprises a pharmaceutically acceptable co-crystal, or a solvate,hydrate, dehydrate, anhydrous, or amorphous form thereof, and one ormore pharmaceutically acceptable excipients or diluents, wherein thepharmaceutical composition or dosage form is formulated forcontrolled-release. Specific dosage forms utilize an osmotic drugdelivery system.

A particular and well-known osmotic drug delivery system is referred toas OROS® (Alza Corporation, Mountain View, Calif. USA). This technologycan readily be adapted for the delivery of compounds and compositions ofthe invention. Various aspects of the technology are disclosed in U.S.Pat. Nos. 6,375,978 B1; 6,368,626 B1; 6,342,249 B1; 6,333,050 B2;6,287,295 B1; 6,283,953 B1; 6,270,787 B1; 6,245,357 B1; and 6,132,420;each of which is incorporated herein by reference. Specific adaptationsof OROS® that can be used to administer compounds and compositions ofthe invention include, but are not limited to, the OROS® Push-Pull™,Delayed Push-Pull™, Multi-Layer Push-Pull™, and Push-Stick™ Systems, allof which are well known. See, e.g., http://www.alza.com. AdditionalOROS® systems that can be used for the controlled oral delivery ofcompounds and compositions of the invention include OROS®-CT andL-OROS®. Id.; see also, Delivery Times, vol. II, issue II (AlzaCorporation).

Conventional OROS® oral dosage forms are made by compressing a drugpowder (e.g. co-crystal) into a hard tablet, coating the tablet withcellulose derivatives to form a semi-permeable membrane, and thendrilling an orifice in the coating (e.g., with a laser). Kim, Chemg-ju,Controlled Release Dosage Form Design, 231-238 (Technomic Publishing,Lancaster, Pa.: 2000). The advantage of such dosage forms is that thedelivery rate of the drug is not influenced by physiological orexperimental conditions. Even a drug with a pH-dependent solubility canbe delivered at a constant rate regardless of the pH of the deliverymedium. But because these advantages are provided by a build-up ofosmotic pressure within the dosage form after administration,conventional OROS® drug delivery systems cannot be used to effectivelydeliver drugs with low water solubility. Id. at 234. Because co-crystalsof this invention can be far more soluble in water than the API itself,they are well suited for osmotic-based delivery to patients. Thisinvention does, however, encompass the incorporation of conventionalcrystalline API (e.g. pure API without co-crystal former), and non-saltisomers and isomeric mixtures thereof, into OROS® dosage forms.

A specific dosage form of the invention comprises: a wall defining acavity, the wall having an exit orifice formed or formable therein andat least a portion of the wall being semipermeable; an expandable layerlocated within the cavity remote from the exit orifice and in fluidcommunication with the semipermeable portion of the wall; a dry orsubstantially dry state drug layer located within the cavity adjacent tothe exit orifice and in direct or indirect contacting relationship withthe expandable layer; and a flow-promoting layer interposed between theinner surface of the wall and at least the external surface of the druglayer located within the cavity, wherein the drug layer comprises aco-crystal, or a solvate, hydrate, dehydrate, anhydrous, or amorphousform thereof. See U.S. Pat. No. 6,368,626, the entirety of which isincorporated herein by reference.

Another specific dosage form of the invention comprises: a wall defininga cavity, the wall having an exit orifice formed or formable therein andat least a portion of the wall being semipermeable; an expandable layerlocated within the cavity remote from the exit orifice and in fluidcommunication with the semipermeable portion of the wall; a drug layerlocated within the cavity adjacent the exit orifice and in direct orindirect contacting relationship with the expandable layer; the druglayer comprising a liquid, active agent formulation absorbed in porousparticles, the porous particles being adapted to resist compactionforces sufficient to form a compacted drug layer without significantexudation of the liquid, active agent formulation, the dosage formoptionally having a placebo layer between the exit orifice and the druglayer, wherein the active agent formulation comprises a co-crystal, or asolvate, hydrate, dehydrate, anhydrous, or amorphous form thereof. SeeU.S. Pat. No. 6,342,249, the entirety of which is incorporated herein byreference.

The invention will now be described in further detail, by way ofexample, with reference to the accompanying drawings.

EXEMPLIFICATION

General Methods for the Preparation of Co-Crystals

a) High Throughput Crystallization Using the CrystalMax Platform

CrystalMax™ comprises a sequence of automated, integrated highthroughput robotic stations capable of rapid generation, identificationand characterization of polymorphs, salts, and co-crystals of APIs andAPI candidates. Worksheet generation and combinatorial mixture design iscarried out using proprietary design software InForm™. Typically, an APIor an API candidate is dispensed from an organic solvent into tubes anddried under a stream of nitrogen. Salts and/or co-crystal formers mayalso be dispensed and dried in the same fashion. Water and organicsolvents may be combinatorially dispensed into the tubes using amulti-channel dispenser. Each tube in a 96-tube array is then sealedwithin 15 seconds of combinatorial dispensing to avoid solventevaporation. The mixtures are then rendered supersaturated by heating to70 degrees C. for 2 hours followed by a 1 degree C./minute cooling rampto 5 degrees C. Optical checks are then conducted to detect crystalsand/or solid material. Once a solid has been identified in a tube, it isisolated through aspiration and drying. Raman spectra are then obtainedon the solids and cluster classification of the spectral patterns isperformed using proprietary software (QForm™).

b) Crystallization from Solution

Co-crystals may be obtained by dissolving the separate components in asolvent and adding one to the other. The co-crystal may then precipitateor crystallize as the solvent mixture is evaporated slowly. Theco-crystal may also be obtained by dissolving the two components in thesame solvent or a mixture of solvents.

c) Crystallization from the Melt

A co-crystal may be obtained by melting the two components together andallowing recrystallization to occur. In some cases, an anti-solvent maybe added to facilitate crystallization.

d) Thermal Microscopy

A co-crystal may be obtained by melting the higher melting component ona glass slide and allowing it to recrystallize. The second component isthen melted and is also allowed to recrystallize. The co-crystal mayform as a separated phase/band in between the eutectic bands of the twooriginal components.

e) Mixing and/or Grinding

A co-crystal may be obtained by mixing or grinding two componentstogether in the solid state.

Analytical Methods

Procedure for DSC Analysis

DSC analysis of the samples was performed using a Q1000 DifferentialScanning Calorimeter (TA Instruments, New Castle, Del., U.S.A.), whichuses Advantage for QW-Series, version 1.0.0.78, Thermal AdvantageRelease 2.0 (⁸2001 TA Instruments-Water LLC). In addition, the analysissoftware used was Universal Analysis 2000 for Windows 95/95/2000/NT,version 3.1 E;Build 3.1.0.40 (⁸2001 TA Instruments-Water LLC).

For the DSC analysis, the purge gas used was dry nitrogen, the referencematerial was an empty aluminum pan that was crimped, and the samplepurge was 50 mL/minute.

DSC analysis of the sample was performed by placing ≦2 mg of sample inan aluminum pan with a crimped pan closure. The starting temperature wastypically 20 degrees C. with a heating rate of 10 degrees C./minute, andthe ending temperature was 300 degrees C. Unless otherwise indicated,all reported transitions are as stated +/−10 degrees C.

Procedure for TGA Analysis

TGA analysis of samples was performed using a Q500 ThermogravimetricAnalyzer (TA Instruments, New Castle, Del., U.S.A.), which usesAdvantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0(82001 TA Instruments-Water LLC). In addition, the analysis softwareused was Universal Analysis 2000 for Windows 95/95/2000/NT, version3.1E;Build 3.1.0.40 (⁸2001 TA Instruments-Water LLC).

For all of the TGA experiments, the purge gas used was dry nitrogen, thebalance purge was 40 mL/minute N₂, and the sample purge was 60 mL/minuteN₂.

TGA of the sample was performed by placing ≦2 mg of sample in a platinumpan. The starting temperature was typically 20 degrees C. with a heatingrate of 10 degrees C./minute, and the ending temperature was 300 degreesC.

Procedure for PXRD Analysis

A powder X-ray diffraction pattern for the samples was obtained using aD/Max Rapid, Contact (Rigaku/MSC, The Woodlands, Tex., U.S.A.), whichuses as its control software RINT Rapid Control software, RigakuRapid/XRD, version 1.0.0 (⁸1999 Rigaku Co.). In addition, the analysissoftware used were RINT Rapid display software, version 1.18(Rigaku/MSC), and JADE XRD Pattern Processing, versions 5.0 and 6.0((⁸1995-2002, Materials Data, Inc.).

For the PXRD analysis, the acquisition parameters were as follows:source was Cu with a K line at 1.5406 Å; x-y stage was manual;collimator size was 0.3 or 0.8 mm; capillary tube (Charles SupperCompany, Natick, Mass., U.S.A.) was 0.3 mm ID; reflection mode was used;the power to the X-ray tube was 46 kV; the current to the X-ray tube was40 mA; the omega-axis was oscillating in a range of 0-5 degrees at aspeed of 1 degree/minute; the phi-axis was spinning at an angle of 360degrees at a speed of 2 degrees/second; 0.3 or 0.8 mm collimator; thecollection time was 60 minutes; the temperature was room temperature;and the heater was not used. The sample was presented to the X-raysource in a boron rich glass capillary.

In addition, the analysis parameters were as follows: the integration2-theta range was 2-40 or 60 degrees; the integration chi range was0-360 degrees; the number of chi segments was 1; the step size used was0.02; the integration utility was cylint; normalization was used; darkcounts were 8; omega offset was 180; and chi and phi offsets were 0.

The relative intensity of peaks in a diffractogram is not necessarily alimitation of the PXRD pattern because peak intensity can vary fromsample to sample, e.g., due to crystalline impurities. Further, theangles of each peak can vary by about +/−0.1 degrees, preferably+/−0.05. The entire pattern or most of the pattern peaks may also shiftby about +/−0.1 degree due to differences in calibration, settings, andother variations from instrument to instrument and from operator tooperator.

Procedure for Raman Acquisition Filtering and Binning

Acquisition

The sample was either left in the glass vial in which it was processedor an aliquot of the sample was transferred to a glass slide. The glassvial or slide was positioned in the sample chamber. The measurement wasmade using an Almega™ Dispersive Raman (Almega™ Dispersive Raman,Thermo-Nicolet, 5225 Verona Road, Madison, Wis. 53711-4495) systemfitted with a 785 nm laser source. The sample was manually brought intofocus using the microscope portion of the apparatus with a 10×powerobjective (unless otherwise noted), thus directing the laser onto thesurface of the sample. The spectrum was acquired using the parametersoutlined in Table A. (Exposure times and number of exposures may vary;changes to parameters will be indicated for each acquisition.)

Filtering and Binning

Each spectrum in a set was filtered using a matched filter of featuresize 25 to remove background signals, including glass contributions andsample fluorescence. This is particularly important as large backgroundsignal or fluorescence limit the ability to accurately pick and assignpeak positions in the subsequent steps of the binning process. Filteredspectra were binned using the peak pick and bin algorithm with theparameters given in Table B. The sorted cluster diagrams for each sampleset and the corresponding cluster assignments for each spectral filewere used to identify groups of samples with similar spectra, which wasused to identify samples for secondary analyses.

TABLE A Raman Spectral acquisition parameters Parameter Setting UsedExposure time (s) 2.0 Number of exposures 10 Laser source wavelength(nm) 785 Laser power (%) 100 Aperture shape pin hole Aperture size (um)100 Spectral range 104-3428 Grating position Single Temperature atacquisition 24.0 (degrees C.)

TABLE B Raman Filtering and Binning Parameters Parameter Setting UsedFiltering Parameters Filter type Matched Filter size 25 QC ParametersPeak Height Threshold 1000 Region for noise test (cm⁻¹)  0-10000 RMSnoise threshold 10000 Automatically eliminate Yes failed spectra Regionof Interest Include (cm⁻¹) 104-3428  Exclude region I (cm⁻¹) Excluderegion II (cm⁻¹) Exclude region III (cm⁻¹) Exclude region IV (cm⁻¹) PeakPick Parameters Peak Pick Sensitivity Variable Peak Pick Threshold 100Peak Comparison Parameters Peak Window (cm⁻¹) 2 Analysis ParametersNumber of clusters VariableProcedure for Single Crystal X-Ray Diffraction

Single crystal x-ray data were collected on a Bruker SMART-APEX CCDdiffractometer (M. J. Zawarotko, Department of Chemistry, University ofSouth Florida). Lattice parameters were determined from least squaresanalysis. Reflection data was integrated using the program SAINT. Thestructure was solved by direct methods and refined by full matrix leastsquares using the program SHELXTL (Sheldrick, G. M. SHELXTL, Release5.03; Siemans Analytical X-ray Instruments Inc.: Madison, Wis.).

The co-crystals of the present invention can be characterized, e.g., bythe TGA or DSC data or by any one, any two, any three, any four, anyfive, any six, any seven, any eight, any nine, any ten, or any singleinteger number of PXRD 2-theta angle peaks or Raman shift peaks listedherein or disclosed in a figure, or by single crystal x-ray diffractiondata.

Example 1

1:1 carbamazepine:saccharin co-crystals (Form I) were prepared. A12-block experiment was designed with 12 solvents. 1152 crystallizationexperiments were carried out using the CMAX platform. The co-crystal wasobtained from a mixture of isopropyl acetate and heptane. Detailedcharacterization of the co-crystal is listed in Table V. (See FIGS. 1and 2)

Example 2

1:1 carbamazepine:nicotinamide co-crystals (Form I) were prepared. A12-block experiment was designed with 12 solvents. 1152 crystallizationexperiments were carried out using the CMAX platform. The co-crystal wasobtained from samples containing toluene, acetone, or isopropyl acetate.Detailed characterization of the co-crystal is listed in Table V. (SeeFIGS. 3 and 4)

Example 3

1:1 carbamazepine:trimesic acid co-crystals (Form I) were prepared. A9-block experiment was designed with 10 solvents. 864 crystallizationexperiments with 8 co-crystal formers and 3 concentrations were carriedout using the CMAX platform. The co-crystal was obtained from samplescontaining methanol. Detailed characterization of the co-crystal islisted in Table V. (See FIG. 5)

Example 4

1:1 celecoxib:nicotinamide co-crystals were prepared. Celecoxib (100 mg,0.26 mmol) and nicotinamide (32.0 mg, 0.26 mmol) were each dissolved inacetone (2 mL). The two solutions were mixed and the resulting mixturewas allowed to evaporate slowly overnight. The precipitated solid wascollected and characterized. Detailed characterization of the co-crystalis listed in Table V.

Example 5

Co-crystals of topiramate and 18-crown-6 were prepared. An equimolaramount of topiramate and 18-crown-6 were dissolved in ether separately.The solution containing topiramate was then added to the solutioncontaining 18-crown-6. A white solid precipitated after minor agitationand was collected and dried. Detailed characterization of the co-crystalis listed in Table V. (See FIGS. 6 and 7)

Example 6

Co-crystals of olanzapine and nicotinamide (Form I and II) wereprepared. A 9-block experiment was designed with 12 solvents. 864crystallization experiments with 10 co-crystal formers and 3concentrations were carried out using the CMAX platform. The co-crystalwas obtained from tubes containing isopropyl acetate. PXRD and DSCcharacterization of the co-crystal (Form I and II) is listed in Table V.(See FIGS. 8, 9, and 30)

Example 7

Co-crystals of celecoxib and 18-crown-6 were prepared. A solution ofcelecoxib (157.8 mg, 0.4138 mmol) in Et₂O (10.0 mL) was added to18-crown-6 (118.1 mg, 0.447 mmol). The opaque solid dissolvesimmediately and a white solid subsequently began to crystallize veryrapidly. The solid was collected via filtration and was washed withadditional Et₂O (5 mL). Detailed characterization of the co-crystal islisted in Table V. (See FIGS. 10 and 11)

Example 8

Co-crystals of itraconazole and succinic acid were prepared.Approximately 51.1 mg of cis-itraconazole free base, 0.75 mL of THF, anda magnetic stir bar were charged into a screw cap vial, heated to refluxto dissolve, and then the vial was closed with the screw cap and placedon top of a hot plate maintained at a temperature between 60 and 75degrees C. A solution of 77.7 mg of succinic acid in 1.58 mL of THF wasprepared. 0.20 mL of the succinic acid solution was added to thecis-itraconazole solution and the solution remained clear. 0.75 mL ofiso-propylacetate was added and the solution was seeded with <1 mg ofthe L-tartaric acid co-crystal salt from Example 10 below. The heat wasturned off and the sample crystallized as it cooled to room temperature.The cooled sample was suction filtered. It was rinsed with 0.2-0.3 mL ofTHF. The filter cake was broken-up and allowed to air-dry for 1 hourprior to analysis. (See FIGS. 12 and 13)

Example 9

Co-crystals of itraconazole and fumaric acid were prepared.Approximately 500 mg of cis-itraconazole free base was placed in a 50 mLscrew top bottle along with 33.33 mL of tetrahydrofuran (THF). 3.0887 mLof fumaric acid stock solution (prepared in Example 1) was then added tothe beaker (resulting in a 1.05:1 ratio of salt former to free base).The cap was screwed on to seal the bottle and the bottle was placed in a70 degrees C. oven (Model # 1400E, VWR Scientific) and heated forapproximately 1 hour. Thereafter, the bottle was removed from the oven,the cap from the bottle was removed, and the sample was allowed toevaporate under flowing air under ambient conditions. When all but about5 mL of the solvent had evaporated, the remaining solvent was removed bydecantation and the solid was isolated by filtering over a Whatmanfilter using suction. This solid was returned back into the 50 mL bottlewith the remaining solid and the bottle was placed into the vacuum ovenat approximately 25 mm Hg and the solid was allowed to dry for 4 daysprior to analysis. (See FIGS. 14 and 15)

Example 10

Co-crystals of itraconazole and tartaric acid were prepared.Approximately 100.4 mg of cis-itraconazole free base, 0.90 mL of THF,and a magnetic stir bar were charged into a screw cap vial, heated toreflux to dissolve, and then the vial was closed with the screw cap andplaced in an oil bath maintained at 70 degrees C. A solution of 138.5 mgof L(+) tartaric acid in 1.15 mL of THF was prepared. 0.21 mL of theL(+)tartaric acid solution was added to the cis-itraconazole solutionand the solution remained clear. 0.90 mL of iso-propylacetate was addedand the solution was seeded with <1 mg of the salt from a preparation ofDL-tartaric acid co-crystal. The sample was allowed to crystallize overabout 5 minutes in the 70 degrees C. oil bath before it was removed andallowed to cool to room temperature. The cooled sample was suctionfiltered. It was rinsed with 0.2-0.3 mL of THF. The filter cake wasbroken-up and allowed to air-dry for 4 hours prior to analysis. (SeeFIGS. 16 and 17)

Example 11

Co-crystals of itraconazole and malic acid were prepared. To prepare theL-malic acid co-crystal salt of cis-itraconazole, 100.4 mg ofcis-itraconazole free base, 0.50 mL of THF, and a magnetic stir bar werecharged into a screw cap vial. A solution of 191.3 mg of L(−)malic acidin 5.0 mL of THF was prepared. 0.50 mL of the L-malic acid solution wasadded to the vial containing cis-itraconazole and the solution washeated with a heat gun to dissolve. The solution was allowed to cool andwas then seeded with <1 mg of the salt from cis-itraconazole-L-tartaricacid co-crystal. The cooled crystals were filtered in a centrifugefilter tube. The filter cake was broken-up and allowed to air-dry priorto analysis. (See FIGS. 18 and 19)

Example 12

Co-crystals of itraconazole HCl and tartaric acid were prepared.Approximately 212.7 mg of L-tartaric acid and 118 microL of 37% HCl weredissolved in 25 mL of hot dioxane. This solution was added to 1.0 g ofcis-itraconazole dissolved in 50 mL of hot dioxane with stirring. Themixture was heated until a clear solution formed and was then allowed tocool to room temperature. Upon cooling, 50 mL tert-butyl methyl etherwas added and the crystals were harvested by vacuum filtration on aBuchner funnel with #4 Whatman filter paper. The crystals were washed 3times with 5 mL aliquots of cold tert-butyl methyl ether and left to airdry. Approximately 573 mg of a crystalline form of cis-itraconazoleHCl-tartaric acid (1:1:0.5) co-crystal were obtained. (See FIGS. 20 and21)

Example 13

Co-crystals of modafinil and malonic acid were prepared. Using a 250mg/ml modafinil-acetic acid solution, malonic acid was dissolved on ahotplate (about 67 degrees C.) at a 1:2 modafinil to malonic acid ratio.The mixture was dried under flowing nitrogen overnight. A powdery whitesolid was produced. After further drying for 1 day, acetic acid isremoved (as determined by TGA) and the crystal structure, as determinedby PXRD, remains the same. (See FIG. 22)

Example 14

Co-crystals of modafinil and benzamide were prepared. Modafinil (1 mg,0.0037 mmol) and benzamide (0.45 mg, 0.0037 mmol) were dissolved in1,2-dichloroethane (400 microL). The solution was allowed to evaporateto dryness and the resulting solid was characterized using PXRD. PXRDdata for the co-crystal is listed in Table V. (See FIG. 23)

Example 15

Co-crystals of modafinil and mandelic acid were prepared. Modafinil (1mg, 0.0037 mmol) and mandelic acid (0.55 mg, 0.0037 mmol) were dissolvedin acetone (400 microL). The solution was allowed to evaporate todryness and the resulting solid was characterized using PXRD. PXRD datafor the co-crystal is listed in Table V. (See FIG. 24)

Example 16

Co-crystals of modafinil and glycolic acid were prepared. Modafinil (1mg, 0.0037 mmol) and glycolic acid (0.30 mg, 0.0037 mmol) were dissolvedin acetone (400 microL). The solution was allowed to evaporate todryness and the resulting solid was characterized using PXRD. PXRD datafor the co-crystal is listed in Table V. (See FIG. 25)

Example 17

Co-crystals of modafinil and fumaric acid were prepared. Modafinil (1mg, 0.0037 mmol) and fumaric acid (0.42 mg, 0.0037 mmol) were dissolvedin 1,2-dichloroethane (400 microL). The solution was allowed toevaporate to dryness and the resulting solid was characterized usingPXRD. PXRD data for the co-crystal is listed in Table V. (See FIG. 26)

Example 18

Co-crystals of modafinil and maleic acid were prepared. Using a 250mg/ml modafinil-acetic acid solution, maleic acid was dissolved on ahotplate (about 67 degrees C.) at a 2:1 modafinil to maleic ratio. Themixture was dried under flowing nitrogen overnight. A clear amorphousmaterial remained. Solids began to grow after 2 days stored in a sealedvial at room temperature. (See FIG. 43)

Example 19

Co-crystals of olanzapine and nicotinamide (Form III) were prepared.Olanzapine (40 μL of 25 mg/mL stock solution in tetrahydrofuran) andnicotinamide (37.6 μL of 20 mg/mL stock solution in methanol) were addedto a glass vial and dried under a flow of nitrogen. To the solid mixturewas added isopropyl acetate (100 μL) and the vial was sealed with analuminum cap. The suspension was then heated at 70 degrees C. for twohours in order to dissolve all of the solid material. The solution wasthen cooled to 5 degrees C. and maintained at that temperature for 24hours. After 24 hours the vial was uncapped and the mixture wasconcentrated to 50 μL of total volume. The vial was then resealed withan aluminum cap and was maintained at 5 degrees C. for an additional 24hours. Large, yellow plates were observed and were collected (Form III).The solid was characterized with single crystal x-ray diffraction andpowder x-ray diffraction. PXRD characterization of the co-crystal islisted in Table V. (See FIGS. 31 and 32A-D)

Single crystal x-ray analysis reveals that the olanzapine:nicotinamide(Form III) co-crystal is made up of a ternary system containingolanzapine, nicotinamide, water and isopropyl acetate in the unit cell.The co-crystal crystallizes in the monoclinic space group P2₁/c andcontains one olanzapine, one nicotinamide, 4 waters and one isopropylacetate solvate in the asymmetric unit. The packing diagram is made upof a two-dimensional hydrogen-bonded network with the water moleculesconnecting the olanzapine and nicotinamide moieties. The packing diagramis also comprised of alternating olanzapine and nicotinamide layersconnected through hydrogen bonding via the water and isopropyl acetatemolecules, as shown in FIG. 32B. The olanzapine layer propagates alongthe b axis at c/4 and 3c/4. The nicotinamide layer propagates along theb axis at c/2. The top of FIG. 32C illustrates the nicotinamidesuperstructure. The nicotinamide molecules form dimers which hydrogenbond to chains of 4 water molecules. The water chains terminate withisopropyl acetate molecules on each side.

Crystal data: C₄₅H₆₄N₁₀O₇S₂, M=921.18, monoclinic P21/c; a=14.0961(12)Å, b=12.5984(10) Å, c=27.219(2) Å, α=90°, β=97.396(2)°, γ=90°, T=100(2)K, Z=4, D_(c)=1.276 Mg/m³,U=4793.6(7) Å³, λ=0.71073 Å; 24952 reflectionsmeasured, 8457 unique (R_(int)=0.0882). Final residuals were R₁=0.0676,wR₂=0.1461 for I>2σ(I), and R₁=0.1187, wR₂=0.1687 for all 8457 data.

Example 20

Co-crystals of 5-fluorouracil and urea were prepared. To 5-fluorouracil(1 g, 7.69 mmol) and urea (0.46 g, 7.69 mmol) was added methanol (100mL). The solution was heated at 65 degrees C. and sonicated until allthe material dissolved. The solution was then cooled to 5 degrees C. andmaintained at that temperature overnight. After about 3 days a whiteprecipitate was observed and collected. The solid was characterized byDSC, PXRD, Raman spectroscopy, and TGA. Characterization data are listedin Table V. (See FIGS. 33-36)

Example 21

Co-crystals of hydrochlorothiazide and nicotinic acid were prepared.Hydrochlorothiazide (I2.2 mg, 0.041 mmol) and nicotinic acid (5 mg,0.041 mmol) were dissolved in methanol (1 mL). The solution was thencooled to 5 degrees C. and maintained at that temperature for 12 hours.A white solid precipitated and was collected and characterized usingPXRD. (See FIG. 37)

Example 22

Co-crystals of hydrochlorothiazide and 18-crown-6 were prepared.Hydrochlorothiazide (100 mg, 0.33 mmol) was dissolved in diethyl ether(15 mL) and was added to a solution of 18-crown-6 (87.2 mg, 0.33 mmol)in diethyl ether (15 mL). A white precipitate immediately began to formand was collected and characterized as the hydrochlorothiazide:18-crown-6 co-crystal using PXRD. (See FIG. 38)

Example 23

Co-crystals of hydrochlorothiazide and piperazine were prepared.Hydrochlorothiazide (17.3 mg, 0.058 mmol) and piperazine (5 mg, 0.058mmol) were dissolved in a 1:1 mixture of ethyl acetate and acetonitirle(1 mL). The solution was then cooled to 5 degrees C. and maintained atthat temperature for 12 hours. A white solid precipitated and wascollected and characterized using PXRD. (See FIG. 39)

Example 24

Acetaminophen:4,4′-bipyridine:water (1:1:1 stoichiometry)

50 mg (0.3307 mmol) acetaminophen and 52 mg (0.3329 mmol)4,4′-bipyridine were dissolved in hot water and allowed to stand. Slowevaporation yielded colorless needles of a 1:1:1acetaminophen/4,4′-bipyridine/water co-crystal, as shown in FIG. 44A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). C₃₆H₄₄N₂O₄,M=339.84, triclinic, space group PĪ, a=7.0534(8), b=9.5955(12),c=19.3649(2) Å, α=86.326(2), β80.291(2), γ=88.880(2)°, U=1308.1(3) Å³,T=200(2) K, Z=2, μ(Mo—Kα)=0.090 mm⁻¹, D_(c)=1.294 Mg/m³, λ=0.71073 Å,F(000)=537, 2θ_(max)=25.02°; 6289 reflections measured, 4481 unique(R_(int)=0.0261). Final residuals for 344 parameters were R₁=0.0751,wR₂=0.2082 for I>2σ(I), and R₁=0.1119, wR₂=0.2377 for all 4481data.

Crystal packing: The co-crystals contain bilayered sheets in which watermolecules act as a hydrogen bonded bridge between the network bipyridinemoieties and the acetaminophen. Bipyridine guests are sustained by π-υstacking interactions between two network bipyridines. The layers stackvia π-π interactions between the phenyl groups of the acetaminophenmoieties.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 57.77degrees C. (endotherm); m.p.=58-60 degrees C. (MEL-TEMP); (acetaminophenm.p.=169 degrees C., 4,4′-bipyridine m.p.=111-114 degrees C.).

Example 25

Phenyloin:Pyridone (1:1 stoichiometry)

28 mg (0.1109 mmol) phenyloin and 11 mg (0.1156 mmol) 4-hydroxypyridonewere dissolved in 2 mL acetone and 1 mL ethanol with heating andstirring. Slow evaporation yielded colorless needles of a 1:1phenyloin/pyridone co-crystal, as shown in FIG. 45A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), C₂₀H₁₇N₃O₃,M=347.37, monoclinic P2₁/c; a=16.6583(19), b=8.8478(10), c=11.9546(14)Å, β=96.618(2)°, U=1750.2(3) Å³, T=200(2) K, Z=4, μ(Mo—Kα)=0.091 mm⁻¹,D_(c)=1.318 Mg/m³, λ=0.71073 Å, F(000)=728, 2θ_(max)=56.60°; 10605reflections measured, 4154 unique (R_(int)=0.0313). Final residuals for247 parameters were R₁=0.0560, wR₂=0.1356 for I>2σ(I), and R₁=0.0816,wR₂=0.1559 for all 4154 data.

Crystal packing: The co-crystal is sustained by hydrogen bonding ofadjacent phentoin molecules between the carbonyl and the amine closestto the tetrahedral carbon, and by hydrogen bonding between pyridonecarbonyl functionalities and the amine not involved inphenyloin-phenyloin interactions. The pyridone carbonyl also hydrogenbonds with adjacent pyridone molecules forming a one-dimensionalnetwork.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), characteristic peaksfor the co-crystal were identified as: 2° amine found at 3311 cm⁻¹,carbonyl (ketone) found at 1711 cm⁻¹, olephin peak found at 1390 cm⁻¹.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 233.39degrees C. (endotherm) and 271.33 degrees C. (endotherm); m.p.=231-233degrees C. (MEL-TEMP); (phenyloin m.p.=295 degrees C., pyridone m.p.=148degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA), a29.09% weight loss starting at 192.80 degrees C., 48.72% weight lossstarting at 238.27 degrees C., and 18.38% loss starting at 260.17degrees C. followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα(λ=1.540562), 30 kV, 15 mA). The powder data were collected over anangular range of 3° to 40°2θ in continuous scan mode using a step sizeof 0.02═ 2θ and a scan speed of 2.0°/minute. PXRD: Showed analogouspeaks to the simulated PXRD derived from the single crystal data. In allcases of recrystallization and solid state reaction, experimental(calculated): 5.2 (5.3); 11.1 (11.3); 15.1 (15.2); 16.2 (16.4); 16.7(17.0); 17.8 (17.9); 19.4 (19.4); 19.8 (19.7); 20.3 (20.1); 21.2 (21.4);23.3 (23.7); 26.1 (26.4); 26.4 (26.6); 27.3 (27.6); 29.5 (29.9).

Example 26

Aspirin (acetylsalicylic acid):4,4′-bipyridine (2:1 stoichiometry)

50 mg (0.2775 mmol) aspirin and 22 mg (0.1388 mmol) 4,4′-bipyridine weredissolved in 4 mL hexane. 8 mL ether was added to the solution andallowed to stand for one hour, yielding colorless needles of a 2:1aspirin/4,4′-bipyridine co-crystal, as shown in FIG. 46A-D.Alternatively, aspirin/4,4′-bipyridine (2:1 stoichiometry) can be madeby grinding the solid ingredients in a pestle and mortar.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), C₂₈H₂₄N₂O₈,M=516.49, orthorhombic Pbcn; a=28.831(3), b=11.3861(12), c=8.4144(9) Å,U=2762.2(5) Å³, T=173(2) K, Z=4, μ(Mo—Kα)=0.092 mm⁻¹, D_(c)=1.242 Mg/m³,λ=0.71073 Å, F(000)=1080, 2θ_(max)=25.02°; 12431 reflections measured,2433 unique (R_(int)=0.0419). Final residuals for 202 parameters wereR₁=0.0419, wR₂=0.1358 for I>2σ(I), and R₁=0.0541, wR₂=0.1482 for all2433 data.

Crystal packing: The co-crystal contains the carboxylic acid-pyridineheterodimer that crystallizes in the Pbcn space group. The structure isan inclusion compound containing disordered solvent in the channels. Inaddition to the dominant hydrogen bonding interaction of theheterodimer, π-π stacking of the bipyridine and phenyl groups of theaspirin and hydrophobic interactions contribute to the overall packinginteractions.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), characteristic (—COOH)peak at 1679 cm⁻¹ was shifted up and less intense at 1694 cm⁻¹, where asthe lactone peak is shifted down slightly from 1750 cm⁻¹ to 1744 cm⁻¹.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 95.14degrees C. (endotherm); m.p.=91-96 degrees C. (MEL-TEMP); (aspirinm.p.=1345 degrees C., 4,4′-bipyridine m.p.=111-114 degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA),weight loss of 9% starting at 22.62 degrees C., 49.06% weight lossstarting at 102.97 degrees C. followed by complete decompositionstarting at 209.37 degrees C.

Example 27

Ibuprofen:4,4′-Bipyridine (2:1 stoichiometry)

50 mg (0.242 mmol) racemic ibuprofen and 18 mg (0.0960 mmol)4,4′-bipyridine were dissolved in 5 mL acetone. Slow evaporation of thesolvent yielded colorless needles of a 2:1 ibuprofen/4,4′-bipyridineco-crystal, as shown in FIG. 47A-D.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), C₃₆H₄₄N₂O₄,M=568.73, triclinic, space group P-1; a=5.759(3), b=11.683(6),c=24.705(11) Å, α=93.674(11), β=90.880(10), γ=104.045(7)°, U=1608.3(13)Å³, λ=200(2) K, Z=2, μ(Mo—Kα)=0.076 mm⁻¹, D_(c)=1.174 Mg/m³, λ=0.71073Å, F(000)=612, 2θ_(max=)23.29°; 5208 reflections measured, 3362 unique(R_(int)=0.0826). Final residuals for 399 parameters were R₁=0.0964,wR₂=0.2510 for I>2σ(I), and R₁=0.1775, wR₂=0.2987 for all 3362 data.

Crystal packing: The co-crystal contains ibuprofen/bipyridineheterodimers, sustained by two hydrogen bonded carboxylic acidpyridinesupramolecular synthons, arranged in a herringbone motif that packs inthe space group P-1. The heterodimer is an extended version of thehomodimer and packs to form a two-dimensional network sustained by π-πstacking of the bipyridine and phenyl groups of the ibuprofen andhydrophobic interactions from the ibuprofen tails.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). Analysis observedstretching of aromatic C—H at 2899 cm⁻¹; N—H bending and scissoring at1886 cm⁻¹; C═O stretching at 1679 cm⁻¹; C—H out-of-plane bending forboth 4,4′-bipyridine and ibuprofen at 808 cm⁻¹ and 628 cm⁻¹.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 64.85degrees C. (endotherm) and 118.79 degrees C. (endotherm); m.p.=113-120degrees C. (MEL-TEMP); (ibuprofen m.p.=75-77 degrees C., 4,4′-bipyridinem.p.=111-114 degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA),13.28% weight loss between room temperature and 100.02 degrees C.immediately followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα(λ=1.540562), 30 kV, 15 mA). The powder data were collected over anangular range of 3° to 40° 2θ in continuous scan mode using a step sizeof 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from thesingle crystal data, experimental (calculated): 3.4 (3.6); 6.9 (7.2);10.4 (10.8); 17.3 (17.5); 19.1 (19.7).

Example 28

Flurbiprofen:4,4′-bipyridine (2:1 stoichiometry)

50 mg (0.2046 mmol) flurbiprofen and 15 mg (0.0960 mmol) 4,4′-bipyridinewere dissolved in 3 mL acetone. Slow evaporation of the solvent yieldedcolorless needles of a 2:1 flurbiprofen/4,4′-bipyridine co-crystal, asshown in FIG. 48A-D.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), C₄₀H₃₄F₂N₂O₄,M=644.69, monoclinic P2₁/n; a=5.860(4), b=47.49(3), c=5.928(4) Å,β=107.382 (8)°, U=1574.3(19) Å³, T=200(2) K, Z=2, μ(Mo—Kα)=0.096 mm⁻¹,D_(c)=1.360 Mg/m³, λ=0.71073 Å, F(000)=676, 2θ_(max)=21.69°; 4246reflections measured, 1634 unique (R_(int)=0.0677). Final residuals for226 parameters were R₁=0.0908, wR₂=0.2065 for I>2σ(I), and R₁=0.1084,wR₂=0.2209 for all 1634 data.

Crystal packing: The co-crystal contains flurbiprofen/bipyridineheterodimers, sustained by two hydrogen bonded carboxylic acidpyridinesupramolecular synthon, arranged in a herringbone motif that packs inthe space group P2₁/n. The heterodimer is an extended version of thehomodimer and packs to form a two-dimensional network sustained by π-πstacking and hydrophobic interactions of the bipyridine and phenylgroups of the flurbiprofen.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), aromatic C—Hstretching at 3057 cm⁻¹ and 2981 cm⁻; N—H bending and scissoring at 1886cm⁻¹; C═O stretching at 1690 cm⁻¹; C═C and C═N ring stretching at 1418cm⁻¹.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 162.47degrees C. (endotherm); m.p.=155-160 degrees C. (MEL-TEMP);(flurbiprofen m.p.=110-111 degrees C., 4,4′-bipyridine m.p.=111-114degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA),30.93% weight loss starting at 31.13 degrees C. and a 46.26% weight lossstarting at 168.74 degrees C. followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα(λ=1.540562), 30 kV, 15 mA), the powder data were collected over anangular range of 3° to 40° 2θin continuous scan mode using a step sizeof 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from thesingle crystal data: experimental (calculated): 16.8 (16.8); 17.1(17.5); 18.1 (18.4); 19.0 (19.0); 20.0 (20.4); 21.3 (21.7); 22.7 (23.0);25.0 (25.6); 26.0 (26.1); 26.0 (26.6); 26.1 (27.5); 28.2 (28.7); 29.1(29.7).

Example 29

Flurbiprofen:trans-1,2-bis(4-pyridyl) ethylene (2:1 stoichiometry)

25 mg (0.1023 mmol) flurbiprofen and 10 mg (0.0548 mmol)trans-1,2-bis(4-pyridyl) ethylene were dissolved in 3 mL acetone. Slowevaporation of the solvent yielded colorless needles of a 2:1flurbiprofen/1,2-bis(4-pyridyl) ethylene co-crystal, as shown in FIG.49A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), C₄₂H₃₆F₂N₂O₄,M=670.73, monoclinic P2₁/n; a=5.8697(9), b=47.357(7), c=6.3587(10) Å,β=109.492(3)°, U=1666.2(4) Å³, T=200(2) K, Z=2, μ(Mo—Kα)=0.093 mm⁻¹,D_(c)=1.337 Mg/m³, λ=0.71073 Å, F(000)=704, 2θ_(max)=21.69°, 6977reflections measured, 2383 unique (R_(int)=0.0383). Final residuals for238 parameters were R₁=0.0686, wR₂=0.1395 for I>2θ(I), and R₁=0.1403,wR₂=0.1709 for all 2383 data.

Crystal packing: The co-crystal contains flurbiprofen/1,2-bis(4-pyridyl)ethylene heterodimers, sustained by two hydrogen bonded carboxylicacid-pyridine supramolecular synthons, arranged in a herringbone motifthat packs in the space group P2₁/n. The heterodimer from1,2-bis(4-pyridyl) ethylene further extends the homodimer relative toexample 28 and packs to form a two-dimensional network sustained by π-πstacking and hydrophobic interactions of the bipyridine and phenylgroups of the flurbiprofen.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), aromatic C—Hstretching at 2927 cm⁻¹ and 2850 cm⁻¹; N—H bending and scissoring at1875 cm⁻¹; C═O stretching at 1707 cm⁻¹; C═C and C═N ring stretching at1483 cm⁻¹.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 100.01degrees C., 125.59 degrees C. and 163.54 degrees C. (endotherms);m.p.=153-158 degrees C. (MEL-TEMP); (flurbiprofen m.p.=110-111 degreesC., trans-1,2-bis(4-pyridyl) ethylene m.p.=150-153 degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA),91.79% weight loss starting at 133.18 degrees C. followed by completedecomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα(λ=1.540562), 30 kV, 15 mA), the powder data were collected over anangular range of 3° to 40° 2θ in continuous scan mode using a step sizeof 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from thesingle crystal data, experimental (calculated): 3.6 (3.7); 17.3 (17.7);18.1 (18.6); 18.4 (18.6); 19.1 (19.3); 22.3 (22.5); 23.8 (23.9); 25.9(26.4); 28.1 (28.5).

Example 30

Carbamazepine:p-Phthalaldehyde (1:1 stoichiometry)

25 mg (0.1058 mmol) carbamazepine and 7 mg (0.0521 mmol)p-phthalaldehyde were dissolved in approximately 3 mL methanol. Slowevaporation of the solvent yielded colorless needles of a 1:1carbamazepine/p-phthalaldehyde co-crystal, as shown in FIG. 50A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer), C₃₈H₃₀N₄O₄,M=606.66, monoclinic C2/c; a=29.191(16), b=4.962(3), c=20.316(11) Å,β=92.105(8)°, U=2941(3) Å³, T=200(2) K, Z=4, μ(Mo—Kα)=0.090 mm⁻¹,D_(c)=1.370 Mg/m³, λ=0.71073 Å, F(000)=1272, 2θ_(max)=43.66°, 3831reflections measured, 1559 unique (R_(int)=0.0510). Final residuals for268 parameters were R₁=0.0332, wR₂=0.0801 for I>2σ(I), and R₁=0.0403,wR₂=0.0831 for all 1559 data.

Crystal packing: The co-crystals contain hydrogen bonded carboxamidehomodimers that crystallize in the space group C2/c. The 1° amines ofthe homodimer are bifurcated to the carbonyl of the p-phthalaldehydeforming a chain with an adjacent homodimer. The chains pack in acrinkled tape motif sustained by π-π interactions between phenyl ringsof the CBZ.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). The 1° amineunsymmetrical and symmetrical stretching was shifted down to 3418 cm⁻¹;aliphatic aldehyde and 1° amide C═O stretching was shifted up to 1690cm⁻¹; N—H in-plane bending at 1669 cm⁻¹; C—H aldehyde stretching at 2861cm⁻¹ and H—C═O bending at 1391 cm⁻¹.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 128.46degrees C. (endotherm), m.p.=121-124 degrees C. (MEL-TEMP),(carbamazepine m.p.=190.2 degrees C., p-phthalaldehyde m.p.=116 degreesC.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA),17.66% weight loss starting at 30.33 degrees C. then a 17.57% weightloss starting at 100.14 degrees C. followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα(λ=1.540562), 30 kV, 15 mA). The powder data were collected over anangular range of 3° to 40° 2θ in continuous scan mode using a step sizeof 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from thesingle crystal data, experimental (calculated): 8.5 (8.7); 10.6 (10.8);11.9 (12.1); 14.4 (14.7) 15.1 (15.2); 18.0 (18.1); 18.5 (18.2); 19.8(18.7); 23.7 (24.0); 24.2 (24.2); 26.4 (26.7); 27.6 (27.9); 27.8 (28.2);28.7 (29.1); 29.3 (29.6); 29.4 (29.8).

Example 31

Carbamazepine:nicotinamide (Form II) (1:1 stoichiometry)

25 mg (0.1058 mmol) carbamazepine and 12 mg (0.0982 mmol) nicotinamidewere dissolved in 4 mL of DMSO, methanol or ethanol. Slow evaporation ofthe solvent yielded colorless needles of a 1:1carbamazepine/nicotinamide co-crystal, as shown in FIG. 51.

Using a separate method, 25 mg (0.1058 mmol) carbamazepine and 12 mg(0.0982 mmol) nicotinamide were ground together with mortar and pestle.The solid was determined to be 1:1 carbamazepine/nicotinamidemicrocrystals (PXRD).

Crystal data: (Bruker SMART-APEX CCD Diffractometer), C₂₁H₁₈N₄O₂,M=358.39, monoclinic P2₁/n; a=5.0961(8), b=17.595(3), c=19.647(3) Å,β=90.917(3)°, U=1761.5(5) Å³, T=200(2) K, Z=4, μ(Mo—Kα)=0.090 mm⁻¹,D_(c)=1.351 Mg/m³, λ=0.71073 Å, F(000)=752, 2θ_(max)=56.600°, 10919reflections measured, 4041 unique (R_(int)=0.0514). Final residuals for248 parameters were R₁=0.0732, wR₂=0.1268 for I>2σ(I), and R₁=0.1161,wR₂=0.1430 for all 4041 data.

Crystal packing: The co-crystals contain hydrogen bonded carboxamidehomodimers. The 1° amines are bifurcated to the carbonyl of thenicotinamide on each side of the dimer. The 1° amines of eachnicotinamide are hydrogen bonded to the carbonyl of the adjoining dimer.The dimers form chains with π-π interactions from the phenyl groups ofthe CBZ.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), unsymmetrical andsymmetrical stretching shifts down to 3443 cm⁻¹ and 3388 cm⁻¹ accountingfor 1° amines; 1° amide C═O stretching at 1690 cm⁻¹; N—H in-planebending at 1614 cm⁻¹; C═C stretching shifted down to 1579 cm⁻¹; aromaticH's from 800 cm⁻¹ to 500 cm⁻¹ are present.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 74.49degrees C. (endotherm) and 159.05 degrees C. (endotherm), m.p.=153-158degrees C. (MEL-TEMP), (carbamazepine m.p.=190.2 degrees C.,nicotinamide m.p.=150-160 degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA),57.94% weight loss starting at 205.43 degrees C. followed by completedecomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα(λ=1.540562), 30 kV, 15 mA). The powder data were collected over anangular range of 3° to 40° 2θ in continuous scan mode using a step sizeof 0.02° 2θ and a scan speed of 2.0°/minute. PXRD: Showed analogouspeaks to the simulated PXRD derived from the single crystal data. PXRDanalysis experimental (calculated): 6.5 (6.7); 8.8 (9.0); 10.1 (10.3);13.2 (13.5); 15.6 (15.8); 17.7 (17.9); 17.8 (18.1); 18.3 (18.6); 19.8(20.1); 20.4 (20.7); 21.6 (22.); 22.6 (22.8); 22.9 (23.2); 26.4 (26.7);26.7 (27.0); 28.0 (28.4).

Example 32

Carbamazepine:saccharin (Form II) (1:1 stoichiometry)

25 mg (0.1058 mmol) carbamazepine and 19 mg (0.1037 mmol) saccharin weredissolved in approximately 4 mL ethanol. Slow evaporation of the solventyielded colorless needles of a 1:1 carbamazepine/saccharin cocrystal, asshown in FIG. 52. Solubility measurements indicate that thismultiple-component crystal of carbamazepine has improved solubility overpreviously known forms of carbamazepine (e.g., increased molarsolubility and longer solubility in aqueous solutions).

Crystal data: (Bruker SMART-APEX CCD Diffractometer), C₂₂H₁₇N₃O₄S₁,M=419.45, triclinic P-1; a=7.5140(11), b=10.4538(15), c=12.6826(18) Å,α=83.642(2)°, β=85.697(2)°, γ=75.411(2)°, U=957.0(2) Å³, T=200(2) K,Z=2, μ(Mo—Kα)=0.206 mm⁻¹, D_(c)=1.456 Mg/m³, λ=0.71073 Å, F(000)=436,2θ_(max)=56.20°; 8426 reflections measured, 4372 unique(R_(int)=0.0305). Final residuals for 283 parameters were R₁=0.0458,wR₂=0.1142 for I>2σ(I), and R₁=0.0562, wR₂=0.1204 for all 4372 data.

Crystal packing: The co-crystals contain hydrogen bonded carboxamidehomodimers. The 2° amines of the saccharin are hydrogen bonded to thecarbonyl of the CBZ on each side forming a tetramer. The crystal has aspace group of P-1 with π-π interactions between the phenyl groups ofthe CBZ and the saccharin phenyl groups.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), unsymmetrical andsymmetrical stretching shifts up to 3495 cm⁻¹ accounting for 1° amines;C═O aliphatic stretching was shifted up to 1726 cm⁻¹ N—H in-planebending at 1649 cm⁻¹; C═C stretching shifted down to 1561 cm⁻¹; (O═S═O)sulfonyl peak at 1330 cm⁻¹ C—N aliphatic stretching 1175 cm⁻¹.

Differential Scanning Calorimetry: (TA Instruments 2920 DSC), 75.31degrees C. (endotherm) and 177.32 degrees C. (endotherm), m.p.=148-155degrees C. (MEL-TEMP); (carbamazepine m.p.=190.2 degrees C., saccharinm.p.=228.8 degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA),3.342% weight loss starting at 67.03 degrees C. and a 55.09% weight lossstarting at 118.71 degrees C. followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using Cu Kα(λ=1.540562), 30 kV, 15 mA). The powder data were collected over anangular range of 3° to 40° 2θ in continuous scan mode using a step sizeof 0.02° 2θ and a scan speed of 2.0°/minute. PXRD derived from thesingle crystal data, experimental (calculated): 6.9 (7.0); 12.2 (12.2);13.6 (13.8); 14.0 (14.1); 14.1 (14.4); 15.3 (15.6); 15.9 (15.9); 18.1(18.2); 18.7 (18.8); 20.2 (20.3); 21.3 (21.5); 23.7 (23.9); 26.3 (26.4);28.3 (28.3).

Example 33

Carbamazepine:2,6-pyridinedicarboxylic acid (2:3 stoichiometry)

36 mg (0.1524 mmol) carbamazepine and 26 mg (0.1556 mmol)2,6-pyridinedicarboxylic acid were dissolved in approximately 2 mLethanol. Slow evaporation of the solvent yielded clear needles of a 1:1carbamazepine/2,6-pyridinedicarboxylic acid co-crystal, as shown in FIG.54A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). C₂₂H₁₇N₃O₅,M=403.39, orthorhombic P2(1)2(1)2(1); a=7.2122, b=14.6491, c=17.5864Å,α=90°, β=90°, γ=90°, V=1858.0(2) Å³, T=100 K, Z=4, μ(MO-Kα)=0.104mm⁻¹, D_(c)=1.442 Mg/m³, λ=0.71073 Å, F(000)840, 2θ_(max)=28.3. 16641reflections measured, 4466 unique (R_(int)=0.093). Final residuals for271 parameters were R₁=0.0425 and wR₂=0.0944 for I>2σ(I).

Crystal packing: Each hydrogen on the CBZ 1° amine is hydrogen bonded toa carbonyl group of a different 2,6-pyridinedicarboxylic acid moiety.The carbonyl of the CBZ carboxamide is hydrogen bonded to two hydroxidegroups of one 2,6-pyridinedicarboxylic acid moitey.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3439 cm⁻¹, (N—Hstretch, 1° amine, CBZ); 1734 cm⁻¹, (C═O); 1649 cm⁻¹, (C═C).

Melting Point: 214-216 degrees C. (MEL-TEMP). (carbamazepinem.p.=191-192 degrees C., 2,6-pyridinedicarboxylic acid m.p.=248-250degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA). 69%weight loss starting at 215 degrees C. and a 17% weight loss starting at392 degrees C. followed by complete decomposition.

Example 34

Carbamazepine:5-nitroisophthalic acid (1:1 stoichiometry)

40 mg (0.1693 mmol) carbamazepine and 30 mg (0.1421 mmol)5-nitroisophthalic acid were dissolved in approximately 3 mL methanol orethanol. Slow evaporation of the solvent yielded yellow needles of a 1:1carbamazepine/5-nitroisophthalic acid co-crystal, as shown in FIG.55A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). C₄₇H₄₀N₆O₁₆,M=944.85, monoclinic C2/c; a=34.355(8), b=5.3795(13), c=23.654(6)Å,α=90°, β=93.952(6)°, γ=90°, V=4361.2(18)Å³, T=200(2) K, Z=4,μ(MO-Kα)=0.110 mm⁻¹, D_(c)=1.439 Mg/m³, λ=0.71073 Å, F(000)1968,2θ_(max)=26.43°. 11581 reflections measured, 4459 unique(R_(int)=0.0611). Final residuals for 311 parameters were R₁=0.0725,wR₂=0.1801 for I>2σ(I), and R₁=0.1441, wR₂=0.1204 for all 4459 data.

Crystal packing: The co-crystals are sustained by hydrogen bondedcarboxylic acid homodimers between the two 5-nitroisophthalic acidmoieties and hydrogen bonded carboxy-amide heterodimers between thecarbamazepine and 5-nitroisophthalic acid moiety. There is solventhydrogen bonded to an additional N—H donor from the carbamazepinemoiety.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3470 cm⁻¹, (N—Hstretch, 1° amine, CBZ); 3178 cm⁻¹, (C—H stretch, alkene); 1688 cm⁻¹,(C═O); 1602 cm⁻¹, (C═C).

Differential Scanning Calorimetry: (TA Instruments 2920 DSC). 190.51degrees C. (endotherm). m.p.=NA (decomposes at 197-200 degrees C.)(MEL-TEMP). (carbamazepine m.p.=191-192 degrees C., 5-nitroisophthalicacid m.p.=260-261 degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA).32.02% weight loss starting at 202 degrees C., a 12.12% weight lossstarting at 224 degrees C. and a 17.94% weight loss starting at 285degrees C. followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using CuKα(λ=1.540562), 30 kV, 15 mA). The powder data were collected over anangular range of 3 to 40 2 in continuous scan mode using a step size of0.02 2 and a scan speed of 2.0/min. PXRD: Showed analogous peaks to thesimulated PXRD derived from the single crystal data. PXRD analysisexperimental (calculated): 10.138 (10.283), 15.291 (15.607), 17.438(17.791), 21.166 (21.685), 31.407 (31.738), 32.650 (32.729).

Example 35

Carbamazepine: 1,3,5,7-adamantane tetracarboxylic acid (1:1stoichiometry)

15 mg (0.1524 mmol) carbamazepine and 20 mg (0.1556 mmol)1,3,5,7-adamantanetetracarboxylic acid were dissolved in approximately 1mL methanol or 1 mL ethanol. Slow evaporation of the solvent yieldsclear plates of a 2:1 carbamazepine/1,3,5,7-adamantanetetracarboxylicacid co-crystal, as shown in FIG. 56A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). C₄₄H₄₀N₂O₁₀,M=784.80, monoclinicC2/c; a=18.388(4), b=12.682(3), c=16.429(3) Å,β=100.491(6)°, V=3767.1(14) Å³, T=100(2) K, Z=4, μ(MO-Kα)=0.099 mm⁻¹,D_(c)=1.384 Mg/m³, λ=0.71073 Å, F(000)1648, 2θ_(max)=28.20°. 16499reflections measured, 4481 unique (R_(int)=0.052). Final residuals for263 parameters were R₁=0.0433 and wR₂=0.0913 for I>2σ(I).

Crystal packing: The co-crystals form a single 3D network of fourtetrahedron, linked by square planes similar to the PtS topology. Thecrystals are sustained by hydrogen bonding.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3431 cm⁻¹, (N—Hstretch, 1° amine, CBZ); 3123 cm⁻¹, (C—H stretch, alkene); 1723 cm⁻¹,(C═O); 1649 cm⁻¹, (C═C).

Melting Point: (MEL-TEMP). 258-260 degrees C. (carbamazepinem.p.=191-192 degrees C., adamantanetetracarboxylic acid m.p.=>390degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA). 9%weight loss starting at 189 degrees C., a 52% weight loss starting at251 degrees C. and a 31% weight loss starting at 374 degrees C. followedby complete decomposition.

Example 36

Carbamazepine:benzoquinone (1:1 stoichiometry)

25 mg (0.1058 mmol) carbamazepine and 11 mg (0.1018 mmol) benzoquinonewas dissolved in 2 mL methanol or THF. Slow evaporation of the solventproduced an average yield of yellow crystals of a 1:1carbamazepine/benzoquinone co-crystal, as shown in FIG. 57A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). C₂₁H₁₆N₂O₃,M=344.36, monoclinic P2(1)/c; a=10.3335(18), b=27.611(5), c=4.9960(9) Å,β=102.275(3)°, V=1392.9(4) Å³, T=100(2) K, Z=3, D_(c)=1.232 Mg/m³,μ(MO-Kα)=0.084 mm⁻¹, λ=0.71073 Å, F(000)540, 2θ_(max)=28.24°. 8392reflections measured, 3223 unique (R_(int)=0.1136). Final residuals for199 parameters were R₁=0.0545 and wR₂=0.1358 for I>2σ(I), and R₁=0.0659and wR₂=0.1427 for all 3223 data.

Crystal packing: The co-crystals contain hydrogen bonded carboxamidehomodimers. Each 1° amine on the CBZ is bifurcated to a carbonyl groupof a benzoquinone moiety. The dimers form infinite chains.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3420 cm⁻¹, (N—Hstretch, 1° amine, CBZ); 2750 cm⁻¹, (aldehyde stretch); 1672 cm⁻¹,(C═O); 1637 cm⁻¹, (C═C, CBZ).

Melting Point: 170 degrees C. (MEL-TEMP). (carbamazepine m.p.=191-192degrees C., benzoquinone m.p.=115.7 degrees C.).

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA).20.62% weight loss starting at 168 degrees C. and a 78% weight lossstarting at 223 degrees C. followed by complete decomposition.

Example 37

Carbamazepine:trimesic Acid (Form II) (1:1 stoichiometry)

36 mg (0.1524 mmol) carbamazepine and 31 mg (0.1475 mmol) trimesic acidwere dissolved in a solvent mixture of approximately 2 mL methanol and 2mL dichloromethane. Slow evaporation of the solvent mixture yieldedwhite starbursts of a 1:1 carbamazepine/trimesic acid co-crystal, asshown in FIG. 58A-B.

Crystal data: (Bruker SMART-APEX CCD Diffractometer). C₂₄H₁₈N₂O₇,M=446.26, monoclinic C2/c; a=32.5312(50), b=5.2697(8), c=24.1594(37)Å,α=90°, β=98.191(3)°, γ=90°, V=4099.39(37) Å³, T=−173 K, Z=8,μ(MO-Kα)=0.110 mm⁻¹, D_(c)=1.439 Mg/m³, λ=0.71073 Å, F(000)1968,2θ_(max)=26.43°. 11581 reflections measured, 4459 unique(R_(int)=0.0611). Final residuals for 2777 parameters were R₁=0.1563,wR₂=0.1887 for I>2σ(I), and R₁=0.1441, wR₂=0.1204 for all 3601 data.

Crystal packing: The co-crystals are sustained by hydrogen bondedcarboxylic acid homodimers between carbamazepine and trimesic acidmoieties and hydrogen bonded carboxylic acid-amine heterodimers betweentwo trimesic acid moieties arranged in a stacked ladder formation.

Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3486 cm⁻¹ (N—Hstretch, 1° amine, CBZ); 1688 cm⁻¹ (C═O, 1° amide stretch, CBZ); 1602cm⁻¹ (C═C, CBZ).

Differential Scanning Calorimetry: (TA Instruments 2920 DSC). 273degrees C. (endotherm). m.p.=NA, decomposes at 278 degrees C.(MEL-TEMP). (carbamazepine m.p.=191-192 degrees C., trimesic acidm.p.=380 degrees C.)

Thermogravimetric Analysis: (TA Instruments 2950 Hi-Resolution TGA).62.83% weight loss starting at 253 degrees C. and a 30.20% weight lossstarting at 278 degrees C. followed by complete decomposition.

Powder x-ray diffraction: (Rigaku Miniflex Diffractometer using CuKα(λ=1.540562), 30 kV, 15 mA). The powder data were collected over anangular range of 3 to 40 2 in continuous scan mode using a step size of0.02 2 and a scan speed of 2.0/min. PXRD analysis experimental: 10.736,12.087, 16.857, 24.857, 27.857.

TABLE V Detailed Characterization of Co-Crystals All PXRD peaks are inunits of degrees 2-theta All Raman shifts are in units of cm⁻¹Carbamazepine: Saccharin PXRD (Form I): 7.01, 12.07, 14.09, 15.41,18.47, 20.13, 22.01, 23.57, 24.41, 28.31 (FIG. 1) PXRD (Form II): 6.9,12.2, 13.6, 14.0, 14.1, 15.3, 15.9, 18.1, 18.7, 20.2, 21.3, 23.7, 26.3,28.3 DSC (Form I): Broad endotherm at 161.9 degrees C. (FIG. 2) TGA(Form I): Decomposition above 200 degrees CDSC (Form II): Endothermictransitions at 75.31 and 177.32 degrees C. TGA (Form II): 3.342 percentweight loss starting at 67.03 degrees C., 55.09 percent weight lossstarting at 118.71 degrees C., followed by decomposition Method: CMAXCarbamazepine: Nicotinamide PXRD (Form I): 4.97, 6.67, 8.75, 10.25,13.25, 17.91, 18.49, 19.95, 20.49, 22.73, 24.39, 26.49 (FIG. 3) PXRD(Form II): 6.5, 8.8, 10.1, 13.2, 15.6, 17.7, 17.8, 18.3, 19.8, 20.4,21.6, 22.6, 22.9, 26.4, 26.7, 28.0 DSC (Form I): Sharp endotherm at156.9 degrees C. (FIG. 4) TGA (Form I): Decomposition beginning at ~150degrees CDSC (Form II): Endothermic transitions at 74.49 and 159.05degrees C. TGA (Form II): 57.94 percent weight loss starting at 205.43degrees C., followed by decomposition Method: CMAX Carbamazepine:Trimesic acid PXRD (Form I): 10.89, 12.23, 14.83, 16.25, 17.05, 18.13,18.47, 21.47, 21.95, 24.57, 25.11, 27.99 (FIG. 5) PXRD (Form II): 10.74,12.09, 16.86, 24.86, 27.86 DSC (Form II): Endothermic transition at 273degrees C. TGA (Form II): 62.83 percent weight loss starting at 253degrees C., 30.20 percent weight loss starting at 278 degrees C.,followed by decomposition Method: CMAX Celecoxib: Nicotinamide PXRD:3.77, 7.56, 9.63, 14.76, 15.21, 16.01, 17.78, 18.68, 19.31, 20.44,21.19, 22.10 DSC: Two endothermic transitions at 117.2 and 118.8 degreesC. and a sharp endotherm at 129.7 degrees C. TGA: Decompositionbeginning at ~150 degrees C. Raman: 1617.5, 1598.7, 1452.1, 1370.3,1162.5, 1044.3, 972.9, 796.4, 631.8, 392.5, 205.9 Method: Slowevaporation of a 1:1 solution from acetone Topiramate: 18-Crown-6 PXRD:10.79, 11.07, 12.17, 13.83, 16.13, 18.03, 18.51, 18.79, 19.21, 21.43,22.25, 24.11 (FIG. 6) DSC: Sharp endotherm at 134.7 degrees C., followedby an exotherm at 203 degrees C. (FIG. 7) TGA: Rapid decompositionbeginning at ~135 degrees C. and leveling off slightly after 200 degreesC. Raman: 2994.5, 2942.7, 1471.6, 1427.4, 1261.7, 849.4, 804.5, 745.1,629.2, 280.4, 225.9 Method: Addition of an ether solution containing 1equivalent of topiramate to an ether solution containing 18-crown-6.Product precipitated following minor agitation of the combined mixtureand was collected. Olanzapine: Nicotinamide PXRD (Form I): 4.89, 8.65,12.51, 14.19, 15.59, 17.15, 19.71, 21.05, 23.95, 24.59, 25.53, 26.71(FIG. 8) PXRD (Form II): 6.41, 12.85, 18.67, 21.85, 24.37 (FIG. 30) PXRD(Form III): 6.41, 12.85, 14.91, 18.67, 21.85, 24.37 (FIG. 31) DSC (FormI): Slightly broad endotherm at 126.1 degrees C. (FIG. 9) Method: Seeabove Celecoxib: 18-Crown-6 PXRD: 8.73, 11.89, 12.57, 13.13, 15.01,16.37, 17.03, 17.75, 18.45, 20.75, 22.37, 23.11, 24.33, 24.97, 26.61,28.15 (FIG. 10) DSC: Sharp endotherm at 189.6 degrees C. (FIG. 11) TGA:Decomposition above 200 degrees C. with a 25% weight loss between~190-210 degrees C. Method: A solution containing one equivalent ofcelecoxib in ether was added to a solution containing 18-crown-6. Awhite solid formed immediately and was collected. Itraconazole: SuccinicAcid PXRD: 3.0, 6.0, 8.1, 9.0, 17.1, 24.5 (FIG. 12) DSC: Singleendothermic transition at 160.1 degrees C. ± 1.0 degrees C. (FIG. 13)TGA: Less than 0.1% volatile components by weight Method: See aboveItraconazole: Fumaric Acid PXRD: 4.6, 5.9, 9.2, 10.6, 19.1, 20.8 (FIG.14) DSC: The material had a weak endothermic transition at 141.7 degreesC. and a strong endothermic transition at 179.58 degrees C. (FIG. 15)TGA: The sample loses 0.5% of its weight on the TGA between roomtemperature and 100 degrees C. Method: Itraconazole: Tartaric Acid PXRD:4.1, 6.2, 8.3, 20.7, 25.6, 26.3 (FIG. 16) DSC: An endothermic transitionat 180.74 degrees C. (FIG. 17) TGA: Less than 0.1% volatile componentsby weight by TGA. Method: See above Itraconazole: Malic acid PXRD: 4.4,5.9, 8.8, 17.7, 20.0, 21.1, 22.6 (FIG. 18) DSC: The sample has a strongendothermic transition at 154.36 degrees C. (FIG.19) TGA: The samplecontained less than 0.1% volatile components by weight Method: See aboveItraconazoleHCl: Tartaric acid PXRD: 3.7, 11.0, 13.8, 16.5, 17.8 (FIG.20) DSC: The sample has a peak endothermic transition at 161degrees C.(FIG. 21) TGA: The sample contained less than 0.1% volatile componentsby weight Method: See above Modafinil: Malonic acid PXRD: 5.00, 9.17,16.81, 18.26, 19.43, 21.36, 21.94, 22.77, 24.49, 25.63, 28.45 (FIG. 22)DSC: Endothermic transition at 106.23 degrees C. (FIG. 40) Raman: 1601,1183, 1032, 1004, 814, 633, 265, 222 (FIG. 42) Method: See aboveModafinil: Benzamide PXRD: 5.11, 9.35, 10.25, 10.79, 14.07, 16.87,18.33, 19.53, 21.38, 22.05, 22.89, 23.57, 24.73, 25.19, 25.81, 26.51,28.60 (FIG. 23) Method: Slow evaporation from a 1:1 solution in1,2-dichoroethane Modafinil: Mandelic acid PXRD: 6.11, 6.75, 9.53,10.31, 14.77, 15.77, 16.99, 18.03, 20.01, 21.61, 22.47, 23.27, 25.27,25.75, 27.23 (FIG. 24) Method: Slow evaporation from a 1:1 solution inacetone Modafinil: Glycolic acid PXRD: 6.09, 9.51, 14.91, 15.97, 19.01,20.03, 21.59, 22.43, 22.75, 23.75, 25.03, 25.71 (FIG. 25) Method: Slowevaporation from a 1:1 solution in acetone Modafinil: Fumaric acid PXRD:5.87, 7.19, 8.95, 12.49, 13.99, 16.13, 17.09, 18.19, 19.99, 21.57,23.48, 25.01, 25.79, 28.17, 28.87, 29.69, 32.19 (FIG. 26) Method: Slowevaporation from a 1:1 solution in 1,2-dichoroethane Modafinil: Maleicacid PXRD: 4.69, 6.15, 9.61, 10.23, 15.65, 16.53, 17.19, 18.01, 19.27,19.53, 19.97, 21.83, 22.45, 25.65 (FIG. 43) Method: See above5-fluorouracil: Urea PXRD: 11.23, 12.69, 13.27, 15.93, 16.93, 20.37,23.65, 25.55, 26.87, 32.49 (FIG. 36) DSC: Sharp endotherm at 207.6degrees C. (FIG. 33) TGA: 32 percent weight loss between 150 and 220degrees C. (FIG. 34) Raman: 1347.1, 1024.4, 756.9, 643.7, 545.3 (FIG.35) Method: See above Hydroclorothiazide: Nicotinic acid PXRD: 8.57,13.23, 14.31, 16.27, 17.89, 18.75, 21.13, 21.45, 24.41, 25.73, 26.57,27.43 (FIG. 37) Method: See above Hydrochlorothiazide: 18-crown-6 PXRD:9.97, 10.43, 11.57, 11.81, 12.83, 14.53, 15.67, 16.61, 19.05, 20.31,20.65, 21.09, 21.85, 22.45, 23.63, 24.21, 25.33, 26.73 (FIG. 38) Method:See above Hydrochlorothiazide: piperazine PXRD: 6.85, 13.75, 15.93,18.71, 20.67, 20.93, 23.27, 24.17, 28.33, 28.87, 30.89 (FIG. 39) Method:See above Acetaminophen: 4,4′-bipyridine:water DSC: Endothermictransition at 57.77 degrees C. Method: See above Phenytoin: PyridonePXRD: 5.2, 11.1, 15.1, 16.2, 16.7, 17.8, 19.4, 19.8, 20.3, 21.2, 23.3,26.1, 26.4, 27.3, 29.5 DSC: Endothermic transitions at 233.39 and 271.33degrees C. TGA: 29.09 percent weight loss starting at 192.8 degrees C.,48.72 percent weight loss starting at 238.27 degrees C., 18.38 percentweight loss starting at 260.17 degrees C., followed by decompositionMethod: See above Aspirin: 4,4′-bipyridine DSC: Endothermic transitionat 95.14 degrees C. TGA: 9 percent weight loss starting at 22.62 degreesC., 49.06 percent weight loss starting at 102.97 degrees C.,decomposition starting at 209.37 degrees C. Method: See above Ibuprofen:4,4′-bipyridine PXRD: 3.4, 6.9, 10.4, 17.3, 19.1 DSC: Endothermictransitions at 64.85 and 118.79 degrees C. TGA: 13.28 percent weightloss between room temperature and 100.02 degrees C. followed bydecomposition Method: See above Flurbiprofen: 4,4′-bipyridine PXRD:16.8, 17.1, 18.1, 19.0, 20.0, 21.3, 22.7, 25.0, 26.0, 26.0, 26.1, 28.2,29.1 DSC: Endothermic transition at 162.47 degrees C. TGA: 30.93 percentweight loss starting at 31.13 degrees C., 46.26 percent weight lossstarting at 168.74 degrees C., followed by decomposition Method: Seeabove Flurbiprofen: trans-1,2-bis (4-pyridyl) ethylene PXRD: 3.6, 17.3,18.1, 18.4, 19.1, 22.3, 23.8, 25.9, 28.1 DSC: Endothermic transitions at100.01, 125.59, and 163.54 degrees C. TGA: 91.79 percent weight lossstarting at 133.18 degrees C. followed by decomposition Method: Seeabove Carbamazepine: p-phthalaldehyde PXRD: 8.5, 10.6, 11.9, 14.4, 15.1,18.0, 18.5, 19.8, 23.7, 24.2, 26.4, 27.6, 27.8, 28.7, 29.3, 29.4 DSC:Endothermic transition at 128.46 degrees C. TGA: 17.66 percent weightloss starting at 30.33 degrees C., 17.57 percent weight loss starting at100.14 degrees C., followed by decomposition Method: See aboveCarbamazepine: 2,6-pyridinecarboxylic acid TGA: 69 percent weight lossstarting at 215 degrees C., 17 percent weight loss starting at 392degrees C., followed by decomposition Method: See above Carbamazepine:5-nitroisophthalic acid PXRD: 10.14, 15.29, 17.44, 21.17, 31.41, 32.65TGA: 32.02 percent weight loss starting at 202 degrees C., 12.12 percentweight loss starting at 224 degrees C., 17.94 percent weight lossstarting at 285 degrees C., followed by decomposition Method: See aboveCarbamazepine: 1,3,5,7-adamantane tetracarboxylic acid TGA: 9 percentweight loss starting at 189 degrees C., 52 percent weight loss startingat 251 degrees C., 31 percent weight loss starting at 374 degrees C.,followed by decomposition Method: See above Carbamazepine: BenzoquinoneTGA: 20.62 percent weight loss starting at 168 degrees C., 78 percentweight loss starting at 223 degrees C., followed by decompositionMethod: See above

Example 38

A co-crystal with a modulated dissolution profile has been prepared.Celecoxib: nicotinamide co-crystals were prepared via methods shown inexample 4. (See FIG. 27)

Example 39

A co-crystal with a modulated dissolution profile has been prepared.Itraconazole: succinic acid, itraconazole:tartaric acid anditraconazole:malic acid co-crystals were prepared via methods shown inexamples 8, 10 and 11. (See FIG. 28)

Example 40

A co-crystal of an unsaltable or difficult to salt API has beenprepared. Celecoxib: nicotinamide co-crystals were prepared via methodsshown in example 4.

Example 41

A co-crystal with an improved hygroscopicity profile has been prepared.Celecoxib: nicotinamide co-crystals were prepared via methods shown inexample 4. (See FIG. 29)

Example 42

A co-crystal with reduced form diversity as compared to the API has beenprepared. Co-crystals of carbamazepine and saccharin have been preparedvia method shown in example 1.

Co- MW MP # # pKa Crystal Former (g/mol) (° C.) Class Functionaliltyacceptors donors Molecular Structure Values 1-Hydroxy-2- naphthoic acid188.18 191-192 2 Carboxylic acid, alcohol 1 2

2.7, 13.5 4-aminobenzoic acid 137.14 187-188 2 Amine, carboxylic acid 13

4.7, 4.8 4-aminopyridine 94.11 158-159 3 Amine, pyridine 1 2

10 4-Chlorobenzene- sulfonic acid 192.63 67 1 SO₃H 3 1

0-1 4-ethoxyphenyl urea 180.2 173-174 3 Amide, NH 2 3

~7-9 7-oxo-DHEA 303 190-192 1 Alcohol, Ketone 3 1

Acesulfame 163.15 123-124 3 SO₂, Amide 4 1

~5-7 Acetohydroxamic acid 75.07 89-92 3 Amide, NH, OH 2 2

8.7 Adenine 135.13 200 (sub.) 1 Amide, NH 3 3

3.8 Adipic Acid 146.14 152 1 Carboxylic acid 2 2 HOOC(CH₂)₄COOH 4.44,5.44 Alanine 89.09 289-291 1 Amine, carboxillic acid 1 3

2.35, 9.87 Allopurinaol 136.11 >350 3 OH, NH 4 2

10.2 Arginine 174.2 244 (dec.) 1 Amine, COOH 2 7

2.18, 9.09, 13.2 Ascorbic acid 176.12 190-192 1 C═O, OH 6 4

4.17, 11.57 Asparagine 132.12 234-235 1 Amine, amide, COOH 3 5

2.02, 8.5 Aspartic acid 133.1 270-271 1 Amine, COOH 2 4

1.88, 3.65, 9.60 Benzenesulfonic Acid 158.18 43-44 1 SO₃H 2 1

0.70, 1.58 Benzoic acid* 122.12 122-123 2 COOH 1 1

4.19 Caffeine 194.19 238 3 C═O 3 0

Camphoric acid 200.23 186-189 2 Carboxylic acid 2 2

4.72, 5.83 Capric acid 172.27 31.4 1 Carboxylic acid 1 1 CH₃(CH₂)₈COOH4.9 Chrysin 254.24 285 1 Phenol, ether, ketone 2 2

Cinnamic acid 144.2 133 3 Carboxylic acid 1 1

4.4 Citric Acid 192.12 153 1 OH, COOH 4 4

3.13, 4.76, 6.40 Clemizole 325.84 167 1 Pyrrolidine 3 0

Cyclamic acid 179.24 169-170 3 NH, SO₃H 2 2

−2 Cysteine 121.15 — 1 Amine, COOH, SH 2 4

1.71, 8.33, 10.78 Dimethylglycine 103.1 178-192 1 Amine, Carboxylic acid2 1

2.5 D-Ribose 150.13 87 1 Alcohol, ether 1 4

Fumaric acid 116.07 287 1 COOH 2 2

3.03, 4.38 Galactaric acid 210.14 255 (dec) 1 Carboxylic acid, alcohol 26

3.08, 3.63 Genistein 270.24 297-298 1 Alcohol, Phenol, ether, ketone 2 3

Gentisic acid 154.12 199-200 form I, 205 form II 2 Carboxylic acid,alcohol, phenol 1 3

2.93 Glucamine, N-Methyl 195.22 128-129 1 Alcohol, Amine 5 6

8.03(B) Gluconic acid 196.15 131 1 OH, COOH 6 6

3.76 Glucosamine 179.17 88 1 OH 5 6

6.91 Glucuronic acid 194.14 165 1 Carboxylic acid, alcohol, aldehyde 2 5

3.18 Glutamic acid 147.13 160 1 Amine, COOH 2 4

2.19, 4.25, 9.67 Glutamine 146.15 185-186 1 Amine, Amide, COOH 2 5

2.17, 9.13 Glutaric acid 132.11 98-98 1 COOH 2 2

2.7, 4.5 Glycine 75.07 182 1 Amine, COOH 2 3

2.34, 9.6 Glycolic acid 76.05 80 1 OH, COOH 2 2

3.82 Hippuric acid 179.17 187-188 1 Amide, NH, COOH 2 2

3.55 Histidine 155.16 287 (dec.) 1 Amine, COOH, Imidazole 2 4

1.78, 5.97, 8.97 Hydroquinone* 110.11 170-171 2 OH, Phenol 2 2

~10 Imidazole 68.08 90-91 1 NH 1 1

6.92 Ipriflavone 280.32 115-117 1 Ketone, ether 3 0

Isoleucine 131.17 168-170 (sub.) 1 Amine, COOH 1 3

2.32, 9.76 Lactobionic acid 358.3 128-130 2 Alcohol, carboxylic acid,ether 1 9

3.2 Lauric acid 200.32 44-48 1 Carboxylic acid 1 1 CH₃(CH₂)₁₀COOH ~4.5Leucine 131.17 145-148 (sub.) 1 Carboxylic acid, amine 1 3

2.36, 9.6 Lysine 146.19 225 (dec.) 1 Amine, COOH 1 5

2.2, 8.9, 10.28 Maleic 116.07 138-139 1 COOH 2 2

1.92, 6.23 Malic acid 134.09 131-132 1 OH, COOH 3 3

3.46, 5.1 Malonic 104.06 135 1 COOH 2 2

2.83, 5.70 Mandelic acid 152.15 119 1 OH, COOH 2 2

3.37 Methionine 149.21 280-282 (dec.) 1 Amine, COOH, S-Me 2 3

2-3, 9 Nicotinamide 122.12 128-131 1 Pyridine, amide 2 2

3.3 Nicotinic acid 123.11 236-237 2 Carboxylic acid, pyridine 2 1

2.07(B), 4.85 Orotic acid 156.1 345-346 2 Carboxilic acid, lactam 3 3

5.85, 8.95 Oxalic acid 90.04 189 (dec) 2 Carboxilic acid 2 2

1.27, 4.27 Palmitic acid 256.43 63-64 1 Carboxylic acid 1 1CH₃(CH₂)₁₄COOH 4.9 Pamoic 388.38 280 (dec) 2 Carboxylic acid, phenol 2 4

2.51, 3.1 Phenylalanine 165.19 283 (dec.) 1 Amine, COOH 1 3

~2, ~9 Piperazine 86.14 106 1 NH 0 2

9.82(B) Procaine 236.31 61 1 Amine, C═O 2 2

8.9(B) Proline 115.13 220-222 (dec.) 1 COOH, NH 1 2

1.99, 10.6 p-Toluenesulfonic acid 172.2 106-107 2 Sulfonic acid 2 1

−1.34 Pyridoxamine 168 193-194 2 OH, Amine, Pyridine 3 4

~9 Pyridoxine 170 160 2 Alcohol, Pyridine 3 3

~9 Pyroglutamic acid 129.12 162 2 Carboxylic acid, Lactam 2 2

3.32 Quercetin 302.24 314 dec. 1 Phenol, ether, ketone 2 5

Resveratrol 228.24 253-255 1 Phenol 0 3

Saccharin 183.19 228-230 1 Amide, C═O, S═O, N—H 3 1

2 Salicylic acid, 4-amino 153.14 150-151 3 COOH, OH, Analine 1 4

3.25, 10, 3.5(B) Salicylic acid 138.12 159 3 COOH, OH 2 2

2.98, 13.82 Sebacic acid 202.25 134.5 1 Carboxylic acid 2 2HOOC(CH₂)₈COOH 4.59, 5.59 Serine 105.09 228 (dec.) 1 Carboxylic acid,amine, OH 2 3

2.21, 9.15 Stearic acid 284.47 70-71 1 Carboxylic acid 1 1CH₃(CH₂)₁₆COOH 4.9 Succinic acid 118.09 185-187 1 Carboxylic acid 2 2

4.21, 5.64 Tartaric acid 150.09 205-206 1 Carboxylic acid 4 4

3.02, 4.36 Threonine 119.12 255-257 (dec.) 1 Amine, COOH, OH 2 4

2.15, 9.12 TRIS 121.13 171-172 2 Amine, OH 3 5

5.91, 8.3 Tryptophan 204.23 289 (dec.) 1 Amine, COOH, Indole 1 4

2.38, 9.39 Tyrosine 181.19 342-344 1 Amine, COOH, OH 2 3

2.2, 9.11, 10.07 Urea 60.06 Dec. 1 C═O, NH2 1 4

~8 Valine 117.15 315 1 Amine, COOH 1 3

~4.5, ~9 Vitamin K5 209.68 280-282 (dec.) 3 Amine, OH 1 3

~9 Xylitol 152.15 93-95 (1) 2 OH 5 5

~9

TABLE II Co-crystal Former Co-crystal Former Functional GroupInteracting Group 1,5-Napthalene-disulfonic Acid Sulfonic Acid pyridineketone aldehyde ether ester amide Carboxylic Acid 1-Hydroxy-2-naphthoicacid Carboxylic Acid alcohol ketone thiol amide amine analine phenol1-Hydroxy-2-naphthoic acid alcohol alcohol ketone thiol amide amineanaline phenol 4-Aminobenzoic Acid Amine alcohol ketone thiol amideamine analine phenol 4-Aminobenzoic Acid Carboxylic Acid alcohol ketonethiol amide amine analine phenol 4-aminopyridine Amine alcohol ketonethiol amide amine analine phenol 4-aminopyridine Pyridine *alcoholpyridinium * *amide nitro *amine *Carboxylic Acid4-Chlorobenzene-Sulfonic Sulfonic Acid pyridine ketone aldehyde etherester amide Carboxylic Acid Acid 4-ethoxyphenyl Urea Amide alcoholketone thiol amide amine analine phenol 4-ethoxyphenyl Urea Aminealcohol ketone thiol amide amine analine phenol 7-oxo-DHEA alcoholalcohol ketone thiol amide amine analine phenol 7-oxo-DHEA Ketonealcohol thiol amide amine analine phenol Acesulfame Sulfone pyridineketone aldehyde ether ester amide carboxilic acid Acesulfame Amidealcohol ketone thiol amide amine analine phenol Acetohydroxamic AcidAmide alcohol ketone thiol amide amine analine phenol AcetohydroxamicAcid Amine alcohol ketone thiol amide amine analine phenolAcetohydroxamic Acid Alcohol alcohol ketone thiol amide amine analinephenol Adenine Amine alcohol ketone thiol amide amine analine phenolAdenine N *alcohol pyridinium * *amide nitro *amine *carboxilic acidAdipic acid Carboxylic Acid alcohol ketone thiol amide amine analinephenol Alanine Amine alcohol ketone thiol amide amine analine phenolAlanine Carboxylic Acid alcohol ketone thiol amide amine analine phenolAllopurinaol Alcohol alcohol ketone thiol amide amine analine phenolAllopurinaol Amine alcohol ketone thiol amide amine analine phenolArginine Amine alcohol ketone thiol amide amine analine phenol ArginineCarboxylic Acid alcohol ketone thiol amide amine analine phenol AscorbicAcid Ketone alcohol thiol amide amine analine phenol Ascorbic AcidAlcohol alcohol ketone thiol amide amine analine phenol Ascorbic AcidCarboxylic Acid alcohol ketone thiol amide amine analine phenolAsparagine Amine alcohol ketone thiol amide amine analine phenolAsparagine Amide alcohol ketone thiol amide amine analine phenolAsparagine Carboxylic Acid alcohol ketone thiol amide amine analinephenol Aspartic Acid Amine alcohol ketone thiol amide amine analinephenol Aspartic Acid Carboxylic Acid alcohol ketone thiol amide amineanaline phenol Benzenesulfonic Acid Sulfonic Acid pyridine ketonealdehyde ether ester amide Carboxylic Acid Benzoic Acid Carboxylic Acidalcohol ketone thiol amide amine analine phenol Caffeine Ketone alcoholthiol amide amine analine phenol Camphoric acid Carboxylic Acid alcoholketone thiol amide amine analine phenol Capric acid Carboxylic Acidalcohol ketone thiol amide amine analine phenol Genistein Ketone alcoholthiol amide amine analine phenol Genistein Phenol amine amide sulfoxiden pyridine cyano aldehyde Genistein Ether aromatic-N amide aminearomatic_s Sp2 amine sulfoxide chlorate Cinnamic acid Carboxylic Acidalcohol ketone thiol amide amine analine phenol Citric Acid Alcoholalcohol ketone thiol amide amine analine phenol Citric Acid CarboxylicAcid alcohol ketone thiol amide amine analine phenol ClemizolePyrrolidine *alcohol pyridinium * *amide nitro *amine *carboxilic acidCyclamic Acid Amine alcohol ketone thiol amide amine analine phenolCyclamic Acid Sulfonic Acid pyridine ketone aldehyde ether ester amideCarboxylic Acid Cysteine Amine alcohol ketone thiol amide amine analinephenol Cysteine Carboxylic Acid alcohol ketone thiol amide amine analinephenol Cysteine Thiol carboxylic acid sodium aldehyde ketone -N cadmiumDimethylglycine Carboxylic Acid alcohol ketone thiol amide amine analinephenol Dimethylglycine Amine alcohol ketone thiol amide amine analinephenol D-ribose Ether aromatic-N amide amine aromatic_s Sp2 aminesulfoxide chlorate D-ribose Alcohol alcohol ketone thiol amide amineanaline phenol Fumaric Acid Carboxylic Acid alcohol ketone thiol amideamine analine phenol Galactaric acid Carboxylic Acid alcohol ketonethiol amide amine analine phenol Galactaric acid alcohol alcohol ketonethiol amide amine analine phenol Chrysin Ketone alcohol thiol amideamine analine phenol Chrysin Phenol amine amide sulfoxide n pyridinecyano aldehyde Chrysin Ether aromatic-N amide amine aromatic_s Sp2 aminesulfoxide chlorate Gentisic acid Carboxylic Acid alcohol ketone thiolamide amine analine phenol Gentisic acid Phenol amine amide sulfoxide npyridine cyano aldehyde Glucamine, N-methyl alcohol alcohol ketone thiolamide amine analine phenol Glucamine, N-methyl Amine alcohol ketonethiol amide amine analine phenol Gluconic Acid Alcohol alcohol ketonethiol amide amine analine phenol Gluconic Acid Carboxylic Acid alcoholketone thiol amide amine analine phenol Glucosamine alcohol alcoholketone thiol amide amine analine phenol Glucuronic acid Carboxylic Acidalcohol ketone thiol amide amine analine phenol Glucuronic acid alcoholalcohol ketone thiol amide amine analine phenol Glucuronic acid Aldehydealcohol ketone thiol amide amine analine phenol Glutamic Acid Aminealcohol ketone thiol amide amine analine phenol Glutamic Acid CarboxylicAcid alcohol ketone thiol amide amine analine phenol Glutamine Aminealcohol ketone thiol amide amine analine phenol Glutamine Amide alcoholketone thiol amide amine analine phenol Glutamine Carboxylic Acidalcohol ketone thiol amide amine analine phenol Glutaric Acid CarboxylicAcid alcohol ketone thiol amide amine analine phenol Glycine Aminealcohol ketone thiol amide amine analine phenol Glycine Carboxylic Acidalcohol ketone thiol amide amine analine phenol Glycolic Acid Alcoholalcohol ketone thiol amide amine analine phenol Glycolic Acid CarboxylicAcid alcohol ketone thiol amide amine analine phenol Hippuric Acid Amidealcohol ketone thiol amide amine analine phenol Hippuric Acid Aminealcohol ketone thiol amide amine analine phenol Hippuric Acid CarboxylicAcid alcohol ketone thiol amide amine analine phenol Histidine Aminealcohol ketone thiol amide amine analine phenol Histidine CarboxylicAcid alcohol ketone thiol amide amine analine phenol Histidine Imidazoleimidazole chlorine acetamide carboxylate thione nitro HydroquinoneAlcohol alcohol ketone thiol amide amine analine phenol HydroquinonePhenol amine amide sulfoxide n pyridine cyano aldehyde Imidazole Aminealcohol ketone thiol amide amine analine phenol Ipriflavone Etheraromatic-N amide amine aromatic_s Sp2 amine sulfoxide chlorateIpriflavone Ketone alcohol thiol amide amine analine phenol IsoleucineAmine alcohol ketone thiol amide amine analine phenol IsoleucineCarboxylic Acid alcohol ketone thiol amide amine analine phenollactobionic acid Carboxylic Acid alcohol ketone thiol amide amineanaline phenol Lactobionic acid alcohol alcohol ketone thiol amide amineanaline phenol Lactobionic acid Ether aromatic-N amide amine aromatic_sSp2 amine sulfoxide chlorate Lauric acid Carboxylic Acid alcohol ketonethiol amide amine analine phenol Leucine Carboxylic Acid alcohol ketonethiol amide amine analine phenol Leucine Amine alcohol ketone thiolamide amine analine phenol Lysine Amine alcohol ketone thiol amide amineanaline phenol Lysine Carboxylic Acid alcohol ketone thiol amide amineanaline phenol Maleic Carboxylic Acid alcohol ketone thiol amide amineanaline phenol Malic Acid Alcohol alcohol ketone thiol amide amineanaline phenol Malic Acid Carboxylic Acid alcohol ketone thiol amideamine analine phenol Malonic Carboxylic Acid alcohol ketone thiol amideamine analine phenol Mandelic Acid Alcohol alcohol ketone thiol amideamine analine phenol Mandelic Acid Carboxylic Acid alcohol ketone thiolamide amine analine phenol Methionine Amine alcohol ketone thiol amideamine analine phenol Methionine Carboxylic Acid alcohol ketone thiolamide amine analine phenol Methionine Thioether -N amide amine _s Sp2amine sulfoxide chlorate Nicotinamide Pyridine *alcohol * *amide nitro*amine *Carboxylic Acid Nicotinamide Amide alcohol ketone thiol amideamine analine phenol Nicotinic Acid Carboxylic Acid alcohol ketone thiolamide amine analine phenol Nicotinic Acid Pyridine *alcohol * *amidenitro *amine *Carboxylic Acid Orotic acid Carboxylic Acid alcohol ketonethiol amide amine analine phenol Orotic acid Lactam alcohol ketone thiolamide amine analine phenol Oxalic acid Carboxylic Acid alcohol ketonethiol amide amine analine phenol Palmitic acid Carboxylic Acid alcoholketone thiol amide amine analine phenol Pamoic acid Carboxylic Acidalcohol ketone thiol amide amine analine phenol Pamoic acid alcoholalcohol ketone thiol amide amine analine phenol Pamoic acid Phenol amineamide sulfoxide n pyridine cyano aldehyde Phenylalanine Amine alcoholketone thiol amide amine analine phenol Phenylalanine Carboxylic Acidalcohol ketone thiol amide amine analine phenol Piperazine Amine alcoholketone thiol amide amine analine phenol Procaine Amine alcohol ketonethiol amide amine analine phenol Procaine Ketone alcohol thiol amideamine analine phenol Proline Carboxylic Acid alcohol ketone thiol amideamine analine phenol Proline Amine alcohol ketone thiol amide amineanaline phenol p-Toluenesulfonic acid Sulfonic Acid pyridine ketonealdehyde ether ester amide Carboxylic Acid Pyridoxamine Alcohol alcoholketone thiol amide amine analine phenol Pyridoxamine Amine alcoholketone thiol amide amine analine phenol Pyridoxamine Pyridine *alcohol **amide nitro *amine *Carboxylic Acid Pyridoxine (4-Pyridoxic Acid)Pyridine *alcohol pyridinium * *amide nitro *amine *Carboxylic AcidPyridoxine (4-Pyridoxic Acid) Alcohol alcohol ketone thiol amide amineanaline phenol Pyroglutamic acid Carboxylic Acid alcohol ketone thiolamide amine analine phenol Pyroglutamic acid Lactam alcohol ketone thiolamide amine analine phenol Quercetin Ketone alcohol thiol amide amineanaline phenol Quercetin Phenol amine amide sulfoxide n pyridine cyanoaldehyde Quercetin Ether aromatic-N amide amine aromatic_s Sp2 aminesulfoxide chlorate Resveratrol Ketone alcohol thiol amide amine analinephenol Resveratrol Phenol amine amide sulfoxide n pyridine cyanoaldehyde Saccharin Amide alcohol ketone thiol amide amine analine phenolSaccharin Ketone alcohol thiol amide amine analine phenol SaccharinSulfoxide pyridine ketone aldehyde ether ester amide Carboxylic AcidSaccharin Amine alcohol ketone thiol amide analine phenol Salicylic AcidCarboxylic Acid alcohol ketone thiol amide amine analine phenolSalicylic Acid Alcohol alcohol ketone thiol amide amine analine phenolSalicylic Acid, 4-amino Carboxylic Acid alcohol ketone thiol amide amineanaline phenol Salicylic Acid, 4-amino alcohol alcohol ketone thiolamide amine analine phenol Salicylic Acid, 4-amino Amine alcohol ketonethiol amide amine analine phenol Sebacic acid Carboxylic Acid alcoholketone thiol amide amine analine phenol Serine Carboxylic Acid alcoholketone thiol amide amine analine phenol Serine Amine alcohol ketonethiol amide amine analine phenol Serine Alcohol alcohol ketone thiolamide amine analine phenol Stearic acid Carboxylic Acid alcohol ketonethiol amide amine analine phenol Succinic Acid Carboxylic Acid alcoholketone thiol amide amine analine phenol Tartaric Acid Carboxylic Acidalcohol ketone thiol amide amine analine phenol Threonine Amine alcoholketone thiol amide amine analine phenol Threonine Carboxylic Acidalcohol ketone thiol amide amine analine phenol Threonine alcoholalcohol ketone thiol amide amine analine phenol Tris Amine alcoholketone thiol amide amine analine phenol Tris Alcohol alcohol ketonethiol amide amine analine phenol Tryptophan Amine alcohol ketone thiolamide amine analine phenol Tryptophan Carboxylic Acid alcohol ketonethiol amide amine analine phenol Tryptophan Indole *alcohol pyridinium **amide nitro *amine *carboxilic acid Tyrosine Amine alcohol ketone thiolamide amine analine phenol Tyrosine Carboxylic Acid alcohol ketone thiolamide amine analine phenol Tyrosine Alcohol alcohol ketone thiol amideamine analine phenol Urea Ketone alcohol thiol amide amine analinephenol Urea Amine alcohol ketone thiol amide amine analine phenol UreaAmide alcohol ketone thiol amide amine analine phenol Valine Aminealcohol ketone thiol amide amine analine phenol Valine Carboxylic Acidalcohol ketone thiol amide amine analine phenol Vitamin K5 Amine alcoholketone thiol amide amine analine phenol Vitamin K5 Alcohol alcoholketone thiol amide amine analine phenol Xylitol Alcohol alcohol ketonethiol amide amine analine phenol Co-crystal Former Interacting Group1,5-Napthalene-disulfonic Acid amine metals thioether sulfate alcohol1-Hydroxy-2-naphthoic acid phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals aldehyde 1-Hydroxy-2-naphthoic acid phosphatesulfate sulfone nitrate pyridine carboxilic acid metals aldehyde4-Aminobenzoic Acid phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals 4-Aminobenzoic Acid phosphate sulfate sulfonenitrate pyridine Carboxylic Acid metals 4-aminopyridine phosphatesulfate sulfone nitrate pyridine carboxilic acid metals 4-aminopyridine*sulfonamide *ketone ether triazole ammonium oxime *chlorine4-Chlorobenzene-Sulfonic amine metals thioether sulfate alcohol Acid4-ethoxyphenyl Urea phosphate sulfate sulfone nitrate pyridineCarboxylic Acid metals 4-ethoxyphenyl Urea phosphate sulfate sulfonenitrate pyridine carboxilic acid metals 7-oxo-DHEA phosphate sulfatesulfone nitrate pyridine carboxilic acid metals aldehyde 7-oxo-DHEAphosphate sulfate sulfone nitrate pyridine Carboxylic Acid metalsAcesulfame amine metals thioether sulfate alcohol Acesulfame phosphatesulfate sulfone nitrate pyridine Carboxylic Acid metals AcetohydroxamicAcid phosphate sulfate sulfone nitrate pyridine carboxilic acid metalsAcetohydroxamic Acid phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals Acetohydroxamic Acid phosphate sulfate sulfonenitrate pyridine Carboxylic Acid metals Adenine phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Adenine *sulfonamide*ketone ether triazole ammonium oxime *chlorine Adipic acid phosphatesulfate sulfone nitrate pyridine carboxilic acid metals Alaninephosphate sulfate sulfone nitrate pyridine carboxilic acid metalsAlanine phosphate sulfate sulfone nitrate pyridine carboxilic acidmetals Allopurinaol phosphate sulfate sulfone nitrate pyridineCarboxylic Acid metals Allopurinaol phosphate sulfate sulfone nitratepyridine carboxilic acid metals Arginine phosphate sulfate sulfonenitrate pyridine carboxilic acid metals Arginine phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Ascorbic Acid phosphatesulfate sulfone nitrate pyridine Carboxylic Acid metals Ascorbic Acidphosphate sulfate sulfone nitrate pyridine Carboxylic Acid metalsAscorbic Acid phosphate sulfate sulfone nitrate pyridine carboxilic acidmetals Asparagine phosphate sulfate sulfone nitrate pyridine carboxilicacid metals Asparagine phosphate sulfate sulfone nitrate pyridineCarboxylic Acid metals Asparagine phosphate sulfate sulfone nitratepyridine carboxilic acid metals Aspartic Acid phosphate sulfate sulfonenitrate pyridine carboxilic acid metals Aspartic Acid phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Benzenesulfonic Acidamine metals thioether sulfate alcohol Benzoic Acid phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Caffeine phosphatesulfate sulfone nitrate pyridine Carboxylic Acid metals Camphoric acidphosphate sulfate sulfone nitrate pyridine carboxilic acid metals Capricacid phosphate sulfate sulfone nitrate pyridine carboxilic acid metalsGenistein phosphate sulfate sulfone nitrate pyridine Carboxylic Acidmetals Genistein alchohol ester ether n-oxide chlorine fluorineGenistein chlorine cyano ester amine nitro nitrate bromine Cinnamic acidphosphate sulfate sulfone nitrate pyridine carboxilic acid metals CitricAcid phosphate sulfate sulfone nitrate pyridine Carboxylic Acid metalsCitric Acid phosphate sulfate sulfone nitrate pyridine carboxilic acidmetals Clemizole *sulfonamide *ketone ether triazole ammonium oxime*chlorine Cyclamic Acid phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals Cyclamic Acid amine metals thioether sulfatealcohol Cysteine phosphate sulfate sulfone nitrate pyridine carboxilicacid metals Cysteine phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals Cysteine arsenic chlorine alcohol potassium Ru RbSb Dimethylglycine phosphate sulfate sulfone nitrate pyridine carboxilicacid metals Dimethylglycine phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals D-ribose chlorine cyano ester amine nitro nitratebromine D-ribose phosphate sulfate sulfone nitrate pyridine CarboxylicAcid metals Fumaric Acid phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals Galactaric acid phosphate sulfate sulfone nitratepyridine carboxilic acid metals Galactaric acid phosphate sulfatesulfone nitrate pyridine carboxilic acid metals aldehyde Chrysinphosphate sulfate sulfone nitrate pyridine Carboxylic Acid metalsChrysin alchohol ester ether n-oxide chlorine fluorine Chrysin chlorinecyano ester amine nitro nitrate bromine Gentisic acid phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Gentisic acid alchoholester ether n-oxide chlorine fluorine Glucamine, N-methyl phosphatesulfate sulfone nitrate pyridine carboxilic acid metals aldehydeGlucamine, N-methyl phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals Gluconic Acid phosphate sulfate sulfone nitratepyridine Carboxylic Acid metals Gluconic Acid phosphate sulfate sulfonenitrate pyridine carboxilic acid metals Glucosamine phosphate sulfatesulfone nitrate pyridine Carboxylic Acid metals Glucuronic acidphosphate sulfate sulfone nitrate pyridine carboxilic acid metalsGlucuronic acid phosphate sulfate sulfone nitrate pyridine carboxilicacid metals aldehyde Glucuronic acid phosphate sulfate sulfone nitratepyridine aromatic carboxilic acid metals Glutamic Acid phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Glutamic Acid phosphatesulfate sulfone nitrate pyridine carboxilic acid metals Glutaminephosphate sulfate sulfone nitrate pyridine carboxilic acid metalsGlutamine phosphate sulfate sulfone nitrate pyridine Carboxylic Acidmetals Glutamine phosphate sulfate sulfone nitrate pyridine carboxilicacid metals Glutaric Acid phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals Glycine phosphate sulfate sulfone nitratepyridine carboxilic acid metals Glycine phosphate sulfate sulfonenitrate pyridine carboxilic acid metals Glycolic Acid phosphate sulfatesulfone nitrate pyridine Carboxylic Acid metals Glycolic Acid phosphatesulfate sulfone nitrate pyridine carboxilic acid metals Hippuric Acidphosphate sulfate sulfone nitrate pyridine carboxilic acid metalsHippuric Acid phosphate sulfate sulfone nitrate pyridine carboxilic acidmetals Hippuric Acid phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals Histidine phosphate sulfate sulfone nitratepyridine carboxilic acid metals Histidine phosphate sulfate sulfonenitrate pyridine carboxilic acid metals Histidine cyanamide ketone cyanoCarboxylic alcohol thiol amine Acid Hydroquinone phosphate sulfatesulfone nitrate pyridine Carboxylic Acid metals Hydroquinone alchoholester ether n-oxide chlorine fluorine Imidazole phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Ipriflavone chlorinecyano ester amine nitro nitrate bromine Ipriflavone phosphate sulfatesulfone nitrate pyridine Carboxylic Acid metals Isoleucine phosphatesulfate sulfone nitrate pyridine carboxilic acid metals Isoleucinephosphate sulfate sulfone nitrate pyridine carboxilic acid metalslactobionic acid phosphate sulfate sulfone nitrate pyridine carboxilicacid metals Lactobionic acid phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals aldehyde Lactobionic acid chlorine cyano esteramine nitro nitrate bromine Lauric acid phosphate sulfate sulfonenitrate pyridine carboxilic acid Leucine phosphate sulfate sulfonenitrate pyridine Carboxylic Acid metals Leucine phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Lysine phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Lysine phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Maleic phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Malic Acid phosphatesulfate sulfone nitrate pyridine Carboxylic Acid metals Malic Acidphosphate sulfate sulfone nitrate pyridine carboxilic acid metalsMalonic phosphate sulfate sulfone nitrate pyridine carboxilic acidmetals Mandelic Acid phosphate sulfate sulfone nitrate pyridineCarboxylic Acid metals Mandelic Acid phosphate sulfate sulfone nitratepyridine carboxilic acid metals Methionine phosphate sulfate sulfonenitrate pyridine carboxilic acid metals Methionine phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Methionine chlorinecyano ester amine nitro nitrate bromine Nicotinamide *sulfonamide*ketone ether triazole ammonium oxime *chlorine Nicotinamide phosphatesulfate sulfone nitrate pyridine Carboxylic Acid metals Nicotinic Acidphosphate sulfate sulfone nitrate pyridine Carboxylic Acid metalsNicotinic Acid *sulfonamide *ketone ether triazole ammonium oxime*chlorine Orotic acid phosphate sulfate sulfone nitrate pyridinecarboxilic acid Orotic acid phosphate sulfate sulfone nitrate pyridineCarboxylic Acid metals Oxalic acid phosphate sulfate sulfone nitratepyridine carboxilic acid Palmitic acid phosphate sulfate sulfone nitratepyridine carboxilic acid Pamoic acid phosphate sulfate sulfone nitratepyridine carboxilic acid Pamoic acid phosphate sulfate sulfone nitratepyridine carboxilic acid metals aldehyde Pamoic acid alchohol esterether n-oxide chlorine fluorine Phenylalanine phosphate sulfate sulfonenitrate pyridine carboxilic acid metals Phenylalanine phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Piperazine phosphatesulfate sulfone nitrate pyridine carboxilic acid metals Procainephosphate sulfate sulfone nitrate pyridine carboxilic acid metalsProcaine phosphate sulfate sulfone nitrate pyridine Carboxylic Acidmetals Proline phosphate sulfate sulfone nitrate pyridine carboxilicacid metals Proline phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals p-Toluenesulfonic acid amine metals thioethersulfate alcohol Pyridoxamine phosphate sulfate sulfone nitrate pyridineCarboxylic Acid metals Pyridoxamine phosphate sulfate sulfone nitratepyridine carboxilic acid metals Pyridoxamine *sulfonamide *ketone ethertriazole ammonium oxime *chlorine Pyridoxine *sulfonamide *ketone ethertriazole ammonium oxime *chlorine (4-Pyridoxic Acid) Pyridoxinephosphate sulfate sulfone nitrate pyridine Carboxylic Acid metals(4-Pyridoxic Acid) Pyroglutamic acid phosphate sulfate sulfone nitratepyridine carboxilic acid metals Pyroglutamic acid phosphate sulfatesulfone nitrate pyridine Carboxylic Acid metals Quercetin phosphatesulfate sulfone nitrate pyridine Carboxylic Acid metals Quercetinalchohol ester ether n-oxide chlorine fluorine Quercetin chlorine cyanoester amine nitro nitrate bromine Resveratrol phosphate sulfate sulfonenitrate pyridine Carboxylic Acid metals Resveratrol alchohol ester ethern-oxide chlorine fluorine Saccharin phosphate sulfate sulfone nitratepyridine Carboxylic Acid metals Saccharin phosphate sulfate sulfonenitrate pyridine Carboxylic Acid metals Saccharin amine metals thioethersulfate alcohol Saccharin phosphate sulfate sulfone nitrate pyridineCarboxylic Acid metals Salicylic Acid phosphate sulfate sulfone nitratepyridine carboxilic acid metals Salicylic Acid phosphate sulfate sulfonenitrate pyridine Carboxylic Acid metals Salicylic Acid, 4-aminophosphate sulfate sulfone nitrate pyridine carboxilic acid metalsSalicylic Acid, 4-amino phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals aldehyde Salicylic Acid, 4-amino phosphatesulfate sulfone nitrate pyridine carboxilic acid metals Sebacic acidphosphate sulfate sulfone nitrate pyridine carboxilic acid metals Serinephosphate sulfate sulfone nitrate pyridine Carboxylic Acid metals Serinephosphate sulfate sulfone nitrate pyridine carboxilic acid metals Serinephosphate sulfate sulfone nitrate pyridine Carboxylic Acid metalsStearic acid phosphate sulfate sulfone nitrate pyridine carboxilic acidmetals Succinic Acid phosphate sulfate sulfone nitrate pyridineCarboxylic Acid metals Tartaric Acid phosphate sulfate sulfone nitratepyridine Carboxylic Acid metals Threonine phosphate sulfate sulfonenitrate pyridine carboxilic acid metals Threonine phosphate sulfatesulfone nitrate pyridine carboxilic acid metals Threonine phosphatesulfate sulfone nitrate pyridine Carboxylic Acid metals Tris phosphatesulfate sulfone nitrate pyridine carboxilic acid metals Tris phosphatesulfate sulfone nitrate pyridine Carboxylic Acid metals Tryptophanphosphate sulfate sulfone nitrate pyridine carboxilic acid metalsTryptophan phosphate sulfate sulfone nitrate pyridine carboxilic acidmetals Tryptophan *sulfonamide *ketone ether triazole ammonium oxime*chlorine Tyrosine phosphate sulfate sulfone nitrate pyridine carboxilicacid metals Tyrosine phosphate sulfate sulfone nitrate pyridinecarboxilic acid metals Tyrosine phosphate sulfate sulfone nitratepyridine Carboxylic Acid metals Urea phosphate sulfate sulfone nitratepyridine Carboxylic Acid metals Urea phosphate sulfate sulfone nitratepyridine carboxilic acid metals Urea phosphate sulfate sulfone nitratepyridine Carboxylic Acid metals Valine phosphate sulfate sulfone nitratepyridine carboxilic acid metals Valine phosphate sulfate sulfone nitratepyridine carboxilic acid metals Vitamin K5 phosphate sulfate sulfonenitrate pyridine carboxilic acid metals Vitamin K5 phosphate sulfatesulfone nitrate pyridine Carboxylic Acid metals Xylitol phosphatesulfate sulfone nitrate pyridine Carboxylic Acid metals Co-crystalFormer Interacting Group 1,5-Napthalene-disulfonic Acid1-Hydroxy-2-naphthoic acid ester ether cyano furan bromine chlorines-heterocyclic 1-Hydroxy-2-naphthoic acid ester ether cyano furanbromine chlorine s-heterocyclic 4-Aminobenzoic Acid aldehyde ester ethercyano furan bromine chlorine 4-Aminobenzoic Acid aldehyde ester ethercyano furan bromine chlorine 4-aminopyridine aldehyde ester ether cyanofuran bromine chlorine 4-aminopyridine thiol n-heterocyclic ringthionedisulfide pyrrolidindione iodine hydrazone thiocyanate4-Chlorobenzene-Sulfonic Acid 4-ethoxyphenyl Urea aldehyde ester ethercyano furan bromine chlorine 4-ethoxyphenyl Urea aldehyde ester ethercyano furan bromine chlorine 7-oxo-DHEA ester ether cyano furan brominechlorine s-heterocyclic 7-oxo-DHEA aldehyde ester ether cyano furanbromine chlorine Acesulfame Acesulfame aldehyde ester ether cyano furanbromine chlorine Acetohydroxamic Acid aldehyde ester ether cyano furanbromine chlorine Acetohydroxamic Acid aldehyde ester ether cyano furanbromine chlorine Acetohydroxamic Acid aldehyde ester ether cyano furanbromine chlorine Adenine aldehyde ester ether cyano furan brominechlorine Adenine thiol n-heterocyclic ring thionedisulfidepyrrolidindione iodine hydrazone thiocyanate Adipic acid aldehyde esterether cyano furan bromine chlorine Alanine aldehyde ester ether cyanofuran bromine chlorine Alanine aldehyde ester ether cyano furan brominechlorine Allopurinaol aldehyde ester ether cyano furan bromine chlorineAllopurinaol aldehyde ester ether cyano furan bromine chlorine Argininealdehyde ester ether cyano furan bromine chlorine Arginine aldehydeester ether cyano furan bromine chlorine Ascorbic Acid aldehyde esterether cyano furan bromine chlorine Ascorbic Acid aldehyde ester ethercyano furan bromine chlorine Ascorbic Acid aldehyde ester ether cyanofuran bromine chlorine Asparagine aldehyde ester ether cyano furanbromine chlorine Asparagine aldehyde ester ether cyano furan brominechlorine Asparagine aldehyde ester ether cyano furan bromine chlorineAspartic Acid aldehyde ester ether cyano furan bromine chlorine AsparticAcid aldehyde ester ether cyano furan bromine chlorine BenzenesulfonicAcid Benzoic Acid aldehyde ester ether cyano furan bromine chlorineCaffeine aldehyde ester ether cyano furan bromine chlorine Camphoricacid aldehyde ester ether cyano furan bromine chlorine Capric acidaldehyde ester ether cyano furan bromine chlorine Genistein aldehydeester ether cyano furan bromine chlorine Genistein bromine iodine ketonesulfonic acid sulfate phosphate phosphonic acid carboxylic acidGenistein aldehyde ketone peroxide epoxide heterocyclic-S iodineCinnamic acid aldehyde ester ether cyano furan bromine chlorine CitricAcid aldehyde ester ether cyano furan bromine chlorine Citric Acidaldehyde ester ether cyano furan bromine chlorine Clemizole thioln-heterocyclic ring thionedisulfide pyrrolidindione iodine hydrazonethiocyanate Cyclamic Acid aldehyde ester ether cyano furan brominechlorine Cyclamic Acid Cysteine aldehyde ester ether cyano furan brominechlorine Cysteine aldehyde ester ether cyano furan bromine chlorineCysteine Dimethylglycine aldehyde ester ether cyano furan brominechlorine Dimethylglycine aldehyde ester ether cyano furan brominechlorine D-ribose aldehyde ketone peroxide epoxide heterocyclic-S iodineD-ribose aldehyde ester ether cyano furan bromine chlorine Fumaric Acidaldehyde ester ether cyano furan bromine chlorine Galactaric acidaldehyde ester ether cyano furan bromine chlorine Galactaric acid esterether cyano furan bromine chlorine s-heterocyclic Chrysin aldehyde esterether cyano furan bromine chlorine Chrysin bromine iodine ketonesulfonic acid sulfate phosphate phosphonic acid carboxylic acid Chrysinaldehyde ketone peroxide epoxide heterocyclic-S iodine Gentisic acidaldehyde ester ether cyano furan bromine chlorine Gentisic acid bromineiodine ketone sulfonic acid sulfate phosphate phosphonic acid carboxylicacid Glucamine, N-methyl ester ether cyano furan bromine chlorines-heterocyclic Glucamine, N-methyl aldehyde ester ether cyano furanbromine chlorine Gluconic Acid aldehyde ester ether cyano furan brominechlorine Gluconic Acid aldehyde ester ether cyano furan bromine chlorineGlucosamine aldehyde ester ether cyano furan bromine chlorine Glucuronicacid aldehyde ester ether cyano furan bromine chlorine Glucuronic acidester ether cyano furan bromine chlorine s-heterocyclic Glucuronic acidaldehyde ester ether cyano furan bromine chlorine Glutamic Acid aldehydeester ether cyano furan bromine chlorine Glutamic Acid aldehyde esterether cyano furan bromine chlorine Glutamine aldehyde ester ether cyanofuran bromine chlorine Glutamine aldehyde ester ether cyano furanbromine chlorine Glutamine aldehyde ester ether cyano furan brominechlorine Glutaric Acid aldehyde ester ether cyano furan bromine chlorineGlycine aldehyde ester ether cyano furan bromine chlorine Glycinealdehyde ester ether cyano furan bromine chlorine Glycolic Acid aldehydeester ether cyano furan bromine chlorine Glycolic Acid aldehyde esterether cyano furan bromine chlorine Hippuric Acid aldehyde ester ethercyano furan bromine chlorine Hippuric Acid aldehyde ester ether cyanofuran bromine chlorine Hippuric Acid aldehyde ester ether cyano furanbromine chlorine Histidine aldehyde ester ether cyano furan brominechlorine Histidine aldehyde ester ether cyano furan bromine chlorineHistidine phosphinic acid hemihydrate chlorine sulfonyl sulfoxide amidefluorine sulfonate ester Hydroquinone aldehyde ester ether cyano furanbromine chlorine Hydroquinone bromine iodine ketone sulfonic acidsulfate phosphate phosphonic acid carboxylic acid Imidazole aldehydeester ether cyano furan bromine chlorine Ipriflavone aldehyde ketoneperoxide epoxide heterocyclic-S iodine Ipriflavone aldehyde ester ethercyano furan bromine chlorine Isoleucine aldehyde ester ether cyano furanbromine chlorine Isoleucine aldehyde ester ether cyano furan brominechlorine lactobionic acid aldehyde ester ether cyano furan brominechlorine Lactobionic acid ester ether cyano furan bromine chlorines-heterocyclic Lactobionic acid aldehyde ketone peroxide epoxideheterocyclic-S iodine Lauric acid aldehyde ester ether cyano furanbromine chlorine Leucine aldehyde ester ether cyano furan brominechlorine Leucine aldehyde ester ether cyano furan bromine chlorineLysine aldehyde ester ether cyano furan bromine chlorine Lysine aldehydeester ether cyano furan bromine chlorine Maleic aldehyde ester ethercyano furan bromine chlorine Malic Acid aldehyde ester ether cyano furanbromine chlorine Malic Acid aldehyde ester ether cyano furan brominechlorine Malonic aldehyde ester ether cyano furan bromine chlorineMandelic Acid aldehyde ester ether cyano furan bromine chlorine MandelicAcid aldehyde ester ether cyano furan bromine chlorine Methioninealdehyde ester ether cyano furan bromine chlorine Methionine aldehydeester ether cyano furan bromine chlorine Methionine aldehyde ketoneperoxide epoxide Ag Se heterocyclic-S iodine Nicotinamide thioln-heterocyclic ring thionedisulfide pyrrolidindione iodine hydrazonethiocyanate Nicotinamide aldehyde ester ether cyano furan brominechlorine Nicotinic Acid aldehyde ester ether cyano furan brominechlorine Nicotinic Acid thiol n-heterocyclic ring thionedisulfidepyrrolidindione iodine hydrazone thiocyanate Orotic acid aldehyde esterether cyano furan bromine chlorine Orotic acid aldehyde ester ethercyano furan bromine chlorine Oxalic acid aldehyde ester ether cyanofuran bromine chlorine Palmitic acid aldehyde ester ether cyano furanbromine chlorine Pamoic acid aldehyde ester ether cyano furan brominechlorine Pamoic acid ester ether cyano furan bromine chlorines-heterocyclic Pamoic acid bromine iodine ketone sulfonic acid sulfatephosphate phosphonic acid carboxylic acid Phenylalanine aldehyde esterether cyano furan bromine chlorine Phenylalanine aldehyde ester ethercyano furan bromine chlorine Piperazine aldehyde ester ether cyano furanbromine chlorine Procaine aldehyde ester ether cyano furan brominechlorine Procaine aldehyde ester ether cyano furan bromine chlorineProline aldehyde ester ether cyano furan bromine chlorine Prolinealdehyde ester ether cyano furan bromine chlorine p-Toluenesulfonic acidPyridoxamine aldehyde ester ether cyano furan bromine chlorinePyridoxamine aldehyde ester ether cyano furan bromine chlorinePyridoxamine thiol n-heterocyclic ring thionedisulfide iodine hydrazonethiocyanate Pyridoxine thiol n-heterocyclic ring thionedisulfidepyrrolidindione iodine hydrazone thiocyanate (4-Pyridoxic Acid)Pyridoxine aldehyde ester ether cyano furan bromine chlorine(4-Pyridoxic Acid) Pyroglutamic acid aldehyde ester ether cyano furanbromine chlorine Pyroglutamic acid aldehyde ester ether cyano furanbromine chlorine Quercetin aldehyde ester ether cyano furan brominechlorine Quercetin bromine iodine ketone sulfonic acid sulfate phosphatephosphonic acid carboxylic acid Quercetin aldehyde ketone peroxideepoxide heterocyclic-S iodine Resveratrol aldehyde ester ether cyanofuran bromine chlorine Resveratrol bromine iodine ketone sulfonic acidsulfate phosphate phosphonic acid carboxylic acid Saccharin aldehydeester ether cyano furan bromine chlorine Saccharin aldehyde ester ethercyano furan bromine chlorine Saccharin Saccharin aldehyde ester ethercyano furan bromine chlorine Salicylic Acid aldehyde ester ether cyanofuran bromine chlorine Salicylic Acid aldehyde ester ether cyano furanbromine chlorine Salicylic Acid, 4-amino aldehyde ester ether cyanofuran bromine chlorine Salicylic Acid, 4-amino ester ether cyano furanbromine chlorine s-heterocyclic Salicylic Acid, 4-amino aldehyde esterether cyano furan bromine chlorine Sebacic acid aldehyde ester ethercyano furan bromine chlorine Serine aldehyde ester ether cyano furanbromine chlorine Serine aldehyde ester ether cyano furan brominechlorine Serine aldehyde ester ether cyano furan bromine chlorineStearic acid aldehyde ester ether cyano furan bromine chlorine SuccinicAcid aldehyde ester ether cyano furan bromine chlorine Tartaric Acidaldehyde ester ether cyano furan bromine chlorine Threonine aldehydeester ether cyano furan bromine chlorine Threonine aldehyde ester ethercyano furan bromine chlorine Threonine aldehyde ester ether cyano furanbromine chlorine Tris aldehyde ester ether cyano furan bromine chlorineTris aldehyde ester ether cyano furan bromine chlorine Tryptophanaldehyde ester ether cyano furan bromine chlorine Tryptophan aldehydeester ether cyano furan bromine chlorine Tryptophan thiol n-heterocyclicring thionedisulfide pyrrolidindione iodine hydrazone thiocyanateTyrosine aldehyde ester ether cyano furan bromine chlorine Tyrosinealdehyde ester ether cyano furan bromine chlorine Tyrosine aldehydeester ether cyano furan bromine chlorine Urea aldehyde ester ether cyanofuran bromine chlorine Urea aldehyde ester ether cyano furan brominechlorine Urea aldehyde ester ether cyano furan bromine chlorine Valinealdehyde ester ether cyano furan bromine chlorine Valine aldehyde esterether cyano furan bromine chlorine Vitamin K5 aldehyde ester ether cyanofuran bromine chlorine Vitamin K5 aldehyde ester ether cyano furanbromine chlorine Xylitol aldehyde ester ether cyano furan brominechlorine Co-crystal Former Interacting Group 1,5-Napthalene-disulfonicAcid 1-Hydroxy-2-naphthoic acid pyridine cyano n-heterocyclic ketonephosphate ester fluorine carbamate 1-Hydroxy-2-naphthoic acid pyridinecyano n-heterocyclic ketone phosphate ester fluorine carbamate4-Aminobenzoic Acid s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine 4-Aminobenzoic Acid s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine 4-aminopyridines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine 4-aminopyridine *bromine hydroxamic acid cyano carboxamide*sulfonic acid *phosphoric acid N-oxide 4-Chlorobenzene-Sulfonic Acid4-ethoxyphenyl Urea s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine 4-ethoxyphenyl Urea s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine 7-oxo-DHEA pyridinecyano n-heterocyclic ketone phosphate ester fluorine carbamate7-oxo-DHEA s-heterocyclic pyridine cyano n-heterocyclic ketone phosphateester fluorine Acesulfame Acesulfame s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Acetohydroxamic Acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Acetohydroxamic Acid s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Acetohydroxamic Acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Adenine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Adenine *bromine hydroxamic acid cyanocarboxamide *sulfonic acid *phosphoric acid N-oxide Adipic acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Alanine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Alanine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Allopurinaols-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Allopurinaol s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Arginine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Arginine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine AscorbicAcid s-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Ascorbic Acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Ascorbic Acid s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine Asparagines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Asparagine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Asparagine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Aspartic Acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Aspartic Acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Benzenesulfonic Acid Benzoic Acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Caffeine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Camphoric acid s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Capric acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Genistein s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Genistein nitro sulfone analine Genistein esterether carboxylic acid sulfate sulfone alcohol Cinnamic acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Citric Acid s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Citric Acid s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Clemizole *brominehydroxamic acid cyano carboxamide *sulfonic acid *phosphoric acidN-oxide Cyclamic Acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Cyclamic Acid Cysteine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Cysteines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Cysteine Dimethylglycine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Dimethylglycines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine D-ribose ester ether carboxylic acid sulfate sulfone alcoholD-ribose s-heterocyclic pyridine cyano n-heterocyclic ketone phosphateester fluorine Fumaric Acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Galactaric acid s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine Galactaric acidpyridine cyano n-heterocyclic ketone phosphate ester fluorine carbamateChrysin s-heterocyclic pyridine cyano n-heterocyclic ketone phosphateester fluorine Chrysin nitro sulfone analine Chrysin ester ethercarboxylic acid sulfate sulfone alcohol Gentisic acid s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Gentisicacid nitro sulfone analine Glucamine, N-methyl pyridine cyanon-heterocyclic ketone phosphate ester fluorine carbamate Glucamine,N-methyl s-heterocyclic pyridine cyano n-heterocyclic ketone phosphateester fluorine Gluconic Acid s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Gluconic Acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Glucosamine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Glucuronic acid s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Glucuronic acid pyridinecyano n-heterocyclic ketone phosphate ester fluorine carbamateGlucuronic acid s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Glutamic Acid s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Glutamic Acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Glutamine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Glutamine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Glutamine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine GlutaricAcid s-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Glycine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Glycine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Glycolic Acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Glycolic Acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Hippuric Acid s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine Hippuric Acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Hippuric Acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Histidine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Histidine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine HistidineHydroquinone s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Hydroquinone nitro sulfone analine Imidazoles-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Ipriflavone ester ether carboxylic acid sulfate sulfone alcoholIpriflavone s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Isoleucine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Isoleucine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorinelactobionic acid s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Lactobionic acid pyridine cyano n-heterocyclicketone phosphate ester fluorine carbamate Lactobionic acid ester ethercarboxylic acid sulfate sulfone alcohol Lauric acid s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Leucines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Leucine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Lysine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Lysine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Maleics-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Malic Acid s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Malic Acid s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Malonic s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine MandelicAcid s-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Mandelic Acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Methionine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Methionine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Methionineester ether carboxylic acid sulfate sulfone alcohol Nicotinamide*bromine hydroxamic acid cyano carboxamide *sulfonic acid *phosphoricacid N-oxide Nicotinamide s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Nicotinic Acid s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine Nicotinic Acid*bromine hydroxamic acid cyano carboxamide *sulfonic acid *phosphoricacid N-oxide Orotic acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Orotic acid s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine Oxalic acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Palmitic acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Pamoic acid s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine Pamoic acidpyridine cyano n-heterocyclic ketone phosphate ester fluorine carbamatePamoic acid nitro sulfone analine Phenylalanine s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine Phenylalanines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Piperazine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Procaine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Procaine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Prolines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Proline s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine p-Toluenesulfonic acid Pyridoxamines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Pyridoxamine s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Pyridoxamine *bromine hydroxamic acidcyano carboxamide *sulfonic acid *phosphoric acid N-oxide Pyridoxine*bromine hydroxamic acid cyano carboxamide *sulfonic acid *phosphoricacid N-oxide (4-Pyridoxic Acid) Pyridoxine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine (4-Pyridoxic Acid)Pyroglutamic acid s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Pyroglutamic acid s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Quercetin s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Quercetinnitro sulfone analine Quercetin ester ether carboxylic acid sulfatesulfone alcohol Resveratrol s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Resveratrol nitro sulfone analineSaccharin s-heterocyclic pyridine cyano n-heterocyclic ketone phosphateester fluorine Saccharin s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Saccharin Saccharin s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine SalicylicAcid s-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Salicylic Acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Salicylic Acid, 4-amino s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine SalicylicAcid, 4-amino pyridine cyano n-heterocyclic ketone phosphate esterfluorine carbamate Salicylic Acid, 4-amino s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Sebacic acids-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Serine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Serine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Serine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Stearicacid s-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Succinic Acid s-heterocyclic pyridine cyano n-heterocyclicketone phosphate ester fluorine Tartaric Acid s-heterocyclic pyridinecyano n-heterocyclic ketone phosphate ester fluorine Threonines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Threonine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Threonine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Tris s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Triss-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Tryptophan s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Tryptophan s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Tryptophan *brominehydroxamic acid cyano carboxamide *sulfonic acid *phosphoric acidN-oxide Tyrosine s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Tyrosine s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Tyrosine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Ureas-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Urea s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Urea s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Valine s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Valines-heterocyclic pyridine cyano n-heterocyclic ketone phosphate esterfluorine Vitamin K5 s-heterocyclic pyridine cyano n-heterocyclic ketonephosphate ester fluorine Vitamin K5 s-heterocyclic pyridine cyanon-heterocyclic ketone phosphate ester fluorine Xylitol s-heterocyclicpyridine cyano n-heterocyclic ketone phosphate ester fluorine Co-crystalFormer Interacting Group 1,5-Napthalene-disulfonic Acid1-Hydroxy-2-naphthoic acid imidazole BF4 1-Hydroxy-2-naphthoic acidimidazole BF4 4-Aminobenzoic Acid carbamate imidazole BF4 N-SO2 thioureaiodine 4-Aminobenzoic Acid carbamate imidazole BF4 N-SO2 thiourea iodine4-aminopyridine carbamate imidazole BF4 N-SO2 thiourea iodine4-aminopyridine ester ether fluorine acetate thionedithiadiazocyclopentadienyl 4-Chlorobenzene-Sulfonic Acid 4-ethoxyphenylUrea carbamate imidazole BF4 N-SO2 thiourea iodine epoxide peroxide4-ethoxyphenyl Urea carbamate imidazole BF4 N-SO2 thiourea iodine7-oxo-DHEA imidazole BF4 7-oxo-DHEA carbamate imidazole BF4 N-SO2thiourea iodine Acesulfame Acesulfame carbamate imidazole BF4 N-SO2thiourea iodine epoxide peroxide Acetohydroxamic Acid carbamateimidazole BF4 N-SO2 thiourea iodine epoxide peroxide AcetohydroxamicAcid carbamate imidazole BF4 N-SO2 thiourea iodine Acetohydroxamic Acidcarbamate imidazole BF4 N-SO2 thiourea iodine epoxide Adenine carbamateimidazole BF4 N-SO2 thiourea iodine Adenine ester ether fluorine acetatethione dithiadiazocyclopentadienyl Adipic acid carbamate imidazole BF4N-SO2 thiourea iodine Alanine carbamate imidazole BF4 N-SO2 thioureaiodine Alanine carbamate imidazole BF4 N-SO2 thiourea iodineAllopurinaol carbamate imidazole BF4 N-SO2 thiourea iodine epoxideAllopurinaol carbamate imidazole BF4 N-SO2 thiourea iodine Argininecarbamate imidazole BF4 N-SO2 thiourea iodine Arginine carbamateimidazole BF4 N-SO2 thiourea iodine Ascorbic Acid carbamate imidazoleBF4 N-SO2 thiourea iodine Ascorbic Acid carbamate imidazole BF4 N-SO2thiourea iodine epoxide Ascorbic Acid carbamate imidazole BF4 N-SO2thiourea iodine Asparagine carbamate imidazole BF4 N-SO2 thiourea iodineAsparagine carbamate imidazole BF4 N-SO2 thiourea iodine epoxideperoxide Asparagine carbamate imidazole BF4 N-SO2 thiourea iodineAspartic Acid carbamate imidazole BF4 N-SO2 thiourea iodine AsparticAcid carbamate imidazole BF4 N-SO2 thiourea iodine Benzenesulfonic AcidBenzoic Acid carbamate imidazole BF4 N-SO2 thiourea iodine Caffeinecarbamate imidazole BF4 N-SO2 thiourea iodine Camphoric acid carbamateimidazole BF4 N-SO2 thiourea iodine Capric acid carbamate imidazole BF4N-SO2 thiourea iodine Genistein carbamate imidazole BF4 N-SO2 thioureaiodine Genistein Genistein phospphate cyanamide Cinnamic acid carbamateimidazole BF4 N-SO2 thiourea iodine Citric Acid carbamate imidazole BF4N-SO2 thiourea iodine epoxide Citric Acid carbamate imidazole BF4 N-SO2thiourea iodine Clemizole ester ether fluorine acetate thionedithiadiazocyclopentadienyl Cyclamic Acid carbamate imidazole BF4 N-SO2thiourea iodine Cyclamic Acid Cysteine carbamate imidazole BF4 N-SO2thiourea iodine Cysteine carbamate imidazole BF4 N-SO2 thiourea iodineCysteine Dimethylglycine carbamate imidazole BF4 N-SO2 thiourea iodineDimethylglycine carbamate imidazole BF4 N-SO2 thiourea iodine D-ribosephospphate cyanamide D-ribose carbamate imidazole BF4 N-SO2 thioureaiodine epoxide Fumaric Acid carbamate imidazole BF4 N-SO2 thioureaiodine Galactaric acid carbamate imidazole BF4 N-SO2 thiourea iodineGalactaric acid imidazole BF4 Chrysin carbamate imidazole BF4 N-SO2thiourea iodine Chrysin Chrysin phospphate cyanamide Gentisic acidcarbamate imidazole BF4 N-SO2 thiourea iodine Gentisic acid Glucamine,N-methyl imidazole BF4 Glucamine, N-methyl carbamate imidazole BF4 N-SO2thiourea iodine Gluconic Acid carbamate imidazole BF4 N-SO2 thioureaiodine epoxide Gluconic Acid carbamate imidazole BF4 N-SO2 thioureaiodine Glucosamine carbamate imidazole BF4 N-SO2 thiourea iodine epoxideGlucuronic acid carbamate imidazole BF4 N-SO2 thiourea iodine Glucuronicacid imidazole BF4 Glucuronic acid carbamate imidazole BF4 alkanearomatic N-SO2 thiourea iodine epoxide Glutamic Acid carbamate imidazoleBF4 N-SO2 thiourea iodine Glutamic Acid carbamate imidazole BF4 N-SO2thiourea iodine Glutamine carbamate imidazole BF4 N-SO2 thiourea iodineGlutamine carbamate imidazole BF4 N-SO2 thiourea iodine epoxide peroxideGlutamine carbamate imidazole BF4 N-SO2 thiourea iodine Glutaric Acidcarbamate imidazole BF4 N-SO2 thiourea iodine Glycine carbamateimidazole BF4 N-SO2 thiourea iodine Glycine carbamate imidazole BF4N-SO2 thiourea iodine Glycolic Acid carbamate imidazole BF4 N-SO2thiourea iodine epoxide Glycolic Acid carbamate imidazole BF4 N-SO2thiourea iodine Hippuric Acid carbamate imidazole BF4 N-SO2 thioureaiodine epoxide peroxide Hippuric Acid carbamate imidazole BF4 N-SO2thiourea iodine Hippuric Acid carbamate imidazole BF4 N-SO2 thioureaiodine Histidine carbamate imidazole BF4 N-SO2 thiourea iodine Histidinecarbamate imidazole BF4 N-SO2 thiourea iodine Histidine Hydroquinonecarbamate imidazole BF4 N-SO2 thiourea iodine epoxide HydroquinoneImidazole carbamate imidazole BF4 N-SO2 thiourea iodine Ipriflavonephospphate cyanamide Ipriflavone carbamate imidazole BF4 N-SO2 thioureaiodine Isoleucine carbamate imidazole BF4 N-SO2 thiourea iodineIsoleucine carbamate imidazole BF4 N-SO2 thiourea iodine lactobionicacid carbamate imidazole BF4 N-SO2 thiourea iodine Lactobionic acidimidazole BF4 Lactobionic acid phospphate cyanamide Lauric acidcarbamate imidazole BF4 N-SO2 thiourea iodine Leucine carbamateimidazole BF4 N-SO2 thiourea iodine Leucine carbamate imidazole BF4N-SO2 thiourea iodine Lysine carbamate imidazole BF4 N-SO2 thioureaiodine Lysine carbamate imidazole BF4 N-SO2 thiourea iodine Maleiccarbamate imidazole BF4 N-SO2 thiourea iodine Malic Acid carbamateimidazole BF4 N-SO2 thiourea iodine epoxide Malic Acid carbamateimidazole BF4 N-SO2 thiourea iodine Malonic carbamate imidazole BF4N-SO2 thiourea iodine Mandelic Acid carbamate imidazole BF4 N-SO2thiourea iodine epoxide Mandelic Acid carbamate imidazole BF4 N-SO2thiourea iodine Methionine carbamate imidazole BF4 N-SO2 thiourea iodineMethionine carbamate imidazole BF4 N-SO2 thiourea iodine Methioninephospphate Nicotinamide ester ether fluorine acetate thionedithiadiazocyclopentadienyl Nicotinamide carbamate imidazole BF4 N-SO2thiourea iodine epoxide peroxide Nicotinic Acid carbamate imidazole BF4N-SO2 thiourea iodine Nicotinic Acid ester ether fluorine acetate thionedithiadiazocyclopentadienyl Orotic acid carbamate imidazole BF4 N-SO2thiourea iodine Orotic acid carbamate imidazole BF4 N-SO2 thioureaiodine epoxide peroxide Oxalic acid carbamate imidazole BF4 N-SO2thiourea iodine Palmitic acid carbamate imidazole BF4 N-SO2 thioureaiodine Pamoic acid carbamate imidazole BF4 N-SO2 thiourea iodine Pamoicacid imidazole BF4 Pamoic acid Phenylalanine carbamate imidazole BF4N-SO2 thiourea iodine Phenylalanine carbamate imidazole BF4 N-SO2thiourea iodine Piperazine carbamate imidazole BF4 N-SO2 thiourea iodineProcaine carbamate imidazole BF4 N-SO2 thiourea iodine Procainecarbamate imidazole BF4 N-SO2 thiourea iodine Proline carbamateimidazole BF4 N-SO2 thiourea iodine Proline carbamate imidazole BF4N-SO2 thiourea iodine p-Toluenesulfonic acid Pyridoxamine carbamateimidazole BF4 N-SO2 thiourea iodine epoxide Pyridoxamine carbamateimidazole BF4 N-SO2 thiourea iodine Pyridoxamine ester ether fluorineacetate thione dithiadiazocyclopentadienyl Pyridoxine ester etherfluorine acetate thione dithiadiazocyclopentadienyl (4-Pyridoxic Acid)Pyridoxine carbamate imidazole BF4 N-SO2 thiourea iodine epoxide(4-Pyridoxic Acid) Pyroglutamic acid carbamate imidazole BF4 N-SO2thiourea iodine Pyroglutamic acid carbamate imidazole BF4 N-SO2 thioureaiodine epoxide peroxide Quercetin carbamate imidazole BF4 N-SO2 thioureaiodine Quercetin Quercetin phospphate cyanamide Resveratrol carbamateimidazole BF4 N-SO2 thiourea iodine Resveratrol Saccharin carbamateimidazole BF4 N-SO2 thiourea iodine epoxide peroxide Saccharin carbamateimidazole BF4 N-SO2 thiourea iodine Saccharin Saccharin carbamateimidazole BF4 N-SO2 thiourea iodine Salicylic Acid carbamate imidazoleBF4 N-SO2 thiourea iodine Salicylic Acid carbamate imidazole BF4 N-SO2thiourea iodine epoxide Salicylic Acid, 4-amino carbamate imidazole BF4N-SO2 thiourea iodine Salicylic Acid, 4-amino imidazole BF4 SalicylicAcid, 4-amino carbamate imidazole BF4 N-SO2 thiourea iodine Sebacic acidcarbamate imidazole BF4 N-SO2 thiourea iodine Serine carbamate imidazoleBF4 N-SO2 thiourea iodine Serine carbamate imidazole BF4 N-SO2 thioureaiodine Serine carbamate imidazole BF4 N-SO2 thiourea iodine epoxideStearic acid carbamate imidazole BF4 N-SO2 thiourea iodine Succinic Acidcarbamate imidazole BF4 N-SO2 thiourea iodine Tartaric Acid carbamateimidazole BF4 N-SO2 thiourea iodine Threonine carbamate imidazole BF4N-SO2 thiourea iodine Threonine carbamate imidazole BF4 N-SO2 thioureaiodine Threonine carbamate imidazole BF4 N-SO2 thiourea iodine epoxideTris carbamate imidazole BF4 N-SO2 thiourea iodine Tris carbamateimidazole BF4 N-SO2 thiourea iodine epoxide Tryptophan carbamateimidazole BF4 N-SO2 thiourea iodine Tryptophan carbamate imidazole BF4N-SO2 thiourea iodine Tryptophan ester ether fluorine acetate thionedithiadiazocyclopentadienyl Tyrosine carbamate imidazole BF4 N-SO2thiourea iodine Tyrosine carbamate imidazole BF4 N-SO2 thiourea iodineTyrosine carbamate imidazole BF4 N-SO2 thiourea iodine epoxide Ureacarbamate imidazole BF4 N-SO2 thiourea iodine Urea carbamate imidazoleBF4 N-SO2 thiourea iodine Urea carbamate imidazole BF4 N-SO2 thioureaiodine epoxide peroxide Valine carbamate imidazole BF4 N-SO2 thioureaiodine Valine carbamate imidazole BF4 N-SO2 thiourea iodine Vitamin K5carbamate imidazole BF4 N-SO2 thiourea iodine Vitamin K5 carbamateimidazole BF4 N-S02 thiourea iodine epoxide Xylitol carbamate imidazoleBF4 N-SO2 thiourea iodine epoxide

TABLE III Functional Group Functional Group Structure Interacting Grouppyridine

*alcohol pyridinium *amide nitro *amine *carboxilic acid imidazol

imidazole chlorine acetamide carboxylate thione nitro Hydroxamic acid

hydroxamic acid alcohol phosphinic ester alkane pyridine amide peroxideR—O—OH ester peroxide amide ether alkane N-heterocycle epoxide

alkane bromine alcohol ester epoxide amide thioester

aromatic thioester alkane sulfamide hydroxy bromine thioketone

alkane thioketone ketone SULFAMIDE AMINE thiol Functional Group pyridine*sulfonamide *ketone ether triazole alkane ammonium oxime *chlorinealkyne imidazole cyanamide ketone cyano carboxilic alcohol alkane thiolamine phosphinic acid acid hemihydrate Hydroxamic acid sulfonamidecarboxylate phosphine amine aromatic peroxide aromatic alcoholpyrimidinedione analine thiazole peroxy acid ketone carboxilic acidazide epoxide alkene hydrazone aromatic thioether ketone aldehydechlorine carboxilic acid alkyne thioester iodine amine cyano thioketoneamide chlorine nitro thioketone sulfoxide oxo chlorine bromine AROMATICalkene sulfone iodine AZOXY pyridin thiol n-heterocyclic ringthionedisulfide pyrrolidindione iodine hydrazone thiocyanate *brominearomatic imidazole chlorine sulfonyl sulfoxide amide fluorine sulfonateester Hydroxamic acid peroxide phosphine oxide sulfonamide analineepoxide ammonium fluorine nitro amine cyano thio ster thioketonepotassium epoxide n-oxide cyano iron cobalt amine sulfate pyridinehydroxamic acid cyano carboxamide *sulfonic acid *phosphoric acidN-oxide ester ether fluorine acetate thione imidazole Hydroxamic acidperoxide epoxide thioester thioketone pyridine dithiadiazocyclopentadienyl imidazole Hydroxamic acid peroxide epoxide thioesterthioketone Functional Group Functional Group Structure Interacting Groupnitrate ester

aromatic amide alkane chlorine nitrate ester bromine Thiophosphateester-O

amine imidazole cyclic amide Phosphate ester

aromatic alcohol phosphate ester aromatic N- ring pyridine analineKetone

alcohol ketone thiol amide amine analine Aldehyde

alcohol ketone thiol amide amine analine Thiol R—SH carboxylic acidsodium aldehyde ketone aromatic-N cadmium Alcohol R—OH alcohol ketonethiol amide amine analine Functional Group nitrate est r alcohol etheracetate Thiophosphate ester-O Phosphate ester amine sodium potassiumlithium carboxylic amide alkane acid Ketone phenol phosphate sulfatesulfone nitrate pyridine aromatic carboxilic acid metals Aldehyde phenolphosphate sulfate sulfone nitrate pyridine aromatic carboxilic acidmetals Thiol alkane arsenic chlorine alcohol potassium Ru aromatic Rb SbAlcohol phenol phosphate sulfate sulfone nitrate pyridine aromaticcarboxilic acid metals nitrate ester Thiophosphate ester-O Phosphateester Ketone aldehyde ester ether cyano furan bromine chlorines-heterocyclic Aldehyde aldehyde ester ether cyano furan brominechlorine s-heterocyclic Thiol Alcohol aldehyde ester ether cyano furanbromine chlorine s-heterocyclic nitrate ester Thiophosphate ester-OPhosphate ester Ketone pyridine cyano n-heterocyclic ketone phosphatefluorine carbamate imidazole BF4 alkane ester Aldehyde pyridine cyanon-heterocyclic ketone phosphate fluorine carbamate imidazole BF4 alkaneester Thiol Alcohol pyridine cyano n-heterocyclic ketone phosphatefluorine carbamate imidazole BF4 alkane ester nitrat ester Thiophosphatest r-O Phosphate ester Ketone aromatic N-SO2 thiourea iodine Aldehydearomatic N-SO2 thiourea iodine epoxide Thiol Alcohol aromatic N-SO2thiourea iodine epoxide Functional Group Functional Group StructureInteracting Group Thioether

aromatic-N amide amine aromatic_s Sp2 amine sulfoxide Ether

aromatic-N amide amine aromatic_s Sp2 amine sulfoxide Cyanamide

cyano amine potassium aromatic-N bromine sodium Thiocyanate

aromatic-S ester ether sP2 amine

thioether ether metals MoOCl4 BF4 bromine Amine primary R—NH₂ alcoholketone thiol amide amine analine Amine secondary R₂—NH alcohol ketonethiol amide amine analine Functional Group Thioether chlorate chlorinealkyne cyano ester amine nitro nitrate bromine Ether chlorate chlorinealkyne cyano ester amine nitro nitrate bromine Cyanamide imidazole ethern-heterocyclic alcohol cesium Ag Thiocyanate sP2 amine chlorine Sp2amine sulfate Osmium Amin primary phenol phosphate sulfate sulfonenitrate pyridine aromatic carboxilic acid metals Amine secondary phenolphosphate sulfate sulfone nitrate pyridine aromatic carboxilic acidmetals Thioether aldehyde ketone peroxide epoxide Ag Se hetero- iodineester cyclic-S Ether aldehyde ketone peroxide epoxide Ag Se hetero-iodine ester cyclic-S Cyanamide Thiocyanate sP2 amine Amine primaryaldehyde ester ether cyano furan bromine chlorine s-heterocyclic Aminesecondary aldehyde ester ether cyano furan bromine chlorines-heterocyclic Thioether ether carboxylic sulfate sulfone alkane alcoholphospphate acid Ether ether carboxylic sulfate sulfone alkane alcoholphospphate cyanamide acid Cyanamide Thiocyanate sP2 amine Amine primarypyridine cyano n-heterocyclic ketone phosphate fluorine carbamateimidazole BF4 alkane ester Amine secondary pyridine cyano n-heterocyclicketone phosphate fluorine carbamate imidazole BF4 alkane ester ThioetherEther Cyanamide Thiocyanate sP2 amine Amine primary aromatic N-SO2thiourea iodine Amine secondary aromatic N-SO2 thiourea iodineFunctional Group Functional Group Structure Interacting Group Amin trtiary R₃—N alcohol ketone thiol amide amine analine Amide

alcohol ketone thiol amide amine analine Sulfonic acid

pyridine ketone aldehyde ether ester amide Phosphinic acid

alkane potassium lithium n-heterocyclic oxime amide Phosphonic acid

alkane potassium lithium n-heterocyclic oxime amide Carboxylic acid

alcohol ketone thiol amide amine analine Functional Group Amine tertiaryphenol phosphate sulfate sulfone nitrate pyridine aromatic carboxilicacid metals Amide phenol phosphate sulfate sulfone nitrate pyridinearomatic carboxilic acid metals Sulfonic acid carboxilic acid aminemetals thioether sulfate alcohol Phosphinic acid phenol aromatic aminealcohol metals Phosphonic acid phenol aromatic amine alcohol metalscarboxylic Sp2 amine analine acid Carboxylic acid phenol phosphatesulfate sulfone nitrate pyridine aromatic carboxilic acid metals Aminetertiary aldehyde ester ether cyano furan bromine chlorines-heterocyclic Amide aldehyde ester ether cyano furan bromine chlorines-heterocyclic Sulfonic acid Phosphinic acid Phosphonic acid etherphosphonic aromatic-N ketone aldehyde imidazole acid Carboxylic acidaldehyde ester ether cyano furan bromine chlorine s-heterocyclic Aminetertiary pyridine cyano n-heterocyclic ketone phosphate fluorinecarbamate imidazole BF4 alkane ester Amide pyridine cyano n-heterocyclicketone phosphate fluorine carbamate imidazole BF4 alkane ester Sulfonicacid Phosphinic acid Phosphonic acid Carboxylic acid pyridine cyanon-heterocyclic ketone phosphate fluorine carbamate imidazole BF4 alkaneester Amine tertiary aromatic N-SO2 thiourea iodine Amide aromatic N-SO2thiourea iodine epoxide peroxide Sulfonic acid Phosphinic acidPhosphonic acid Carboxylic acid aromatic N-SO2 thiourea iodineFunctional Group Functional Group Structure Interacting Group Sulfateester

pyridine ketone aldehyde ether ester amide Oxime

alcohol alkane amine amide ether ester Nitrile

metal ketone phenol alcohol cyano Diazo

Oxime Nitro NO₂ pyridine ketone aldehyde ether ester amideS-heterocyclic ring

alcohol thioketone thioether s-heterocyclic ketone aromatic Thiophene

chlorine fluorine amide ketone NO SO Functional Group Sulfate estercarboxilic acid amine metals thioether sulfate alcohol Oxime pyridinen-aromatic chlorate chlorine Sp2-N diazo thioketone cyano n-oxideNitrile amine analine bromine amide alkane carboxylic chlorinen-heterocyclic aromatic acid Diazo Nitro carboxilic acid amine metalsthioether sulfate alcohol S-heterocyclic alkene amine chlorine BF4sulfate ester NO ether amide ring Thiophene CO Sulfate ester Oximeketone aldehyde carboxylic acid bromine aromatic pyridine BF4 Nitrilepotassium aldehyde thioether pyridine n-aromatic bromine ethers-aromatic thiophene Diazo Nitro S-heterocyclic iodine carboxylic sodiumcyano chloride furan ring acid Thiophene Sulfate ester Oxime NitrileDiazo Nitro S-heterocyclic ring Thiophene Sulfate ester Oxime NitrileDiazo Nitro S-heterocyclic ring Thiophene Functional Group FunctionalGroup Structure Interacting Group N-heterocyclic ring

alcohol thioketone thioether s-heterocyclic ketone aromaticO-heterocyclic ring

alcohol thioketone thioether s-heterocyclic ketone aromatic Pyrrole

chlorine fluorine amide ketone NO SO Furan

s-heterocyclic Functional Group N-heterocyclic alkene amine chlorine BF4sulfate ester NO ether amide ring O-heterocyclic alkene amine chlorineBF4 sulfate ester NO ether amide ring Pyrrole CO imidazole pyridinen-aromatic aldehyde carboxylic sulfate chlorine bromine acid FuranN-heterocyclic iodine carboxylic sodium cyano chloride aldehyde ringacid O-heterocyclic iodine carboxylic sodium cyano chloride aldehydering acid Pyrrole oxime alcohol phenol ester ether Furan N-heterocyclicring O-heterocyclic ring Pyrrole Furan N-heterocyclic ringO-heterocyclic ring Pyrrol Furan

TABLE IV API API Patent Example of Example of Generic Name Chemical NameCAS No. Reference Therapeutic Use Indication (−)-amlodipine3,5-Pyridinedicarboxylic acid, 103129-82-4 WO 9310779 Antihypertensive,Hypertension, 2-((2-aminoethoxy)methyl)-4-(2- other generalchlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl-5-methyl ester, (S)-[CAS](−)-halofenate (−)-Benzeneacetic acid, 4-chloro-Alpha-[3- U.S. 6,262,118Antidiabetic Diabetes, (trifluoromethyl)-phenoxy]-, 2- Type II(acetylamino)ethyl ester (R)-salbutamol 1,3-Benzenedimethanol,Alpha1-(((1,1- Formulation, Asthmadimethylethyl)amino)methyl)-4-hydroxy- modified- [CAS] release, <=24 hr(R)-salbutamol 1,3-Benzenedimethanol, Alpha1-(((1,1- 34391-04-3 U.S.5,547,994 Antiasthma Asthma dimethylethyl)amino)methyl)-4-hydroxy- [CAS](R,R)-formoterol Formamide, N-(2-hydroxy-5-(1-hydroxy-2- 67346-49-0 U.S.5,795,564 Antiasthma Asthma ((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-(R- (R*,R*))-[CAS] (S)-doxazosin(S)-1-(4-amino-6,7-dimethoxy-2- 70918-18-2 WO 9409785 Prostate disordersBenign quinazolinyl)-4-(1,4-benzodioxan-2-yl prostaticcarbonyl)piperazine hyperplasia (S)-fluoxetine Benzenepropanamide,N-methyl-Gamma- Antimigraine Migraine (4-(trifluoromethyl)phenoxy)-(S)(S)-oxybutynin Benzeneacetic acid, Alpha-cyclohexyl- 119618-22-3Urological Incontinence Alpha-hydroxy-, 4-(diethylamino)-2- butynylester, (S)-[CAS] 1,2-Naphthoquinone 524-42-5 17α-Hydroxyprogesterone68-96-2 17-Methyltestosterone 58-18-4 195mPt-cisplatin Platinum-195m,diamminedichloro, U.S. 6,074,626 Anticancer, Cancer, liver (SP-4-2)-alkylating 1α-Hydroxycholecalciferol 41294-56-8 1-Naphthyl Salicylate550-97-0 1-Naphthylamine-4- 84-86-6 sulfonic Acid 1-Theobromineacetic5614-56-2 Acid 2,4,6-Tribromo-m-cresol 4619-74-32,6-Diamino-2′-butyloxy- 617-19-6 3,5′-azopyridine 21- 566-78-9Acetoxypregnenolone 2-Amino-4-picoline 695-34-1 2-Aminothiazole 96-50-42-ethoxybenzoic acid 2-Ethoxybenzoic acid DE 5134001 Analgesic, NSAIDPain, general 2-Naphthol 135-19-3 2-Naphthyl Benzoate 93-44-7 2-NaphthylLactate 93-43-6 2-Naphthyl Salicylate 613-78-5 2-p- 80-02-4Sulfanilylanilinoethanol 2-Thiouracil 141-90-2 3′,3″,5′,5″- 76-62-0Tetra- bromophenolphthalein 3-Amino-4- 589-44-6 hydroxybutyric Acid3-Bromo-d-camphor 76-29-9 3-Hydroxycamphor 10373-81-63-O-Lauroylpyridoxol 1562-13-6 Diacetate 3-Pentadecylcatechol 492-89-73-Quinuclidinol 1619-34-7 4,4′-Oxydi-2-butanol 821-33-04,4′-Sulfinyldianiline 119-59-5 4-Amino-3- 352-21-6 hydroxybutyric Acid4-Amino-3- 1078-21-3 phenylbutyric Acid 4-aminosalicylic acid Benzoicacid, 4-amino-2-hydroxy-[CAS] 65-49-6 GI inflammatory/ Inflammatorybowel disorders bowel disease 4-Chloro-m-cresol 59-50-74-Hexylresorcinol 136-77-6 4-Salicyloylmorpholine 3202-84-4 5′-Nitro-2′-553-20-8 propoxyacetanilide 5-aminolevulinic acid, Pentanoic acid,5-amino-4-oxo- [CAS] 106-60-5 Dermatological Keratosis 5-azacitidine1,3,5-Triaxin-2(1H)-one, 4-amino-1-β-D- 320-67-2 Anticancer,Myelodysplastic ribofuransyl- [CAS] antimetabolite syndrome5-Bromosalicyl- 5798-94-7 hydroxamic Acid 5F-DF-2032-(4-Amino-3-methylphenyl)-6- Anticancer, other Cancer, breasthydroxybenzothiazole 5-FU 2,4(1H,3H)-Pyrimidinedione, 5-fluoro 51-21-8Formulation, Cancer, general [CAS] parenteral, targeted 5-HT3antagonists U.S. 6,037,360 Male sexual Premature dysfunction ejaculation6-Azauridine 54-25-1 6-Mercaptopurine 50-44-2 8-Hydroxyquinoline148-24-3 9-Aminocamptothecin 91421-43-1 A-151892N[2-(2,2,2-Trifluoro-1-hydroxy-1- Urological Overactivetrifluoromethyl-ethyl)-naphthalen-1-yl] bladder amide α₁-Antitrypsin9041-92-3 A-5021 6H-Purin-6-one, 2-amino-9-(((1S,2R)-1,2- 145512-85-2Antiviral, other Infection, bis(hydroxymethyl)cyclopropyl)methyl)1,9-varicella dihydro-[CAS] zoster virus abacavir 2-Cyclopentene-1-methanol,4-(2-amino-6- 136470-78-5 EP 434450 Antiviral, anti-HIV Infection,(cyclopropylamino)-9H-purin-9-yl)-, (1S- 188062-50-2 HIV/AIDS cis)-[CAS]abaperidone 7-[3-[4-(6-Fluoro-1,2-benzisoxazol-3- 183849-43-6 WO 9632389Neuroleptic Schizophrenia yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one abarelix D-Alaninamide, N-acetyl-3-(2-183552-38-7 U.S. 5,843,902 Anticancer, Cancer,naphthalenyl)-D-alanyl-4-chloro-D- hormonal prostatephenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- [CAS] Abciximab 143653-53-6Abecarnil 111841-85-1 abetimus 169147-32-4 U.S. 5,552,391Immunosuppressant Lupus erythematosus, systemic abirateroneAndrosta-5,16-dien-3-ol, 17-(3-pyridinyl)-, 154229-18-2 GB 2265624Anticancer, Cancer, prostate acetate (ester), (3β)-[CAS] hormonalα-Bisabolol 515-69-5 ABLC Amphotericin B [CAS] 1397-89-3 Formulation,Infection, 30652-87-0 conjugate, Candida, general carbohydrate ABT-751Benzenesulfonamide, N-[2-[(4- 141430-65-1 EP 472053 Anticancer, otherCancer, general hydroxyphenyl)amino]-3-pyridinyl]-4- methoxy-[CAS]AC-5216 N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl- Anxiolytic Anxiety,general 8-oxo-2-phenyl-9H-purin-9-yl)acetamide Acadesine 2627-69-2acamprosate 1-Propanesulfonic acid, 3-(acetylamino)- 77337-76-9 GB2051789 Dependence Addiction, [CAS] treatment alcohol Acamprosate77337-73-6 Acarbose 56180-94-0 acebrophylline 7H-Purine-7-acetic acid,1,2,3,6-tetrahydro- 96989-76-3 DE 3425007 Antiasthma Asthma1,3-dimethyl-2,6-dioxo-,compd. with trans- 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]cyclohexanol (1:1)[CAS] acebutololButanamide, N-[3-acetyl-4-[2-hydroxy-3- 34381-68-5 U.S. 3,726,919Antihypertensive, [(1-methylethyl)amino]propoxy]phenyl]-, 37517-30-9adrenegic (+/−)-[CAS] Acecainide 32795-44-1 Acecarbromal 77-66-7aceclofenac Benzeneacetic acid, 2-[(2,6- 89796-99-6 EP 119932Anti-inflammatory Pain, dichlorophenyl)amino]-, carboxymethylmusculoskeletal ester[CAS] Acedapsone 77-46-3 Acediasulfone 80-03-5Acefylline 652-37-9 Aceglutamide 2490-97-3 aceglutamide Aluminum,pentakis(N2-acetyl-L- 12607-92-0 DE 2127176 Antiulcer Ulcer, GI,glutaminoato)tetrahydroxytri-[CAS] general acemetacin 1H-Indole-3-aceticacid, 1-(4- 53164-05-9 U.S. 3,910,952 Anti-inflammatorychlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester [CAS]Acenocoumarol 152-72-7 Acetal 105-57-7 Acetamidoeugenol 305-13-5Acetaminophen 103-90-2 Acetaminosalol 118-57-0 Acetanilide 103-84-4Acetarsone 97-44-9 Acetazolamide 59-66-5 Acetiamine 299-89-8Acetohexamide 968-81-0 Acetohydroxamic Acid 546-88-3 Acetophenazine2751-68-0 Acetophenone 98-86-2 Acetosulfone 128-12-1 acetoxoloneOlean-12-en-30-oic acid, 3β-hydroxy-11- 29728-34-5 U.S. 3,764,618Antiulcer oxo-acetate, aluminium salt [CAS] 6277-14-1 Acetrizoat129-63-5 Acetyl 3590-05-4 Sulfamethoxypyrazine Acetylcarnitine14992-62-2 Acetylcholine 66-23-9 Acetylcholine 60-31-1 Acetylcysteine616-91-1 Acetylleucine 149-90-6 Monoethanolamine Acetylpheneturide13402-08-9 acetylsalicylic acid Benzoic acid, 2-(acetyloxy)-[CAS]50-78-2 Formulation, Pain, general 53075-6 optimized, microencapsulateα-Chloralose 15879-93-3 aciclovir 6H-Purin-6-one,2-amino-1,9-dihydro-9-[(2- 59277-89-3 Formulation, Infection, herpeshydroxyethoxy)methyl]-[CAS] dermal,topical simplex virus Acifran72420-38-3 acipimox Pyrazinecarboxylic acid, 5-methyl-, 4-oxide51037-30-0 GB 1361967 Hypolipaemic/ Hyper- [CAS] Antiatherosclerosislipidaemia, general acitazanolast Acetic acid, oxo[[3-(1H-tetrazol-5-114607-46-4 EP 256507 Ophthalmological Conjunctivitisyl)phenyl]amino]-[CAS] acitretin 2,4,6,8-Nonatetraenoic acid,9-(4-methoxy- 55079-83-9 SB 1468401 Antipsoriasis Psoriasis2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E) [CAS] aclarubicin57576-44-0 U.S. 3,988,315 Anticancer, 75443-99-1 antibiotic Aclatonium55077-30-0 Napadisilate Aconitine 302-27-2 Acranil ® 1684-42-0Acriflavine 8048-52-0 Acrisorcin 7527-91-5 acrivastine 2-Propenoic acid,3-[6-[1-(4-methylphenyl)- 87848-99-5 EP 85959 Antipruritic/ Rhinitis,allergic, 3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, inflamm,allergic general (E,E)-[CAS] acrivastine + Benzenemethanol, Alpha-[1-Antiallergic, Rhinitis, allergic, pseudoephedrine (methylamino)ethyl]-,hydrochloride, [S- non-asthma seasonal (R*,R*)]-, mixtwith 2-Propenoicacid, 3-[6- [1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, (E,E)- actagardine derivative3,3-dimethyl-1-propylamide HCl Peptide antibiotic Infection,monocarboxamide actagardine general Actarit 18699-02-0 ACTH 900-60-2Acyclovir 59277-89-3 adapalene 2-Naphthalenecarboxylic acid, 6-(4-106685-40-9 EP 199636 Antiacne Acne methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-[CAS] ADCON-L GL 402 [CAS] 137802-74-5 Formulation, otherFibrosis, epidural Adefovir 106941-25-7 adefovir dipivoxil Propanoicacid, 2,2-dimethyl-, (((2-(-6- 142340-99-6 EP 205826 Antiviral, otherInfection, amino-9H-purin-9- hepatitis-yl)ethoxy)methyl)phosphinylidene)bis(oxy B virus methylene)ester-[CAS]Adenoscan 6-Amino-9-β-D-ribofuranosyl-9H-purine 58-61-7 Imaging agentDiagnosis, [CAS] coronary Adenosine Triphosphate 56-65-5 ADEPT156079-88-8 Immunoconjugate, Cancer, other colorectal Adinazolam37115-32-5 Adiphenine 64-95-9 ADL-10-0101 WO 9732857 Analgesic, otherPain, general Adrafinil 63547-13-7 Adrenalone 99-45-6 Adrenochrome54-06-8 adrogolide Benzo(f)thieno(2,3-c)quinoline-9,10-diol, 166591-11-3U.S. 5,597,832 Dependence Addiction, 4,5,5a,6,7,11b-hexahydro-2-propyl-,171752-56-0 treatment cocaine diacetate (ester), hydrochloride (5aR-trans)-[CAS] AEOL-10150 U.S. 6,103,714 Neuroprotective Unspecified AET56-10-0 α-Ethylbenzyl Alcohol 93-54-9 AF-2259 Benzeneacetic acid,Alpha-methyl-4-(2- 66332-77-2 DE 2726435 Anti-inflammatory Inflammation,methylpropyl)-, 2-methoxyphenyl ester general [CAS] Afloqualone56287-74-2 AG-041R 1H-Indole-3-acetamide, 1-(2,2- 199800-49-2 WO 9419322Alimentary/ Unspecified diethoxyethyl)-2,3-dihydro-N-(4- Metaboloc,other methylphenyl)-3-((((4- methylphenyl)amino)carbonyl)amino-2- oxo-,(3R)-[CAS] AG-2037 N-(5-[2-(2-amino-4(3H)-oxo-5,6,7,8- Anticancer,Cancer, general tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]-antimetabolite 4-methylthieno-2-yl)glutamic acid α-Glucose-1- 59-56-3phosphate AGN-194310 Benzoic acid, 4-((4-(4-ethylphenyl)-2,2-229961-45-9 WO 9709297 Dermatological Psoriasisdimethyl-2H-1-benzothiopyran-6- yl)ethynyl)-[CAS] agomelatine Acetamide,N-(2-(7-methoxy-1- 138112-76-2 EP 447285 Antidepressant Sleep disorder,naphthalenyl)ethyl)-[CAS] general Ahistan 518-61-6 AHL-157 U.S.5,411,972 Hypolipaemic/ Atherosclerosis Antiatherosclerosis AIT-0349H-Purine-9-propanamide, 1,6-dihydro-6- 138117-48-3 U.S. 5,447,939Cognition enhancer Dementia, oxo-N-(3-(2-oxo-1-pyrrolidinyl)propyl)-senile, [CAS] general AIT-202 N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-3-(6-WO 9957120 Antidepressant Unspecifiedoxo-6,9-dihydro-1H-purin-9-yl)propion- amide AJ-9677 Acetic acid,((3-((2R)-2-(((2R)-2-(3- 244081-42-3 Antidiabetic Diabetes,chlorophenyl)-2- Type II hydroxyethyl)amino)propyl)-1H-indol-7-yl)oxy)-[CAS] AJG-049 WO 9733885 Gastroprokinetic Motility dysfunction,GI, general Ajmaline 12/07/4360 Alacepril 74258-86-9 albaconazole4(3H)-Quinazolinone, 7-chloro-3-[(1R,2R)- 187949-02-6 WO 9705131Antifungal Infection, 2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-Candida, 3-(1H01,2,4-triazol-1-yl)propyl]-[CAS] general albendazoleCarbamic acid, [5-(propylthio)-1H- 54029-12-8 GB 1454326 AnthelminticInfection, benzimidazol-2-yl]-, methyl ester [CAS] 54965-21-8 helminth,Albuterol 18559-94-9 general Albutoin 830-89-7 alclofenac Benzeneaceticacid, 3-chloro-4-(2- 22131-79-9 GB 1174535 Anti-inflammatorypropenyloxy)-[CAS] alclometasone Pregna-1,4-diene-3,20-dione,7-chloro-11- 66734-13-2 U.S. 4,124,707 Antipruritic/ Inflammation,hydroxy-16-methyl-17,21-bis(1- 67452-97-5 inflamm, allergic dermaloxopropoxy)-, (7Alpha, 11β, 16Alpha)- [CAS] Alcuronium 23214-96-2Aldioxa 5579-81-7 Aldol 107-89-1 Aldosterone 52-39-1 alendronatePhosphonic acid, (4-amino-1- 121268-17-5 GB 2118042 OsteoporosisOsteoporosis hydroxybutylidene)bis-[CAS] 129318-43-0 treatmentAlendronic Acid 66376-36-1 Alexidine 22573-93-9 alfacalcidol9,10-Secocholesta-5,7,10(19)-triene-1,3- 41294-56-8 OsteoporosisOsteodystrophy diol, (1Alpha,3β,5Z,7E)-[CAS] treatment Alfadolone23930-37-2 Alfaxalone 23930-19-0 Alfentanil 71195-58-9 alfimeprase259074-76-5 Fibrinolytic Peripheral vascular disease alfuzosin2-Furancarboxamide, N-[3-[(4-amino-6,7- 81403-68-1 GB 2013679 Prostatedisorders Benign prostatic dimethoxy-2-quinazolinyl)methylamino]-81403-80-7 hyperplasia tetrahydro-[CAS] alfuzosin 2-Furancarboxamide,N-[3-[(4-amino-6,7- 81403-68-1 dimethoxy-2-quinazolinyl)methylamino]-81403-80-7 Formulation, Benign prostatic propyl]tetrahydro-[CAS]modified-release, hyperplasia Algestone 595-77-7 other Algestone24356-94-3 Acetophenide Algin 9005-38-3 Alglucerase 143003-46-7Alibendol 26750-81-2 aliskiren (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-173334-57-1 Antihypertensive, Hypertension,methylpropyl)-4-hydroxy-2-isopropyl-7-[4- renin system generalmethoxy-3-(3-methoxypropoxy)benzyl]-8- methylnonanamide alitertinoin9-cis retinoic acid 03/08/5300 Antipruritic/ Eczema, general inflamm,allergic alizapride 1H-Benzotriazole-5-carboxamide, 6- 59338-93-1 GB1475234 Antiemetic Nausea and methoxy-N-[[1-(2-propenyl)-2- vomiting,pyrrolidinyl]methyl]-[CAS] general Alkannin 517-88-4 Alkofanone7527-94-8 Allantoin 97-59-6 Allobarbital 52-43-7 Allopurinol 315-30-0Allyl Isothiocyanate 57-06-7 Allylestrenol 432-60-0 almagate Magnesium,[carbonato(2-)]heptahydroxy- 66827-12-1 U.S. 4,447,417 Antacid/(aluminum)tri-, dihydrate 72526-11-5 Antiflatulent [CAS] alminoprofenBenzeneacetic acid, Alpha-methyl-4[(2- 39718-89-3 U.S. 3,957,850Analgesic, NSAID methyl-2-propenyl)amino]-[CAS] almitrine1,3,5-Triazine-2,4-diamine, 6-[4-[bis(4- 27469-53-0 GB 1256513Respiratory Bronchitis, fluorophenyl)methyl]-1-piperazinyl]-N,N′-di-29608-49-9 chronic 2-propenyl-, dimethanesulfonate [CAS] almotriptanPyrrolidine, 1-(((3-(2-(dimethylamino)ethyl)- 154323-57-6 WO 9402460Antimigraine Migraine 1H-indol-5-yl)methyl)sulfonyl)-[CAS] Aloe-Emodin481-72-1 Aloin 5133-19-7 alosetron2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl- 122852-42-0 EP 306323 GIinflammatory/ Irritable bowel 1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-122852-69-1 bowel disorders syndrome b]indol-1-one [CAS] 132414-02-9alovudine Thymidine, 3′-deoxy-3′-fluoro-[CAS] 25526-93-6 EP 470355Antiviral, anti-HIV Infection, HIV/AIDS Aloxiprin 9014-67-9 Alpha-1protease U.S. 5,780,014 Formulation, Emphysema, inhibitor inhalable,topical alpha-1 antitrypsin deficiency Alpha- Ergocryptine,9,10-dihydro- 29261-93-6 Formulation, other Parkinson'sdihydroergocryptine methanesulfonate (salt)-[CAS] disease Alphaprodine77-20-3 Alpidem 82626-01-5 Alpiropride 81982-32-3 alprazolam4H-[1,2,4]Triazolo[4,3-a][1,4]- 28981-97-7 U.S. 3,987,052 AnxiolyticAnxiety, benzodiazepine, 8-chloro-1-methyl- general 6-phenyl-[CAS]Alprenolol 13655-52-2 alsactide Alpha-1-17-Carticotropin,1-β-alanine-17- 34765-96-3 U.S. 3,749,704 ACTH Arthritis,[N-(4-aminobutyl)-L-lysinamide]-[CAS] rheumatoid ALT-711 Thiazolium,4,5-dimethyl-3-(2-oxo-2- 181069-80-7 WO 9622095 SymptomaticHypertension, phenylethyl)-, bromide [CAS] antidiabetic generalAlthiazid 5588-16-9 altinicline Pyridine, 3-ethynyl-5-((2S)-1-methyl-2-179120-92-4 U.S. 5,594,011 Antiparkinsonian Parkinson'spyrrolidinyl)-[CAS] disease altretamine 1,3,5-Triazine-2,4,6-triamine,645-05-6 U.S. 3,424,752 Anticancer, Cancer,N,N,N′,N′,N″,N″-hexamethyl-[CAS] alkylating ovarian aluminium chlorideAluminium chloride, hexahydrate 7446-70-0 Dermatological Hyperhidrosishexahydrate 7784-13-6 Aluminon 569-58-4 Aluminum Acetate 8006-13-1Solution Aluminum Chlorate 15477-33-5 Aluminum 1327-41-9 HydroxychlorideAluminum Potassium 10043-67-1 Sulfate Aluminum Sodium 10102-71-3 Sulfatealusulf Aluminum hydroxide sulfate 61115-28-4 DE 2510663 UrologicalHyperphos- (AI7(OH)17(SO4)2), dodecahydrate [CAS] phataemia Alverine150-59-4 alvimopan Glycine, N-[(2S)-2-[[(3R,4R)-4-(3- 156053-89-3 EP657428 GI inflammatory/ Ileus hydroxyphenyl)-3,4-dimethyl-1- boweldisorders piperidinyl]methyl]-1-oxo-3-phenylpropyl]- [CAS] alvocidib4H-1-Benzopyran-4-one, 2-(2- 131740-09-5 Anticancer, other Cancer, renalchlorophenyl)-5,7-dihydroxy-8-(3-hydroxy- 146426-40-61-methyl-4-piperidinyl)-, cis-(−)-[CAS] ALX-0646 WO 9506638 AntimigraineMigraine AM-24 2,4,6-Triiodophenol 609-23-4 GI inflammatory/ Crohn'sdisease bowel disorders AM-36 1-Piperazineethanol, 4-[[3,5-bis(1,1-199467-52-2 Neuroprotective Unspecifieddimethylrthyl)-4-hydroxyphenyl]methyl]- Alpha-(4-chlorophenyl)-[CAS]AM-477 2-Methoxyoestradiol Antiasthma Asthma Amantadine 768-94-5amantanium 1-Decanaminium, N,N-dimethyl-N-[2- 58158-77-3 U.S. 4,288,609Antifungal Infection, [(tricyclo[3.3.1.13,7]dec-1- generalylcarbonyl)oxy]ethyl]-, bromide [CAS] Ambazon 539-21-9 Ambenonium115-79-7 ambrisentan (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)-177036-94-1 Vasodilator, Heart failureoxy]-3-methoxy-3,3-diphenylpropanoic acid peripheral ambroxolCyclohexanol, 4-[[(2-amino-3,5- 18683-91-5 GB 1178034 COPD treatmentBronchitis, dibromophenyl)methyl]amino]-, trans- 23828-92-4 chronic[CAS] Ambucaine 119-29-9 Ambuphylline 5634-34-4 Ambusid 3754-19-6Ambutonium Bromide 115-51-5 amcinonide Pregna-1,4-diene-3,20-dione, 21-51022-69-6 DE 2437847 Antipsoriasis (acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11- hydroxy-, (11β, 16Alpha)-[CAS]AMD-3100 1,4,8,11-Tetraazacyclotetradecane, 1,11- 155148-31-5 U.S.5,612,478 Haematological Chemotherapy-(1,4-phenylenebis(methylene))bis-, induced injury, octahydrochloride[CAS] bone marrow, Amdinocillin 32887-01-7 leucopenia AmdinocillinPivoxil 32886-97-8 amdoxovir 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-145514-04-1 EP 656778 Antiviral, anti-HIV Infection,9H-purin-9-yl)-(2R-cis)-[CAS] HIV/AIDS amelubant Carbamic acid,((4-((3-((4-(1-(4- 346735-24-8 DE 10000907 COPD treatment Chronichydroxyphenyl)-1- obstructive methylethyl)phenoxy)methyl)phenyl)-pulmonary methoxy)phenyl)iminomethyl)-ethyl ester disease [CAS]Americaine Benzenemethanaminium, N,N-dimethyl-N- 129128-13-8Formulation, Pain, general [2-[2-[4-(1,1,3,3- inhalable, othertetramethylbutyl)phenoxy]ethoxy]ethyl]-, chloride, mixt. with ethyl4-aminobenzoate [CAS] Amezinium 30578-37-1 Amfenac 51579-82-9Amidephrine 3354-67-4 Amidinomycin 3572-60-9 amifostine Ethanethiol,2-[(3-aminopropyl)amino]-, 20537-88-6 EP 131500 Radio/ Chemotherapy-dihydrogen phosphate (ester)-[CAS] 63717-27-1 chemoprotective inducedinjury, renal amiglumide Pentanoic acid, 5-(dipentylamino)-4-((2-119363-62-1 WO 8805774 GI inflammatory/ Pancreatitisnaphthalenylcarbonyl)amino)-5-oxo-(R)- bowel disorders [CAS] amikacin37517-28-5 Formulation, Infection, 39831-55-5 optimized, generalmicroencapsulate Amiloride 2609-46-3 Aminacrine 90-45-9 amineptineHeptanoic acid, 7-[(10,11-dihydro-5H- 30272-08-3 U.S. 3,758,528Antidepressant dibenzo[a,d]cyclohepten-5-yl)amino]- 57574-09-1 [CAS]Aminitrozole 140-40-9 Amino Acid Preparations Aminocaproic Acidaminoglutethimide 2,6-Piperidinedione, 3-(4-aminophenyl)-3- 125-84-8U.S. 3,944,671 Anticancer, Cancer, breast ethyl-[CAS] hormonalAminoguanidine 79-17-4 Aminohippurate Aminometradine 642-44-4Aminopentamide 60-46-8 aminophylline 1H-Purine-2,6-dione,3,7-dihydro-1,3- 317-34-0 Formulation, Asthma dimethyl-, compd. with1,2-ethanediamine modified- (2:1) [CAS] release, other Aminopromazine58-37-7 Aminopyrine 58-15-1 Aminoquinuride 3811-56-1 Aminorex 2207-50-3amiodarone Methanone, (2-butyl-3-benzofuranyl)[4-[2- 1951-25-3 U.S.3,248,401 Antiarrhythmic Arrhythmia,(diethylamino)ethoxy]-3,5-diiodophenyl]- 19774-82-4 general [CAS]Amiphenazole 490-55-1 Amiprilose 56824-20-5 amisulpride Benzamide,4-amino-N-[(1-ethyl-2- 71675-85-9 U.S. 4,401,822 NeurolepticSchizophrenia pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2- methoxy-[CAS]Amitriptyline 50-48-6 amitriptyline + 1-Propanamine,3-(10,11-dihydro-5H-Formulation, Pain, ketamine dibenzo[a,d]cyclohepten-5-ylidene)-N,N-fixed-dose neuropathic dimethyl + cyclohexanone,2-(2- combinationschlorophenyl)-2-(methylamino) Amitriptylinoxide 4317-14-0 amlexanox5H-[1]Benzopyrano[2,3-b]pyridine-3- 68302-57-8 U.S. 4,299,963 AntiasthmaAsthma carboxylic acid, 2-amino-7-(1-methylethyl)- 5-oxo-[CAS]amiodipine 3,5-Pyridinedicarboxylic acid, 2-[(2- 111470-99-6 EP 89167Antianginal Hypertension, aminoethoxy)methyl]-4-(2-chlorophenyl)-88150-42-9 general 1,4-dihydro-6-methyl-, 3-ethyl 5-methyl 88150-47-4ester [CAS] Ammoniacum 03/07/9000 Ammonium Benzoate 1863-63-4 AmmoniumMandelate 530-31-4 Ammonium Salicylate 528-94-9 Ammonium Valerate42739-38-8 Amobarbital 57-43-2 Amocarzine 36590-19-9 Amodiaquin 86-42-0amorolfine Morpholine, 4-[3-[4-(1,1- 78613-35-1 EP 24334 AntifungalInfection, dimethylpropyl)phenyl]-2-methylpropyl]- 78613-38-4 fungal,general 2,6-dimethyl-, cis-[CAS] Amoscanat 26328-53-0 amosulalolBenzenesulfonamide, 5-[1-hydroxy-2-[[2- 70958-86-0 EP 136103Antihypertensive, Hypertension, (2-methoxyphenoxy)ethyl]amino]ethyl]-2-85320-68-9 adrenergic general methyl-, (+/−)-[CAS] Amotriphene 5585-64-8amoxapine Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1- 14028-44-5 GB1192812 Antidepressant Depression, piperazinyl)-[CAS] generalamoxicillin 4-Thia-1-azobicyclo[3,2,0]heptane-2- 26787-78-0 Formulation,Infection, carboxylic acid, 6-[[amino(4- 61336-70-7 modified-release,general hydroxyphenyl)acetyl]amino]-3,3-dimethyl- other7-oxo-,[2S-[2Alpha,5Alpha,6β(S*)]][CAS] amoxicillin + 74469-00-4 GB1508977 Formulation, Infection, potassium fixed-dose respiratoryclavulan combinations tract, general AMPAlex Piperidine,1-(6-quinoxalinylcarbonyl)- 154235-83-3 U.S. 5,650,409 PsychostimulantAttention [CAS] deficit disorder Amphetamine 300-62-9 Amphetaminil17590-01-1 amphotericin B Amphotericin B compd. with (3β)-cholest-5-120895-52-5 U.S. 4,822,777 Formulation, Infection, en-3-yl hydrogensulfate (1:1) [CAS] 1397-89-3 optimized, general liposomes ampicillin4-Thia-1-azabicyclo[3.2.0]heptane-2- 69-53-4 carboxylic acid, 6-7177-48-2 Fomulation, Infection,[(aminophenylacetyl)amino]-3,3-dimethyl-7- fixed-dose general oxo-,[2S-[2Alpha,5Alpha,6β(S*)]] combinations Ampiroxicam 99464-64-9 Ampligen38640-92-5 amprenavir Carbamic acid, (3-(((4- 161814-49-9 U.S. 5,783,701Antiviral, anti-HIV Infection, aminophenyl)sulfonyl)(2- HIV/AIDSmethylpropyl)amino)-2-hydroxy-1- (phenylmethyl)propyl)-, tetrahydro-3-furanyl ester, (3S-(3R*(1R*,2S*)))-[CAS] amrinose[3,4′-Bipyridin]-6(1H)-one, 5-amino-[CAS] 60719-84-8 U.S. 4,004,012Cardiostimulant 75898-90-7 amrubicin 5,12-Naphthacenedione,9-acetyl-9-amino- 92395-36-3 EP 107486 Anticancer, antibiotic Cancer,lung, 7-[(2-deoxy-β-D-erythro- non-smallpentopyranosyl)oxy]-7,8,9,10-tetrahydro- cell 6,11-dihydro-,hydrochloride, (7S,cis)- [CAS] amsacrine Methanesulfonamide, N-[4-(9-51264-14-3 Anticancer, other Cancer,acridinylamino)-3-methoxyphenyl]-[CAS] leukaemia, acute lymphocyticamtolmetin guacil Glycine, N-[[1-methyl-5-(4-methylbenzoyl)- 87344-06-7GB 2115417 Analgesic, NSAID Arthritis, 1H-pyrrol-2-yl]acetyl]-,2-methoxyphenyl rheumatiod ester [CAS] Amylocaine 532-59-2 AN-152 WO9719954 Anticancer, antibiotic Cancer, prostate anabolic steroids WO9848812 Cardiovascular Heart failure Anagestone 2740-52-5 anagrelideImidazo[2,1-b]quinazolin-2(3H)-one, 6,7- 58579-51-4 GB 1418822Haematological Thrombocytosis dichloro-1,5-dihydro-, monohydrochloride68475-42-3 [CAS] anastrozole 1,3-benzenediacetonitrile, 120511-73-1 EP296749 Anticancer, hormonal Cancer, breastAlpha,Alpha,Alpha,Alpha′-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-[CAS] Anazolene 3861-73-2 Ancitabine31698-14-3 Ancrod 9046-56-4 andolastN-4′-[5-Tetrazolyl]-phenyl-4-(5-tetrazolyl)- 132640-22-3 EP 460083Antiasthma Asthma benzamide Androisoxazole 360-66-7 Androstenediol521-17-5 anecortave 21-(Acetyloxy)-17-hydroxypregna-4,9(11)- 7753-60-8Ophthalmological Macular diene-3,20-dione degeneration Anethole4180-23-8; 104-46-1 (unspecified) Anethole Trithione 532-11-6 AngiogenixU.S. 6,417,205 Cardiovascular Cardio- myopathy, ischaemic Angiotensin1407-47-2 anhydrovinblastine Vincaleukoblastine, 3′,4′-didehydro-4′-38390-45-3 U.S. 6,011,041 Anticancer, other Cancer, deoxy-[CAS] generalanidulafungin Echinocandin B, 1-((4R,5R)-4,5-dihydroxy- 166663-25-8 U.S.6,384,013 Antifungal Infection,N2-((4″-(pentyloxy)(1,1′:4′,1″-terphenyl)-4- Candida,yl)carbonyl)-L-ornithine)-[CAS] general Anilerdine 144-14-9 Aniracetam72432-10-1 Anisindione 117-37-3 Anisomycin 22862-76-6 Anisotropine80-50-2 Methylbromide anistreplase Anistreplase [CAS] 81669-57-0 EP28489 Fibrinolytic Infarction, myocardial Antazoline 91-75-8Anthiolimine 305-97-5 Anthralin 1143-38-0 Anthramycin 4803-27-4Anthrarobin 577-33-3 Anthrax inhibitor U.S. 6,436,933 Anti-infective,Infection, other anthrax antiangiogenic U.S. 6,426,067 Anticancer, otherCancer, dendrimers general Anticort L-Ascorbic acid, mixt with 2-186646-39-9 WO 9640038 Anabolic Cachexia (diethylamino)ethyl4-aminobenzoate monohydrochloride, disodium hydrogen phosphate,potassium benzoate and zinc sulfate (1:1) [CAS] antidepressants U.S.5,898,036 Antidepressant Depression, general anti-invasins U.S.6,303,302 Antifungal Infection, fungal, general Antimony Potassium28300-74-5 Tartrate Antimony Sodium 539-54-8 Thioglycollate Antimony6533-78-4 Thioglycollamide Antiprogestin 19-Norpregna-4,9-dien-3-211254-73-8 DE 19703061 Anticancer, Cancer, breastone,(acetylphenyl)-20,20,21,21,21- hormonal pentafluoro-17-hydroxy-(11β,17Alpha) [CAS] Antipyrine 60-80-0 Antipyrine Salicylate 520-07-0antithrombin III Antithrombin, III [CAS] 9000-94-6 Blood fractionAntithrombin III 90170-80-2 deficiency AR-116081 U.S. 6,107,324Neuroleptic Unspecified AR-A2(R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)- Anxiolytic Anxiety, general1,2,3,4-tetrahydro-2-naphthyl]-4- morpholinobenzamide Arachidonic Acid506-32-1 aranidipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-86780-90-7 GB 2111978 Antihypertensive, Hypertension,2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2- other general oxopropylester-[CAS] arbekacin D-Streptamine, O-3-amino-3-deoxy-Alpha- 51025-85-5U.S. 4,001,208 Aminoglycoside Infection,D-glucopyranosyl-(1-6)-O-[2,6-diamino- 75282-65-4 antibiotic general2,3,4,6-tetradeoxy-Alpha-D-erythro- hexopyranosyl-(1-4)]-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-[CAS] Arbidol 1H-indole-3-carboxylicacid, 6-bromo-4- 131707-23-8 WO 9008135 Immunostimulant, Infection,((dimethylamino)methyl)-5-hydroxy-1- other influenzamethyl-2-((phenylthio)methyl)-, ethylester, virus monohydrochloride[CAS] arbutamine 1,2-Benzenediol, 4-[1-hydroxy-2-[[4-(4- 128470-16-6 WO9220324 Diagnostic Diagnosis, hydroxyphenyl)butyl]amino]ethyl]-, (R)-coronary [CAS] Arcitumomab 154361-48-5 ardeparin Heparin [CAS] 9005-49-6Anticoagulant Thrombosis, venous arecoline1,2,5,6-Tetrahydro-1-methyl-3-pyridine Formulation, Alzheimer'scarboxylic acid methyl ester transdermal, patch disease argatroban2-Piperidinecarboxylic acid, 1-[5- 74863-84-6 EP 8746 AnticoagulantThrombosis, [(aminoiminomethyl)amino]-1-oxo-2- arterial[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl- [CAS] Arginine 74-79-3Ariflo ® 153259-65-5 aripiprazole 2(1H)-Quinolinone, 7-[4-[4-(2,3-129722-12-9 EP 367141 Neuroleptic Schizophreniadichlorophenyl)-1-piperazinyl]butoxy]-3,4- dihydro-[CAS] anxiolyticsU.S. 5,756,538 Anxiolytic Anxiety, general AP-521N-Piperonyl-2-amino-1,2,3,4- 151227-08-6 WO 9321189 Anxiolytic Anxiety,tetrahydrobenzo(b)thieno(2,3-c)pyridine-3- general carbamide AP-5280U.S. 5,965,118 Anticancer, Cancer, alkylating general Apalcillin63469-19-2 apaziquone 1H-indole-4,7-dione, 5-(1-aziridinyl)-3-114560-48-4 WO 8706227 Anticancer, Cancer,(hydroxymethyl)-2-(3-hydroxy-1-propenyl)- alkylating breast 1-methyl-,(E)-[CAS] Apazone 13539-59-8 α-Phenylbutyramide 90-26-6 Apocodeine641-36-1 apomine Phosphonic acid, (2-(3,5-bis(1,1- 126411-13-0Anticancer, other Cancer, dimethylethyl)-4- prostatehydroxyphenyl)ethylidene)bis-tetrakis(1- methylethyl) ester [CAS]apomorphine 4H-Dibenzo[de,g]quinoline-10,11-diol, 314-19-2 Formulation,Impotence 5,6,6a,7-tetrahydro-6-methyl-, 58-00-4 transmucosal,hydrochloride nasal apraclonidine 1,4-Benzenediamine,2,6-dichloro-N1-(4,5- 66711-21-5 U.S. 4,517,199 Antiglaucoma Glaucomadihydro-1H-imidazol-2-yl)-[CAS] 73218-79-8 aprepitant3H-1,2,4-Triazol-3-one, 5-[[(2R,3S)-2- 170729-80-3 U.S. 5,719,147Antiemetic Chemotherapy- [(1R)-1-[3,5- inducedbis(trifluoromethyl)phenyl]ethoxy]-3-(4- nausea andfluorophenyl)-4-morpholinyl]methyl]-1,2- vomiting dihydro-[CAS]aprindine 1,3-Propanediamine, N-(2,3-dihydro-1H- 33237-74-0 GB 1321424Antiarrhythmic inden-2-yl)-N′,N′-diethyl-N-phenyl-[CAS] 37640-71-4Aprobarbital 77-02-1 Apronalide 528-92-7 Aprotinin 9087-70-1 Aptiganel137159-92-3 AQ4N 9,10-Anthracenedione, 1,4-bis((2- 136470-65-0 U.S.5,132,327 Anticancer, other Cancer,(dimethyloxidoamino)ethyl)amino)-5,8- general dihydroxy-[CAS] AquavanU.S. 6,204,257 Anaesthetic, Anaesthesia injectable arofylline1H-Purine-2,6-dione, 3-(4-chlorophenyl)- 136145-07-8 EP 435811 COPDtreatment Chronic 3,7-dihydro-1-propyl-[CAS] obstructive pulmonarydisease arotinolol 2-Thiophenecarboxamide, 5-[2-[[3-[(1,1- 104766-23-6U.S. 3,932,400 Antihypertensive, Hypertension,dimethylethyl)amino]-2-hydroxypropyl]thio]- 68377-92-4 adrenergicgeneral 4-thiazolyl]-, (±)-[CAS] Arsacetin 618-22-4 arsenic trioxideArsenic oxide (As2O3) [CAS] 1327-53-3 Anticancer, other Cancer,Arsphenamine 139-93-5 leukemia, Aesthinol 119-96-0 acute Arteether75887-54-6 myelogenous Arteflene 123407-36-3 (Z-form) Artemether71963-77-4 Artemisinin 63968-64-9 artemotil3,12-Epoxy-12H-pyrano[4,3-j]-1,2- 75887-54-6 Antimalarial Infection,benzodioxepin, 10-ethoxydecahydro-3,6,9- malaria trimethyl-, [3R-(3Alpha,5aβ,6β,8aβ,9aAlpha,10Alpha,12β, 12aR*)]-[CAS] artesunateButanedioic acid mono- 88495-63-0 Formulation, Infection,[(3R,5aS,6R,8aS,9R,10R,12R,12aR)- transmu- malariadecahydro-3,6,9-trimethyl-3,12-epoxy-12H- cosal, systemicpyrano[4,3-j]-1,2-benzodioxepin-10- yl]ester arzoxifeneBenzo(b)thiophene-6-ol, 2-(4- 182133-27-3 WO 9609041 Anticancer, Cancer,methoxyphenyl)-3-(4-(2-(1- hormonal breastpiperidinyl)ethoxy)phenoxy)-[CAS] AS-3201Spiro(pyrrolidine-3,4′(1′H)-pyrrolo(1,2- 147254-64-6 EP 520320Symptomatic Diabetic a)pyrazine)-1′,2,3′,5(2′H)-tetrone, 2′-((4-antidiabetic complication, bromo-2-fluorophenyl)methyl)-, (3′R)- general[CAS] ASA Benzoic acid, 2-(acetyloxy)-[CAS] 50-78-2 Formulation, Pain,general 56449-07-1 modified-release, other α-Santonin 481-06-1Ascaridole 512-85-6 Ascorbic Acid 50-81-7 asenapine1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5- 85650-56-2 WO 9523600Neuroleptic Psychosis, chloro-2,3,3a,12b-tetrahydro-2-methyl-, generaltrans-, (Z)-2-butenedioate (1:1) [CAS] asimadoline Benzeneacetamide,N-[2-(3-hydroxy-1- 153205-46-0 DE 4215213 GI inflammatory/ Irritablebowel pyrrolidinyl)-1-phenylethyl]-N-methyl- bowel disorders syndromeAlpha-phenyl-, [S-(R*,R*)]-[CAS] asoprisnil11β-[4-(Hydroxyiminomethyl)phenyl]-17β- 199396-76-1 EP 0648778Mensturation Endometriosis methoxy-17Alpha-(methoxymethyl)estra-disorders 4,9-dien-3-one Asoxime 34433-31-3 Aspartic Acid 56-84-8Aspidin 584-28-1 Aspidinol 519-40-4 Aspirin 50-78-2 Aspirin,Dipyridamole aspoxicillin Glycinamide, N-methyl-D-asparaginyl-N-(2-63358-49-6 GB 1533413 Penicillin, injectable Infection,carboxy-3,3-dimethyl-7-oxo-4-thia-1- respiratoryazabicyclo[3.2.0]hept-6-yl)-D-2-(4- tract, general hydroxyphenyl)-,[2S-(2Alpha,5Alpha,6β)]- [CAS] AST-120 AST 120 [CAS] 90597-58-3Urological Renal failure Astemizole 68844-77-9 asulacrine4-Acridinecarboxamide, 9-[[2-methoxy-4- 80841-47-0 EP 39224 Anticancer,other Cancer, [(methylsulfonyl)amino]phenyl]amino]-N,5- 80841-48-1general dimethyl-[CAS] AT-1015 (N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-Antithrombotic Thrombosis, ylidene)-piperdino]ethyl]-1-formyl-4- generalpiperidinecarboxamide monohydrochloride monohydrate atamestaneAndrosta-1,4-diene-3,17-dione, 1-methyl- 96301-34-7 DE 3338212Anticancer, hormonal Cancer, breast [CAS] atazanavir2,5,6,10,13-Pentaazatetradecanedioic 229975-97-7 Antiviral, anti-HIVInfection, acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy- HIV/AIDS4,11-dioxo-9-(phenylmethyl)-6-((4-(2- pyridinyl)phenyl)methyl)-dimethylester, (3S,8S,9S,12S)-, sulfate (1:1) (salt) [CAS] atenololBenzeneacetamide, 4-[2-hydroxy-3-[(1- 29122-68-7 GB 1285038Antihypertensive, Hypertension, methylethyl)amino]propoxy]-[CAS]73677-19-7 adrenergic general atenolol + Benzeneacetamide,4-[2-hydroxy-3-[(1- 73677-19-7 U.S. 3,836,671 Formulation, Hypertension,chlorthalidone methylethyl)amino]propoxy]-, mixt. with 2- fixed-dosegeneral chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H- combinationsisoindol-1-yl)benzenesulfonamide [CAS] atenolol + nifedipineBenzeneacetamide, 4-[2-hydroxy-3-[(1- Formulation, Hypertension,methylethyl)amino]propoxy]-, + 4-( 2′- fixed-dose generalnitrophenyl)-2,6-dimethyl-3,5- combinationsdicarbomethoxy-1,4-dihydropyridine α-Terpineol 98-55-5 Atevirdine136816-75-6 atipamezole 1H-Imidazole, 4-(2-ethyl-2,3-dihydro-1H-104054-27-5 EP 183492 Reproductive/ Sexual inden-2-yl)-[CAS] gonadal,dysfunction, general female atiprimod dimaleate2-Azaspivo[4.5]decane-2-propanamine, 130065-61-1 U.S. 5,744,495Antiarthritic, Arthritis, N,N-diethyl-8,8-dipropyl, dimaleateimmunological rheumatoid ATL-146e U.S. 6,232,297 Imaging agentUnspecified α-Tocopherol 59-02-9 atomoxetine Benzenepropanamine,N-methyl-Gamma- 82248-59-7 EP 52492 Neurological Attention(2-methylphenoxy)-, (R)-[CAS] 83015-36-3 deficit disorder atorvastatin1H-Pyrrole-1-heptanoic acid, 2-(4- 134523-03-8 EP 409281 Hypolipaemic/Hyper- fluorophenyl)-β,delta-dihydroxy-5-(1- 134523-00-5Antiatherosclerosis cholesterolaemia methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-[CAS] atosiban Oxytocin, 1-(3-mercaptopropanoinacid)-2- 90779-69-4 EP 112809 Labour inhibitor Labour, preterm(O-ethyl-D-tyrosine)-4-L-threonine-8-L- ornithine-[CAS] atovaquone1,4-Naphthalenedione, 2-[4-(4- 95233-18-4 EP 123238 AntifungalInfection, chlorophenyl)cyclohexyl]-3-hydroxy-, trans- Pneumocystis[CAS] jiroveci atovaquone + 1,4-Naphthalenedione, 2-[4-(4- AntimalarialInfection, proguanil chlorophenyl)cyclohexyl]-3-hydroxy-, trans +malaria N-(4-chloro-phenyl)-N-(1- methylethyl)imidiodicarbonimidicdiamide atracurium Isoquinolinium, 2,2′-[1,5- 64228-81-5 U.S. 4,179,557Muscle relaxant Surgery adjunct pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4- dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-[CAS]] atrasentan3-Pyrrolidenecarboxylic acid, 4-(1,3- 173937-91-2 WO 9730045 Anticancer,other Cancer, prostate benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)-[CAS] Atrial Natriuretic85637-73-6 Peptide Atrolactamide 2019-68-3 Atropine 51-55-8 Augmentin74469-00-4 Formulation, Infection, modified- respiratory release, othertract, general auranofin Gold, (1-thio-β-D-glucopyranose 2,3,4,6-34031-32-8 U.S. 3,708,579 Antiarthritic, other Arthritis,tetraacetato-S)(triethylphosphine)-[CAS] rheumatoid Aurothioglucose12192-57-3 avasimibe Sulfamic acid, [[2,4,6-tris(1- 166518-60-1 U.S.5,491,172 Hypolipaemic/ Atherosclerosis methylethyl)phenyl]acetyl]-,2,6-bis(1- Antiatherosclerosis methylethyl)phenyl ester [CAS] Avobenzone70356-09-1 AWD-12-281 AWD 12-281 [CAS] 257892-33-4 Antiallergic,Rhinitis, allergic, non-asthma general Azacitidine 320-67-2 Azacyclonol115-46-8 azanidazole 2-Pyrimidinamine, 4-[2-(1-methyl-5-nitro-62973-76-6 U.S. 3,882,105 Antibacterial, other Infection,1H-imidazol-2-yl)ethenyl]-,(E)-[CAS] trichomoniasis azapropazone1H-Pyrazolo[1,2-a][1,2,4]benzotriazine- 13539-59-8 FR 1440629Anti-inflammatory 1,3(2H)-dione, 5-(dimethylamine)-9-methyl-2-propyl-[CAS] Azaserine 115-02-6 azasertron2H-1,4-Benzoxazine-8-carboxamide, N-1- 123040-16-4 EP 313393 AntiemeticNausea and azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4- 123040-94-8 vomiting,dihydro-4-methyl-3-oxo-, 123040-96-0 general monohydrochloride-[CAS]123040-69-7 Azatadine 3964-81-6 azathipprine6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]- 446-86-6 Formulation, oral,Transplant 1H-purine other rejection, bone marrow AZD-4282 glycineAnalgesic, other Pain, neuropathic AZD-61403,4-Difluorophenylcyclopropylamine Antithrombotic Thrombosis, arterialazelaic acid Nonanedioic acid [CAS] 123-99-9 Antiacne Acne azelastine1(2H)-Phthalazinone, 4-[(4- 58581-89-8 GB 1377231 Antiasthma Asthmachlorophenyl)methyl]-2-(hexahydro-1- 79307-93-0 methyl-1H-azepin-4-yl)-,monohydrochloride [CAS] azelnidipine 3,5-Pyridinedicarboxylic acid,2-amino-1,4- 123524-52-7 EP 266922 Antihypertensive, Hypertension,dihydro-6-methyl-4-(3-nitrophenyl)-, 3-[1- other general(diphenylmethyl)-3-azetidinyl] 5-(1- methylethyl)ester, (+/−)-[CAS]Azidamfenicol 13838-08-9 Azidocillin 17243-38-8 Azimilide 149908-53-2Azintamide 1830-32-6 azithromycin 9-deoxo-9a-aza-9a-methyl-9a-76801-85-9 U.S. 4,328,334 Macrolide antibiotic Infection,homoerythromycin-A 83905-01-5 respiratory 92395-24-9 tract, lowerazlocillin 4-Thia-1-azabicyclo[3.2.0]heptane-2- 37091-65-9 GB 1392849Penicillin, injectable Infection, carboxylic acid,3,3-dimethyl-7-oxo-6-[[[[(2- 37091-66-0 generaloxo-1-imidazolidinyl)carbonyl]amino]- phenylacetyl]amino]-, [2S-[2alpha.,5Alpha, 6β(S*)]]-[CAS] Azosemide 27589-33-9 aztreonam Propanoicacid, 2-[[[1-(2-amino-4-thiazolyl)- 104184-69-2 GB 2071650 Beta-lactamantibiotic Infection, 2-[(2-methyl-4-oxo-1-sulfo-3- 78110-38-0 generalazetidinyl)amino]-2- oxoethylidene]amino]oxy]-2-methyl-, [2S-[2Alpha,3β(Z)]]-[CAS] azulene Sodium 5-isopropyl-3,8-dimethyl-1-6223-35-4 EP 88958 Formulation, Inflammation, azulene sulfonatemodified- general release, other bacampicillin4-Thia-1-azabicyclo[3.2.0]heptane-2- 37661-08-8 GB 1363506 Penicillin,oral Infection, carboxylic acid, 6- 50972-17-3 general[(aminophenylacetyl)amino]-3,3-dimethyl-7- oxo-,1-[(ethoxycarbonyl)oxy]ethyl ester, [2S-[2Alpha,5Alpha,6β(S*))]]-[CAS]Bacitracin 1405-87-4 baclofen β-(Aminomethyl)-4- 1134-47-0 Formulation,implant Spastic chlorobenzenepropanoic acid [CAS] paralysis Baicalein491-67-8 balofloxacin 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-127294-70-6 EP 342675 Quinolone Infection,fluoro-1,4-dihydro-8-methoxy-7-[3- antibacterial urinary tract(methylamino)-1-piperidinyl]-4-oxo-[CAS] balsalazide Benzoic acid,5-[[4-[[(2- 80573-04-2 U.S. 4,412,992 GI inflammatory/ Colitis,carboxyethyl)amino]carbonyl]phenyl]azo]-2 bowel disorders ulcerativehydroxy-, (E)-[CAS] bambuterol Carbamic acid, dimethyl-, 5-[2-[(1,1-81732-46-9 EP 43807 Antiasthma Asthmadimethylethyl)amino]-1-hydroxyethyl]-1,3- 81732-65-5 phenylene ester,monohydrochloride [CAS] Bamethan 3703-79-5 Bamifylline 2016-63-9Bamipine 4945-47-5 Barbital 57-44-3 barnidipine 3,5-Pyridinedicarboxylicacid, 1,4-dihydro- 104713-75-9 U.S. 4,220,649 Antihypertensive,Hypertension, 2,6-dimethyl-4-(3-nitrophenyl)-, methyl-1- 104757-53-1other general (phenylmethyl)-3-pyrrolidinyl ester, [S- 71863-56-4(R*,R*)]- BAS-118 N-Methyl-3-[2-(2- Antibacterial, other Infection,napthyl)acetylamino]benzamide Helicobacter pylori Basic Aluminum1339-92-0 Carbonate Gel Baslilximab 179045-86-4 Batimastat 130370-60-4Batroxobin 9039-61-6 Bay-41-2272 5-cyclopropyl-2-[1(2-fluoro-benzyl)-1H-Male sexual Sexual pyrazolo[3,4-b]pyridine-3-yl]pyrimidin- dysfunctiondysfunction, 4ylamine male, general Bay-41-85432-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4- Cardiovascular Unspecifiedb]pyridin-3-yl]-5-(4-morpholinyl)pyrimidine- 4,6-diamine BAY-43-9006N-(4-chloro-3-(trifluoromethyl)phenyl)-N′- Anticancer, other Cancer,liver (4-(2-(N-methylcarbamoyl)-4- pyridyloxy)phenyl)urea BAY-57-1293N-[5(aminosulfonyl)-4-methyl-1,3-thiazol-2- Antiviral, other Infection,yl]-N-methyl-2-[4-(2- herpes pyridinyl)phenyl]acetamide simplex virusbazedoxifen TSE 424 [CAS] 198481-33-3 EP 802183 OsteoporosisOsteoporosis treatment β-Benzalbutyramide 7236-47-7 BBR-3464Platinum(4+), hexaaminedichlorobis(μ-(1,6- 172903-00-3 U.S. 5,744,497Anticancer, Cancer, lung, hexanediamine-N:N′))tri-stereoisomer,alkylating non-small cell tetranitrate [CAS] BBR-3576 U.S. 5,519,029Anticancer, antibiotic Cancer, prostate BBR-3610 U.S. 6,060,616Anticancer, alkylating Cancer, general β-Carotene 7235-40-7 BCH-1868(−)-2-R-dihydroxyphosphinyol-5-(S)- Anticancer, Cancer, general(guanin-9′-yl-methyl)tetrahydrofuran antimetabolite Bebeerine 477-60-1Beclamide 501-68-8 beclometasone Pregna-1,4-diene-3,20-dione, 9-chloro-5534-09-8 WO 0006132 Formulation, Asthma11β,17,21-trihydroxy-16β-methyl, [CAS] 4419-39-0 inhalable, solutionBefloxatone 134564-82-2 befunolol Ethanone, 1-[7-[2-hydroxy-3-[(1-39543-79-8 Antiglaucoma methylethyl)amino]propoxy]-2- 39552-01-7benzofuranyl]-[CAS] Bemegride 64-65-3 Benactyzine 302-40-9 benazepril1H-1-Benzazepine-1-acetic acid, 3-[[1- 86541-74-4 EP 72352Antihypertensive, Hypertension, (ethoxycarbonyl)-3-phenylpropyl]amino]-86541-75-5 renin system general 2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]-86541-78-8 [CAS] bencyclane 1-Propanamine, N,N-dimethyl-3-[[1-14286-84-1 WO 9829409 Vasodilator, (phenylmethyl)cycloheptyl]oxy]-,(E)-2- 2179-37-5 peripheral butenedioate (1:1) [CAS] bendazac L-Lysine,mono[[[1-(phenylmethyl)1H- 81919-14-4 GB 2081708 Ophthalmologicalindazol-3-yl]oxy]acetate][CAS] 20187-55-7 Bendroflumethiazide 73-48-3Benexate 78718-25-9 benfluorex Ethanol, 2-[[1-methyl-2-[3- 23602-78-0 GB1175516 Hypolipaemic/ (trifluoromethyl)phenyl]ethyl]amino]-, 23642-66-2Antiatherosclerosis benzoate (ester) [CAS] Benfotiamine 22457-89-2Benfurodil 3447-95-8 benidipine 3,5-Pyridinedicarboxylic acid,1,4-dihydro- 105979-17-7 EP 63365 Antihypertensive, Hypertension,2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1- 91599-74-5 other general(phenylmethyl)-3-piperidinyl ester, monohydrochloride(R*,R*)-(+/−)-[CAS] Benorylate 5003-48-5 Benoxaprofen 67434-14-4Benoxinate 99-43-4 Benperidol 2062-84-2 Benproperine 2156-27-6Benserazide 322-35-0 bentazepam 2H-[1]Benzothieno[2,3-e]-1,4-diazepin-2-29462-18-8 DE 2005276 Anxiolytic one,1,3,6,7,8,9-hexahydro-5-phenyl[CAS] Bentiromide 37106-97-1 Bentoquatam1340-69-8 Benzalkonium 8001-54-5 Benzarone 1477-19-6 benzbromaroneMethanone, (3,5-dibromo-4- 3562-84-3 U.S. 3,012,042 Antigouthydroxyphenyl)(2-ethyl-3-benzofuranyl)- [CAS] Benzethonium 121-54-0Benzetimide 14051-33-3 Benzilonium 1050-48-2 Benziodarone 68-90-6benznidazole N-benzyl-2-nitroimidazole-1-acetamide 22994-85-0 GB 1138529Protozoacide benzocaine Benzoic acid, 4-amino-, ethyl ester 94-09-7Formulation, Pain, fixed-dose musculoskeletal combinations Benzoctamine17243-39-9 Benzonatate 104-31-4 Benzoxonium Chloride 19379-90-9 benzoylperoxide Peroxide, dibenzoyl [CAS] 94-36-0 Formulation, other AcneBenzoylpas 13898-58-3 Benzphetamine 156-08-1 Benzpiperylon 53-89-4Benzquinamide 63-12-7 Benzthiazide 91-33-8 Benztropine 132-17-2benzydamine 1-Propanamine, N,N-dimethyl-3-[[1- 132-69-4 Stomatological,(phenylmethyl)-1H-indazol-3-yl]oxy]-[CAS] 642-72-8 reproductive/gonadal,anti-inflammatory Benzyl Benzoate 120-51-4 Benzylhydrochloro- 1824-50-6thiazide Benzylmorphine 14297-87-1 Bephenium 3818-50-6 Hydroxynaphthoatebepotastine 1-Piperidinebutanoic acid, 4-((4- 190786-44-8 WO 9829409Antiallergic, non- Allergy, general chlorophenyl)-2-pyridinylmethoxy)-,(S)-, 190786-43-7 asthma monobenzenesulfonate [CAS] bepridil1-Pyrrolidineethanamine, β-[(2- 64706-54-3 EP 146155 Antianginal Angina,general methylpropoxy)methyl]-N-phenyl-N- 74764-40-2(phenylmethyl)-[CAS] 74764-75-3 beraprost1H-Cyclopenta[b]benzofuran-5-butanoic 88475-69-8 U.S. 4,474,802Prostaglandin Peripheral acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-88430-50-6 vascular disease hydroxy-4-methyl-1-octen-6-ynyl)-[CAS]Berberine 2086-83-1 Bergapten 484-20-8 Bermoprofen 78499-27-1Besipirdine 119257-34-0 betahistine 2-Pyridineethanamine, N-methyl-,5579-84-0 Formulation, Meniere's disease dihydrochloride 5638-76-6modified- release, <=24 hr betaine Betaine-[CAS] 107-43-7 Metabolic andHomocystinuria enzyme disorders betamethasonePregna-1,4-diene-3,20-dione, 9-fluoro- 378-44-9 Formulation, dermal,Psoriasis 11,17,21-trihydroxy-16-methyl-, (11β,16β)- topical [CAS]Betamipron 3440-28-6 Betasine 3734-24-5 betaxolol 2-Propanol, 1-[4-[2-63659-18-7 U.S. 4,252,984 Antihypertensive, Hypertension,(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1- 63659-19-8 adrenergic general,methylethyl)amino]-[CAS] glaucoma Betazole 105-20-4 Bethanechol 590-63-6Bethanidine 55-73-2 Betoxycaine 3818-62-0 β-Eucaine 500-34-5 bevantolol2-Propanol, 1-[[2-(3,4- 42864-78-8 U.S. 3,857,891 Antihypertensive,Hypertension, dimethoxyphenyl)ethyl]amino]-3-(3- 59170-23-9 adrenergicgeneral methylphenoxy)-[CAS] Bevonium 5205-82-3 bexarotene Benzoic acid4-(1-(5,6,7,8-tetrahydro- 153559-49-0 WO 9321146 Anticancer, otherCancer, 3,5,5,8,8-pentamethyl-2- lymphoma, naphthalenyl)-[CAS] T-cellbenzafibrate Propanoic acid, 2-[4-[2-[(4- 41859-67-0 GB 1359264Hypolipaemic/ chlorobenzoyl)amino]ethyl]phenoxy]-2- Antitherosclerosismethyl-[CAS] Bezitramide 15301-48-1 BG-9928 166374-48-7 CardiostimulantHeart failure BIA-2-024 10,11-dihydro-10-hydroxyimino-5H- 199997-15-4 WO9745416 Antiepileptic Epilepsy, dibenz/b,f/azepine-5-carboxamide generalBIA-2-093 (S)-(−)-10-acetoxy-10,11-dihydro-5H- 236395-14-5 AntiepilepticEpilepsy, dibenzo/b,f/azepine-5-carboxamide-[CAS] general BIA-3-2021-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl- 274925-86-9 EP 1010688Antiparkinsonian Parkinson's ethanone disease Bialamicol 493-75-4biapenem 5H-Pyrazolo[1,2-a][1,2,4]triazol-4-ium, 6- 120410-24-4 EP289801 Beta- Infection, [[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-lactam antibiotic beta- oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-lactamase 6,7-dihydro-, hydroxide, inner salt, [4R- resistant[4Alpha,5β,6β(R*)]]-[CAS] Bibenzonium 15585-70-3 Bibrocathol 6915-57-7bicalutamide Propanamide, N-[4-cyano-3- 90357-06-5 EP 100172 Anticancer,Cancer, (trifluoromethyl)phenyl]-3-[(4- hormonal prostatefluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (+/−)-[CAS] bicifadine3-Azabicyclo[3.1.0]hexane, 1-(4- 66504-75-4 DE 2740562 Analgesic, otherPain, general methylphenyl)-, (+/−)-[CAS] 71195-57-8 bicyclic U.S.6,294,585 Dermatological Unspecified monoterpene diols Bidisomide116078-65-0 Bietamiverine 479-81-2 Bietanautine 6888-11-5 Bietaserpine53-18-9 bifermelane 1-Butanamine, N-methyl-4-[2- 62232-46-6 GB 1512880Cognition enhancer Attention (phenylmethyl)phenoxy]-, hydrochloride90293-01-9 deficit [CAS] disorder Bifluranol 34633-34-6 bifonazole1H-Imidazole, 1-([1,1′-biphenyl]-4- 60628-96-8 U.S. 4,118,487 AntifungalInfection, ylphenylmethyl)-[CAS] 60629-08-5 fungal, 60629-09-6 generalbimatoprost 5-Heptenamide, 7-(3,5-dihydroxy-2-(3- 155206-00-1 U.S.5,688,819 Prostaglandin Glaucomahydroxy-5-phenyl-1-pentenyl)cyclopentyl)- N-ethyl(1R-(1Alpha(Z)2β(1E,3S,3Alpha,5Alpha)) [CAS] bimoclomolN-[2-hydroxy-3-(1-piperidinyl)propoxy]-3- 130493-04-8 U.S. 5,147,874Symptomatic Neuropathy, pyridinecarboximidoyl chloride, (Z)-2-antidiabetic diabetic butanedioate (1:1) bimosiamose(1,1′-Biphenyl)-3-acetic acid, 3′,3′′′-(1,6- 187269-40-5 U.S. 5,444,050Antiasthma Asthma hexanediyl)bis(6′-Alpha-D- mannopyranosyloxy)-, [CAS]Binifibrate 69047-39-8 binodenoson Adenosine, 2- 144348-08-3Vasodilator, Diagnosis, ((cyclohexylmethylene)hydrazino)-[CAS] coronarycoronary Biomed-101 U.S. 6,423,744 Anticancer, other Cancer, renalBiotin 58-85-5 Biperiden 514-65-8 birlcodar 2-Piperidinecarboxylic acid,1-(oxo(3,4,5- 174254-13-8 Radio/ Cancer,trimethoxyphenyl)acetyl)-,4-(3-pyridinyl)-1- 159997-94-1 chemosensitizerbreast (3-(3-pyridinyl)propyl)butyl ester, (S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:2) [CAS] biriperone 1-Butanone,1-(4-fluorophenyl)-4- 42021-34-1 DE 2333922 Neuroleptic (3,4,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4- b]indol-2(1H)-yl)-[CAS]Bisacodyl 603-50-9 Bisantrene 78186-34-2 Bisbentiamine 2667-89-2Bisdequalinium 52951-36-7 Bismuth Aluminate 12284-76-3 Bismuth53897-25-9 Butylthiolaurate Bismuth Ethyl 52951-37-8 Camphorate Bismuth138-58-9 Iodosubgallate Bismuth Sodium 53778-50-0 Iodide Bismuth Sodium5798-43-6 Triglycollamate Bismuth Subcarbonate 5892-10-4 BismuthSubgallate 22650-86-8 Bismuth Subnitrate 1304-85-4 Bismuth Subsalicylate14882-18-9 Bismuth 5175-83-7 Tribromophenate bisoprolol 2-Propanol,1-[4-[[2-(1- 104344-23-2 GB 1532380 Antihypertensive, Heart failuremethylethoxy)ethoxy]methyl]phenoxy]-3- 66722-44-9 adrenergic[(1-methylethyl)amino]-[CAS] bisoprolol + HCTZ 2-Propanol, 1-[4-[[2-(1-Formulation, fixed- Hypertension, methylethoxy)ethoxy]methyl]phenoxy]-3-dose combinations general [(1-methylethyl)amino] mixt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7- sulfonamide 1,1-dioxidebisoprolol + 2-Propanol, 1-[4-[[2-(1- Formulation, fixed- Hypertension,trichloromethiazide methylethoxy)ethoxy]methyl]phenoxy]-3- dosecombinations general [(1-methylethyl)amino] mixt. with 6-chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide1,1- dioxide Bisoxatin 14008-48-1 Bithionol 97-18-7 Bitolterol30392-40-6 Bitoscanat 4044-65-9 BL-3875 WO 0218378 Anti-inflammatoryUnspecified bleomycin Bleomycin [CAS] 11056-06-7 Formulation, Cancer,head 9041-93-4 transdermal, and neck enhanced blonanserinCycloocta[b]pyridine, 2-(4-ethyl-1- 132810-10-7 EP 385237 NeurolepticSchizophrenia piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-[CAS] BMS-184476 EP 639577 Anticancer, otherCancer, breast BMS-387032 cis-(+/−)-2-(Ethylthio)-5,7-dihydroxy-8-(3- WO9742949 Anticancer, other Cancer, hydroxy-1-methyl-4-piperidinyl)-4H-1-general benzopyran-4-one BN-824514-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di- Neuroprotective Unspecifiedtert-butylphenol, dihydrochloride BNP-7787 Ethanesulfonic acid,2,2′-dithiobis-. 16208-51-8 Radio/ Chemotherapy- disodium salt [CAS]chemoprotective induced nausea and vomiting BO-653 5-Benzofuranol,4,6-bis(1,1-dimethylethyl)- 157360-23-1 WO 9408930 Hypolipaemic/Atherosclerosis 2,3-dihydro-2,2-dipentyl-[CAS] AntiatherosclerosisBolandiol 19793-20-5 Bolasterone 1605-89-6 Boldenone 846-48-0 bopindolol2-Propanol, 1-[(1,1-dimethylethyl)amino]-3- 62658-63-3 U.S. 4,340,541Antihypertensive, Hypertension, [(2-methyl-1H-indol-4-yl)oxy]-, benzoate82857-38-3 adrenergic general (ester), (+/−)-[CAS] Bornyl Chloride464-41-5 Bornyl Salicylate 560-88-3 bortezomib Boronic acid,[(1R)-3-methyl-1-[[(2S)-1-oxo 179324-69-7 U.S. 6,271,199 Anticancer,other Cancer, 3-phenyl-2- myeloma[(pyrazinylcarbonyl)amino]propyl]amino]- butyl]-[CAS] Bromocriptine25614-03-3 Bromo- 118-23-0 diphenhydramine Bromoform 75-25-2 Bromopride4093-35-0 Bromo- 3679-64-9 salicychloranilide bromperidol 1-Butanone,4-[4-(4-bromophenyl)-4- 10457-90-6 U.S. 3,438,991 Neuroleptic Psychosis,hydroxy-1-piperidinyl]-1-(4-fluorophenyl)- general [CAS] Brompheniramine86-22-6 Broparoestrol 479-68-5 Bropirimine 56741-95-8 brostallicin4-(2-Bromoacrylamido)-N′′′-(2- Anticancer, other Cancer,guanidinoethyl)-1-1′,1″,1′′′-tetramethyl- generalN,4′:N′,4″:N′′′,4′′′′-quarter-[pyrrole-2- carboxamide][CAS] brotizolam6H-Thieno[3,2-f][1,2,4]triazolo[4,3- 57801-81-7 U.S. 4,094,984Hypnotic/Sedative a][1,4]diazepine, 2-bromo-4-(2-chlorophenyl)-9-methyl-[CAS] Brovincamine 57475-17-9 Brozuridine 59-14-3Broxyquinoline 521-74-4 Brucine 357-57-3 β-Sitosterol 83-46-5 Bucetin1083-57-4 Bucillamine 65002-17-7 Bucindolol 71119-11-4 bucladesineAdenosine, N-(1-oxobutyl)-, cyclic 3′,5′- 362-74-3 JP 51113896Cardiostimulant Wound (hydrogen phosphate) 2′-butanoate [CAS] healingBuclizine 82-95-1 Buclosamide 575-74-6 Bucolome 841-73-6 bucricaine9-Acridinamine, N-butyl-1,2,3,4-tetrahydro-, 82636-28-0 Anaesthetic,local monohydrochloride [CAS] bosentan Benzenesulfonamide, 4-(1,1-147536-97-8 EP 633259 Vasodilator, Hypertension,dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2- peripheral pulmonarymethoxyphenoxy)[2,2′-bipyrimidin]-4-yl]- [CAS] BP2,94 Phenol,2-[[[(1R)-2-(1H-imidazol-4-yl)-1- 139191-80-3 WO 9117146 RespiratoryRhinitis, methylethyl]imino]phenylmethyl]-[CAS] general BP4.897N-[4-[4-(2-methoxyphenyl)-1- EP 779284 Dependence Addiction,piperazinyl]butyl]naphthalene-2- treatment cocaine carboxamideβ-Propiolactone 57-57-8 Bradycor 140661-97-8 Brain Natriuretic114471-18-0 Peptide Brallobarbital 561-86-4 brasofensine8-Azabicyclo(3.2.1)octane-2- 171655-91-7 WO 9528401 AntiparkinsonianParkinson's carboxaldehyde, 3-(3,4-dichlorophenyl)-8- disease methyl-,O-methyloxime, (1R- (1Alpha,2β(E),3Alpha,5Alpha))-[CAS] Brequinar96187-53-0 Bretylium 61-75-6 Brilliant Green 633-03-4 brimonidine6-Quinoxalinamine, 5-bromo-N-(4,5- 59803-98-4 DE 2538620 AntiglaucomaGlaucoma dihydro-1H-imidazol-2-yl)-[CAS] brinzolamide2H-Thieno(3,2-e)-1,2-thiazine-6- 138890-62-7 U.S. 5,378,703 AntiglaucomaGlaucoma sulfonamide, 4-(ethylamino)-3,4-dihydro-2- (3-methoxypropyl)-,1,1-dioxide, (R)- [CAS] brivudin Uridine, 5-(2-bromoethenyl)-2′-deoxy,(E)- 69304-47-8 Antiviral, other Infection, [CAS] varicella zoster virusBrodimoprim 56518-41-3 Bromazepam 1812-30-2 bromfenac Benzeneaceticacid, 2-amino-3-(4- 91714-93-1 Formulation, Inflammation,bromobenzoyl)-[CAS] 91714-94-2 mucosal, topical ocular Bromhexine3572-43-8 Bromindione 1146-98-1 Bromisovalum 496-67-3 Bucumolol58409-59-9 budesonide Pregna-1,4-diene-3,20-dione, 16,17- 51333-22-3 GB1429922 Antiasthma Asthma [butylidenebis(oxy)]-11,21-dihydroxy-,(11β,16Alpha)-[CAS] budesonide + Pregna-1,4-diene-3,20-dione, 16,17-Formulation, fixed- Asthma formoterol[butylidenebis(oxy)]-11,21-dihydroxy-, dose combinations (11β,1bAlpha) +formamide, N-[2-hydroxy- 5-[1-hydroxy-2-[[2-(4-methoxyphenol)-1-methylethyl]amino]ethyl]phenyl]-(R*,R*)- (±) budipine Piperidine,1-(1,1-dimethylethyl)-4,4- 57982-78-2 DE 2825322 AntiparkinsonianParkinson's diphenyl-[CAS] 63661-61-0 disease Budralazine 36798-79-5Bufeniode 22103-14-6 Bufetolol 53684-49-4 bufexamacp-butoxyacetohydroxamic acid 2438-72-4 U.S. 3,479,396 Anti-inflammatorybuflomedil 1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6- 35543-24-9 GB1325192 Vasodilator, trimethoxyphenyl)-[CAS] 55837-25-7 peripheralBuformin 692-13-7 Bufuralol 54340-62-4 Bumadizon 3583-64-0 bumetanideBenzoic acid, 3-(aminosulfonyl)-5- 28395-03-1 U.S. 3,806,534Antihypertensive, Hypertension, (butylamino)-4-phenoxy-[CAS] diureticgeneral bunaftine 1-Naphthalenecarboxamide, N-butyl-N-[2- 32421-46-8 DE2009894 Antiarrhythmic (diethylamino)ethyl]-[CAS] Bunamiodyl Sodium1923-76-8 bunazosin 1H-1,4-Diazepine, 1-(4-amino-6,7- 52712-76-2 GB1398455 Antihypertensive, Hypertension,dimethoxy-2-quinazolinyl)hexahydro-4-(1- 80755-51-7 adrenergic generaloxobutyl)-[CAS] bunitrolol Benzonitrile, 2-[3-[(1,1- 34915-68-9 U.S.3,940,489 Antihypertensive, dimethylethyl)amino]-2-hydroxypropoxy]-adrenergic [CAS] bupivacaine 2-Piperidinecarboxamide, 1-butyl-N-(2,6-38396-39-3 Formulation, Anaesthesia dimethylphenyl)-[CAS] 2180-92-9modified-release, >24 hr Bupranolol 14556-46-8 buprenorphine6,14-Ethenomorphinan-7-methanol, 17- 52485-79-7 U.S. 3,433,791Analgesic, other (cyclopropylmethyl)-Alpha-(1,1- 53152-21-9dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha(S)]-[CAS] bupropion1-Propanone, 1-(3-chlorophenyl)-2-[(1,1- 31677-93-7 U.S. 4,425,363Antidepressant Depression, dimethylethyl)amino]-, (+/−)-[CAS] 34911-55-2general Buramate 4663-83-6 buserelin Luteinizing hormone-releasingfactor (pig), 57982-77-1 GB 1523623 Releasing hormones Cancer,6-[O-(1,1-dimethylethyl)-D-serine]-9-(N- 68630-75-1 prostateethyl-L-prolinamide)-10-deglycinamide- [CAS] buspirone8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4- 36505-84-7 EP 276536Anxiolytic Anxiety, (2-pyrimidinyl)-1-piperazinyl]butyl]-[CAS] generalbusulfan 1,4-Butanediol, dimethanesulfonate [CAS] 55-98-1 Formulation,Cancer, optimized, general microparticles busulfan 1,4-Butanediol,dimethanesulfonate [CAS] 55-98-1 Formulation, Cancer, parenteral, otherleukaemia, acute myeolgenous Butabarbital 143-81-7 Butacaine 149-16-6Butacetin 2109-73-1 Butalamine 22131-35-7 Butalbital 77-26-9Butallylonal 1142-70-7 butamben 4-Aminobenzoic acid butyl ester [CAS]94-25-7 Formulation, Pain, cancer modified- release, other butamirateBenzeneacetic acid, Alpha-ethyl-, 2[2- 18109-80-3 Antitussive Cough(diethylamino)ethoxy]ethylester, 2-hydroxy- 18109-81-41,2,3-propanetricarboxylate (1:1) [CAS] Butanilicaine 3785-21-5Butaperazine 653-03-2 Butaverine 55837-14-4 Butazolamide 16790-49-1Butedronic Acid 51395-42-7 butenafine 1-Naphthalenemethanamine,N-((4-(1,1- 101827-46-7 EP 164697 Antifungal Infection,dimethylethyl)phenyl)methyl)-N-methyl- 101828-21-1 dermatological [CAS]Butethal 77-28-1 Butethamate 14007-64-8 Butethamine 2090-89-3 Buthalital510-90-7 Buthiazide 2043-38-1 Butibufen 55837-18-8 Butidrine 1506-12-3butobendine benzoic acid, 3,4,5-trimethoxy-, 1,2- 55769-64-7 U.S.4,012,473 Antiarrhythmic Arrhythmia,ethanediylbis[(methylimino)(2-ethyl-2,1- 55769-65-8 generalethanediyl)]ester, [S-(R*,R*)]-[CAS] butoconazole 1H-Imidazole,1-[4-(4-chlorophenyl)-2- 64872-76-0 GB 1567431 Antifungal Infection,[(2,6-dichlorophenyl)thio]butyl]-, (+/−)- 64872-77-1 Candida, [CAS]general Butoctamide 32838-26-9 Butofilolol 64552-17-6 butorphanolMorphinan-3,14-diol, 17-(cyclobutylmethyl)-, 42408-82-2 GB 1412129Analgesic, other [S-(R*,R*)]-2,3-dihydroxybutanedioate 58786-99-5 (1:1)(salt) [CAS] Butoxycaine 3772-43-8 Butriptyline 35941-65-2 Butropium29025-14-7 Buzepide 3691-21-2 BVT-5182 WO 0208178 Anorectic/ ObesityAntiobesity BXT-51072 2H-1,2-Benzoselenazine, 3,4-dihydro-4,4-173026-17-0 GI inflammatory/ Colitis, dimethyl-[CAS] bowel disordersulcerative C-1311 6H-Imidazol[4,5,1-de]acridin-6-one, 5-[[2- Anticancer,other Cancer, (diethylamino)ethyl]amino]-8-hydroxy-, general 2HCl, 2H2Ocabergoline Ergoline-8-carboxamide, N-[3- 81409-90-7 GB 2103603Antiprolactin Gala- (dimethylamino)propyl]-N- 85329-89-1 ctorrhoea[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)-[CAS] Cabergoline81409-90-7 Cacodylic Acid 75-60-5 Cactinomycin 8052-16-2 cadexomeriodine Cadexomer iodine [CAS] 94820-09-4 Anti-infective, other Ulcer,venostasis Cadmium Salicylate 19010-79-8 Cadralazine 64241-34-5Cafaminol 30924-31-3 caffeine 1,2,3,-Propanetricarboxylic acid,2-hydroxy 69-22-7 Respiratory Apnoea mixt. with3,7-dihydro-1,4,7-trimethyl-1H- 58-08-2 purine-2,6-dione [CAS]Calcifediol 19356-17-3 Calcipotriene 112965-21-6 calcipotriol9,10-Secochola-5,7,10(19),22-tetraene- 112965-21-6 WO 8700834Antipsoriasis Psoriasis 1,3,24-triol, 24-cyclopropyl-,(1Alpha,3β,5Z,7E,22E)-[CAS] calcipotriol +9,10-Secochola-5,7,10(19),22-tetraene- Formulation, Psoriasisbeclometasone 1,3,24-triol, 24-cyclopropyl-, fixed-dose(1Alpha,3β,5Z,7E,22E) + Pregna-1,4- combinations diene-3,20-dione,9-chloro-11β,17,21- trihydroxy-16β-methyl, 17,21-dipropionate calcitriol9,10-Secocholesta-5,7,10(19)-triene- 32222-06-3 Antipsoriasis Psoriasis1,3,25-triol, (1Alpha,3β,5Z,7E)-[CAS] Calcium 3-Aurothio-2- 5743-29-3propanol-1-sulfonate Calcium 69-46-5 Acetylsalicylate Calcium 33659-28-8Bromolactobionate Calcium Carbonate 471-34-1 Calcium Gluconate 299-28-5Calcium 27214-00-2 Glycerophosphate calcium CalciumD-(+)-4-(2,4-dihydroxy-3,3- 17097-76-6 EP 117260 Neurological Attentionhopantothenate dimethylbutyramido)butyrate deficit (hemihydrate) [CAS]disorder Calcium Iodobehenate 1319-91-1 Calcium Iodosterate 1301-16-2Calcium Lactate 814-80-2 Calcium Levulinate 591-64-0 Calcium Mesoxalate21085-60-9 Calcium N- 16649-79-9 Carbamoylaspartate calciumpolycarbophil Polycarbophil, calcium salt-[CAS] 126040-58-2 GIinflammatory/ Irritable 9003-97-9 bowel disorders bowel syndrome CalciumPropionate 4075-81-4 Calcium Succinate 140-99-8 caldaret5-methyl-2-(1-piperazinyl)-benzenesulfonic 133804-44-1 CardiostimulantHeart failure acid monohydrate Calusterone 17021-26-0 Camazepam36104-80-0 camostat Benzeneacetic acid, 4-[[4- 59721-28-7 U.S. 4,021,472GI inflammatory/ Pancreatitis [(aminoiminomethyl)amino]benzoyl]oxy]-,59721-29-8 bowel disorders 2-(dimethylamino)-2-oxoethyl ester,71079-09-9 monomethanesulfonate [CAS] Camphor 76-22-2 Camphotamide4876-45-3 camptothecin 4-Ethyl-4-hydroxy-1H-pyrano- Formulation, Cancer,[I3′4′:6,7]indolizinol[1,2-b;]quinoline- optimized, general3,14(4H,12H)-dione microemulsion Candesartan 139481-59-7 candesartancilexetil 1H-Benzimidazole-7-carboxylic acid, 2- 145040-37-5 EP 520423Antihypertensive, Hypertension, ethoxy-1-[[2′-(1H-tetrazol-5-yl)[1,1′-renin system general biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, (+/−)-[CAS] Candoxatril123122-55-4 canertinib N-[4-(3-(Chloro-4-fluoro-phenylamino)-7-(3-289499-45-2 Anticancer, other Cancer, lung,morpholin-4-yl-propoxy)-quinazolin-6-yl]- non-small cell acrylamideCanrenone 976-71-6 Cantharidin 56-25-7 cantuzumab mertansine Maytansine,N2-deacetyl-N2-(3-mercapto- 139504-50-0 Immunotoxin Cancer,1-oxopropyl)-, conjugated humanized colorectal C242 monoclonal antibodycapecitabine Cytidine, 5-deoxy-5-fluoro-N- 154361-50-9 EP 602454Anticancer, Cancer, [(pentyloxy)carbonyl]-[CAS] antimetabolite breastCapobenic Acid 21434-91-3 capravirine 1H-imidazole-2-methanol, 5-(3,5-178979-85-6 Antiviral, anti-HIV Infection,dichlorophenyl)thio-4-(1-methylethyl)-1-(4- HIV/AIDS pyridinyl)methylcarbamate (ester) [CAS] Capromab 151763-64-3 capsaicin creamN-[(4-hydroxy-3-methoxyphenyl)methyl]-8- 404-86-4 Formulation, dermal,Pain, post- methyl-, (E)-[CAS] topical herpetic Captodiamine 486-17-9captopril L-Proline, 1-(3-mercapto-2-methyl-1- 62571-86-2 U.S. 4,105,776Antihypertensive, Hypertension, oxopropyl)-, (S)-[CAS] renin systemgeneral captopril + HCTZ L-Proline, 1-(3-mercapto-2-methyl-1-110075-07-5 U.S. 4,217,347 Antihypertensive, oxopropyl)-, (S)-, mixt.with 6-chloro-3,4- renin system dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide [CAS] Capuride 5579-13-5 carabersat Benzamide,N-(6-acetyl-3,4-dihydro-3- 184653-84-7 WO 9811890 AntiepilepticEpilepsy, hydroxy-2,2-dimethyl-2H-1-benzopyran-4- general yl)-4-fluoro,(3R-trans)-[CAS] Caramiphen 77-22-5 carazolol 2-Propanol,1-(9H-carbazol-4-yloxy)-3-[(1- 57775-29-8 DE 2240599 Antihypertensive,methylethyl)amino]-[CAS] adrenergic Carbachol 51-83-2 carbamazepine5H-Dibenz[b,f]azepine-5-carboxamide 298-46-4 Formulation, Epilepsy,[CAS] modified- general release, other Carbamide Peroxide 124-43-6Carbarsone 121-59-5 Carbaryl 63-25-2 Carbazochrome 13051-01-9 51460-26-5carbendazim Methyl-2-benzimidazolecarbamate Anticancer, other Cancer,general Carbenicillin 4697-36-3 Carbenoxolone 5697-56-3 Carbetapentane77-23-6 Carbicarb Carbonic acid disodium salt, mixt. with 72227-05-5Alimentary/ Acidosis monosodium salt-[CAS] Metabolic, other Carbidopa28860-95-9 carbidopa + S-Alpha Hydrazino-3,4-dihydroxy-AlphaFormulation, Parkinson's levodopa-1 methyl benzene propanoic acidfixed-dose disease monohydrate + 3-hydroxy-L-tyrosine combinationsCarbimazole 22232-54-8 Carbinoxamine 486-16-8 Carbocloral 541-79-7carbocysteine 151756-26-2 EP 546272 Cystic fibrosis Cystic 638-23-3treatment fibrosis Carbon Tetrachloride 56-23-5 carboplatin Platinum,diammine[1,1- 41575-94-4 Anticancer, Cancer,cyclobutanedicarboxylate(2-)]-, (SP-4-2)- alkylating ovarian [CAS]Carboprost 35700-23-3 carboprost Prosta-5,13-dien-1-oic acid, 9,11,15-58551-69-2 U.S. 3,728,382 Prostaglandin Abortion trometamoltrihydroxy-15-methyl-, 74849-93-7 (5Z,9.alpha.,11Alpha,13E,15S)-, compd.with 2-amino-2-(hydroxymethyl)-1,3- propanediol(1:1) [CAS] Carboquone2,5-Cyclohexadiene-1,4-dione, 2-[2- 24279-91-2 DE 1905224 Anticancer,[(aminocarbonyl)oxy]-1-methoxyethyl]-3,6- antibioticbis(1-aziridinyl)-5-methyl-[CAS] Carbromal 77-65-6 Carbubarb 960-05-4Carbutamide 339-43-5 Carbuterol 34866-47-2 Carfimate 3567-38-2 carglumicacid N-Carbamoyl-L-glutamic acid 1188-38-1 Metabolic and Hyper- enzymedisorders ammonaemia Cargutocin 33605-67-3 Carindacillin 35531-88-5cariporide Benzamide, N-(aminoiminomethyl)-4-(1- 159138-80-4 EP 589336Antianginal Angina, methylethyl)-3-(methylsulfonyl)-[CAS] 159138-81-5general Cariporide 159138-80-4 Carisoprodol 78-44-4 carmofur1(2H)-Pyrimidinecarboxamide, 5-fluoro-N- 61422-45-5 U.S. 4,071,519Anticancer, hexyl-3,4-dihydro-2,4-dioxo-[CAS] antimetabolite Carmoxirole98323-83-2 carmustine Urea, N,N′-bis(2-chloroethyl)-N-nitroso- 154-93-8Formulation, implant Cancer, brain [CAS] Carnitine 461-06-3 Caroverine23465-76-1 Caroxazone 18464-39-6 Carphenazine 2622-30-2 Carpipramine5942-95-0 carprofen 9H-Carbazole-2-acetic acid, 6-chloro- 53716-49-7U.S. 3,896,145 Anti-inflammatory Alpha-methyl-, (+/−)-[CAS] Carsalam2037-95-8 carteolol 2(1H)-Quinolinone, 5-[3-[(1,1- 51781-06-7 U.S.3,910,924 Antihypertensive, Glaucomadimethylethyl)amino]-2-hydroxypropoxy]- 51781-21-6 adrenergic3,4-dihydro-, monohydrochloride [CAS] Carticaine 23964-58-1 Carubicin50935-04-1 Carumonam 87638-04-8 Carvacrol 499-75-2 carvedilol2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2- 72956-09-3 EP 4920Antihypertensive, Hypertension, (2-methoxyphenoxy)ethyl]amino]-[CAS]adrenergic general Carvone 99-49-0 Cascarillin 10118-56-6 caspofunginPneumocandin B0, 1-((4R,5S)-5-((2- 162808-62-0 WO 9421677 AntifungalInfection, aminoethyl)amino)-N2-(10,12-dimethyl-1- 179463-17-3Aspergillus oxotetradecyl)-4-hydroxy-L-ornithine)-5-(threo-3-hydroxy-L-ornithine)-, diacetate (salt) [CAS] Catechin 154-23-4cathepsin K inhibitors N-(1-benzothien-2-ylcarbonyl)-N-[2-(2- WO 9613523Osteoporosis Osteoporosis fluorophenyl)-4-oxo-1,2,3,4- treatmenttetrahydropyrimidin-5-yl]-L-leucinamide cathepsin S inhibitorsN-(1-benzothien-2-ylcarbonyl)-N-[2-(2- Antiasthma Asthmafluorophenyl)-4-oxo-1,2,3,4- tetrahydropyrimidin-5-yl]-L-leucinamideCC-401 U.S. 6,342,595 Immunosuppressant Arthritis, rheumatoid CCI-779Rapamycin 42-(3-hydroxy-2- 162635-04-3 Anticancer, Cancer, renal(hydroxymethyl)-2-methylpropanoate) antibiotic [CAS] CCR5 antagonists WO9732019 Antiviral, anti-HIV Infection, HIV/AIDS CDC-394 U.S. 634061Anticancer, other Cancer, myeloma CDC-801 U.S. 5,605,914 GIinflammatory/ Crohn's bowel disorders disease CEE-03-3101H-3-Benzazepin-7-ol, 5-(2,3-dihydro-7- 128022-68-4 EP 347672 DependenceAddiction, benzofuranyl)-2,3,4,5,-tetrahydro-3- treatment alcoholmethyl-8-nitro, (5S)-[CAS] cefactor5-Thia-1-azabicycol[4.2.0]oct-2-ene-2- 53994-73-3 GB 1461323Cephalosporin, oral Infection, carboxylic acid, 7- 70356-03-5Haemophilus [(aminophenylacetyl)amino]-3-chloro-8- influenzae oxo-,[6R-[6Alpha,7β(R*)]]-[CAS] prophylaxis cefadroxil5-Thia-1-azabicycol[4.2.0]oct-2-ene-2- 50370-12-2 GB 1240687Cephalosporin, oral Infection, carboxylic acid, 7-[[amino(4- 66592-87-8general hydroxyphenyl)acetyl]amino]-3-methyl-8- oxo-,[6R-[6Alpha,7β(R*)]]-[CAS] cefalexin5-Thia-1-azabicycol[4.2.0]oct-2-ene-2- 105879-42-3 U.S. 4,775,751Cephalosporin, oral Infection, carboxylic acid, 7- 15686-71-2respiratory [(aminophenylacetyl)amino]-3-methyl-8- tract, upper oxo-,[CAS] cefalexin pivoxil 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-27726-31-4 Cephalosporin, oral Infection, carboxylic acid, 7- general[(aminophenylacetyl)amino]-3-methyl-8- oxo-,(2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7β(R*)]]-[CAS] cefamandole7-D-mandelamido-3[[(1-methyl-1H-tetrazol- 34444-01-4 U.S. 3,641,021Cephalosporin, Infection, 5-yl)thio]methyl]-3-cephem-4-carboxylicinjectable general acid cefatrizine5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 51627-14-6 GB 1460914Cephalosporin, oral Infection, carboxylic acid, 7-[[amino(4- generalhydroxyphenyl)acetyl]amino]-8-oxo-3-[(1H-1,2,3-triazol-4-ylthio)methyl]-, [6R- [6Alpha,7β(R*)]]-[CAS] Cefazedone56187-47-4 Cefazolin 25953-19-9 Cefbuperazone 76610-84-9 cefcapenepivoxil 7β-[(Z)-2-(2-amino-4-thiazolyl)-2- 105889-45-0 GB 2173194Cephalosporin, oral Infection, pentenoylamino]-3-carbamoyloxymethyl-3-105889-46-1 respiratory cephem-4-carboxylic acid, tract, generalpivaloyloxymethyl ester HCl-[CAS] Cefclidin 105239-91-6 cefdinir5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 91832-40-5 EP 105459Cephalosporin, oral Infection, carboxylic acid, 7-[[(2-amino-4-dermatological thiazolyl)(hydroxyimino)acetyl]amino]-3- ethenyl-8-oxo-,[6R-[6Alpha,7β(Z)]]-[CAS] cefditoren pivoxil5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 104145-95-1 JP 61178991Cephalosporin, oral Infection, carboxylic acid, 7-[[(2-amino-4-104146-53-4 general thiazolyl)(methoxyimino)acetyl]amino]-3-[2-117467-28-4 (4-methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [6R- [3(Z),6Alpha,7β(Z)]]-[CAS]cefepime Pyrrolidinium, 1-[[7-[[(2-amino-4- 107648-80-6 EP 531981Cephalosporin, Infection, thiazolyl)(methoxyimino)acetyl]amino]-2-123171-59-5 injectable respiratory carboxy-8-oxo-5-thia-1- 88040-23-7tract, lower azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1- methyl-,hydroxide, inner salt, [6R- [6Alpha,7β(Z)]]-[CAS] Cefetamet 65052-63-3cefetamet pivoxil 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 111696-23-2 GB1581854 Cephalosporin, oral Infection, carboxylic acid, 7-[[(2-amino-4-general thiazolyl)(methoxyimino)acetyl]amino]-3- methyl-8-oxo-,(2,2-dimethyl-1- oxopropoxy)methyl ester, monohydrochloride,[6R-[6Alpha,7β(Z)]]- [CAS] cefixime5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 79350-37-1 EP 30630Cephalosporin, oral Infection, carboxylic acid, 7-[[(2-amino-4- generalthiazolyl)[(carboxymethoxy)imino]acetyl]- amino]-3-ethenyl-8-oxo-, [6R-[6Alpha,7β(Z)]]-[CAS] cefmenoxime 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-65085-01-0 GB 1536281 Cephalosporin, Infection, carboxylic acid,7-[[(2-amino-4- 75738-58-8 injectable ocularthiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8- oxo-,[6R-[6Alpha,7β(Z)]]-[CAS] cefmetazole5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 56796-20-4 GB 1449420Cephalosporin, Infection, carboxylic acid, 7- 56796-39-5 infectablegeneral [[[(cyanomethyl)thio]acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5- yl)thio]methyl]-8-oxo-,(6R-cis)-[CAS] cefminox 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-84305-41-9 EP 24879 Cephalosporin, Infection, carboxylic acid,7-[[[(2-amino-2- injectable urinary tractcarboxyethyl)thio]acetyl]amino]-7- methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R- [6Alpha,7Alpha,7(S*)]]-[CAS] cefodizime5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 69739-16-8 U.S. 4,590,267Cephalosporin, Infection, carboxylic acid, 7-[[(2-amino-4- 86329-79-5injectable respiratory thiazoyl)(methoxyimino)acetyl]amino]-3- tract,lower [[[5-(carboxymethyl)-4-methyl-2- thiazolyl]thio]methyl]-8-oxo-,[6R- [6Alpha,7β(Z)]]-[CAS] cefonicid5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 61270-78-8 GB 1547473Cephalosporin, Infection, carboxylic acid, 7-[(hydroxyphenylacetyl)-61270-58-4 injectable general amino]-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-, disodium salt, [6R-[6Alpha,7β(R*)]]-[CAS]cefoperazone 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 62893-19-0 GB1508071 Cephalosporin, Infection, carboxylic acid,7-[[[[(4-ethyl-2,3-dioxo-1- injectable generalpiperazinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R- [6Alpha,7β(R*)]]-[CAS]cefoperazone + 92739-15-6 U.S. 4,234,579 Antibiotic, other Infection,sulbactam general Ceforanide 60925-61-3 cefoselis5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 122841-12-7 EP 307804Cephalosporin, Infection, carboxylic acid, 7-[[(2-amino-4- 122841-10-5injectable general thiazolyl)(methoxyimino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-amino-1H-pyrazol-1-yl]methyl]-8-oxo-, [6R- [6Alpha,7β(Z)]] cefotazime(6R,7R)-7-[[(2-amino-4- 64485-93-4 GB 1580621 Cephalosporin, Infection,thiazolyl)(methoxyimino)acetyl]amino]- 63527-52-6 injectable generalcephalsporanic acidsodium salt Cefotetan 69712-56-7 cefotiam5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 61622-34-2 U.S. 4,080,498Cephalosporin, Infection, carboxylic acid, 7-[[(2-amino-4- 66309-69-1injectable general thiazolyl)acetyl]amino]-3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5- yl]thio]methyl]-8-oxo-,(6R-trans)-[CAS] cefotiam hexetil 1-(cyclohexloxycarbonyloxy)ethyl7β-[2-(2- 95789-30-3 EP 128029 Cephalosporin, oral Infection,aminothiazol-4-yl)acetamido]-3-[[[1-(2- respiratorydimethylaminoethyl)-1H-tetrazol-5- tract, loweryl]thio]methyl]ceph-3-em-4-carboxylate 2HCl [CAS] cefoxitin5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2- 33564-30-5 GB 1348984Cephalosporin, oral Infection, carboxylic acid, 3- 35607-66-0 general(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, monosodium salt, (6R-cis)-[CAS]cefozopran Imidazo[1,2-b]pyridazinium, 1-[[7-[[(5- 113359-04-9 EP 203271Cephalosporin, Infection, amino-1,2,4-thiadiazol-3- injectable generalyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3- yl]methyl]-, hydroxide,inner salt, [6R- [6Alpha,7β(Z)]]-[CAS] cefpimizole Pyridinium,1-[[2-carboxy-7-[[[[(5-carboxy- 84880-03-5 EP 60028 Cephalosporin,Infection, 1H-imidazol-4-yl)carbonyl]amino]- 85287-61-2 injectablerespiratory phenylacetyl]amino]-8-oxo-5-thia-1- tract, generalazabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4- (2-sulfoethyl)-, hydroxide,inner salt, [6R-[6Alpha,7β(R*)]]-[CAS] cefpiramide5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 70797-11-4 U.S. 4,156,724Cephalosporin, Infection, carboxylic acid, 7-[[[[(4-hydroxy-6-methyl-injectable general 3-pyridinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R- [6Alpha,7β(R*)]]-[CAS]cefpirome 5H-1-Pyrindinium, 1-[[7-[[(2-amino-4- 84957-29-9 EP 64740Cephalosporin, Infection, thiazolyl)(methoxyimino)acetyl]amino]-2-98753-19-6 injectable respiratory carboxy-8-oxo-5-thia-1- tract, lowerazabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7- dihydro-,hydroxide, innersalt, [6R- [6Alpha,7β(Z)]]-[CAS] Cefpodoxime 87239-81-4 Proxetilcefprozil 5-Thio-1-azabicyclo[4.2.0]oct-2-ene-2- 92665-29-7 GB 2173798Cephalosporin, oral Infection, carboxylic acid, 7-[[amino(4-dermatological hydroxyphenyl)acetyl]amino]-8-oxo-3-(1- propenyl)-,[6R-[6Alpha,7β(R*)]]-[CAS] cefroxadine5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 51762-05-1 GB 1435111Cephalosporin, oral Infection, carboxylic acid, 7-[(amino-1,4- generalcyclohexadien-1-ylacetyl)amino]-3- methoxy-8-oxo-, [6R-[6Alpha,7β(R*)]]-[CAS] cefsulodin Pyridinium, 4-(aminocarbonyl)-1-[[2- 52152-93-9 GBCephalosporin, Infection, carboxy-8-oxo-7- 62587-73-9 injectablepseudomonal [(phenylsulfoacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt,[6R-[6Alpha,7β(R*)]]- [CAS] ceftazidime Pyridinium,1-[[7-[[(2-amino-4-thiazolyl)[(1- 72558-82-8 GB 2025398 Cephalosporin,Infection, carboxy-1-methylethoxy)imino]acetyl]amino]- injectablerespiratory 2-carboxy-8-oxo-5-thia-1- tract, upperazabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt,[6R-[6Alpha,7β(Z)]]- [CAS] Cefteram 82547-58-8 Ceftezole 26973-24-0ceftibuten 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 97519-39-6 EPCephalosporin, oral Infection, carboxylic acid,7-[[2-(2-amino-4-thiazolyl)- respiratory4-carboxy-1-oxo-2-butenyl]amino]-8-oxo-, tract, lower[6R-[6Alpha,7β(Z)]]-[CAS] ceftizoxime5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 68401-81-0 GB 1600735Cephalosporin, Infection, carboxylic acid, 7-[[2-(2-amino-4-thiazolyl)-68401-82-1 injectable general (methoxyimino)acetyl]amino]-8-oxo-,[6R-[6Alpha,7β(Z)]]-[CAS] ceftizoxime5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 113812-94-5 JP 62209112Cephalosporin, oral Infection, alapivoxil carboxylic acid,7-[[[2-[(2-amino-1- 135767-36-1 general oxopropyl)amino]-4-thiazolyl](methoxyimino)acetyl]amino]-8- oxo-,(2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7β(Z(S*))]]-[CAS] ceftriaxone5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 73384-59-5 GB 2022090Cephalosporin, Infection, carboxylic acid, 7-[[(2-amino-4- 74578-69-1injectable respiratory thiazolyl)(methoxyimino)acetyl]amino]-8- tract,lower oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, [6R- [6Alpha,7β(Z)]]-[CAS]cefuroxime axetil 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 15686-71-2 GB1571683 Cephalosporin, oral Infection, carboxylic acid, 3- 64544-07-6respiratory [[(aminocarbonyl)oxy]methyl]-7-[[2- tract, upperfuranyl(methoxyimino)acetyl]amino]-8-oxo-, 1-(acetyloxy)ethyl ester,[6R- [6Alpha,7β(Z)]]-[CAS] cefuroxime5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 55268-75-2 GB 1453049Cephalosporin, Infection, carboxylic acid, 3- 56238-63-2 injectablegeneral [[(aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, 1-(acetyloxy)ethyl ester,[6R- [6Alpha,7β(Z)]]-[CAS] Cefuzonam 82219-78-1 U.S. 5,760,068Antiarthritic, other Arthritis, celecoxib Benzenesulfonamide, 4-(5-(4-169590-42-5 rheumatoid methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-[CAS] celgosivir Butanoic acid,octahydro-1,7,8-trihydroxy- 121104-96-9 U.S. 5,017,563 Antiviral, otherInfection, 6-indolizinyl ester, [1S- hepatitis virus,(1Alpha,6β,7Alpha,8β,8aβ)]-[CAS] general celiprolol Urea,N′-[3-acetyl-4-[3-[(1,1- 56980-93-9 GB 1441359 Antihypertensive, Angina,dimethylethyl)amino]-2- 57470-78-7 adrenergic unstablehydroxypropoxy]phenyl]-N,N-diethyl-[CAS] Cellulose Ethyl HydroxyethylEther CEP-1347 9,12-Epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′- 156177-65-0 WO9731002 Antiparkinsonian Parkinson'skl]pyrrolo[3,4-i][1,6]benzodiazocine-10- disease carboxylic acid,5,16-bis((ethylthio)methyl)- 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- [CAS] CEP-7019,12-Epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′- 111358-88-4 Anticancer,kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one-, antimetabolite Cancer,2,3,9,10,11,12-hexahydro-10-hydroxy-10- prostate(hydroxymethyl)-9-methyl-, (9S,10S,12R)- [CAS] Cephacetrile 23239-41-0Cephaeline 493-17-0 Cephalexin 15686-71-2 Cephaloglycin 3577-1-3Cephaloridine 50-59-9 Cephalosporin C 61-24-5 Cephalothin 153-61-7Cephapirin 24356-60-3 Cephradine 38821-53-3 Cerivastatin 145599-86-6Ceronapril 111223-26-8 certoparin Heparin [CAS] 9005-49-6 AnticoagulantThrombosis, venous Ceruletide 17650-98-5 CerviprostProsta-5,13-dien-1-oic acid, 11,15- 363-24-6 Formulation,dihydroxy-9-oxo-, (5Z,11Alpha,13E,-15S)- dermal, topical [CAS]Cetalkonium 122-18-9 Cetamolol 34919-98-7 Cethexonium 1794-74-7cethromycin 2H-Oxacyclotetradecino(4,3-d)oxazole- 205110-48-1 EP 929563Macrolide antibiotic Infection, 2,6,8,14(1H,7H,9H)-tetrone 4-respiratory ethyloctahydro-3a,7,9,11,13,15- tract, generalhexamethyl-11-((3-(3-quinolinyl)-2-propenyl)oxy)-10-((33.4.6-trideoxy-3- (dimethylamino)-β-D-xylo-hexapyranosyl)oxy)-,(3aS,4R,7R,9R,10R, 11R,13R,15R,15aR)-[CAS] Cetiedil14176-10-4 Cetirizine 83881-51-0 cetirizine Acetic acid, [2-[4-[(4-83881-51-0 EP 58146 Antiallergic, Allergy, chlorophenyl)phenylmethyl]-1-83881-52-1 non-asthma general piperazinyl]-, [CAS] cetirizine + Aceticacid, [2-[4-[(4- 83881-52-1 Formulation, Allergy, pseudoephedrinechlorophenyl)phenylmethyl]-1- 90-82-4 optimized, generalpiperazinyl]ethoxy]-, dihyrochloride, microencapsulate Benzenemethanol,Alpha-[1- (methylamino)ethyl]-, hydrochloride, [S- (R*,R*)]- Cetotiamine137-76-/8 Cetoxime 25394-78-9 cetraxate Benzenepropanoic acid, 4-[[[4-27724-96-5 JP 48075547 Antiulcer (aminomethyl)cyclohexyl]carbonyl]oxy]-,34675-84-8 trans-[CAS] Cetrimonium 57-09-0 Cetrorelix 120287-85-6Cetyldimethylethyl- 124-03-8 ammonium Cetylpyridinium 123-03-5cevimeline Spiro[1-azabicycol[2.2.2]octane-3,5′- 107220-27-9 EP 205247Stromatological Sjogran's [1,3]oxathiolane], 2′-methyl-, cis-[CAS]107233-08-9 syndrome CG-1521 7-phenyl-2,4,6-heptatrienoylhydroxamicAnticancer, other Cancer, acid general Chaulmoogric Acid 29106-32-9Chenodiol 474-25-9 CHF-3381 EP 951465 Analgesic, other Pain, neuropathicChlophedianol 791-35-5 Chloracizine 800-22-6 chloral 1,1-Ethanediol,2,2,2-trichloro-[CAS] 302-17-0 Formulation, Insomnia 2218-68-0transmucosal, 515-82-2 systemic Chlorambucil 305-03-3 Chloramine-B127-52-6 Chloramine-T 127-65-1 Chloramino- 121-30-2 phenamideChloramphenicol 56-75-7 Chlorazanil 500-42-5 Chlorbenzoxamine 522-18-9Chlorbetamide 97-27-8 Chlorcyclizine 82-93-9 Chlordantoin 5588-20-5Chloriazepoxide 58-25-3 Chlorguanide 500-92-5 Chlorhexadol 3563-58-4chlorhexidine 2,4,11,13- 55-56-1 Formulation, other Xerostomia,Tetraazatetradecanediimidamide, N,N′′′- Periodontitisbis(4-chlorophenyl)-3,12-diimino-[CAS] Chlorisondamine 69-27-2Chlormadinone 302-22-7 Chlormerodrin 62-37-3 Chlormezanone 80-77-3Chlormidazole 3689-76-7 Chlornaphazine 494-03-1 Chloroazodin 502-98-7Chlorophyll 1406-65-1 Chloroprednisone 52080-57-6 Chloroprocaine3858-89-7 Chloropyramine 59-32-5 Chloroquine 54-05-7 Chlorothen 148-65-2Chlorothiazide 58-94-6 Chlorotrianisene 569-57-3 Chloroxine 773-76-2Chloroxylenol 88-04-0 Chlorozotocin 54749-90-5 chlorphenamine2-Pyridinepropanamine, Gamma-(4- 132-22-9 Formulation, Allergy,chlorophenyl)-N,N-dimethyl-[CAS] modified-release, general otherChlorphenesin 104-29-0 886-74-8 Chlorpheniramine 132-22-9Chlorphenoxamide 3576-64-5 Chlorphenoxamine 77-38-3 Chlorphentermine461-78-9 Chlorproethazine 84-01-5 Chlorproguanil 537-21-3chlorproguanil + 4,4′-Sulfonyldianiline + 1-(3,4- 537-21-3 AntimalarialInfection, dapsone Dichlorophenyl)5-isopropylbiguanide 80-08-0 malariaChlorpromazine 50-53-3 Chlorpropamide 94-20-2 Chlorprothixene 113-59-7Chlorquinaldol 72-80-0 Chlortetracycline 57-62-5 Chlorthalidone 77-36-1Chlorthenoxazine(e) 132-89-8 Chlorzoxazone 95-25-0 Cholic Acid 81-25-4Choline 67-48-1 2016-36-6 28319-77-9 choline theophyllinateEthanaminium, 2-hydroxy-N,N,N- 4499-40-5 Formulation, trimethyl-, saltwith 3,7-dihydro-1,3- modified- dimethyl-1H-purine-2,6-dione (1:1) [CAS]release, other choline-L-alfoscerate Ethanaminium, 2-[[2,3- 28319-77-9JP 55028955 Cognition enhancer Amnesiadihydroxypropoxy)hydroxyphosphinyl]oxy]- N,N,N-trimethyl-, hydroxide,inner salt, (R)-[CAS] Chromocarb 4940-39-0 Chromonar 804-10-4Chrysoidine 532-82-1 CHS-828 Guanidine, N-[6-(4-chlorophenoxy)hexyl]-200484-11-3 U.S. 5,696,140 Anticancer, other Cancer,N′-cyano-N″-4-pyridinyl-[CAS] general CI-1031 Glycine,N-[2-[5-(aminoiminomethyl)-2- 183305-24-0 WO 9638421 Antianginal Angina,hydroxyphenoxy]-6-[3-(4,5-dihydro-1- unstablemethyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methyl-[CAS] CI-1040 Benzamide, 2-[(2-chloro-4-212631-79-3 WO 9837881 Anticancer, other Cancer,iodophenyl)amino]-N-(cyclopropylmethoxy) general 3,4-difluoro-[CAS]cibenzoline 1H-Imidazole, 2-(2,2-diphenylcyclopropyl)- 53267-01-9 GB1417174 Antiarrhythmic Arrhythmia, 4,5-dihydro-[CAS] general ciclesonidePregna-1,4-diene-3,20-dione 16,17- 126544-47-6 DE 4129535 AntiasthmaAsthma ((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy) (11β,16Alpha) [CAS] cicletanineFuro[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)- 82747-56-6 U.S. 4,383,998Antihypertensive, 1,3-dihydro-6-methyl-, (+/−)-[CAS] 89943-82-8 otherciclonicate 3-Pyridinecarboxylic acid, 3,3,5- 53449-58-4 DE 1910481Vasodilator, Cancer, lung, trimethylcyclohexyl ester, trans-[CAS]peripheral small cell ciclopirox 2(1H)-Pyridinone,6-cyclohexyl-1-hydroxy- 41621-49-2 U.S. 3,883,545 Antifungal Infection,4-methyl-, [CAS] 29342-05-0 fungal, general Ciclosidomine 66564-16-7ciclosporin A Cyclosporin A-[CAS] 59865-13-3 Formulation, Transplantoptimized, rejection, microemulsion general cidofovir Phosphonic acid,[[2-(4-amino-2-oxo- 113852-37-2 EP 253412 Antiviral, other Infection,1(2H)-pyrimidinyl)-1- cytomegalo- (hydroxymethyl)ethoxy]methyl]-,(S)-[CAS] virus Cifenline 53267-01-9 cilansetron4H-Pyrido[3,2,1-jk]carbazol-11(8H)-one, 120635-74-7 EP 297651 GIinflammatory/ Irritable bowel 5,6,9,10-tetrahydro-10-[(2-methyl-1H-bowel disorders syndrome imidazol-1-yl)methyl]-, (R)-[CAS] Cilastatin82009-34-5 cilazapril 6H-Pyridazino[1,2-a][1,2]diazepine-1- 88768-40-5GB 2128984 Antihypertensive, Hypertension, carboxylic acid,9-[[1-(ethoxycarbonyl)-3- 90139-06-3 renin system generalphenylpropyl]amino]octahydro-10-oxo-, [1S-[1Alpha,9Alpha(R*)]]-[CAS]cilengitide Cyclo(L-arginylglycyl-L-Alpha-aspartyl-D- 188968-51-6 EP770622 Anticancer, other Cancer, lung, phenylalanyl-N-methyl-L-valyl)[CAS] non-small cell cilnidipine 3,5-Pyridinedicarboxylic acid,1,4-dihydro- 102106-21-8 EP 161877 Antihypertensive, Hypertension,2,6-dimethyl-4-(3-nitrophenyl)-, 2- 132203-70-4 other generalmethoxyethyl 3-phenyl-2-propenyl ester- [CAS] cilomilastCis-4-cyano-4-[3-(cyclopentyloxy)-4- 153259-65-5 U.S. 5,602,157 COPDtreatment Chronic methoxyphenyl]cyclohexane-1-carboxylic obstructiveacid pulmonary disease cilostazol 2(1H)-Quinolinone,6-[4-(1-cyclohexyl-1H- 73963-72-1 GB 2033893 Antithrombotic Peripheraltetrazol-5-yl)butoxy]-3,4-dihydro-[CAS] vascular disease Cimetidine51481-61-9 cimetropium 3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,51598-60-8 U.S. 3,853,886 Antipasmodic Muscle spasm,9-(cyclopropylmethyl)-7-(3-hydroxy-1-oxo- general2-phenylpropoxy)-9-methyl-, [7(S)- (1Alpha,2β,4β,5Alpha,7β)]-[CAS]cinacalcet 1-naphthalenemethanamine,Alpha-methyl- 364782-34-3 HormoneHyperpara- N-[3-[3-(trifluoromethyl)phenyl]propyl]-, thyroidsm(AlphaR)-, Cinchonidine 485-71-2 Cinchonine 118-10-5 Cinchophen 132-60-5Cinepazet 23887-41-4 Cinepazide 23887-46-9 cinepazide Piperazine,1-[2-oxo-2-(1-pyrrolidinyl)ethyl]- 26328-04-1 GB 1218591 Vasodilator,Peripheral 4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2- peripheral vascularpropenyl]-, (Z)-2-butenedioate (1:1) [CAS] disease Cinitapride66564-14-5 Cinmetacin 20168-99-4 Cinnamedrine 90-86-8 Cinnarizine298-57-7 cinolazepam 1H-1,4-Benzodiazepine-1-propanenitrile, 7-75696-02-5 DE 2950235 Hypnotic/Sedative Insomniachloro-5-[2-fluorophenyl)-2,3-dihydro-3- hydroxy-2-oxo-[CAS] cinoxacin[1,3]Dioxolo[4,5-g]cinnoline-3-carboxylic 28657-80-9 GB 1296753Quinolone Infection, acid, 1-ethyl-1,4-dihydro-4-oxo-[CAS] antibacterialurinary tract Cinoxate 104-28-9 Cinromide 58473-74-8 Cioteronel89672-11-7 cipamfylline 1H-Purine-2,6-dione, 8-amino-1,3- 132210-43-6 EP389282 Antipruritic/inflamm, Eczema,bis(cyclopropylmethyl)-3,7-dihydro-[CAS] allergic atopic cipralisant1H-Imidazole, 4-[(1R,2R)-2-(5,5-dimethyl- 213027-19-1 U.S. 6,008,240Psychostimulant Attention 1-hexynyl)cyclopropyl]-[CAS] deficit disorderciprofibrate Propanoic acid, 2-[4-(2,2- 52214-84-3 GB 1385828Hypolipaemic/ Hyper- dichlorocyclopropyl)phenoxy]-2-methyl-Antiatherosclerosis lipidaemia, [CAS] general ciprofloxacin3-Quinolinecarboxylic acid, 1-cyclopropyl-6- 85721-33-1 U.S. 4,670,444Quinolone Infection, fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-antibacterial general [CAS] ciprofloxacin + 3-Quinolinecarboxylic acid,1-Cyclopropyl-6 Formulation, Otitis fluocinolone, SALfluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- + fixed-dose (6Alpha, 11β,16Alpha)-6,9-Difluoro- combinations 11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-pregna-1,4- diene-3,20-dione Ciramadol63269-31-8 cisapride Benzamide, 4-amino-5-chloro-N-[1-[3-(4- 81098-60-4EP 76530 Gastroprokinetic fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis-[CAS] cisatracurium Isoquinolinium,2,2′-[1,5- 96946-42-8 U.S. 5,453,510 Muscle relaxant Surgerypentanediylbis[oxy(3-oxo-3,1- adjunct propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]]-1,2,3,4- tetrahydro-6,7-dimethoxy-2-methyl-,[1R- [1Alpha,2Alpha(1′R*,2′R*)]]-, [CAS] cisplatin Platinum,diamminedichloro-, (SP-4-2)- 15663-27-1 U.S. 4,177,263 Anticancer, [CAS]alkylating citalopram 5-Isobenzofurancarbonitrile, 1-[3- 59729-32-7 GB1526331 Antidepressant Depression,(dimethylamino)propyl]-1-(4-fluorophenyl)- 59729-33-8 general1,3-dihydro-[CAS] citicoline Cytidine 5′-(trihydrogen diphosphate), P′-987-78-0 JP 39006541 Cognition enhancer Infarction,[2(trimethylammonio)ethyl]ester, hydroxide, cerebral inner salt [CAS]Citiolone 1195-16-0 Citric Acid 77-92-9 Citrulline 372-75-8 cizolirtineEthanamine, N,N-dimethyl-2-[(1-methyl-1H 142155-44-0 UrologicalIncontinence pyrazol-5-yl)phenylmethoxy]-, 2-hydroxy-1,2,3-propanetricarboxylate [CAS] CJ-136104-(3-[4-(2-Methyl-imidazol-1-yl)- COPD treatment Chronicphenylsulfanyl]-phenyl)-tetrahydro-pyran-4- obstructive carboxylic acidamide pulmonary disease CKD-602 1H-Pyrano[3′,4′:6,7]indolizino[1,2-213819-48-8 WO 9902530 Anticancer, other Cancer,b)quinoline-3,15(4H,12H)-dione, 4-ethyl-4- ovarianhydroxy-11-[2-[(1-methylethyl)amino]ethyl]-, monohydrochloride, (4S)-[CAS]] cladribine Adenosine, 2-chloro-2′-deoxy-[CAS] 4291-63-8 EP 173059Anticancer, Cancer, antimetabolite leukaemia, hairy cell Clanobutin30544-61-7 clarithromycin Erythromycin, 6-O-methyl-[CAS] 81103-11-9 EP41355 Macrolide antibiotic Infection, respiratory tract, lowerClavulanate, Disodium Clavulanic Acid 58001-44-8 Clebopride 55905-53-8Clemastine 15686-51-8 Clemizol 442-52-4 Clenbuterol 37148-27-9Clentiazem 96125-53-0 clevidipine 3,5-Pyridinedicarboxylic acid, 4-(2,3-167221-71-8 WO 9512578 Antihypertensive, Hypertension,dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, other general methyl(1-oxobutoxy)methyl ester (±) [CAS] clevudine2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-2- 163252-36-6 Antiviral, otherInfection, fluoro-β-L-arabinofuranosyl)-5-methyl- hepatitis-B [CAS]virus Clidanac 28968-07-2 Clidinium 3485-62-9 Clinafloxacin 105956-97-6Clindamycin 18323-44-9 clindamycin +L-threo-Alpha-D-galacto-Octopyranoside, Formulation, Acne tretinoinmethyl 7-chloro-6,7,8-trideoxy-6-[[(1- fixed-dose methyl-4-propyl-2-combinations pyrrolidinyl)carbonyl]amino]-1-thio, (2S- trans)- +retinoic acid clindamycin L-Threo-Alpha-D-galacto-octopyranoside,18323-44-9 Formulation, Infection, methyl7-chloro-6,7,8-trideoxy-6-[[(1- 24729-96-2 parenteral, other gynaecolo-methyl-4-propyl-2- gical pyrrolidinyl)carbonyl]amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)- Clinofibrate 30299-08-2 Clinprost88931-51-5 clobazam 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 22316-47-8GB 1214662 Anxiolytic 7-chloro-1-methyl-5-phenyl-[CAS] Clobenfurol3611-72-1 Clobenoside 29899-95-4 Clobenzepam 1159-93-9 Clobenzorex13364-32-4 Clobenztropine 5627-46-3 clobetasolPregna-1,4-diene-3,20-dione, 21-chloro-9- 25122-41-2 Formulation,dermal, Psoriasis fluoro-11,17-dihydroxy-16-methyl-, topical(11β,16β)-[CAS] clobetasone Pregna-1,4-diene-3,11,20-trione, 21-25122-57-0 GB 1253831 Antipruritic/ chloro-9-fluoro-16-methyl-17-(1-54063-32-0 inflamm, allergic oxobutoxy)-, (16β)-[CAS] Clobutinol14860-49-2 Clocapramine 47739-98-0 Clocinizine 298-55-5 Cloconazole77175-51-0 Clocortolone 4828-27-7 clodronate Phosphonic acid,(dichloromethylene)bis- 22560-50-5 Osteoporosis Pain, cancer, [CAS]treatment, Hyper- Anticancer, calcaemia of hormonal malignancy ClodronicAcid 10596-23-3 clofarabine 2-chloro-9-(2-deoxy-2-fluoro-β-D-Anticancer, Cancer, arabinofurasonyl)adenine antimetabolite leukaemia,chronic lymphocytic clofazimine3-(p-chloroanilo)-10-(p-chlorophenyl)-2,10- 2030-63-9 Formulation,Infection, dihydro-2-(isopropylimino)-phenazine optimized, tuberculosismicroencapsulate Clofenamide 671-95-4 Clofibrat 637-07-0 Clofibric Acid882-09-7 Cloflucarban 369-77-7 Clofoctol 37693-01-9 Cloforex 14261-75-7Clomacran 5310-55-4 Clomestrone 4091-75-2 Clometacin 25803-14-9Clomethiazole 533-45-9 Clometocillin 1926-49-4 Clomiphene 911-45-5Clomipramine 303-49-1 Clomocycline 1181-54-0 clonazepam2H-1,4-Benzodiazepin-2-one, 5-(2- 1622-61-3 U.S. 4,316,897 AntiepilepticEpilepsy, chlorophenyl)-1,3-dihydro-7-nitro-[CAS] general clonidine1H-Imidazol-2-amine, N-(2,6- 4205-90-7 U.S. 4,060,084 Formulation,Hypertension, dichlorophenyl)-4,5-dihydro-[CAS] transdermal, patchgeneral Clonitazene 3861-76-5 Clonitrate 2612-33-1 Clonixin 17737-65-4Clopamid 636-54-4 Clopenthixol 982-24-1 Cloperastine 3703-76-2clopidogrel Thieno[3,2-c]pyridine-5(4H)-acetic acid, 120202-48-4 EP99802 Antithrombotic Infarction, Alpha-(2-chlorophenyl)-6,7-dihydro-,90055-48-4 myocardial methyl ester, (S)-[CAS] 113665-84-2 Clopirac42779-82-8 Cloprednol 5251-34-3 cloranolol 2-Propanol,1-(2,5-dichlorophenoxy)-3- 39563-28-5 U.S. 4,310,549 Antihypertensive,[(1,1-dimethylethyl)amino]-[CAS] 54247-25-5 adrenergic Clorazepic Acid23887-31-2 Clorexolone 2127-1-7 cloricromene Acetic acid,[[8-chloro-3-[2- 68206-94-0 U.S. 4,349,566 Vasodilator, Peripheral(diethylamino)ethyl]-4-methyl-2-oxo-2H-1- coronary vascularbenzopyran-7-yl]oxy]-, ethyl ester [CAS] disease Clorindione 1146-99-2Clorprenaline 3811-25-4 Clortermine 10389-73-8 Clospirazine 24527-27-3Clostebol 1093-58-9 Clothiapine 2058-52-8 clotiazepam2H-Thieno[2,3-e]-1,4-diazepin-2-one, 5(2- 33671-46-4 U.S. 3,849,405Anxiolytic Anxiety, chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl- general[CAS] clotrimazole 1-[(2-chlorophenyl)diphenylmethyl]-1H- 23593-75-1U.S. 3,705,172 Antifungal imidazole clotrimazole +Pregna-1,4-diene-3,20-dione, 9-fluoro-11- 92522-91-3 Formulation,Infection, betamethasone hydroxy-16-methyl-17,21-bis(1- fixed-dosefungal, oxopropoxy)-, (11β,16β)-, mixt. with 1-[(2- combinations generalchlorophenyl)diphenylmethyl]-1H- imidazole [CAS] Cloxacillin 61-72-3cloxazolam Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)- 24166-13-0 U.S.3,442,371 Anxiolytic one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-[CAS] Cloxotestosterone 53608-96-1 Cloxyquin130-16-5 clozapine 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro- 5786-21-0U.S. 3,539,573 Neuroleptic Schizophrenia11-(4-methyl-1-piperazinyl)-[CAS] CMI-392 Trans-2-[3-methoxy-4-(2-p-193739-23-0 U.S. 5,648,486 Antipsoriasis Psoriasischlorophenylthio)ethoxy-5-(N′-methyl-N′-hydroxyureidyl)methylphenyl]-5-(3,4,5- trimethoxyphenyl)tetrahydrofuranCMT-3 2-Naphthacenecarboxamide, 15866-90-7 U.S. 5,837,696 Anticancer,other Cancer, 1,4,4a,5,5a,6,11,12a-octahydro- sarcoma,3,10,12,12a-tetrahydroxy-1,11-dioxo-, Kaposi's (4aS,5aR,12aS)-[CAS]CNI-1493 Decanediamide, N,N′-bis[3,5-bis[1- 164301-51-3 U.S. 5,750,573Anti-inflammatory Psoriasis [(aminoiminomethyl)hydrazono]ethyl]-phenyl]-, tetrahydrochloride [CAS] CNS-5161N′-[2-chloro-5-(methylthio)phenyl]-N- 160754-76-7 WO 9427591 Analgesic,other Pain, methyl-N-[3-(methylthio)phenyl]guanide neuropathic [CAS]Cobamamide 13870-90-1 Cocaethylene 529-38-4 Cocaine 50-36-2 Codeine76-57-3 52-28-8 CoFactor 5,10 methylene-tetrahydrofolate Anticancer,Cancer, antimetavolite colorectal Colchicine 64-86-8 colesevelam1-Hexanaminium, N,N,N-trimethyl-6-(2- 182815-44-7 U.S. 5,607,669Hypolipaemic/ Hyper- propenylamino)-, polymer with Antitherosclerosislipidaemia, (chloromethyl)oxirane, 2-propen-1-amine general andN-2-propenyl-1-decanamine, hydrochloride [CAS] colestilan 1H-Imidazole,2-methyl-, polymer with 95522-45-5 JP 59155421 Hypolipaemic/ Hyper-(chloromethyl)oxirane [CAS] Antitherosclerosis cholesterol- aemiaColestipol 26658-42-4 colforsin daropate6-(3-dimethylaminopropionyl)forkolin- 138605-00-2 EP 222413Cardiostimulant Heart failure [CAS] colfosceril3,5,9-Trioxa-4-phosphapentacosan-1- 63-89-8 U.S. 4,826,821 LungSurfactant Respiratory aminium, 4-hydroxy-N,N.N-trimethyl-10- 99732-49-7distress oxo-7-[(1-oxohexadecyl)oxy]-, hydroxide, syndrome, inner salt,4-oxide, (R)-[CAS] infant Collagraft 138331-02-9 Formulation,Regeneration, implant bone Colocynthin 1398-78-3 Colpormon 1247-71-8coluracetam 1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8- 135463-81-9 EP427636 Cognition enhancer Alzheimer'stetrahydro-2,3-dimethylfuro[2,3-b]quinolin- disease 4-yl)-[CAS]combretastatin A-4 disodium combretastatin-A-4-3-O- Anticancer, otherCancer, thyroid prodrug phosphate compound B, U.S. 6,362,165 Antiviral,anti-HIV Infection, Pharmacor HIV/AIDS conivaptin[1,1′-Biphenyl]-2-carboxamide, N-[4-[(4,5- 168626-94-6 WO 9503305 GIinflammatory/ Hyponatraemia dihydro-2-methylimidazo[4,5-d][1- boweldisorders benzazepin-6(1H)-yl)carbonyl]phenyl]-, [CAS] ConnettivinaHyaluronic acid [CAS] 9004-61-9 Vulnerary Convallatoxin 508-75-8Coparaffinate 8001-60-3 Corticorelin Ovine Triflutate Corticosterone50-22-6 Cortisone 53-06-5 Cortivazol 1110-40-3 Cosyntropin 16960-16-0Cotarnine 82-54-2 Cotinine 486-56-6 co-trimazine Benzenesulfonamide,4-amino-N-2- 39474-58-3 Trimethoprim and Infection, pyrimidinyl-, mixt.with 5-[(3,4,5- analogues urinary tract trimethoxyphenyl)methyl]-2,4-pyrimidinediamine [CAS] Coumetarol 4366-18-1 CP-2481H-Indene-3-acetamide, 5-fluoro-2-methyl- 200803-37-8 WO 9747303Anticancer, other Barrett's N-(phenylmethyl)-1-[(3,4,5- oesophagustrimethoxyphenyl)methylene]-, (1Z)- [CAS] CP-461 U.S. 5,948,779Anticancer, other Cancer, prostate CPC-211 Acetic acid, dichloro-,sodium salt [CAS] 2156-56-1 Neuroprotective Acidosis, lactic CPI-1189CPI 1189 [CAS] 210475-67-5 WO 9631462 Congnition enhancer Dementia,AIDS- related CRA-0450 WO 0202549 Anxiolytic Unspecifiedcreatinol-O-phosphate Guanidine, N-methyl-N-[2- 6903-79-3 Antianginal(phosphonooxy)ethyl]-[CAS] CRL-5861 Oxirane, methyl-, polymer withoxirane, 106392-12-5 U.S. 4,837,014 Antisickling Anaemia, sickle block[CAS] cell crobenetine (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11- WO9914199 Neuroprotective Ischaemia, trimethyl-1,2,3,4,5,6,-hexahydro-2,6-cerebral methano-3-benzazocin-10-ol croconazole 1H-Imidazole,1-[1-[2-[(3- 77175-51-0 DE 3021467 Antifungal Infection,chlorophenyl)methoxy]phenyl]ethenyl]- fungal, [CAS] general cromoglicicacid 4H-1-Benzopyran-2-carboxylic acid, 5,5′- 53736-52-0 Formulation,Conjunctiv- [(2-hydroxy-1,3-propanediyl)bis(oxy)]bs4- mucosal, topicalitis oxo-[CAS] cromolyn 4H-1-Benzopyran-2-carboxylic acid, 5,5′-15826-37-6 Formulation, Asthma[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis4- 16110-51-3 inhalable,solution oxo-[CAS] Cropropamide 633-47-6 Crotamiton 483-63-6Crotethamide 6168-76-9 Crystacide U.S. 4,557,935 Formulation, dermal,Infection, topical dermatological CS-502 □ EP 799823 Analgesic, otherPain, general CS-758 4-[(1E,3E)-4-[trans-5-[(1R,2R)-2-(2,4- AntifungalInfection, difluorophenyl)-2-hydroxy-1-methyl-3-(1H- fungal,1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2- generalyl]-1,3-butadienyl]-3-fluorobenzonitrile CS-8341-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic 157542-49-9 EP 599512Beta-lactam Infection, acid, 6-[(1R)-1-hydroxyethyl]-4-methyl-7-antibiotic general oxo-3-[[(3R)-5-oxo-3-pyrrolidinyl]thio]-,(2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)-[CAS] CT-052923[(2H-benzo[d]1,3-dioxalan-5- Cardiovascular Restenosismethyl)amino][4-(6,7-dimethoxyquinazolin-4-yl)piperazinyl]methane-1-thione CT-32228N-(4-bromophenyl)-6-(5-chloro-2- Anticancer, other Cancer,methylphenyl)-[1,3,5]triazine-2,4-diamine general Cupric Citrate866-82-0 Cuproxoline 13007-93-7 CVT-2584 Ethanol, 2,2′-[[6-[[(4-199986-75-9 WO 9805335 Cardiovascular Restenosismethoxyphenyl)methyl]amino]-9-(1- methylethyl)-9H-purin-2-yl]imino]bis-[CAS] CX-659S ((S)-6-amino-5-(6-hydroxy-2,5,7,8- Dermatological Eczema,tetramethylchroman-2-carboxamido)-3- generalmethyl-1-phenyl-2,4-(1H,3H)- pyrmidinedione Cyacetacide 140-87-4Cyamemazine 3546-03-0 Cyanidin 528-58-5 CYC400 WO 00172745 Anticancer,other Cancer, general Cyclacillin 3485-14-1 Cyclandelate 456-59-7Cyclazocine 3572-80-3 Cyclexanone 15301-52-7 Cyclexedrine 532-52-5cyclidrol 3-Cyclohexene-1-methanol, 5-hydroxy- 498-71-5 COPD treatment,Bronchitis, Alpha,Alpha,4-trimethyl-[CAS] Respiratory chronic cyclin D1inhibitors U.S. 6,033,843 Anticancer, Cancer, hormonal breast Cyclizine82-92-8 Cyclobarbital 52-31-3 Cyclobendazole 31431-43-3 cyclobenzaprine1-Propanamine, 3-(5H- 303-53-7 Formulation, Muscledibenzo[a,d]cyclohepten-5-ylidene)-N,N- modified- spasm, dimethyl-[CAS]release, other general Cyclobutyrol 512-16-3 Cyclocumarol 518-20-7Cyclodrine 52109-93-0 Cyclofenil 2624-43-3 Cycloguanil 516-21-2Cyclomethycaine 139-62-8 Cycloniumelodide 6577-41-9 Cyclopentamine102-45-4 Cyclopenthiazide 742-20-1 Cyclopentobarbital 76-68-6Cyclopentolate 512-15-2 cyclophosphamideN,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2- 50-18-0 Formulation, Cancer,oxazaphosphorin-2-amine-2-oxide 6055-19-2 parenteral, targeted generalmonohydrate cyclopiroxalamine 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-41621-49-2 Formulation, Vaginitis 4-methyl-, cmpd with2-aminoethanol(1:1) transdermal, other [CAS] Cycloserine 68-41-7Cyclothiazide 2259-96-3 Cyclovalone 579-23-7 Cymarin 508-77-0 cymserineCarbamic acid, [4-(1-methylethyl)phenyl]-, 145209-39-8 WO 9902154Cognition enhancer Alzheimer's (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-disease trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS] Cynarin(e)30964-13-7 CYP26 inhibitors U.S. 6,063,606 Dermatological UnspecifiedCyproheptadine 129-03-3 cyproterone(1β,2β)-6-Chloro-1,2-dihydro-17-hydroxy- 2098-66-0 Radio/ Chemotherapy-3′H-cyclopropa[1,2]pregna-1,4,6-triene- chemoprotective induced injury,3,20-dione [CAS] general Cysteamine 60-23-1 cystic fibrosis ther[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl- Cystic fibrosis Cysticfibrosis ethyl]phenoxy]methyl]phenyl]methoxy]- treatmentphenyl]iminomethyl]-, ethyl ester cytarabine 2(1H)-Pyrimidinone,4-amino-1-[5-O- 65093-40-5 EP 239015 Anticancer, Myelodysplastic[hydroxy(octadecyloxy)phosphinyl]-β-D- 147-94-4 antimetabolite syndromearabinofuranosyl]-, [CAS] D-24851N-(Pyridin-4-yl)-(1-(4-chlorobenzyl)-indol-3- Anticancer, other Cancer,general yl)-glyoxyl-amide) D-4418 8-Methoxyquinoline-5-[N-(2,5-Antiasthma Asthma dichloropyridin-3-yl)]carboxamide DA-5018Benzeneacetamide, 4-(2-aminoethoxy)-N- 174661-97-3 U.S. 5,242,944Analgesic, other Pain, (3-(3,4-dimethylphenyl)propyl)-3-methoxy-,musculoskeletal monohydrochloride [CAS] DA-6034 U.S. 6,025,387 GIinflammatory/ Crohn's disease bowel disorders DA-7867 KR 9957803Antibacterial, other Infection, general DA-7911 KR 56034 Antiarthritic,other Arthritis, rheumatiod DA-81593-(1-Methyl-7-oxo-3-propyl-6,7-dihydro-1H- KR 353014 Male sexual Sexualpyrazolo-[4,3-d]pyrimidin-5-yl)-N-[2-(1- dysfunction dysfunction,methylpyrrolidin-2-yl)ethyl]-4- male, general propoxybenzenesulfonamideDacarbazine 4342-3-4 Daclizumab 152923-56-3 Dactinomycin 50-76-0dalbavancin 5,31-Dichloro-38-de(methoxycarbonyl)-7- 171500-79-1 Peptideantibiotic Infection, demethyl-19-deoxy-56-O-[2-deoxy-2-(10- dermatolo-methylundecanamido)-β-D- gical glucopyranurosyl]-38-[N-[3-(dimethylamino)propyl]carbamoyl]-42-O- Alpha-D-mannopyranosyl-N15-methylristomycin A aglycone Dalfopristin 112362-50-2 dalfopristin +Virginiamycin M1, 26-((2- 126602-89-9 EP 248703 Antibiotic, otherInfection, quinupristin (diethylamino)ethyl)sulfonyl)-26,27-dihydro-,respiratry (26R,27S)-, mixt with 4-(4- tract, general(dimethylamino)-N-methyl-L- phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4- oxo-L-2-piperidinecarboxylicacid) virginiamycin S1-[CAS] dalteparin Heparin-, [CAS] 9041-08-1 U.S.4,303,651 Anticoagulant Thrombo- prophylaxis Daltroban 79094-20-5δ-Aminolevulinic Acid 106-60-5 danaparoid EP 66908 AnticoagulantThrombosis, venous danazol Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-17230-88-5 GB 905844 Menstruation ol, (17Alpha)-[CAS] disorders Danthron117-10-2 Dantrolene 7261-97-4 dapiprazole 1,2,4-Triazolo[4,3-a]pyridine,5,6,7,8- 72822-12-9 U.S. 4,252,721 Ophthalmological Glaucomatetrahydro-3-[2-[4-(2-methylphenyl)-1- 72822-13-0piperazinyl]ethyl]-[CAS] dapivirine 4-[[4-(2,4,6- 244767-67-7 Antiviral,anti-HIV Infection, trimethylphenyl)amino]pyrimidin-2- HIV/AIDSyl]amino]benzonitrile dapoxetine(+)-(S)-N,N-dimethyl-Alpha-[2-(1-naphthyl- 119356-77-3 EP 288188 Malesexual Premature oxy)ethyl]benzylamine HCl dysfunction ejaculationdapsone 4,4′-Sulfonyldianiline 80-08-0 Formulation, dermal, Acne topicaldaptomycin Daptomycin [CAS] 103060-53-3 EP 178152 Peptide antibioticInfection, dermatological Darbepoetin Alfa darifenacin3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro- 133099-04-4 EP 388054Urological Overactive 5-benzofuranyl)ethyl]-Alpha,Alpha- bladderdiphenyl-. (S)-[CAS] daunorubicin 5,12-Naphthacenedione,8-acetyl-10-[(3- 20830-81-3 U.S. 5,441,745 Formulation, Cancer,amino-2,3,6-trideoxy-Alpha-L-lyxo- optimized, liposomes sarcoma,hexopyranosyl)oxy]-7,8,9,10-tetrahydro- Kaposi's6,8,11-trihydroxy-1-methoxy-, (8S-cis)- [CAS] DAX< SciClone3-diallyl-8-cyclohexylxanthine Cystic fibrosis Cystic treatment fibrosisDB-67 7-tert-Butyldimethylsilyl-10- Anticancer, other Cancer,hydroxycamptothecin general d-Camphocarboxylic 18530-30-8 DCF-987Dextran U.S. 5,514,665 Formulation, other Cystic fibrosis DDT 50-29-3Deaminooxytocin 113-78-0 Deanol 108-01-0 Debrisoquin 1131-64-2Decamethonium 541-22-0 Decimemide 14817-09-5 decitabine1,3,5-Triazin-2(1H)-one, 4-amino-1-(2- 23339-46-0 Anticancer, Myelo-deoxy-β-D-erythro-pentofuranosyl)-[CAS] 2353-33-5 antimetabolitedysplastic syndrome declopramide Benzamide, 4-amino-3-chloro-N-(2-891-60-1 WO 9732582 Anticancer, other Cancer, (diethylamino)ethyl)-[CAS]colorectal Deferiprone 30652-11-0 Deferoxamine 70-51-9 deflazacort5′H-Pregna-1,4-dieno[17,16]oxazole- 14484-47-0 GB 1077393 Hormone Asthma3,20-dione, 21-(acetyloxy)-11-hydroxy-2′- 74712-90-6 methyl-,(11β,16β)-[CAS] Defosfamide 3733-81-1 degarelixN-acetyl-3-(naphtalen-2-yl)-D-alanyl-4- 214766-78-6 Anticancer, Cancer,chloro-D-phenylalanyl-3-(pyridin-3-yl)-D- hormonal prostatealanyl-L-seryl-4-[[[(4S)-2,6- dioxohexahydropyrimidin-4-yl]carbonyl]amino]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D- alaninamide dehydroascorbic acidL-threo-2,3-Hexodiulosonic acid gamma- 490-83-5 Cognition enhancerAlzheimer's lactone disease Dehyrdocholic Acid 81-23-2 Dehydroemetine4914-30-1 delapril Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N- 83435-66-9EP 51391 Antihypertensive, Hypertension,[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L- 83435-67-0 renin systemgeneral alanyl]-, (S)-[CAS] delapri + manidipine Glycine,N-(2,3-dihydro-1H-inden-2-yl)-N- FR 2733911 Formulation, Hypertension,[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L- fixed-dose general alanyl]-,(S)-3,5-Pyridinedicarboxylic acid, combinations1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS] delavirdinePiperazine, 1-[3-[(1-methylethyl)amino]-2- 136817-59-9 WO 9109849Antiviral, anti-HIV Infection,pyridinyl]-4-[[5-(methylsulfonyl)amino]-1H- HIV/AIDSindol-2-yl]carbonyl]-[CAS] Delmadinone 13698-49-2 Delmopinol 79874-76-3delorazepam 2H-1,4-Benzodiazepin-2-one, 7-chloro-5- 2894-67-9 CH 408029Anxiolytic (2-chlorophenyl)-1,3-dihydro-[CAS] delucemine3,3-Bis-(m-fluorophenyl)-N- 186495-99-8 Neuroprotective Ischaemia,methylpropylamine [CAS] cerebral Demanyl 6909-62-2 Demecarium 56-94-0demeclocycline 2-Naphthacenecarboxamide, 7-chloro-4- 127-33-3Formulation, Infection, (dimethylamino)-1,4,4a,5,5a,6,11,12a- modified-general octahydro-3,6,10,12,12a-pentahydroxy- release, <=24 hr1,11-dioxo-, [4S- (4Alpha,4aAlpha,5aAlpha,6β,12Alpha)]- [CAS]Demecolcine 477-30-5 Demegestone 10116-22-0 Demexiptilline 24701-51-7denaverine Benzeneacetic acid, Alpha-(2-ethylbutoxy)- 3321-06-0 DE4133785 Analgesic, NSAID Pain, Alpha-phenyl-, 2-(dimethylamino)ethylmusculo- ester, [CAS] skeletal Denileukin Diftitox 173146-27-5Denopamine 71771-90-9 Denopterin 22006-84-4 Deoxycholic Acid 83-44-3Deoxycorticosterone 64-85-7 Deoxydihydro- 26086-49-7 streptomycinDeoxyepinephrine 501-15-5 Depreotide 161982-62-3 depsipeptide L-Valine,N-[(3S,4E)-3-hydroxy-7- 128517-07-7 EP 352646 Anticancer, antibioticCancer, mercapto-1-oxo-4-heptenyl]-D-valyl-D- generalcysteinyl-(2Z)-2-amino-2-butenoyl-, (4-1)- lactone, cyclic(1-2)-disulfide [CAS] Deptropine 604-51-3 Dequalinium 522-51-0dersalazine Benzoic acid, 2-hydroxy-5-[[4-[3-[4-(2- 188913-57-7 U.S.5,747,477 Anti-inflammatory Colitis, methyl-1H-imidazol[4,5-c]pyridin-1-188913-58-8 ulcerative yl]methyl]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl]azo] (Z) [CAS] Deserpidine 131-01-1 desferrioxamineButanediamide, N′-[5-[[4-[[5- 70-51-9 Antidote Poisoning,(acetylhydroxyamino)pentyl]amino]-1,4- metaldioxobutyl]hydroxyamino]pentyl]-N-(5- aminopentyl)-N-hydroxy-[CAS]Desflurane 57041-67-5 Desipramine 50-47-5 Deslanoside 17598-65-1desloratadine 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8- 100643-71-8U.S. 5,595,997 Antiallergic, Rhinitis,chloro-6,11-dihydro-11-(4-piperidinylidene)- non-asthma allergic, [CAS]perennial deslorelin Luteinizing hormone-releaseing factor (pig),57773-65-6 U.S. 4,034,082 Releasing hormones Cancer,6-D-tryptophan-9-(N-ethyl-L-prolinamide)- prostate10-deglycinamide-[CAS] desmopressin Vasopressin, 1-(3-mercaptopropanoic16679-58-6 DE 2948345 Hormone Enuresis acid)-8-D-arginine-[CAS]Desogestrel 54024-22-5 desogestrel + estradiolEstra-1,3,5(10)-triene-3,17-diol (17β)-, 122364-17-4 Menopausaldisorders Hormone mixt. with (17Alpha)-13-ethyl-11- replacementmethylene-18,19-dinorpregn-4-en-20-yn- therapy 17-ol [CAS] desogestrel,Akzo 18,19-Dinorpregn-4-en-20-yn-17-ol, 13- 54024-55-5 Formulation,oral, Contraceptive, Nobel ethyl-11-methylene-, (17Alpha)-[CAS] otherfemale desogestrel + 18,19-Dinorpregn-4-en-20-yn-17-ol, 13- 54024-22-5U.S. 3,927,046 Formulation, oral, Contraceptive, ethinylestrad (1)ethyl-11-methylene-, (17Alpha)-[CAS] 71138-35-7 other femaleDesomorphine 427-00-9 Desonide 638-94-8 Desoximetasone 382-67-2Detaxtran 9015-73-0 Devacade WO 9308176 Analgesic, other Pain, generaldexamethasone Pregna-1,4-diene-3,20-dione, 9-fluoro- 50-02-2Formulation, other Inflammation, 11,17,21-trihydroxy-16-methyl-,2392-39-4 ocular (11β,16Alpha)-[CAS] 312-93-6 dexanabinol6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1- 112924-45-5 EP 427518Neuroprotective Head trauma dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS-trans)-[CAS] dexecadotril Glycine,N-[2-[(acetylthio)methyl]-1-oxo-3- 112573-72-5 EP 318377 Alimentary/Unspecified phenylpropyl]-, phenylmethyl ester, (R)- Metabolic, other[CAS] dexefaroxan 1H-Imidazole, 2-(2-ethyl-2,3-dihydro-2- 89197-00-2 EP71368 Cognition enhancer Alzheimer's benzofuranyl)-4,5-dihydro-[CAS]89197-32-0 disease Dexetimide 21888-98-2 dexibuprofen Benzeneaceticacid, Alpha-methyl-4-(2- 51146-56-6 Analgesic, NSAID Pain, generalmethylpropyl)-, (AlphaS)-[CAS] dexketoprofen Benzeneacetic acid,3-benzoyl-Alpha- 22161-81-5 Anti-inflammatory Inflammation, methyl-,(S)-[CAS] general dexloxiglumide Pentanoic acid, 4-[(3,4- 119817-90-2 EP0344184 GI inflammatory/ Irritable bowel dichlorobenzoyl)amino]-5-[(3-bowel disorders syndrome methoxypropyl)pentylamino]-5-oxo-, (R)- [CAS]dexmedetomidine 1H-Imidazole, 4-[1-(2,3- 113775-47-6 EP 187471Hypnotic/Sedative Anaesthesia dimethylphenyl)ethyl]-, (R)-[CAS]86347-15-1 dexmethylphenidate 2-Piperidineacetic acid, Alpha-phenyl-,19262-68-1 Psychostimulant Attention methyl ester, (AlphaR,2R)- deficitdisorder Dexpanthenol 81-13-0 dexrazoxane 2,6-Piperazinedione,4,4'-(1-methyl-1,2- 24584-09-6 DE 1910283 Radio/ Chemotherapy-ethanediyl)bis-, (S)-[CAS] chemoprotective induced injury, generalDextran-1 Dextran [CAS] 9004-54-0 Plasma substitute Dextranomer56087-11-7 Dextroamphetamine 51-64-9 dextromethorphan Morphinan,3-methoxy-17-methyl-, 6700-34-1 U.S. 4,221,788 Formulation, oral, Cough,(9Alpha, 13Alpha, 14Alpha)-, 125-71-3 other Emotional labilityDextromoramide 357-56-2 dextropropoxyphene Benzeneethanol,Alpha-[2-(dimethylamino) 469-62-5 Formulation, Pain, general1-methylethyl]-Alpha-phenyl-, propanoate modified- (ester),[S-(R*,S*)]-[CAS] release, other Dezocine 53648-55-8 DF-1012 N-Tropyl7-azaindol-3-ylcarboxamide 163220-65-3 WO 9504742 RespiratoryRespiratory disease, general DFA-IV di-D-fructofuranose 2,6':6,2'dianhydride U.S. 5,700,832 Antianaemic Anaemia, aplastic d-Fenchone4695-62-9 D-Glucuronolactone 32449-92-6 Diab II Diab II 309956-85-2 U.S.6,153,632 Antidiabetic Diabetes, Type II diacerein2-Anthracenecarboxylic acid, 4,5- 13739-02-1 U.S. 4,244,968Antiarthritic, other Arthritis, bis(acetyloxy)-9,10-dihydro-9,10-dioxo-rheumatoid [CAS] Diampromide 552-25-0 Diamthazole 136-96-9Diathymosulfone 5964-62-5 Diatrizoate 737-31-5 diazepam2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3- 439-14-5 Formulation, Anxiety,dihydro-1-methyl-5-phenyl-[CAS] transmucosal, epilepsy, systemic generalDiaziquone 57998-68-2 Diazoxide 364-98-7 dibekacin D-Streptamine,O-3-amino-3-deoxy-Alpha- 34493-98-6 GB 1349302 Aminoglycoside Infection,D-glucopyranosyl-(1-6)-O-[2,6-diamino- 58580-55-5 antibiotic general2,3,4,6-tetradeoxy-Alpha-D-erythro- hexopyranosyl-(1-4)]-2-deoxy-,sulfate (salt)[CAS] Dibenzepin 4498-32-2 Dibromopropamidine 496-00-4Dibucaine 61-12-1 Dichloralphenazone 480-30-8 Dichloramine T 473-34-7Dichlorisone 7008-26-6 Dichlorobenzyl Alcohol 1777-82-8 Dichlorophen97-23-4 Dichlorophenarsine 536-29-8 Dichlorphenamide 120-97-8diclofenac + HA Hyaluronic acid + benzeneacetic acid, 2- Formulation,Keratosis [(2,6-dichlorophenyl)amino]-[CAS] transdermal, systemicdiclofenac Benzeneacetic acid, 2-[(2,6- 15307-79-6 Formulation, Pain,general dichlorophenyl)amino]-, [CAS] 15307-86-5 modified-release,15307-81-0 <=24 hr Dicloxacillin 3116-76-5 Dicumarol 66-76-2 Dicyclomine77-19-0 didanosine Inosine, 2',3'-dideoxy-[CAS] 69655-05-6 U.S.4,861,759 Antiviral, anti-HIV Infection, Dideoxyadenosine 4097-22-7HIV/AIDS didox Benzamide, N,3,4-trihydroxy-[CAS] 69839-83-4 U.S.4,263,322 Anticancer, Cancer, antimetabolite general Dienestrol 84-17-3dienogest 19-Norpregna-4,9-diene-21-nitrile, 17- 65928-58-7 GB 1524917Menstruation Endometriosis hydroxy-3-oxo-, (17Alpha)-[CAS] disordersdienogest + estradiol 19-Norpregna-4,9-diene-21-nirtile, 17-Formulation, Contraceptive, hydroxy-3-oxo-, (17Alpha) + Estra-fixed-dose female 1,3,5(10)-triene-3,17-diol(17β) combinationsDiethadione 702-54-5 Diethazine 60-91-3 Diethylbromo- 511-70-6 acetamideDiethylcarbamazine 90-89-1 diethylpropion 1-Propanone,2-(diethylamino)-1-phenyl- 90-84-6 Formulation, Obesity [CAS] modified-Diethylstilbestrol 56-53-1 release, <=24 hr Difemerine 80387-96-8Difenamizole 20170-20-1 Difenoxin 28782-42-5 Difenpiramide 51481-40-3diflomotecan (5R)-5-Ethyl-9,10-difluoro-1,4,5,13- 220997-97-7Anticancer, other Cancer, tetrahydro-5-hydroxy-3H,15H- generaloxepino[3′,4′:6,indolizino[1,2-b]quinoline- 3,15-dione diflorasonePregna-1,4-diene-3,20-dione, 17,21- 33564-31-7 U.S. 3,980,778Antipsoriasis bis(acetyloxy)-6,9-difluoro-11-hydroxy-16- 2557-49-5methyl-, (6Alpha,11β,16β)-[CAS] Difloxacin 98106-17-3 Diflucortolone2607-6-9 diflunisal 2′,4′-difluoro-4-hydroxy[1,1′-biphenyl]-3-23674-86-4 GB 1175212 Analgesic, NSAID Pain, post- carboxylic acid22494-42-4 operative Difluprednate 23674-86-4 Digitalin 752-61-4Digitoxin 71-63-6 digoxin Card-20(22)-enolide, 3-[(O-2,6-dideoxy-β-20830-75-5 U.S. 4,088,750 Formulation, oral, Heart failureD-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy- enteric-coatedβ-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12,14- dihydroxy-, (3β,5β,12β)-[CAS]Dihexyverine 561-77-3 Dihydralazine 484-23-1 Dihydrocodeine 125-28-0Dihydrocodeinone 466-90-0 Enol dihydroergocryptine Ergocryptine,dihydro-[CAS] 25447-66-9 Formulation, other Depression, generaldihydroergotamine Ergotaman-3′,6′,18-trione, 9,10-dihydro- 511-12-66495535 Formulation, Migraine 12′-hydroxy-2′-methyl-5′-(phenylmethyl)-,modified- (5′Alpha,10Alpha)-[CAS] release, other Dihydromorphine509-60-4 Dihydrostreptomycin 128-46-1 Dihydrotachysterol 67-96-9Dihydroxyaluminum 13682-92-3 539-68-4 Diisopromine 5966-41-6 DiisopropylParaoxon 3254-66-8 Diisopropylamine 660-27-5 dilazep Benzoic acid,3,4,5-trimethoxy-, 35898-87-4 JP 51095086 Vasodilator,(tetrahydro-1H-1,4-diazepine-1,4(5H)- coronary diyl)di-3,1-propanediylester [CAS] Dilevalol 75659-07-3 diloxanide 2-Furancarboxylic acid, 4-3736-81-0 Amoebicide [(dichloroacetyl)methylamino]phenyl ester 579-38-4[CAS] diltiazem 1,5-Benzothiazepin-4(5H)-one, 3- 33286-22-5 U.S.4,721,619 Antianginal Angina,(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- 42399-41-7 U.S. 5,529,791hypertension, dihydro-2-(4-methoxyphenyl)-, (2S-cis)- EP 322277 general[CAS] Dimecrotic Acid 7706-67-4 Dimefline 1165-48-6 Dimemorfan36309-01-0 Dimenhydrinate 523-87-5 Dimenoxadol 509-78-4 Dimepheptanol545-90-4 Dimercaprol 59-52-9 Dimetacrine 4757-55-5 Dimethadione 695-53-4Dimethazan 519-30-2 Dimethindene 5636-83-9 Dimethisoquin 86-80-6Dimethisterone 79-64-1 Dimethocaine 94-15-5 Dimethoxanate 477-93-0Dimethyl Sulfoxide 67-68-5 Dimethylthiambutene 524-84-5 Dimetofrine22950-29-4 Dimorpholamine 119-48-2 dinoprostone Prosta-5,13-dien-1-oicacid, 11,15- 363-24-6 Formulation, Labour, dihydroxy-9-oxo-,(5Z,11Alpha,13E,15S)- modified- induction [CAS] release, <=24 hrdiosmectite Smecta-[CAS] 110070-78-5 FR 2770778 AntidiarrhoealDiarrhoea, general diosmin 4H-1-Benzopyran-4-one, 7-[[6-O-(6-deoxy-520-27-4 DE 2602314 Vasoprotective, Alpha-L-mannopyranosyl)-,beta,-D-systemic glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-[CAS] Dioxadrol 6495-46-1 Dioxaphetyl 467-86-7Dioxethedrine 497-75-6 Dioxybenzone 131-53-3 Diphemanil 62-97-5Diphenadione 82-66-6 Diphencyprone 886-38-4 Diphenhydramine 58-73-1Diphenidol 972-02-1 Diphenoxylate 915-30-0 Diphenylpyraline 147-20-6Diphetarsone 515-76-4 Diphtheria & Tetanus Toxoids And AcellularPertussis Vaccine Adsorbed Dipipanone 467-83-4 dipivefrin Propanoicacid, 2,2-dimethyl-, 4-[1- 52365-63-6 U.S. 3,809,714 AntiglaucomaGlaucoma hydroxy-2-(methylamino)ethyl]-1,2- phenylene ester, (+/−)-[CAS]Dipyridamole 58-32-2 Dipyrocetyl 486-79-3 Dipyrone 5907-38-0 diquafosolUridine 5′-(pentahydrogen tetraphosphate)- 211427-08-6 OphthalmologicalDry eye 5′-ester with uridine, [CAS] syndrome dirithromycinErythromycin, 9-deoxo-11-deoxy-9,11- 62013-04-1 DE 2515075 Macrolideantibiotic Tonsillitis [imino[2-(2-methoxyethoxy)ethylidene]oxy]-,[9S(R)]-[CAS] disodium pamidronate Phosphonic acid, (3-amino-1-57248-88-1 EP 177443 Osteoporosis Hypercal- hydroxypropylidene)bis-,disodium salt treatment caemia of [CAS] malignancy Disofenin 65717-97-7disopyramide 2-Pyridineacetamide, Alpha-[2-[bis(1- 3737-09-5Formulation, Arrhythmia, methylethyl)amino]ethyl]-Alpha-phenyl-modified- general [CAS] release, <=24 hr Distigmine 15879-67-2Disulfamide 671-88-5 Disulfiram 97-77-8 Ditazol 18471-20-0 Dithiazanine514-73-8 dithranol 9(10H)-Anthracenone, 1,8-dihydroxy- 1143-38-0Formulation, Psoriasis [CAS] dermal, topical Ditiocarb 148-18-5Dixanthogen 502-55-6 Dixyrazine 2470-73-7 DJ-927 WO 01027115 Anticancer,other Cancer, general DK-507k (−)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-Quinolone Infection, 5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1- antibacterialgeneral cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo- 3-quinolinecarboxylicacid hydrochloride monohydrate _(DL)-Lactic Acid 598-82-3 DMDC Cytidine,2′-deoxy-2′-methylene-, 113648-25-2 WO 8807049 Anticancer, Cancer,monohydrochloride [CAS] antimetabolite general DMXAA5,6-dimethylxanthenone-4-acetic acid Anticancer, other Cancer, lung,general DNA Stealth U.S. 6,132,776 Antiviral, anti-HIV Infection,Nucleosides HIV/AIDS Dobesilate 20123-80-2 dobutamine 1,2-Benzenediol,4-[2-[[3-(4- 34368-04-2 U.S. 3,987,200 Cardiostimulant hydroxyphenyl)-1-49745-95-1 methylpropyl]amino]ethyl]-, (+/−)-[CAS] Docarpamine74639-40-0 docetaxel (2R,3S)-N-Carboxy-3-phenylisoserine, N- 114977-28-5EP 253738 Anticancer, other Cancer, breast tert-butyl ester, 13-esterwith 5β,20-epoxy- 14808-66-6 1,2Alpha,4,7β,10β,13Alpha-hexahydroxytax-11-en-9-one 4-acetate 2- benzoate-[CAS] docosahexaenoicacid EP 707487 Hypolipaemic/ Hyper- Antiatherosclerosis lipidaemia,general docosanol 1-Docosanol [CAS] 661-19-8 EP 469064 Antiviral, otherInfection, herpes simplex virus docusate 128-49-4 U.S. 4,752,617Formulation, dermal, Infection, 577-11-7 topical herpes simplex virusprophylaxis dofetilide Methanesulfonamide, N-[4-[2-[methyl[2-[4-115256-11-6 EP 245997 Antiarrhythmic Fibrillation,[(methylsulfonyl)amino]phenoxy]ethyl]amino]- atrial ethyl]phenyl]-[CAS]dolasetron mesilate 1H-Indole-3-carboxylic acid, octahydro-3-115956-13-3 EP 266730 Antiemetic Chemotherapy-oxo-2,6-methano-2H-quinolizin-8-yl ester, 115956-12-2 induced(2Alpha,6Alpha,8Alpha,9Alphaβ)-, nausea and monomethanesulfonate-[CAS]vomiting Domiodol 61869-07-6 Domiphen 538-71-6 Domitroban 112966-96-8domperidone 2H-Benzimidazol-2-one, 5-chloro-1-[1-[3- 57808-66-9 U.S.4,066,772 Antiemetic (2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-[CAS] donepezil 1H-Inden-1-one,2,3-dihydro-5,6- 120011-70-3 EP 296560 Cognition Alzheimer'sdimethoxy-2-((1-(phenylmethyl)-4- 120014-06-4 enhancer diseasepiperidinyl)methyl)-, [CAS] donitriptan Piperazine,1-(((3-(2-aminoethyl)-1H-indol- 170912-52-4 Antimigraine Migraine5-yl)oxy)acetyl)-4-(4-cyanophenyl)-[CAS] Dopamine 51-61-6 Dopexamine86197-47-9 doramapimod urea, N-[3-(1,1-dimethylethyl)-1-(4- 285983-48-4Antiarthritic, Arthritis, methylphenyl)-1H-pyrazol-5-yl]-N′-[4-[2-(4-immunological rheumatoid morpholinyl)ethoxy)-1-naphthalenyl]-doranidazole (±)-1,2,4-Butanetriol, 3-((2-nitro-1H- 137339-64-1 WO9414778 Radio/ Surgery imidazol-1-yl)methoxy)-[CAS] chemosensitizeradjunct doripenem (1R,5S,6S)-2-[(3S,5S)-5- 148016-81-3 EP 528678Beta-lactam Infection, (sulfamoylaminomethyl)pyrrolidin-3-yl]thio-antibiotic urinary 6-[(1R)-1-hydroxyethyl]-1-methylcarbapen- tract2-em-3-carboxylic acid dorzolamide4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 120279-96-1 EP 296879Antiglaucoma Glaucoma 4-(ethylamino)-5,6-dihydro-6-methyl-,7,7- dioxide(4S-trans)-[CAS] dorzolamide + timolol4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 120279-96-1 Formulation,Glaucoma 4-(ethylamino)-5,6-dihydro-6-methyl-7,7- 26839-75-8 fixed-dosedioxide (4S-trans) + ethyl 2-propanol, 1- 26921-17-5 combinations[(1,1-dimethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S), (Z)-2- butenedioate (1:1) (salt) [CAS]dosmalfate Aluminium, (μ7-(7-((6-O-(6-deoxy-2,3,4-tri- 122312-55-4Antiulcer Ulcer, gastric O-sulfo-Alpha-L-mannosylpyranosyl)-2,3,4-tri-O-sulfo-β-D-glucopyranosyl)oxy)-5-hydroxy-2-(4-methoxy-3-(sulfooxy)phenyl-4H-1-benzopyran-4-onato(7-)))tetradeca-μ-hydroxyheneicosahydroxytetradeca-μ-hydroxyheneicosahydroxytetradeca-[CAS] dosulepine 1-Propanamine,3-dibenzo[b,e]thiepin- 113-53-1 Antidepressant11(6H)-ylidene-N,N-dimethyl-[CAS] Dotarizine 84625-59-2 Dothiepin113-53-1 Doxacurium 106819-53-8 Doxapram 309-29-5 doxazosin Piperazine,1-(4-amino-6,7-dimethoxy-2- 74191-85-8 GB 2007656 Antihypertensive,Hypertension, quinazolinyl)-4-[(2,3-dihydro-1,4- adrenergic generalbenzodioxin-2-yl)carbonyl]-[CAS] Doxefazepam 40762-15-0 Doxenitoin3254-93-1 doxepin 1-Propanamine, 3-dibenz[b,e]oxepin- 1668-19-5Formulation, Pruritus 11(6H)-ylidene-N,N-dimethyl- dermal, topicaldoxercalciferol 9,10-secoergosta-5,7,10(19),22-tetraene- 54573-75-0 U.S.5,104,854 Hormone Hyperpara- 1,3-diol (1Alpha, 3β, 5Z, 7E, 22E) [CAS]thyroidism doxifluridine Uridine, 5′-deoxy-5-fluoro-[CAS] 3094-09-5 U.S.4,071,680 Anticancer, Cancer, antimetabolite colorectal doxofylline1H-Purine-2,6-dione, 7-(1,3-dioxolan-2- 69975-86-6 U.S. 4,187,308Antiasthma Asthma ylmethyl)-3,7-dihydro-1,3-dimethyl-[CAS] doxorubicin5,12-Naphthacenedione, 10-[(3-amino- 23214-92-8 EP 191824 Formulation,Cancer, 2,3,6-trideoxy-Alpha-L-lyxo- optimized, liposomes generalhexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1- methoxy-, (8S-cis)-[CAS]doxycycline 2-Naphthacenecarboxamine, 4- 564-25-0 Formulation,Periodontitis (dimethylamino)-1,4,4a,5,5a,6,11,12a- 17086-28-1 modified-octahydro-3,5,10,12,12a-pentahydroxy-6- release, immediatemethyl-1,11-dioxo-[4S- (4Alpha,4aAlpha,5Alpha,5aAlpha,6Alpha,-12aAlpha)]-[CAS] doxylamine N,N-Dimethyl-2-[1-phenyl-1-(2- 469-21-4Formulation, Rhinitis, pyridinyl)ethoxy]ethanamine transmucosal,allergic, systemic general DPC-817 β-D-2′,3′-didehydro-2′,3′-dideoxy-5-Antiviral, anti-HIV Infection, fluorocytidine HIV/AIDS DPI-3290 U.S.5,681,830 Analgesic, other Pain, general DQ-1135-Amino-7-[(3S,4R)-(1-aminocyclopropyl)- Quinolone Infection,3-fluoropyrrolidin-1-yl]-1-[(1R,2S)-2-fluoro-] antibacterial general1-cyclopropyl]-1,4-dihydro-8-methyl-4-oxo- 3-quinolinecarboxylic acidDrofenine 1679-76-1 Droloxifene 82413-20-5 Drometrizole 2440-22-4Dromostanolone 58-19-5 dronabinol 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-1972-08-3 Antiemetic Chemotherapy- tetrahydro-6,6,9-trimethyl-3-pentyl-,(6aR- induced nausea trans)-[CAS] and vomiting dronedarone 2-n-Butyl3-[4-(3-di-n-butylamino- Antiarrhythmic Arrhythmia, propoxy)benzoyl]5-general methylsulfonamidobenzofuran Droperidol 548-73-2 Droprenilamine57653-27-7 Dropropizine 17692-31-8 Drospirenone 67392-87-4 Drotaverine14009-24-6 Drotebanol 03/02/3176 droxicam 2H,5H-1,3-Oxazino[5,6-90101-16-9 EP 99770 Anti-inflammatory Inflammation,c][1,2]benzothiazine-2,4(3H)-dione, 5- general methyl-3-(2-pyridinyl)-,6,6-dioxide [CAS] droxidopa L-Tyrosine, β,3-dihydroxy-, threo-[CAS]23651-95-8 EP 128684 Antiparkinsonian Parkinson's disease Droxidopa23651-95-8 DU-125530 1,2-Benzisothiazol-3(2H)-one, 2-[4-[4-(7-161611-99-0 EP 633260 Anxiolytic Anxiety,chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1- general piperazinyl]butyl]-,1,1-dioxide [CAS] duloxetine 2-Thiophenepropanamine, N-methyl-136434-34-9 U.S. 5,362,886 Antidepressant Depression,Gamma-(1-naphthalenyloxy)-, 116539-59-4 general hydrochloride, (S)-[CAS]duramycin WO 9428726 Formulation, Cystic fibrosis inhalable, solutionDurapatite 1306-06-5 dutasteride 4-Azaandrost-1-ene-17-carboxamide, N-164656-23-9 U.S. 5,565,467 Prostate disorders Benign(2,5-bis(trifluoromethyl)phenyl)-3-oxo-, prostatic (5Alpha,17β)-[CAS]hyperplasia DW-1141 N,N-diisopropyl-4-[4-(3- Osteoporosis Osteoporosisaminobenzo[d]isoxazol-6-yloxy)butoxy]-3- treatment methoxybenzamideDW-286a (R)-(−)-7-((4-aminomethyl-4-methyl-3-(Z)- Quinolone Infection,methyloxyimino)pyrrolidin-1-yl)-1- antibacterial generalcyclopropyl-6-fluoro-4-oxo-1,4- dihydro[1,8]naphthyridine-3-carboxylicacid DW-471 U.S. 5,922,871 Antiviral, other Infection, hepatitis-B virusDX-9065a 2-Naphthalenepropanoic acid, 7- 155204-81-2 AntithromboticThrombosis, (aminoiminomethyl)-Alpha-[4-[[1-(1- generaliminoethyl)-3-pyrrolidinyl]oxy]phenyl]-, monohydrochloride,pentahydrate, [S- (R*,R*)]-[CAS] DY-9760e 1H-Indazole,3-[2-[4-(3-chloro-2- 160522-00-9 U.S. 5,681,954 NeuroprotectiveIschaemia, methylphenyl)-1-piperazinyl)ethyl]-1-(1H- cerebralimidazol-4-ylmethyl)-5,6-dimethoxy-[CAS] Dyclonine 586-60-7Dydrogesterone 152-62-5 Dymanthine 124-28-7 Dyphyllin 479-18-5 E-10101-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic 186319-97-1 Beta-lactamInfection, acid, 6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-5- antibioticgeneral [(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, monohydrochloride, (4R,5S,6S)-[CAS]E-2101 N-Ethyl-(1-[1-(2-fluorophenethyl)piperidin- Muscle relaxantMuscle spasm, 4-yl]-1H-indol-6-yl)acetamide general E2F antagonists WO9606943 Anticancer, other Cancer, general E-3620 Benzamide,4-amino-5-chloro-N-(8-methyl- 151213-86-4 EP 554794 Antacid/ Dyspepsia8-azabicyclo[3.2.1]oct-3-yl)-2-[(1-methyl-2- Antiflatulentbutynyl)oxy]-, monohydrochloride, [3(S)- endo]-[CAS] E-5564Alpha-D-Glucopyranose, 3-O-decyl-2- 185954-98-7 EP 536969 Septic shockSepsis deoxy-6-O-(2-deoxy-3-O-((3R)-3- treatmentmethoxydecyl)-6-O-methyl-2-(((11Z)-1-oxo-11-octadecenyl)amino)-4-O-phosphono-β- D-glucopyranosyl)-2-((1,3-dioxotetradecyl)amino)-1-(dihydrogen phosphate), tetrasodium salt [CAS]E-5842 Pyridine, 4-(4-fluorophenyl)-1,2,3,6- 220120-14-9 NeurolepticSchizophrenia tetrahydro-1-[4-(1H-1,3,4-triazol-1-yl)butyl]-,2-hydroxy-1,2,3-propanetricarboxylate (1:1)[CAS] E-62591-(4-Aminosulfonylphenyl)-5-(2,4- Antiarthritic, other Unspecifieddifluorophenyl)-4,5-dihydro-3- trifluoromethyl-1-H-pyrazole EAA-90[2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non- Analgesic, other Pain,1(7)-en-2-yl)-ethyl]phosphonic acid neuropathic ε-Acetamidocaproic57-08-9 Acid ε-Aminocaproic Acid 60-32-2 ebastine 1-Butanone, 1-[4-(1,1-90729-43-4 EP 134124 Antiallergic, non- Rhinitis,dimethylethyl)phenyl]-4-[4- asthma allergic,(diphenylmethoxy)-1-piperidinyl]-[CAS] seasonal eberconazole1H-Imidazole, 1-(2,4-dichloro-10,11- 128326-82-9 ES 2012297 AntifungalInfection, dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)- 130104-32-4 derma-[CAS] tological ebrotidine Benzenesulfonamide, N-[[[2-[[[2- 100981-43-9EP 159012 Antiulcer Ulcer, [(aminoiminomethyl)amino]-4- duodenalthiazoly]methyl]thio]ethyl]amino]methylene]- 4-bromo-[CAS] ebselen1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- 60940-34-3 EP 44971Neuroprotective Haemorrhage, [CAS] subarachnoid Eburnamonine 474-00-0Ecabapide 104775-36-2 ecabet 1-Phenanthrenecarboxylic acid, 33159-27-2DE 3239172 Antiulcer Ulcer, gastric 1,2,3,4,4a,9,10,10a-octahydro-1,4a-86408-72-2 dimethyl-7-(1-methylehtyl)-6-sulfo-, [1R-(1Alpha,4aβ,10aAlpha)]-[CAS] ecadotril Glycine,N-[2-[(acetylthio)methyl]-1-oxo-3- 112573-73-6 EP 318377Antihypertensive, Hypertension, phenylpropyl]-,phenylmethyl ester, (S)-other general [CAS] Ecgonidine 484-93-5 Ecgonine 481-37-8 Echothiophate513-10-0 Econazole 27220-47-9 ecopipam5H-Benzo[d]naphth[2,1-b]azepin-12-ol, 11- 112108-01-7 EP 230270Anorectic/ Obesity chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-,Antiobesity (6aS-trans)-[CAS] ecraprost Prosta-8,13-dien-1-oic acid,11,15- 136892-64-3 EP 423697 Vasodilator, Peripheraldihydroxy-9-(1-oxobutoxy)-, butyl ester, peripheral vascular(11Alpha,13E,15S)-[CAS] disease Ectylurea 95-04-5 ED-719,10-Secocholesta-5,7,10(19)-triene- 104121-92-8 EP 184206 OsteoporosisOsteoporosis 1,3,25-triol, 2-(3-hydroxypropoxy)-, treatment(1Alpha,2β,3β,5Z,7E)-[CAS] edaravone 3H-Pyrazol-3-one,2,4-dihydro-5-methyl-2- 89-25-8 JP 62108814 Neuroprotective Infarction,phenyl-[CAS] cerebral Edatrexate 80576-83-6 Edetate Calcium 62-33-9Disodium Edetate Disodium 139-33-3 Edetate Sodium 64-02-8 EdetateTrisodium 150-38-9 edonentan Butanamide,N-[[2′-[[4,5-dimethyl-3-210891-04-6 Cardiostimulant Heart failureisoxazoyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1′-biphenyl]-2-yl]methyl]-N,3,3- trimethyl-, monohydrateedotreotide [N-[2-[4,7-Bis[(carboxy-kappaO)methyl]-10- 204318-14-9 U.S.6,183,721 Anticancer, Cancer, lung, (carboxymethyl)-1,4,7,10- hormonalsmall cell tetraazacyclododec-1-yl- kappaN1,kappaN4,kappaN10]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threanyl-L-cysteinyl-L- threoninol cyclic(2-7)-disulfidato(3-)]yttrium edoxudine Uridine, 2′-deoxy-5-ethyl-[CAS]15176-29-1 GB 1170565 Antiviral, other Infection, herpes virus, generalEdrecolomab 156586-89-9 Edrophonium 116-38-1 Efalith Butanedioic acid,lithium salt [CAS] 16090-09-8 Antipruritic/ Eczema, inflamm, allergicseborrhoeic efaproxiral Propanoic acid, 2-[4-[2-[(3,5- 131179-95-8 U.S.5,705,521 Radio/ Cancer, brain dimethylphenyl)amino]-2- chemosensitizeroxoethyl]phenoxy]-2-methyl-[CAS] efavirenz 2H-3,1-Benzoxazin-2-one,6-chloro-4- 154598-52-4 WO 9403440 Antiviral, anti-HIV Infection,(cyclopropylethynyl)-1,4-dihydro-4- HIV/AIDS (trifluoromethyl)-,(S)-[CAS] efletirizine [2-[4-[Bis(p-fluorophenyl)methyl]-1- 150756-35-7GB 2311940 Antiallergic, Allergy, general piperazinyl]ethoxy]acetic acidnon-asthma eflornithine DL-Ornithine, 2-(difluoromethyl)-[CAS]70052-12-9 U.S. 4,413,141 Protozoacide, Infection, 67037-37-0 dermal,topical trypanosomiasis, African, Hirsutism Efloxate 119-41-5 eflucimibeBenzeneacetamide, Alpha-(dodecylthio)-N- 202340-45-2 Hypolipaemic/Hyper- (4-hydroxy-2,3,5-trimethylphenyl)-(S)- Antiatherosclerosislipidaemia, [CAS] general efonidipine 3-pyridinecarboxylic acid,5-(5,5-dimethyl- 111011-53-1 EP 230944 Antihypertensive, Hypertension,1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro- 111011-63-3 other general2,6-dimethyl-4-(3-nitrophenyl)-, 2- 111011-76-8(phenyl(phenylmethyl)amino)ethyl ester, P- oxide [CAS] EGIS-72295-Chloro-4-[3-[N-[2-(3,4- 150800-12-7 DE 4243381 AntiarrhythmicArrhythmia, dimethoxyphenyl)ethyl]-N- 190333-92-7 generalmethylamino]propylamino]-3(2H)- pyridazinone fumarate [CAS] eglumegadBicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 176199-48-7 AnxiolyticAnxiety, 2-amino-, (1S,2S,5R,6S)-[CAS] 209216-09-1 general egualen1-Azulenesulfonic acid, 3-ethyl-7-(1- 97683-31-3 EP 147915 AntiulcerUlcer, gastric methylethyl)-, 99287-30-6 Elcosapentaenoic 10417-94-4Acid elarofiban 3-Pyridinepropanoic acid, β-[((3R)-1-[1- 198958-88-2 WO9741102 Antithrombotic Thrombosis, oxo-3-(4-piperidinyl)propyl]-3-general piperidinyl]carbonyl]amino]-, (βS)-[CAS] Elcatonin 60731-46-6Eledoisin 69-25-0 eletriptan 1H-Indole, 3-((1-methyl-2- 143322-58-1 U.S.5,607,951 Antimigraine Migraine pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-(R)-[CAS] Elgodipine 119413-55-7 Ellagic Acid476-66-4 Elliptinium 58337-35-2 Eltoprazine 98224-03-4 elvucitabineβ-L-2′,3′-Didehydro-2′,3′-dideoxy-5- 181785-84-2 Antiviral, otherInfection, fluorocytidine hepatitis-B virus elzasonan(2Z)-4-(3,4-dichlorophenyl)-2-[2-(4- 220322-05-4 AntidepressantDepression, methylpiperazin-1- 361343-20-6 generalyl)benzylidene]thiomorpholin-3-one monohydrochloride-[CAS] Embelin550-24-3 Embramine 3565-72-8 emedastine 1H-Benzimidazole,1-(2-ethoxyethyl)-2- 87233-61-2 EP 79545 Antiallergic, non- Rhinitis,(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-, 87233-62-3 asthma allergic,(E)-2-butenedioate (1:2) [CAS] general Emepronium 3614-30-0 Emetine483-18-1 Emitefur 110690-43-2 EMM-21052517Alpha-Acetoxy-6Alpha-methyl-19-nor- Formulation, Hormone1β,2β-dihydrocyclopropa[1,2′]pregn-4-ene- fixed-dose replacement3,20-dione + Estra-1,3,5(10)-triene-3,17- combinations therapy diol(17β)Emodin 518-82-1 emorfazone 3(2H)-Pyridazinone, 4-ethoxy-2-methyl-5-38957-41-4 JP 7224030 Anti-inflammatory (4-morpholinyl)-[CAS] EMR-62203WO 9806722 Male sexual Impotence dysfunction emtricitabine2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2- 143491-57-0 WO 9214743Antiviral, anti-HIV Infection, (hydroxymethyl)-1,3-oxathiolan-5-yl)-,(2R- HIV/AIDS cis)-[CAS] Emylcamate 78-28-4 enalapril L-Proline,1-[N-[1-(ethoxycarbonyl)-3- 76095-16-4 U.S. 4,374,829 Antihypertensive,phenylpropyl]-L-alanyl]-, (S)-, (Z)-2- renin system butenedioate [CAS]Enalaprilat 76420-72-9 Enallylpropymal 1861-21-8 Encainide 66778-36-7Enciprazine 68576-86-3 Endralazine 39715-02-1 enfenamic acid Benzoicacid, 2-[(2-phenylethyl)amino]- 23049-93-6 IN 103066 Anti-inflammatory[CAS] enflurane Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2- 13838-16-9U.S. 3,469,011 Anaesthetic, Anaesthesia trifluoro-[CAS] inhalationEnilconazole 35554-44-0 Eniluracil 59989-18-3 ENMD-0995S-3-amino-phthalidoglutarimide U.S. 5,712,291 Anticancer, other Cancer,Enocitabine 55726-47-1 myeloma Enol-3-IPA 1H-Indole-3-propanoic acid,Alpha-oxo- 392-12-1 EP 106813 Hypnotic/Sedative Insomnia [CAS] enoxacin1,8-Naphthyridine-3-carboxylic acid, 1- 74011-58-8 U.S. 4,359,578Quinolone Infection, ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-antibacterial general piperazinyl)-[CAS] enoxaparin Heparin, [CAS]9005-49-6 EP 40144 Antithrombotic Thrombosis, 9041-08-1 venous enoximone2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5- 77671-31-9 EP 59948Cardiostimulant Heart failure [4-(methylthio)benzoyl]-[CAS] Enoxolone471-53-4 enprostil 4,5-Heptadienoic acid, 7-[3-hydroxy-2-(3- 73121-56-9GB 2025431 Protaglandin Ulcer, hydroxy-4-phenoxy-1-butenyl)-5- duodenaloxocyclopentyl]-, methyl ester, [1Alpha,2β(1E,3R*),3Alpha]-[CAS]enrasentan 1H-Indene-2-carboxylic acid, 1-(1,3- 167256-08-8 U.S.5,817,693 Antihypertensive, Hypertension,benzodioxol-5-yl)-2,3-dihydro-3-(2-(2- other pulmonaryhydroxyethoxy)-4-methoxyphenyl)-5- propoxy-,(1S-(1Alpha,2β,3Alpha))-[CAS] entacapone 2-Propenamide,2-cyano-3-(4,5-dihydroxy- 130929-57-6 EP 426468 AntiparkinsonianParkinson's 3-nitrophenyl)-N,N-diethyl-[CAS] disease entecavir6H-Purin-6-one, 2-amino-1,9-dihydro-9- 142217-69-4 EP 481754 Antiviral,other Infection, ((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)- hepatitis-B2-methylenecyclopentyl]-[CAS] virus Enviomycin 33103-22-9 epalrestat3-Thiazolidineacetic acid, 5-(2-methyl-3- 82159-09-9 EP 47109Symptomatic Neuropathy, phenyl-2-propenylidene)-4-oxo-2-thioxo-,antidiabetic diabetic (E,E)-[CAS] Epavir L-lysine-cis-5,8,11,14,17-Antiviral, other Infection, eicosapentanoate with L-lysine-cis- herpes4,7,10,13,16,19-doahexanoate simplex virus EPC-K1 L-ascorbic acid2-[3,4-dihydro-2,5,7,8- 127061-56-7 EP 127471 NeuroprotectiveInfarction, tetramethyl-2-(4,8,12-trimethyltridecyl)-2H- cerebral1-benzopyran-6-yl-hydrogen phosphate]potassium-[CAS] eperisone1-Propanone, 1-(4-ethylphenyl)-2-methyl-3- 64840-90-0 U.S. 3,995,047Muscle relaxant Spastic (1-piperidinyl)-[CAS] paralysis epervudineUridine, 2′-deoxy-5-(1-methylethyl)-[CAS] 60136-25-6 DE 2918260Antiviral, other Infection, herpes simplex virus Ephedrine 299-42-3Epicillin 26774-90-3 Epimestrol 7004-98-0 epinastine1H-Dibenz[c,f]imidazo[1,5-a]azepin-3- 80012-43-7 DE 3008944 AntiasthmaAsthma amine, 9,13b-dihydro-[CAS] eoinephrine(R)-4-[1-hydroxy-2-(methylamino)-ethyl]- 51-43-4 Formulation,Anaphylaxis 1,2-benzenediol inhalable, dry powder Epirizole 18694-40-1epirubicin 5,12-Naphthacenedione, 10-[(3-amino- 56390-09-1 GB 1457632Anticancer, 2,3,6-trideoxy-Alpha-L-arabino- 56420-45-2 antibiotichexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1- methoxy-, (8S-cis)-[CAS]Epitiostanol 2363-58-8 eplerenone Pregn-4-ene-7,21-dicarboxylic acid,9,11- 107724-20-9 EP 122232 Antihypertensive, Hypertension,epoxy-17-hydroxy-3-oxo-, Gamma-lactone, diuretic general methyl ester(7Alpha, 11Alpha, 17Alpha)- [CAS] eplivanserin 1-Propanone,1-(2-fluorophenyl)-3-(4- 130580-02-8 EP 373998 Anxiolytic Schizophreniahydroxyphenyl)-, O-(2- (dimethylamino)ethyl)oxime, (Z)-, (E)-2-butenedioate (2:1) (salt) [CAS] epoprostenol Prosta-5,13-dien-1-oicacid, 6,9-epoxy- 35121-78-9 DE 2720999 Prostaglandin Hypertension,11,15-dihydroxy-, 61849-14-7 pulmonary (5Z,9Alpha,11Alpha,13E,15S)-[CAS]Epostane 80471-63-2 Eprazinone 10402-90-1 Epristeride 119169-78-7eprosartan 3-[2-Butyl-1-(4-carboxybenzyl)-1H- 133040-01-4 EP 403159Antihypertensive, Hypertension,imidazol-5-yl]-2-(2-thienylmethyl)-2-(E)- renin system general propenoicacid Eprozinol 32665-36-4 eptapirone 4-methyl-2-[4-(4-(pyrimidin-2-yl)-179756-85-5 Antidepressant Depression,piperazino)-butyl]-2H,4H-1,2,4-triazin-3,5- general dione eptaplatinPlatinum, [(4R,5R)-2-(1-methylethyl)-1,3- 146665-77-2 WO 9216539Anticancer, Cancer, lung, dioxolane-4,5-dimethanamine- alkylating smallcell kappaN4,kappaN5][propanedioato(2-)- kappaO1,kappaO3]-,(SP-4-2)-[CAS] Eptastigmine 101246-68-8 eptazocine1,6-Methano-1H-4-benzazonin-10-ol, 72522-13-5 U.S. 4,082,744 Analgesic,other 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, (1S)- [CAS] Eptifibatide188627-80-7 Equilenin 517-09-9 Equilin 474-86-2 ERA-923 ERA 923 [CAS]352233-89-7 EP 802183 Female Contraceptive, contraceptive femaleerdosteine Acetic acid, [[2-oxo-2-[(tetrahydro-2-oxo-3- 84611-23-4 EP61386 Respiratory Respiratory thienyl)amino]ethyl]thio]-[CAS] disease,general Ergocornine 564-36-3 Ergocorninine 564-37-4 Ergoloid Mesylates8067-24-1 Ergonovine 60-79-7 Ergosterol 57-87-4 ergotamine(5′Alpha)-12′-Hydroxy-2′methyl- 113-15-5 Formulation, Migraine(phenylmethyl)ergotaman-3′,6′, 18-trione inhalable, systemic Eritadenine23918-98-1 erlotinib 4-Quinazolinamine, N-(3-ethynylphenyl)- 183319-69-9WO 9630347 Anticancer, other Cancer, lung, 6,7-bis(2-methoxyethoxy)-,non-small cell monohydrochloride [CAS] ertapenem1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic 153773-82-1 WO 9315078Beta-lactam Infection, acid, 3-[[(3S,5S)-5-[[(3- 153832-46-3 antibioticGI tract carboxyphenyl)amino]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4- methyl-7-oxo-, [CAS]Erythrityl Tetranitrate 7297-25-8 Erythrocentaurin 50276-98-7erythromycin acistrate Erythromycin, 2′-acetate, octadecanoate96128-89-1 U.S. 4,599,326 Macrolide antibiotic Infection, (salt) [CAS]general Erythromycin Estolate 3521-62-8 Erythromycin 23067-13-2Glucoheptonate Erythromycin 3847-29-8 Lactobionate Erythromycin 134-36-1Propionate Erythromycin 643-22-1 Stearate erythromycin Erythromycin,2′-propanoate, compd. with 84252-03-9 EP 57489 Macrolide antibioticInfection, stinoprate N-acetyl-L-cysteine (1:1) [CAS] respiratory tract,lower erythromycin Erythromycin [CAS] 114-07-8 Formulation, dermal, Acnetopical Erythrophleine 36150-73-9 Esaprazole 64204-55-3 escitalopram5-Isobenzofurancarbonitrile, 1-[3- 128196-01-0 EP 347066 AntidepressantDepression, (dimethylamino)propyl]-1-(4-fluorophenyl)- general1,3-dihydro-, (S)-[CAS] Esculin 531-75-9 Eseridine 25573-43-7 esmololBenzenepropanoic acid, 4-[2-hydroxy-3-[(1- 81147-92-4 U.S. 4,387,103Antihypertensive, Tachycardia, methylethyl)amino]propoxy]-, methylester, adrenergic supra- (+/−)-[CAS] ventricular esomeprazole bis(5-methoxy-2-(((4-methoxy-3,5- 161973-10-0 U.S. 5,877,192 AntispasmodicGastro- dimethyl-2-pyridinyl)methyl)sulfinyl)-1H- oesophagealbenzimidazolato) reflux estazolam 4H-[1,2,4]Triazolo[4,3- 29975-16-4U.S. 3,987,052 Hypnotic/Sedative a][1,4]benzodiazepine,8-chloro-6-phenyl- [CAS] estradiol Androst-4-en-3-one, 17-hydroxy-,(17β)- 58-22-0 U.S. 5,460,820 Formulation, Sexual [CAS] transdermal,patch dysfunction, female estradiol Estra-1,2,5(10)-triene-3,17-diol(17β)- 50-28-2 EP 430491 Formulation, Menopausal [CAS] transdermal,systemic symptoms, general estramustine Estra-1,3,5(10)-triene-3,17-diol(17β)-, 3- 2998-57-4 Anticancer, Cancer, [bis(2-chloroethyl)carbamate]17-[CAS] 4891-15-0 alkylating prostate 52205-73-9 Estriol 50-27-1estrogen WO 9924041 Menopausal disorders Menopausal symptoms, generalEstrone 53-16-7 eszopiclone 1-Piperazinecarboxylic acid, 4-methyl-6-(5-138729-47-2 U.S. 5,786,357 Hypnotic/Sedative Insomniachloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H- pyrrolo(3,4-b)pyrazin-5-ylester (S)-[CAS] Etafedrine 7681-79-0 Etafenone 90-54-0 Etamiphyllin314-35-2 Etanercept 185243-69-0 Etanidazole 22668-01-5 Etaqualone7432-25-9 Eterobarb 27511-99-5 Ethacridine 442-16-0 Ethacrynic Acid58-54-8 Ethadion 520-77-4 Ethambutol 74-55-5 Ethamivan 304-84-7Ethamsylate 2624-44-4 Ethanolamine 141-43-5 Ethaverine 486-47-5Ethchlorvynol 113-18-8 Ethenzamide 938-73-8 Ethiazide 1824-58-4Ethinamate 126-52-3 Ethinyl Estradiol 57-63-6 ethinyl estradiol19-Norpregna-1,3,5(10)-trien-20-yne-3,17- 28913-23-7 DE 1949095Formulation, Cancer, diol, 3-(2-propanesulfonate), (17Alpha)- modified-prostate [CAS] release, >24 hr Ethionamide 536-33-4 Ethisterone 434-03-7Ethoheptazine 77-15-6 Ethopropazine 522-00-9 Ethosuximide 77-67-8Ethotoin 86-35-1 Ethoxzolamide 452-35-7 Ethybenztropine 524-83-4 EthylAlcohol 64-17-5 Ethyl Biscoumacetate 548-00-5 Ethyl Chloride 75-00-3Ethyl Dibunate 5560-69-0 Ethyl Ether 60-29-7 ethyl icosapentate5,8,11,14,17-Eicosapentaenoic acid, ethyl 86227-47-6 JP 61043143Antithrombotic Peripheral ester, (all-Z)-[CAS] vascular disease ethylloflazepate 1H-1,4-Benzodiazepine-3-carboxylic acid, 29177-84-2 U.S.3,657,223 Anxiolytic Anxiety, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-general oxo-, ethyl ester [CAS] Ethyl Loflazepate 29177-84-2 Ethylamine75-04-7 Ethylene 74-85-1 Ethylestrenol 965-90-2 Ethylidene 1821-16-5Dicoumarol Ethylmethyl- 441-61-2 thiambutene Ethylmorphine 76-58-4Ethylnorepinephrine 536-24-3 Ethynodiol 1231-93-2 ethynylcytidineUridine, 3′-C-ethynyl-[CAS] 180300-49-6 WO 9618636 Anticancer, Cancer,antimetabolite general Etidocaine 36637-18-0 etidronate Phosphonic acid,(1-hydroxyethylidene)bis-, 2809-21-4 U.S. 4,137,309 OsteoporosisOsteoporosis [CAS] 7414-83-7 treatment Etidronic Acid 2809-21-4Etifelmin 341-00-4 etifoxine 4H-3,1-Benzoxazin-2-amine, 6-chloro-N-21715-46-8 U.S. 3,725,404 Anxiolytic ethyl-4-methyl-4-phenyl-[CAS]Etilefrin 709-55-7 etilevodopa L-Tyrosine, 3-hydroxy-, ethyl ester [CAS]37178-37-3 U.S. 5,354,885 Antiparkinsonian Parkinson's diseaseetiprednol androsta-1,4-diene-17-carboxylic acid, 17- 199331-40-3 GIinflammatory/ Crohn's [(dichloroacetyl)oxy]-11-hydroxy-3-oxo-, boweldisorders disease ethyl ester, (11β,17Alpha)- Etiroxate 17365-01-4Etizolam 40054-69-1 etodolac Pyrano[3,4-b]indole-1-acetic acid, 1,8-41340-25-4 U.S. 3,939,178 Antiarthritic, other Arthritis,diethyl-1,3,4,9-tetrahydro-[CAS] osteo Etodroxizine 17692-34-1etofenamate Benzoic acid, 2-[[3- 30544-47-9 GB 1285400Anti-inflammatory, Inflammation, (trifluoromethyl)phenyl]amino]-, 2-(2-topical general hydroxyethoxy)ethyl ester [CAS] etofibrate3-Pyridinecarboxylic acid, 2-[2-(4- 31637-97-5 U.S. 3,723,446Hypolipaemic/ chlorophenoxy)-2-methyl-1- Antiatherosclerosisoxopropoxy]ethyl ester [CAS] Etofylline 519-37-9 etofylline clofibratePropanoin acid, 2-(4-chlorophenoxy)-2- 54504-70-0 DE 2308826Hypolipaemic/ methyl-, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-Antiatherosclerosis 2,6-dioxo-7H-purin-7-yl)ethyl ester [CAS] EtofyllineNicotinate 13425-39-3 Etoglucid 1954-28-5 Etomidate 33125-97-2Etomidoline 21590-92-1 Etonitazene 911-65-9 etonogestrel18,19-Dinorpregn-4-en-20-yn-3-one, 13- 54048-10-1 Formulation,Contraceptive, ethyl-17-hydroxy-11-methylene, (17Alpha)- implant female[CAS] Etoperidone 52942-31-1 etoposideFuro[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol- 33419-42-0 GB 1205966Anticancer, other Cancer, 6(5aH)-one, 9-[(4,6-O-ethylidene-β-D-testicular glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, [5R-[5Alpha,5aβ,8aAlpha,9β(R*)]]-[CAS] etoposide phosphateFuro[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol- 117091-64-2 EP 302473Anticancer, other Cancer, 6(5aH)-one, 9-[(3,5-dimethoxy-4- testicular(phosphonooxy)phenyl]-9-[(4,6-0- ethylidene-β-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-, [5R- [5Alpha,5aβ,8aAlpha,9β(R*)]]-[CAS] etoricoxib2,3-Bipyridine, 5-chloro-6′-methyl-3-(4- 202409-33-4 WO 9803484Antiarthritic, other Arthritis, (methylsulfonyl)phenyl) [CAS] osteoEtoxadrol 28189-85-7 Etozolin 73-09-6 etretinate 2,4,6,8-Nonatetraenoicacid, 9-(4-methoxy- 54350-48-0 U.S. 4,215,215 Antipsoriasis2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)-[CAS]Etryptamine 2235-90-7 Etymemazine 523-54-6 Eucatropine 100-91-4 Eugenol97-53-0 EUK-134 Manganese, chloro[[2,2- [1,2- 81065-76-1 U.S. 6,046,188Cardiovascular Unspecified ethanediylbis[(nitrilo-kappaN)methylidyne]]bis(6- methoxyphenolato-kappaO]]]-, (SP-5-13)- [CAS]EUK-189 U.S. 6,046,188 Radio/ Chemotherapy- chemoprotective inducedinjury, general Evans Blue 314-13-6 everolimus Rapamycin,42-O-(2-hydroxyethyl)-[CAS] 159351-69-6 WO 9409010 ImmunosuppressantTransplant rejection, general exalamide Benzamide, 2-(hexyloxy)-[CAS]53370-90-4 GB 726786 Antifungal Infection, fungal, general Exametazime105613-48-7 exatecan 10H,13H- 171335-80-1 Anticancer, other Cancer,Benzo[de]pyrano[3′,4′:6,7]indolizino[1,2- pancreaticb]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy- 4-methyl-, (1A,9S)-, [CAS]exemestane Androsta-1,4-diene-3,17-dione, 6- 107868-30-4 DE 3622841Anticancer, hormonal Cancer, methylene-[CAS] breast Exifone 52479-85-3exisulind 1H-Indene-3-acetic acid 5-fluoro-2-methyl- 59973-80-7Anticancer, other Polyp 1-((4-(methylsulfonyl)phenyl)methylene)-,(Z)-[CAS] Exosurf ® 99732-49-7 ezetimibe 2-Azetidinone,1-(4-fluorophenyl)-3-[(3S)-3- 163222-33-1 U.S. 5,846,966 Hypolipaemic/Hypercholest- (4-fluorophenyl)-3-hydroxypropyl]-4-(4- Antitherosclerosiserolaemia hydroxyphenyl)-, (3R,4S)-[CAS] Factor IX 9001-28-9 Factor VIII9001-27-8 Factor XIII 9013-56-3 fadolmidine 1H-Inden-5-ol,2,3-dihydro-3-(1H-imidazol- 189353-32-0 WO 9712874 Analgesic, otherPain, general 4-ylmethyl), monohydrochloride [CAS] Fadrozole 102676-47-1falecalcitriol 9,10-Secocholesta-5,7,10(19)-triene- 83805-11-2 JP03099022 Osteoporosis Hyperpara- 1,3,25-triol,26,26,26,27,27,27-hexafluoro-, treatment thyroidism(1Alpha,3β,5Z,7E)-[CAS] famciclovir 1,3-Propanediol,2-[2-(2-amino-9H-purin-9- 104227-87-4 JP 61085388 Antiviral, otherInfection, yl)ethyl]-, diacetate (ester)-[CAS] gynaecological famotidinePropanimidamide, 3-[[[2- 76824-35-6 U.S. 4,283,408 Antiilcer Ulcer,[(aminoiminomethyl)amino]-4- duodenalthiazolyl]methyl]thio]-N-(aminosulfonyl)- [CAS] fampridine 4-pyridamine504-24-5 Neuroprotective Spinal cord injury fandofloxacin3-Quinolinecarboxylic acid, 6-fluoro-1-(5- 164150-85-0 U.S. 5,496,947Quinolone Infection, fluoro-2-pyridinyl)-1,4-dihydro-7-(4-methyl-164150-99-6 antibacterial urinary tract 1-piperazinyl)-4-oxo, [CAS]Fantofarone 114432-13-2 faropenem daloxate(5R,6S)-6-[1(R)-Hydroxyethyl]-2-[2(R)- Beta-lactam Infection,tetrahydrofuryl]-2-penem-3-carboxylic acid- antibiotic general5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester faropenem4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2- 122547-49-3 EP 410727Beta-lactam Infection, carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-antibiotic ocular (tetrahydro-2-furanyl)-, [5R-[3(R*),5Alpha,6Alpha(R*)]]-[CAS] fasidotril L-Alanine,N-[(2S)-3-(acetylthio)-2-(1,3- 135038-57-2 EP 419327 Antihypertensive,Hypertension, benzodioxol-5-ylmethyl)-1-oxopropyl]-, renin systemgeneral phenylmethyl ester [CAS] fasudil 1H-1,4-Diazepine,hexahydro-1-(5- 103745-39-7 EP 187371 Neuroprotective Vasospasm,isoquinolinylsulfonyl)-[CAS] 105628-07-7 general Fazadinium Bromide49564-56-9 febarbamate 2,4,6(1H,3H,5H)-Prrimidinetrione, 1-[2-13246-02-1 U.S. 3,075,983 Psychostimulant[(aminocarbonyl)oxy]-3-butoxypropyl]-5- ethyl-5-phenyl-[CAS] Febuprol3102-00-9 febuxostat 5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-144060-53-7 WO 9209279 Antigout Hyper-methylpropoxy)phenyl]-4-methyl-[CAS] uricaemia Fedotozine 123618-00-8felbamate 1,3-Propanediol, 2-phenyl-, dicarbamate 25451-15-4 U.S.4,868,327 Antiepileptic Epilepsy, [CAS] general felbinac[1,1′-Biphenyl]-4-acetic acid [CAS] 5728-52-9 EP 127840Anti-inflammatory, topical felodipine 3,5-Pyridinedicarboxylic acid,4-(2,3- 72509-76-3 U.S. 4,264,611 Antihypertensive, Hypertension,dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, other general ethyl methylester [CAS] Felypressin 56-59-7 Femoxetine 59859-58-4 Fenbenicillin1926-48-3 fenbufen [1,1′-Biphenyl]-4-butanoic acid, Gamma- 36330-85-5U.S. 3,784,701 Anti-inflammatory oxo-[CAS] Fenbutrazate 4378-36-3Fencamfamine 1209-98-9 Fencamine 28947-50-4 Fenclozic Acid 17969-20-9Fendiline 13042-18-7 Fendosal 53597-27-6 Fenethylline 3736081Fenfluramine 458-24-2 Fenipentol 583-03-9 fenofibrate Propanoic acid,2-[4-(4- 26129-32-8 Formulation, Hyper-chlorobenzoyl)phenoxy]-2-methyl-, 1- 49562-28-9 modified- lipidaemia,methylethyl ester [CAS] release, <=24 hr general fenoldopam1H-3-Benzazepine-7,8-diol, 6-chloro- 67227-56-9 EP 22330Antihypertensive, Hypertension, 2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-67227-57-0 other general [CAS] Fenoprofen 31879-05-7 Fenoterol13392-18-2 fenoverine 10H-Phenothiazine, 10-[[4-(1,3- 37561-27-6 FR2092639 Antispasmodic benzodioxol-5-ylmethyl)-1-piperazinyl]acetyl]-[CAS] Fenoxazoline 4846-91-7 Fenoxedil 54063-40-0Fenozolone 15302-16-6 Fenpentadiol 15687-18-0 Fenpiprane 3540-95-2Fenpiverinium 125-60-0 Bromide Fenproporex 15686-61-0 Fenquizone20287-37-0 fenretinide Retinamide, N-(4-hydroxyphenyl)-[CAS] 65646-68-6BE 847942 Anticancer, other Cancer, breast Fenspiride 5053066 fentanylPropanamide, N-phenyl-N-[1-(2- 437-38-7 Formulation, Anaesthesia,phenylethyl)-4-piperidinyl]-[CAS] transmucosal, adjunct systemicFentiazac 18046-21-4 Fenticlor 97-24-5 fenticonazole 1H-Imidazole,1-[2-(2,4-dichlorophenyl)-2- 72479-26-6 U.S. 4,221,803 AntifungalInfection, [[4-(phenylthio)phenyl]methoxy]ethyl]- 73151-29-8gynaecological [CAS] Fentonium Bromide 5868064 fepradinolBenzenemethanol, Alpha[[(2-hydroxy-1,1- 36981-91-6 Anti-inflammatory,dimethylethyl)amino]methyl]-, (+/−)-[CAS] 67704-50-1 topical 63075-57-8Feprazone 30748-29-9 Ferric Sodium Edetate 15708-41-5 ferrioxamine B WO9426263 Septic shock Respiratory treatment distress syndrome, adultFerrocholinate 1336-80-7 Ferrous Gluconate 299-29-6 ferumoxytolPolyglucose sorbitol carboxymethyl ether- Imaging agent Diagnosis,coated non-stoichiometric magnetite cancer fesoterodine2-((1R)-3-(bis(1-methylethyl)amino)-1- 286930-03-8 UrologicalIncontinence phenylpropyl)-4-(hydroxymethyl)Phenyl ester,(2E)-2-butenedioate (1:1) (Salt)- [CAS] fexofenadine Benzeneacetic acid,4-[1-hydroxy-4- 153439-40-8 U.S. 5,345,693 Antiallergic, non- Rhinitis,[4(hydroxydiphenylmethyl(-1- 83799-24-0 asthma allergic,piperidinyl]butyl]-Alpha,Alpha-dimethyl-, 138452-21-8 seasonal [CAS]Fibrostat CA 2132416 Vulnerary Wound healing fidarestatSpiro(4H-1-benzopyran-4,4′-imidazolidine)- 136087-85-9 EP 418834Symptomatic Neuropathy, 2-carboxamide, 6-fluoro-2,3-dihydro-2′,5′-antidiabetic diabetic dioxo-, (2S-cis)-, [CAS] fiduxosin8-Phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-]] 208993-54-8 Prostate disordersBenign prostatic tetrahydro-9-methoxy[1]benzopyrano[3,4-c]- hyperplasiapyrrol-2(3H)-yl]butyl]pyrazino[2′,3′:4,5]-thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione finasteride4-Azaandrost-1-ene-17-carboxamide, N- 98319-26-7 EP 155096 Prostatedisorders Benign (1,1-dimethylethyl)-3-oxo-, (5Alpha,17β)- prostatic[CAS] hyperplasia finrozole Benzonitrile, 4-(3-(4-fluorophenyl)-2-160146-16-7 EP 476944 Urological Urinaryhydroxy-1-(1H-1,2,4-triazol-1-yl)-propyl)- retention [CAS] Fipexide34161-24-5 FK-960 N-(4-Acetyl-1-piperazinyl)-4- 133920-70-4 WO 9101979Cognition Alzheimer's fluorobenzamide monohydrate-[CAS] enhancer diseaseFlavopiridol 146426-40-6 flavoxate 4H-1-Benzopyran-8-carboxylic acid, 3-15301-69-6 U.S. 2,921,070 Urological methyl-4-oxo-2-phenyl-, 2-(1-3717-88-2 piperidinyl)ethyl ester [CAS] flecainide Benzamide,N-(2-piperidinylmethyl)-2,5- 54143-55-4 Formulation, Fibrillation,bis(2,2,2-trifluoroethoxy)-, [CAS] 54143-56-5 modified- atrial release,<=24 hr fleroxacin 3-Quinolinecarboxylic acid, 6,8-difluoro-1-79660-53-0 U.S. 4,398,029 Quinolone Infection,(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1- 79660-72-3 antibacterialgeneral piperazinyl)-4-oxo-[CAS] Flesinoxan 98206-10-1 flibanserin2H-Benzimidazol-2-one, 1,3-dihydro-2-(2- 167933-07-5 Reproductive/Sexual (4-(3-(trifluoromethyl)phenyl)-1- gonadal, general dysfunction,piperazinyl)ethyl)-[CAS] female floctafenine Benzoic acid,2-[[8-(trifluoromethyl)-4- 23779-99-9 U.S. 3,644,368 Analgesic, NSAIDquinolinyl]amino]-, 2,3-dihydroxypropyl ester [CAS] flomoxef5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2- 92823-03-5 EP 128536Cephalosporin, Infection, carboxylic acid, 7- 99665-00-6 injectablegeneral [[[(difluoromethyl)thio]acetyl]amino]-3-[[[(1-(2-hydroxyethyl)-1H-tetrazol-5- yl]thio]methyl]-7-methoxy-8-oxo-,(6R-cis)- [CAS] Flopropione 2295-58-1 Florantyrone 519-95-9 Flosequinan76568-02-0 Floxacillin 5250-39-5 Floxuridine 50-91-9 Fluacizine30223-48-4 Fluanisone 1480-19-9 fluasterone Androst-5-en-17-one,16-fluoro-, 112859-71-9 EP 246650 Cardiovascular Keratosis(16Alpha)-[CAS] fluazacort 5'H-Pregna-1,4-dieno[17,16-d]oxazole-19888-56-3 U.S. 3,461,119 Antipruritic/ 3,20-dione,21-(acetyloxy)-9-fluoro-11- inflamm, non- hydroxy-2'-methyl-,(11β,16β)-[CAS] allergic Flucloronide 3693-39-8 flucloxacillin 1847-24-1Formulation, other Infection, 34214-51-2 general Fluconazole1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4- 86386-73-4 EP 96569 AntifungalInfection, difluorophenyl)-Alpha-(1H-1,2,4-triazol-1- dermatologicalylmethyl)-[CAS] Flucytosine 2022-85-7 fludarabine 9H-Purin-6-amine,2-fluoro-9-(5-O- 75607-67-9 U.S. 4,357,324 Anticancer, Cancer,phosphono-β-D-arabinofuranosyl)-[CAS] 21679-14-1 antimetaboliteleukaemia, chronic lymphocytic Fludeoxyglucose F₁₈ 105851-17-0Fludiazepam 3900-31-0 Fludrocortisone 127-31-1 Flufenamic Acid 530-78-9Fluindione 957-56-2 flumazenil 4H-Imidazo[1,5-a][1,4]benzodiazepine-3-78755-81-4 EP 27214 Neurological carboxylic acid,8-fluoro-5,6-dihydro-5- methyl-6-oxo-, ethyl ester [CAS] Flumecinol56430-99-0 Flumequine 42835-25-6 Flumethasone 2135-17-3 Flumethiazide148-56-1 fluarizine Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-30484-77-6 GB 1268710 Antimigraine (3-phenyl-2-propenyl)-, (E)-[CAS]52468-60-7 27848-84-6 flunisolide Pregna-1,4-diene-3,20-dione, 6-fluoro-3385-03-3 U.S. 3,124,571 Antiasthma Rhinitis, 11,21-dihydroxy-16,17-[(1-allergic, methylethylidene)bis(oxy)]-, general(6Alpha,11β,16Alpha)-[CAS] flunitrazepam 2H-1,4-Benzodiazepin-2-one,5-(2- 1622-62-4 U.S. 3,116,203 Hypnotic/fluorophenyl)-1,3-dihydro-1-methyl-7-nitro- Sedative [CAS] Flunoxaprofen66934-18-7 Fluocinolone Acetonide 67-73-2 Fluocinonide 356-12-7Fluocortin Butyl 41767-29-7 Fluocortolone 152-97-6 Fluorescein 2321-07-5Fluoresone 2924-67-6 Fluorometholone 426-13-1 Fluorosalan 4776061fluorouracil 2,4(1H,3H)-Pyrimidinedione, 5-fluoro- 51-21-8 Formulation,Keratosis [CAS] transdermal, enhanced fluoxetine Benzenepropanamine,N-methyl-Gamma- 54910-89-3 U.S. 4,314,081 Antidepressant Depression,[4-(trifluoromethyl)phenoxy]-, (+/−)-[CAS] 56296-78-7 generalFluoxymesterone 76-43-7 Flupentixol 2709-56-0 Fluperolone 2119-75-7Fluphenazine 69-23-8 flupirtine Carbamic acid, [2-amino-6-[[(4-33400-45-2 U.S. 4,481,205 Analgesic, other Pain, post-fluorophenyl)methyl]amino]-3-pyridinyl]-, 56995-20-1 operative ethylester [CAS] 75507-68-5 Fluprednidene Acetate 1255-35-2 Fluprednisolone53-34-9 Fluproquazone 40507-23-1 Flurandrenolide 1524-88-5 Flurazepam17617-23-1 flurbiprofen [1,1′-Biphenyl]-4-acetic acid, 2-fluoro-5104-49-4 U.S. 3,793,457 Anti-inflammatory Alpha-methyl-[CAS]flurithromycin Erythromycin, 8-fluoro-mono(ethyl 82730-23-2 EP 56291Macrolide antibiotic Infection, butanedioate) (ester)-[CAS] respiratorytract, lower Flurogestone 2529-45-5 Flurothyl 333-36-8 Fluroxen 406-90-6Fluspirilene 1841-19-6 flutamide Propanamide, 2-methyl-N-[4-nitro-3-13311-84-7 U.S. 4,329,364 Anticancer, (trifluoromethyl)phenyl]-[CAS]hormonal flutazolam Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)- 27060-91-9U.S. 3,905,956 Anxiolytic one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)- [CAS] fluticasoneAndrosta-1,4-diene-17-carbothioic acid, 80474-14-2 Formulation, Asthma6,9-difluoro-11,17-dihydroxy-16-methyl-3- 90566-53-3 inhalable, solutionoxo-, S-(fluoromethyl) ester, (6Alpha,11β,16Alpha,17Alpha)-[CAS]flutoprazepam 2H-1,4-Benzodiazepin-2-one, 7-chloro-1- 25967-29-7 GB1253368 Anxiolytic Psychosis,(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3- general dihydro-[CAS]flutrimazole 1H-Imidazole, 1-[(2-fluorophenyl)(4- 119006-77-8 EP 352352Antifungal Infection, fluorophenyl)phenylmethyl]-[CAS] dermatologicalFlutropium Bromide 63516-07-4 fluvastatin 6-Heptenoic acid,7-[3-(4-fluorophenyl)-1- 93957-55-2 EP 114027 Hypolipaemic/Hypercholest- (1-methylethyl)-1H-indol-2-yl]-3,5- 93957-54-1Antiatherosclerosis erolaemia dihydroxy-, monosodium salt, [R*,S*-(E)]-(±)-[CAS] fluvoxamine 1-Pentanone, 5-methoxy-1-[4- 54739-18-3 GB 1535226Antidepressant Depression, (trifluoromethyl)phenyl]-O-(2- 61718-82-9general, aminoethyl)oxime, (E)-[CAS] Obsessive- compulsive disorderFolic Acid 59-30-3 Folinic Acid 58-05-9 Fomepizole 7554-65-6 fominobenBenzamide, N-[3-chloro-2-[[methyl[2-(4- 18053-31-1 U.S. 3,661,903Respiratory Eczema, morpholinyl)-2- 24600-36-0 stimulant generaloxoethyl]amino]methyl]phenyl]-[CAS] Fomivirsen 144245-52-3 Fomocaine17692-39-6 Fonazine 7456-24-8 fondaparinux Alpha-D-Glucopyranoside,methyl O-2- 104993-28-4 Anticoagulant Thrombosis,deoxy-6-O-sulfo-2-(sulfamino)-Alpha-D- 114870-03-0 venousglucopyranosyl-(1-4)-O-β-D- glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-diO-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-Alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2- (sulfoamino)-,6-(hydrogen sulfate)[CAS] Formebolone 2454117 formestane Androst-4-ene-3,17-dione,4-hydroxy- 566-48-3 EP 346953 Anticancer, Cancer, breast [CAS] hormonalFormocortal 2825-60-7 formoterol Formamide, N-[2-hydroxy-5-[1-hydroxy-2-43229-80-7 GB 1415256 Antiasthma Asthma [[2-(4-methoxyphenyl)-1-73573-87-2 methylethyl]amino]ethyl]phenyl]-, (R*,R*)- (+/−)-[CAS]fosamprenavir Carbamic acid, ((1S,2R)-3-(((4- 226700-81-8 Antiviral,anti-HIV Infection, aminophenyl)sulfonyl)(2- HIV/AIDSmethylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-C-((3S)-tetrahydro- 3-furanyl ester, [CAS]foscarnet Phosphinecarboxylic acid, dihydroxy-, 34156-56-4 U.S.4,839,445 Antiviral, other Infection, oxide, trisodium salt [CAS]4428-95-9 cytomegalo- virus 63585-09-1 Fosfestrol 522-40-7fosfluconazole 2,4-difluoro-Alpha,Alpha-bis(1H-1,2,4- 194798-83-9Antifungal Infection, triazol-1-ylmethyl)benzyl alcohol, fungal,dihydrogen phosphate (ester) general fosfomycin Phosphonic acid,(3-methyloxiranyl)-, (2R- 23155-02-4 GB 1223923 Antibiotic, otherInfection, cis)-[CAS] 26016-98-8 general fosfomycin Phosphonic acid,(3-methyloxiranyl)-, (2R- 78964-85-9 EP 27597 Antibiotic, otherInfection, trometamol cis)-, compd. with 2-amino-2- urinary tract(hydroxymethyl)-1,3-propanediol (1:1)- [CAS] Fosfosal 6064-83-1fosinopril L-Proline, 4-cyclohexyl-1-[[[2-methyl-1-(1- 88889-14-9 EP63896 Antihypertensive, Hypertension, oxopropoxy)propoxy](4- 98048-97-6renin system general phenylbutyl)phosphinyl]acetyl]-, (2Alpha,4β)-[CAS]fosphenytoin 2,4-Imidazolidinedione, 5,5-diphenyl-3- 92134-98-0 U.S.4,260,769 Antiepileptic Epilepsy, [(phosphonooxy)methyl]-[CAS]93390-81-9 generalized, tonic-clonic fotemustine Phosphonic acid,[1-[[[(2- 92118-27-9 EP 117959 Anticancer, Cancer,chloroethyl)nitrosoamino]carbonyl]amino]- alkylating melanoma ethyl]-,diethyl ester [CAS] Fropenem 106560-14-9 frovatriptan1H-Carbazole-6-carboxamide, 2,3,4,9- 158747-02-5 WO 9922730 AntimigraineMigraine tetrahydro-3-(methylamino)-, (R)-[CAS] Fructose 57-48-7Fructose-1,6- 488-69-7 diphosphate FTC 2(1H)-Pyrimidinone,4-amino-5-fluoro-1-(2- Antiviral, anti-HIV Infection,(hydroxymethyl)-1,3-oxathiolan-5-yl)-(4R) HIV/AIDS FTY-7201,3-Propanediol, 2-amino-2-(2-(4- 162359-56-0 WO 9408943Immunosuppressant Transplant octylphenyl)ethyl)-, hydrochloride [CAS]rejection, general fudosteine Alanine, 3-((3-hydroxypropyl)thio)-[CAS]13189-98-5 U.S. 5,047,428 Antitussive Cough fulvestrantEstra-1,3,5(10)-triene-3,17-diol, 7-[9- 129453-61-8 EP 346014Anticancer, Cancer, [(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-,hormonal breast (7Alpha,17β)-[CAS] fumagiline 2,4,6,8-Decatetraenedioicacid, mono[5- 23110-15-8 Protozoacide Infection,methoxy-4-[2-methyl-3-(3-methyl-2- GI tractbutenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester, [3R-[3Alpha,4Alpha(2R*,3R*),5β,6β(all-E)]]- [CAS] Fumagillin 23110-15-8Furaltadone 139-91-3 Furazabol 1239-29-8 Furazolidone 67-45-8 FurazoliumChloride 5118-17-2 Furonazide 3460-67-1 furosemide Benzoic acid,5-(aminosulfonyl)-4-chloro-2- 54-31-9 Formulation, Hypertension,[(2-furanylmethyl)amino]-[CAS] modified- general release, otherFursultiamine 804-30-8 Furtrethonium 7618-86-2 Fusidic Acid 06/03/6990G1, YM BioSciences 1-(5-bromofur-2-yl)-2-bromo-2-nitroethene AntifungalInfection, gynaecological G25 WO 9804252 Antimalarial Infection, malariaGABA-A Alpha5 WO 0206285 Cognition enhancer Alzheimer's inverseagonist,Mer disease gabapentin Cyclohexaneacetic acid, 1-(aminomethyl)-60142-96-3 U.S. 4,152,326 Antiepileptic Epilepsy, [CAS] general gabexateBenzoic acid, 4-[[6- 39492-01-8 U.S. 3,751,447 GI inflammatory/Pancreatitis [(aminoiminomethyl)amino]-1- 56974-61-9 bowel disordersoxohexyl]oxy]-, ethyl ester, monomethanesulfonate [CAS] gaboxadolIsoxazolo[5,4-c]pyridin-3(2H)-one, 4,5,6,7- 64603-91-4 CA 1125288Hypnotic/Sedative Sleep disorder, tetrahydro-[CAS] general Gadobenat127000-20-8 Dimeglumine Gadobutrol 138071-82-6 Gadodiamide 131410-48-5Gadopentetic Acid 80529-93-7 Gadoteridol 120066-54-8 Gadoversetamide131069-91-5 Gadoxetic Acid 135326-11-3 galantamine(4aS,6R,8aS)-6-Hydroxy-3-methoxy-11- Formulation, Alzheimer'smethyl-5,6,9,10,11,12-hexahydro-4aH- modified-release, diseasebenzofuro[3a,3,2-e,f][2]benzazepine other Galanthamine β-Alanine,2-[4-[(2,6-dideoxy-2-fluoro- 357-70-0 galarubicinAlpha-L-talopyranosyl)oxy]-1,2,3,4,6,11- 140637-82-7 EP 424899Anticancer, Cancer, breast hexahydro-2,5,12-trihydroxy-7-methoxy-140637-86-1 antibiotic 6,11-dioxo-2-naphthacenyl]-2-oxoethyl ester,[CAS] Gallamine Triethiodide 65-29-2 Gallic Acid 149-91-7 galliummaltolate 4H-Pyran-4-one, 3-hydroxy-2-methyl-, Anticancer, other Cancer,gallium complex myeloma gallium nitrate Nitric acid, gallium salt [CAS]13494-90-1 U.S. 4,529,593 Osteoporosis Hypercalcaemia treatment ofmalignancy gallopamil Benzeneacetonitrile, Alpha-[3-[[2-(3,4- 16662-47-8GB 1367677 Antianginal Angina, generaldimethoxyphenyl)ethyl]methylamino]propyl]-3,4,5-trimethoxy-Alpha-(1-methylethyl)- [CAS] γ-Aminobutyric Acid56-12-2 Ganaxolone 38398-32-2 ganciclovir 6H-Purin-6-one,2-amino-1,9-dihydro-9-[[2- 107910-75-8 EP 49072 Antiviral, otherInfection, hydroxy-1-(hydroxymethyl)ethoxy]methyl]- 82410-32-0cytomegalovirus [CAS] ganirelix [N-Ac-D-NaI,D-pCl-Phe,D-PaI,D-124904-93-4 EP 312052 Releasing hormones Infertility,hArg(Et)2,hArg(Et)2,D-Ala]GnRH-[CAS] female ganstigmine Carbamic acid,(2-ethylphenyl)-, (3aS,8aS) 223585-99-7 EP 1023297 Cognition enhancerAlzheimer's 1,2,3,3a,8,8a-hexahydro-1,3a,8- diseasetrimethylpyrrolo[2,3-b]indol-5-yl ester, gantofiban 1-Piperazineaceticacid, 4-[[(5R)-3-[4- 183547-57-1 EP 741133 Antithrombotic Thrombosis,[imino[(methoxycarbonyl)amino]methyl]- generalphenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethylester [CAS] garenoxacin3-Quinolinecarboxylic acid, 1-cyclopropyl-8 223652-82-2 QuinoloneInfection, (difluoromethoxy)-7-((1R)-2,3-dihydro-1- antibacterialrespiratory tract, methyl-1H-isoindol-5-yl)-1,4-dihydro-4-oxo- lowermonomethanesulfonate [CAS] garnocestim 5-73-macrophage inflammatoryprotein 246861-96-1 Radio/ Chemotherapy- 2Alpha (human gene gro2)-[CAS]chemoprotective induced injury, bone marrow, neutropenia gatifloxacin3-Quinolinecarboxylic acid, 1-cyclopropyl-6 112811-59-3 EP 230295Quinolone Infection, fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-antibacterial respiratory 1-piperazinyl)-4-oxo-, (+/−)-[CAS] tract,general Gefarnate 51-77-4 gefitinib 4-Quinazolinamine, N-(3-chloro-4-184475-35-2 WO 9633980 Anticancer, other Cancer, lung,fluorophenyl)-7-methoxy-6-(3-(4- non-small cell morpholinyl)propoxy)[CAS] gemcabene 6,6′-oxybis(2,2-dimethylhexanoate) 209789-08-2Hypolipaemic/ Hyperlipidaemia, Antiatherosclerosis general gemcitabineCytidine, 2′-deoxy-2′, 2′-difluoro-, [CAS] 122111-03-9 GB 2136425Anticancer, Cancer, 95058-81-4 antimetabolite pancreatic gemeprostProsta-2,13-dien-1-oic acid, 11,15- 64318-79-2 GB 1540427 Prostaglandindihydroxy-16,16-dimethyl-9-oxo-, methyl ester,(2E,11Alpha,13E,15R)-[CAS] gemfibrozil Pentanoic acid,5-(2,5-dimethylphenoxy)- 25812-30-0 U.S. 3,674,836 Hypolipaemic/ Hyper-2,2-dimethyl-[CAS] Antiatherosclerosis lipidaemia, general gemifloxacin1,8-Naphthyridine-3-carboxylic acid, 7-(3- 175463-14-6 U.S. 5,869,670Quinolone Infection, (aminomethyl)-4-(methoxyimino)-1- antibacterialrespiratory pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4- tract, generaldihydro-4-oxo-[CAS] gentamicin Gentamicin [CAS] 1403-66-3 Formulation,Infection, implant general Gentian Violet 548-62-9 Gentiopicrin20831-76-9 Gentisic Acid 490-79-9 Gepefrine 18840-47-6 gepirone2,6-Piperidinedione, 4,4-dimethyl-1-[4-[4- Formulation, Depression,(2-pyrimidinyl)-1-piperazinyl]butyl]-[CAS] modified-release, generalother gestodene 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 109852-02-0 GB1569135 Formulation, Contraceptive, 13-ethyl-17-hydroxy-,(17Alpha)-[CAS] 60282-87-3 fixed-dose female combinations gestodene +ethinylest 18,19-Dinopregna-4,15-dien-20-yn-3-one, Formulation,Contraceptive, 13-ethyl-17-hydroxy-, (17Alpha) mixt withmodified-release, female 19-Norpregna-1,3,5(10)-trien-20-yne- >24 hr13,17-diol (17Alpha) Gestonorone Caproate 1253-28-7 Gestrinone16320-04-0 γ-Hydroxybutyrate 591-81-1 gimatecan (4S)-11-[(E)-[(1,1-292618-32-7 Anticancer, other Cancer, braindimethylethoxy)imino]methyl]-4-ethyl-4- hydroxy-1-12-dihydro-14H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline- 3,14(4H)-dione Giractide24870-04-0 Gitoxin 4562-36-1 GL-406349N,N′-Bis[2-[N-[2-(N2,N5-dimethyl-DL- Antifungal Infection,lysylamino)-ethyl]carbamoyl]1H-indol-6-yl]- fungal,1H-indole-2,5-dicarboxamide general Glafenine 3820-67-5 glatiramerL-Glutamic acid, polymer with L-alanine, L- 147245-92-9 WO 5800808Multiple sclerosis Multiple lysine and L-tyrosine, [CAS] 28704-27-0treatment sclerosis, relapsing- remitting Glibornuride 26944-48-9gliclazide Benzenesulfonamide, N- 21187-98-4 GB 1153982 AntidiabeticDiabetes, [[(hexahydrocyclopenta[c]pyrrol-2(1H)- Type IIyl)amino]carbonyl]-4-methyl-[CAS] glimepiride 1H-Pyrrole-1-carboxamide,3-ethyl-2,5- 93479-97-1 WO 9303724 Antidiabetic Diabetes,dihydro-4-methyl-N-[2-[4-[[[[(4- Type IImethylcyclohexyl)amino]carbonyl]amino]-sulfonyl]phenyl]ethyl]-2-oxo-[CAS] γ-Linolenic Acid 506-26-3 glipizidePyrazinecarboxamide, N-[2-[4- 29094-61-9 U.S. 3,669,966 Antidiabetic[[[(cyclohexylamino)carbonyl]amino]sulfonyl]-phenyl]ethyl]-5-methyl-[CAS] gliquidone Benzenesulfonamide, N-33342-05-1 GB 1277847 Antidiabetic Diabetes,[(cyclohexylamino)carbonyl]-4-[2-(3,4- generaldihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-]2(1H)-isoquinolinyl)ethyl]-[CAS] glisolamide 3-Isoxazolecarboxamide,N-[2-[4- 24477-37-0 Antidiabetic Diabetes,[[[(cyclohexylamino)carbonyl]amino]- generalsulfonyl]phenyl]ethyl]-5-methyl-[CAS] Glisoxepid 25046-79-1 Glucametacin52443-21-7 Glucoheptonic Acid 87-74-1 Gluconic Acid 526-95-4 glucosamineD-Glucose, 2-amino-2-deoxy-, [CAS] 29031-19-4 DE 1953689 Antiarthritic,other Arthritis, 3416-24-8 osteo Glucosulfone 554-18-7 glufosfamideβ-D-Glucopyranose, 1-(N,N′-bis(2- 132682-98-5 DE 3835772 Anticancer,Cancer, chloroethyl)pheophorodiamidate)-[CAS] alkylating generalGlutamic Acid 56-86-0 Glutaraldehyde 111-30-8 Glutethimide 77-21-4Glyburide 10238-21-8 Glybuthiazol(e) 535-65-9 Glybuzole 1492-02-0Glycerol 56-81-5 Glycocyamine 352-97-6 Glycol Salicylate 87-28-5Glyconiazide 3691-74-5 Glycopyrrolate 596-51-0 Glyhexamide 451-71-8Glymidine 339-44-6 Glypinamide 1228-19-9 GMDPN-acetylglucosaminyl-N-acetylmuramyl Anti-infective, other Infection,dipeptide general Gold Sodium 12244-57-4 Thiemalat Gold Sodium10233-88-2 Thiosulfate goserelin Luteinizing hormone-releasing factor(pig), 65807-02-5 U.S. 4,100,274 Releasing Cancer,6-[O-(1,1-dimethylethyl)-D-serine]-10- hormones prostate deglycinamide-,2- (aminocarbonyl)hydrazide [CAS] GPI-1485 L-Proline,1-(3,3-dimethyl-1,2-dioxopentyl)-, 186452-09-5 AntiparkinsonianParkinson's 3-(3-pyridinyl)propyl ester [CAS] disease GPI-56932-(Phosphonomethyl)pentanedioic acid U.S. 5,672,592 Analgesic, otherPain, neuropathic Graftskin granisetron 1H-Indazole-3-carboxamide,1-methyl-N- 107007-99-8 EP 200444 Antiemetic Chemotherapy-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, 109889-09-0 induced nauseaendo-[CAS] and vomiting Grepafloxacin 119914-60-2 griseofulvinSpiro[benzofuran-2(3H),1′-[2]cyclohexane]- 126-07-8 Formulation, dermal,Infection, 3,4′-dione, 7-chloro-2′,4,6-trimeth-oxy- topicaldermatological 6′methyl-, (1′S-trans)-[CAS] Guaiacol 90-05-1 Guaiapate852-42-6 Guaiazulene 489-84-9 Guaifenesin 93-14-1 guaimesal4H-1,3-Benzodioxin-4-one, 2-(2- 81674-79-5 GB 2098201 Anti-inflammatorymethoxyphenoxy)-2-methyl-[CAS] Guamecycline 16545-11-2 Guanabenz5051-62-7 Guanadrel 40580-59-4 Guanethidine 55-65-2 Guanfacine29110-47-2 Guanoxabenz 24047-25-4 Guanoxan 2165-19-7 gugulipidPregna-4,17(20)-diene-3,16-dione [CAS] 95975-55-6 EP 447706Hypolipaemic/ Antiatherosclerosis Gusperimus 104317-84-2 GW-280430A(Z)-2-Chlorofumaric acid 1-[3-[-[6,7- Muscle relaxant Anaesthesia,dimethoxy-2(S)-methyl-1(R)-(3,4,5- adjunct trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinium-2-yl]propyl] GW-320659[2S,3S,5R]-2-[3,5-difluorophenyl]-3,5- Anorectic/ Obesitydimethyl-2-morpholinol Antiobesity GYKI-16084 (+)-R-2-[3-[N-(2- U.S.6,194,411 Prostate disorders Benign Benzo[1,4]dioxanylmethyl)amino]-1-prostatic propyl)-3(2H)-pyridazinone hydrochloride hyperplasiaHachimycin 1394-02-1 Halazepam 23092-17-3 Halcinonide 3093-35-4halobetasol Pregna-1,4-diene-3,20-dioe, 21-chloro- 66852-54-8 U.S.4,619,921 Antipsoriasis Psoriasis6,9-difluoro-11-hydroxy-16-methyl-17-(1- oxopropoxy)-,(6Alpha,11β,16(-[CAS] halofantrine 9-Phenanthrenemethanol, 1,3-dichloro-36167-63-2 EP 138374 Antimalrial Infection,Alpha-[2-(dibutylamino)ethyl]-6- 69756-53-2 malaria(trifluoromethyl)-[CAS] halometasone Pregna-1,4-diene-3,20-dione,2-chloro-6,9- 50629-82-8 U.S. 4,076,737 Antipruritic/difluoro-11,17,21-trihydroxy-16-methyl-, inflamm, allergic(6Alpha,11β,16Alpha)-[CAS] Haloperidol 52-86-8 Halopredone 57781-14-3Haloprogin 777-11-7 Halopropane 679-84-5 Halothane 151-67-7 Haloxazolam59128-97-1 harkoseride 2(R)-Acetamido-N-benzyl-3- WO 9733861Antiepileptic Epilepsy, methoxypropionamide general HE-200016Alpha-Bromo-3β-hydroxy-5Alpha- Antiviral, anti-HIV Infection,androstane-17-one HIV/AIDS Healos WO 9714376 MusculoskeletalRegeneration, bone Hematoporphyrin 14459-29-1 Hepronicate 7237-81-2Heptabarbital 509-86-4 Heptaminol 372-66-7 Hetacillin 3511-16-8Hetastarch 9004-62-0 Hexachlorophene 70-30-4 Hexadimethrine 28728-55-4Bromide Hexafluorenium 317-52-2 Bromide Hexamethonium 60-26-4 Hexamidine3811-75-4 Hexapropymate 358-52-1 Hexedine 5980-31-4 Hexestrol 84-16-2Hexestrol Bis(β- 2691-45-4 diethylaminoethyl ether) Hexethal 144-00-3Hexetidine 141-94-6 Hexobarbital 56-29-1 Hexobendine 54-03-5 HexocycliumMethyl 115-63-9 Sulfate Hexoprenaline 3215-70-1 Hextend Hextend [CAS]235746-51-7 U.S. 5,407,428 Plasma substitute Surgery adjunct Hexylcaine532-76-3 HF-0299 11b-hydroxy androstenedione Osteoporosis Osteoporosistreatment HGP-2 Benzeneacetic acid, 4-[2-hydroxy-3-[(1- 121009-31-2Antiglaucoma Glaucoma methylethyl)amino]propoxy]-, 2-tricyclo[3.3.1.13,7]dec-1-ylethyl ester, (2Z)- 2-butenedioate (1:1)(salt) [CAS] HGP-6^(A) 8-Azoniabicyclo[3.2.1]octabe, 3-(3-ethoxy-113932-41-5 Antiepileptic Epilepsy,1,3-dioxo-2-phenylpropoxy)-8,8-dimethyl-, general (3-endo)-, methylsulfate [CAS] hidrosmin Hydrosmin-[CAS] 120250-44-4 Vasoprotective,systemic histamine histamine 51-45-6 EP 0493468 Anticancer, Cancer,immunological melanoma Histapyrrodine 493-80-1 histrelin Luteinizinghormone-releasing factor (pig), 76712-82-8 EP 217659 Releasing hormonesPrecocious 6-[1-(phenylmethyl)-D-histidine]-9-(N-ethyl- pubertyL-prolinamide)-10-deglycinamide-[CAS] HM-101 HM 101 [CAS] 217311-70-1Osteoporosis Osteoporosis treatment HMN-214 (E)-4-[2-[2-(p- Anticancer,other Cancer, methoxybenzenesulfonamide)- generalphenyl]ethenyl]pyridine-1-oxide Homatropine 87-00-3 Homocamfin 535-86-4Homochlorcyclizine 848-53-3 Hopantenic Acid 18679-90-8 HP-228Glycinamide, N-acetyl-L-norleucyl-L- 172617-89-9 EP 759770 Analgesic,other Pain, post- glutaminyl-L-histidyl-D-phenylalanyl-L- operativearginyl-D-tryptophyl-[CAS] Huperzine A 102518-79-6 hyaluronan Hyaluronicacid [CAS] 9004-61-9 Formulation, other Restenosis Hycanthone 3105-97-3Hydnocarpic Acid 459-67-6 Hydralazine 86-54-4 Hydrastine 118-08-1Hydrastinine 6592-85-4 Hydrochlorothiazide 58-93-5 hydrocodoneMorphinan-6-one, 4,5-epoxy-3-hydroxy-17- 466-99-9 Formulation, Pain,general methyl-,(5Alpha)-[CAS] 125-29-1 modified- release, otherHydrocortamate 76-47-1 hydrocortisone Pregn-4-ene-3,20-dione,21-(acetyloxy)-11- 74050-20-7 DE 2826257 Dermatological Unspecifiedhydroxy-17-(1-oxopropoxy)-, (11β)-[CAS] 50-23-7 hydrocortisonePregn-4-ene-3,20-dione, 11-hydroxy-17-(1- 72590-77-3 DE 2910899Antipruritic/inflamm, butyrate propio oxobutoxy)-21-(1-oxopropoxy)-,(11β)- allergic [CAS] Hydroflumethiazide 135-09-1 hydromorphoneMorphinan-6-one,4,5-epoxy-3-hydroxy-17- 103-90-2 Formulation, Pain,general methyl-,(5Alpha)-, mixt with acetamide, N- 16590-41-3 fixed-dose(4-hydroxyphenyl)-, mixt with morphinan-6- 466-99-9 combinations one,17-(cyclopropylmethyl)-4,5-epoxy- 3,14-dihydroxy-, (5Alpha)-Hydroquinidine 1435-55-8 Hydroquinine 522-66-7 Hydroquinone 123-31-9Hydroxocobalamin 13422-51-0 Hydroxyamphetamine 1518-86-1Hydroxychloroquine 118-42-3 Hydroxydione 53-10-1 Hydroxypethidine468-56-4 Hydroxyphenamate 50-19-1 Hydroxypropyl 9004-64-2 CelluloseHydroxystilbamidine 495-99-8 Hydroxytetracaine 490-98-2 Hydroxyzine68-88-2 Hylan G-F 20 Hymecromone 90-33-5 hyoscyamine benzeneacetic acid,Alpha(hydroxymethyl)-, 101-31-5 Formulation, oral, Ulcer, GI,8-methyl-8-azabicyclo [3.2.1.]oct-3-yl orally-disintegrating generalester, [3(S)-endo], hypericin Phenanthro[1,10,9,8-opqra]perylene-7,14-548-04-9 Anticancer, other Cancer, brain dione,1,3,4,6,8,13-hexahydroxy-10,11- dimethyl-[CAS] IACFT 180468-34-2ibandronic acid Phosphonic acid, [1-hydroxy-3- 114084-78-5 EP 252504Osteoporosis Hypercalcaemia (methylpentylamino)propylidene]bis-treatment of malignancy [CAS] ibopamine Propanoic acid, 2-methyl-, 4-[2-66195-31-1 GB 1551661 Cardiostimulant Heart failure(methylamino)ethyl]-1,2-phenylene ester- [CAS] ibopamine Propanoic acid,2-methyl-, 4-[2- 66195-31-1 Formulation, Surgery adjunct(methylamino)ethyl]-1,2-phenylene ester- mucosal, topical [CAS]Ibritumomab 206181-63-7 Tiuxetan ibrolipim Phosphonic acid,[[4-[[(4-bromo-2- 133208-93-2 EP 402033 Hypolipaemic/ Hypertri-cyanophenyl)amino]carbonyl]phenyl]- Antiatherosclerosis glyceridaemiamethyl]-, diethyl ester [CAS] ibudilast 1-Propanone, 2-methyl-1-[2-(1-50847-11-5 EP 215438 Antiasthma Asthmamethylethyl)pyrazolo[1,5-a]pyridin-3-yl]- [CAS] Ibufenac 1553-60-2ibuprofen piconol Benzeneacetic acid, Alpha-methyl-4-(2- 64622-45-3 DE2658610 Antipruritic/inflamm, Eczema, methylpropyl)-, 2-pyridinylmethylester non-allergic contact [CAS] ibuprofen Benzeneacetic acid,Alpha-methyl-4-(2- 15687-27-1 Formulation, Inflammation,methylpropyl)-[CAS] modified- general release, other Ibuproxam53648-05-8 ibutilide Methanesulfonamide, N-[4-[4- 122647-31-8 JP60239458 Antiarrhythmic Fibrilation,(ethylheptylamino)-1-hydroxybutyl]phenyl]-, 122647-32-9 atrial (+/−)-,[CAS] ICA-17043 U.S. 6,288,122 Antisickling Anaemia, sickle cellicodextrin Dextrin-[CAS] 9004-53-9 Urological Renal failure idarubicin5,12-Naphthacenedione, 9-acetyl-7-[(3- 58957-92-9 U.S. 4,471,052Anticancer, Cancer, amino-2,3,6-trideoxy-Alpha-L-lyxo- 86189-66-4antibiotic leukaemia, hexopyranosyl)oxy]-7,8,9,10-tetrahydro- acute6,9,11-trihydroxy-, (7S-cis)-[CAS] lymphocytic Idazoxan 79944-58-4IdB-1016 2-(2,3-dihydro-2-(4-hydroxy-3- 134499-06-2 EP 209038Anticancer, Cancer, methoxyphenyl)-3-(hydroxymethyl)-1,4- hormonalovarian benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one phosphatidylcholine complex idebenone2,5-Cyclohexadiene-1,4-dione, 2-(10- 58186-27-9 EP 58057 NeuroprotectiveIschaemia, hydroxydecyl)-5,6-dimethoxy-3-methyl- cerebral [CAS] IDN-51094-Hexenoic acid, 3-[[(1,1- 186348-05-0 U.S. 5,264,591 Anticancer, otherCancer, dimethylethoxy)carbonyl]amino]-2-hydroxy- colorectal 5-methyl-,(3aS,4R,7R,8aS,9S,10aR,12aS,12bR,13S, 13aS)-7,12a-bis(acetyloxy)-13-(benzoyloxy)- 3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-9-hydroxy-5,8a,14,14- tetramethyl-2,8-dioxo-6,13a-methano-13aH-oxeto [2″,3″,5′,6′] benzo[1,2:4,5] cyclodeca [1,2-d] dioxyl-4-ylester, 2R,3S) [CAS] Idoxifen 116057-75-1 idraparinuxAlpha-D-Glucopyranoside, methyl O-2,3,4- 149920-56-9 AU 698456Antithrombotic Thrombosis, tri-O-methyl-6-O-sulfo-Alpha-D- venousglucopyranosyl-(1,4)-O-2,3-di-O-methyl-β-D-glucopyranuronosyl-(1,4)-O-2,3,6-tri-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-Alpha-L-idopyranuronosyl- (1-4)-, tris(hydrogen sulfate)nonasodium salt [CAS] idrocilamide 2-Propenamide, N-(2-hydroxyethyl)-3-6961-46-2 U.S. 3,659,014 Anti-inflammatory, phenyl-[CAS] topicalifenprodil (7)-2-(4-benzyl piperidino)-1-p- 23210-58-4hydroxyphenylpropanol tartrate 23210-56-2 U.S. 3,509,164 Neuroprotectiveifosfamide 2H-1,3,2-Oxazaphosphorin-2-amine, N,3- 3778-73-2 U.S.3,732,340 Anticancer, Cancer, lung,bis(2-chloroethyl)tetrahydro-,2-oxide [CAS] alkylating generaliguratimod N-[3-(Formylamino)-4-oxo-6-phenoxy-4H- 123663-49-0 DE 3834204Antiarthritic, Arthritis, chromen-7-yl] methanesulfonamide otherrheumatoid ilaprazole 1H-Benzimidazole, 2-(((4-methoxy-3- 172152-36-2U.S. 5,703,097 Antiulcer Ulcer, GI, methyl-2-pyridinyl)methyl)sulfinyl)-5-(1H- general pyrrol-1-yl)-[CAS] ilomastatButanediamide, N4-hydroxy-N1-(1-(1H- 142880-36-2 U.S. 5,892,112 COPDtreatment Emphysema, indol-3-ylmethyl)-2-(methylamino)-2- smoking-oxoethyl)-2-(2-methylpropyl)-, (S-(R*,S*))- related [CAS] iloperidoneEthanone, 1-[4-[3-[4-(6-fluoro-1,2- 133454-47-4 U.S. 5,776,963Neuroleptic Schizophrenia benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-[CAS] iloprost trometamol Pentanoic acid,5-[hexahydro-5-hydroxy-4- 78919-13-8 DE 3417638 Prostaglandin Peripheral(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)- vascularpentalenylidene]-[CAS] disease ILX23-7553 1Alpha,25-Hydroxy-16-ynevitamin D3 Anticancer, other Cancer, general imatinib4-((Methyl-1-piperazinyl)methyl)-N-[4- 152459-95-5 U.S. 5,521,184Anticancer, other Cancer, methyl-3-[[4-(3-pyridinyl)-2- leukaemia,pyrimidinyl]amino]-phenyl]benzamide chronic methanesulfonate myelogenousimidapril 4-Imidazolidinecarboxylic acid, 3-[2-[[(1- 89371-37-9 EP 95163Antihypertensive, Hypertension,(ethoxycarbonyl)-3-phenylpropyl]amino]-1- 89396-94-1 renin system,general, oxopropyl]-1-methyl-2-oxo-, [4S- Musculoskeletal Cachexia[3[R*(R*)],4R*]]-[CAS] imidazole salicylate Benzoic acid, 2-hydroxy-,compd. with 1H- 36364-49-5 U.S. 4,329,340 Anti-inflammatory Pain,general imidazole (1:1) [CAS] imipenem1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic 64221-86-9 GB 1570990Beta-lactam Infection, acid, 6-(1-hydroxyethyl)-3-[[2- 74431-23-5antibiotic general [(iminomethyl)amino]ethyl]thio]-7-oxo-, [5R-81129-83-1 [5Alpha,6Alpha(R*)]]-[CAS] Imipramine 50-49-7 ImipramineN-Oxide 6929-98-7 imiquimod 1H-Imidazol[4,5-c]quinolin-4-amine, 1-(2-99011-02-6 EP 145340 Antiviral, other Infection, methylpropyl)-[CAS]human papilloma virus Imolamine 318-23-0 implitapide Benzeneacetamide,Alpha-cyclopentyl-4- 177469-96-4 EP 705831 Hypolipaemic/ Athero-((2,4-dimethyl-9H-pyrido(2,3-b)indol-9- Antiatherosclerosis sclerosisyl)methyl)-N-((1R)-2-hydroxy-1- phenylethyl)-(AlphaS)-[CAS] Improsulfan13425-98-4 Inaperisone 99323-21-4 incadronate Phosphonic acid,138330-18-4 Musculoskeletal Hypercalcaemia[(cycloheptylamino)methylene]bis-, [CAS] of malignancy Incadronic Acid124351-85-5 Indalpine 63758-79-2 Indanazoline 40507-78-6 indapamide4-chloro-N-(2-methylindolin-1-yl)-3- 26807-65-8 GB 1203691Antihypertensive, Hypertension, sulfamoylbenzamide diuretic generalIndecainid 74517-78-5 indeloxazine Morpholine,2-[(1H-inden-7-yloxy)methyl]- 60929-23-9 JP 52083773 Cognition enhancerAlzheimer's [CAS] 65043-22-3 disease Indeloxazine 65043-22-3 indenolol2-Propanol, 1-[1H-inden-4(or 7)-yloxy]-3- 30190-87-5 GB 1290343Antihypertensive, [(1-methylethyl)amino]-[CAS] 60607-68-3 adrenergic68906-88-7 indinavir D-erthro-Pentonamide, 2,3,5-trideoxy-N- 150378-17-9EP 0541168 Antiviral, anti-HIV Infection,(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2- 157810-81-6 HIV/AIDS(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2- (phenylmethyl),[1S-[1Alpha(R*),2Alpha]]-, [CAS] indiplon Acetamide,N-methyl-N-(3-(3-(2- 325715-02-4 U.S. 6,399,621 Hypnotic/SedativeInsomnia thienylcarbonyl)pyrazolo(1,5-a) pyrimidin-7- yl)phenyl)-[CAS]indisetron 1H-Indazole-3-carboxamide, N-(3,9- 160472-97-9 AntiemeticNausea and dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, vomiting,diendo-[CAS] general indisulam 1,4-Benzenedisulfonamide, N-(3-chloro-165668-41-7 AAnticancer, other Cancer, lung, 1H-indol-7-yl)-[CAS]non-small cell Indobufen 63610-08-2 Indocyanine Green 3599-32-4indometacin 1H-Indole-3-acetic acid, 1-(4- 53-86-1 Formulation,Inflammation, chlorobenzoyl)-5-methoxy-2-methyl-[CAS] modified- generalrelease, other Indoprofen 31842-01-0 indoramin Benzamide,N-[1-[2-(1H-indol-3-yl)ethyl]-4- 26844-12-2 GB 1218570 Antihypertensive,piperidinyl]-[CAS] 38821-52-2 adrenergic Induclem U.S. 5,993,810 Labourinducer Labour, induction Infliximab 170277-31-3 Inosine Pranobex36703-88-5 Inositol 87-89-8 Inositol Niacinate 6556112 Iobenguane80663-95-2 Iobenzamic Acid 3115057 Iobitridol 136949-58-1 Iocarmic Acid10397-75-8 Iocetamic Acid 16034-77-8 Iodamide 440-58-4 iodine Iodine[CAS] 7553-56-2 Formulation, oral, Fibrocystic other breast disorderIodipamide 606-17-7 Iodixanol 92339-11-2 Iodoalphionic Acid 577-91-3iodochlorhydroxyquin 5-Chloro-7-iodo-8-quinolinol 130-26-7 Cognitionenhancer Alzheimer's disease Iodoform 75-47-8 Iodopyracet 300-37-8Iodopyrrole 87-58-1 Iodoquinol 83-73-8 Iofetamine ₁₂₃I 75917-92-9Ioglycamic Acid 2618-25-9 Iohexol 66108-95-0 Iomeglamic Acid 25827-76-3Iomeprol 78649-41-9 Iopamidol 60166-93-0 Iopanoic Acid 96-83-3 Iopentol89797-00-2 Iophendylate 99-79-6 Iophenoxic Acid 96-84-4 Iopromide73334-07-3 Iopronic Acid 41473-08-9 Iopydol 5579-92-0 Iopydone 5579-93-1Iothalamic Acid 2276-90-6 Iotrolan 79770-24-4 Ioversol 87771-40-2Ioxaglic Acid 59017-64-0 Ioxilan 107793-72-6 IP-751(3R,4R)-(delta6)-THC-DMH-11-oic acid WO 9401429 Analgesic, other Pain,neuropathic Ipidacrine 62732-44-9 IPL-576092 Stigmastan-15-one,22,29-epoxy- 137571-30-3 U.S. 6,046,185 Antiasthma Asthma3,4,6,7,29-pentahydroxy-, (3Alpha,4β,5Alpha,6Alpha,7β,14β,22S)- [CAS]Ipodate 5587-89-3 ipratropium bromide 66985-17-9 Formulation, Chronic22254-24-6 inhalable, solution obstructive pulmonary disease ipratpopium(endo,syn)-(±)-3-(3-Hydroxy-1-oxo-2- Formulation, Asthmaphenylpropoxy)-8-methyl-8-(1-methylethyl)- inhalable, topical8-azoniabicyclo[3.2.1]octane ipratropium(endo,syn)-(±)-3-(3-Hydroxy-1-oxo-2- Formulation, Asthmaphenylpropoxy)-8-methyl-8-(1-methylethyl)- inhalable, topical8-azoniabicyclo[3.2.1]octane iprazochrome Hydrazinecarboxamide,2-[1,2,3,6- 7248-21-7 Haemostatictetrahydro-3-hydroxy-1-(1-methylethyl)-6- oxo-5H-indol-5-ylidene]-[CAS]ipriflavone 4H-1-Benzopyran-4-one, 7-(1- 35212-22-7 EP 214647Osteoporosis Osteoporosis methylethoxy)-3-phenyl-[CAS] treatmentIprindole 5560-72-5 Iproclozid 3544-35-2 Iponiazid 54-92-2 Ipsapiron95847-70-4 irbesartan 2-n-butyl-4-spirocyclopentane-1-[((2'- 138402-11-6WO 9114679 Antihypertensive, Hypertension,tetrazol-5-yl)biphenyl-4-yl)methyl]-2- renin system generalimidazolin-5-one IRFI-042 Butanedioic acid, mono[2-[2- 134867-62-2 U.S.5,114,966 Cardiovascular Atherosclerosis(acetylthio)ethyl]-2,3-dihydro-4,6,7- trimethyl-5-benzofuranyl] ester,(+/−)- [CAS] IRFI-165 N-Cyclopentyl-1-methylimidazo[1,2- 191349-26-5 EP865442 Antidepressant Depression, a]quinoxalin-4-amine generalIridomyrmecin 485-43-8 irindalone -Imidazolidinone, 1-[2-[4-[3-(4-104113-57-7 EP 183349 Antidepressant Depression,fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1- 96478-43-2 generalpiperazinyl]ethyl]-, (1R-trans)-[CAS] Irinotecan 97682-44-5 irofulvenSpiro[cyclopropane-1,5′-[5H]inden]-7′(6′H)- 125392-76-9 U.S. 5,563,176Anticancer, other Cancer, one, 6′-hydroxy-2′,4′,6′-trimethyl-, (R)-prostate [CAS] Iron Sorbitex 1338-16-5 irsogladine1,3,5-Triazine-2,4-diamine, 6-(2,5- 57381-26-7 U.S. 4,657,907Antihypertensive, Hypertension, dichlorophenyl)-[CAS] 57381-28-9diuretic general 57381-33-6 IS-741 Cyclohexanecarboxamide, N-[2-141283-87-6 EP 465913 GI inflammatory/ Pancreatitis[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3- bowel disorderspyridinyl)-[CAS] isaglitazone 2,4-Thiazolidinedione, 5-[[6-[(2-161600-01-7 U.S. 5,594,016 Antidiabetic Diabetes,fluorophenyl)methoxy]-2- Type II naphthalenyl]methyl]-[CAS] ISAtx-247 NZ502362 Immunosuppressant Transplant rejection, general Isbogrel89667-40-3 isepamicin D-Streptamine, O-6-amino-6-deoxy-Alpha- 58152-01-5U.S. 4,029,882 Aminoglycoside Infection,D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C- 58152-03-7 antibioticdermatological methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2- hydroxy-1-oxopropyl)-2-deoxy-,(S)-[CAS] Isoaminile 77-51-0 Isobutyl p- 94-14-4 AminobenzoateAsocarboxazid 59-63-2 isoconazole 1-[2-[2-6-dichlorobenzyloxy)-2-(2-,4-24168-96-5 GB 1244530 Antifungal Infection, dichlorophenyl)ethyl]27523-40-6 fungal, general Isoetharine 530-08-5 isofloxythepin1-Piperazineethanol, 4-[3-fluoro-10,11- 106819-39-0 GB 2010843Neuroleptic dihydro-8-(1- 106819-41-4methylethyl)dibenzo[b,f]thiepin-10-yl]- 70931-18-9 [CAS] isofluraneEthane, 2-chloro-2-(difluoromethoxy)-1,1,1- 26675-46-7 U.S. 3,535,388Anaesthetic, Anaesthesia trifluoro-[CAS] inhalation Isoflurophate55-91-4 Isoladol 530-34-7 Isomethadone 466-40-0 Isometheptene 503-01-5Isoniazid 54-85-3 Isonixin 57021-61-1 Isopromethazine 303-14-0Isopropamide Iodide 71-81-8 Isopropyl Alcohol 67-63-0 isopropylunoprostone 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3- 120373-24-2 EP289349 Prostaglandin Glaucoma oxodecyl)cyclopentyl)-,1-methylethylester, (1R-(1Alpha(Z), 2β,3Alpha,5Alpha))- [CAS]Isoproterenol 7683-59-2 Isosorbide 652-67-5 isosorbide dinitrateD-Glucitol, 1,4:3,6-dianhydro-, dinitrate 87-33-2 Formulation, Angina,[CAS] modified- general release, other isosorbide mononitrateD-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate 16051-77-7 Formulation,Angina, [CAS] modified- general release, other Isothipendyl 482-15-5isotretinoin Retinoic acid, 13-cis-[CAS] 4759-48-2 U.S. 4,843,096Antiacne Acne Isovaleryl 533-32-4 Diethylamide Isoxepac 55453-87-7Isoxicam 34552-84-6 Isoxsuprine 395-28-8 isradipine3,5-Pyridinedicarboxylic acid, 4-(4- 75695-93-1 GB 2037766Antihypertensive, Hypertension,benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, other general methyl1-methylethyl ester [CAS] israpafant6H-Thieno[3,2-f][1,2,4]triazolo[4,3- 117279-73-9 EP 268242 AntiasthmaAsthma a][1,4]diazepine, 4-(2-chlorophenyl)-6,9- dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-[CAS] ISV-403 U.S. 5,447,926 Formulation,Conjunctivitis mucosal, topical Itasetron 123258-84-4 ITF-282 ITF 282[CAS] 93615-44-2 GB 2115821 Antianaemic Anaemia, general itoprideBenzamide, N-[[4-[2- 122892-31-3 EP 306827 Gastroprokinetic Gastritis(dimethylamino)ethoxy]phenyl]methyl]-3,4- dimethoxy-, monohydrochloride[CAS] itraconazole 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-84625-61-8 EP 6711 Antifungal Infection,dichlorophenyl)-2-(1H-1,2,4-triazol-1- fungal, ylmethyl)-1,3-dioxolan-4-general yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-[CAS] Itramin 13445-63-1 itriglumide1-Naphthalenepropanoic acid, β-[2-[[2-(8- 201605-51-8 WO 9800404Anxiolytic Anxiety, azaspiro[4.5]dec-8-ylcarbonyl)-4,6- generaldimethylphenyl]amino]-2-oxoethyl]-, (βR)- [CAS] iturelix D-AlaninamideN-acetyl-3-(2-naphthalenyl) 112568-12-4 WO 8901944 Fertility enhancerInfertility, D-alanyl-4-chloro-D-phenylalanyl-3-(3- femalepyridinyl)-D-alanyl-L-seryl-N6-(3- pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-[CAS] ivabradine7,8-dimethoxy-3-(3-[[(1S)(4,5- Antianginal Angina,dimethoxybenzocyclobutan-1- generalyl)methyl]methylamino]propyl)-1,3,4,5- tetrahydro-2H-benzazepin-2-oneixabepilone 17-Oxa-4-azabicyclo(14.1.0)heptadecane- 219989-84-1Anticancer, other Cancer, 5,9-dione, 7,11-dihydroxy-8,8,10,12,16- breastpentamethyl-3-(1-methyl-2-(2-methyl-4- thiazolyl)ethenyl,(1R,3S,7S,10R,11S,12S,16R) [CAS] J-1041325H-Cyclopenta[b]pyridine-6-carboxylic 198279-45-7 WO 9737665Antihypertensive, Heart failure acid,5-(1,3-benzodioxol-5-yl)-2-butyl-7- other[2[(2S)-2-carboxypropyl]-4-methoxyphenyl]- 6,7-dihydro-,(5S,6R,7R)-[CAS] J-107088 5H-Indole(2,3-a)pyrrolo(3,4-c)carbazole-174402-32-5 Anticancer, other Cancer, 5,7(6H)-dione,12-β-D-glucopyranosyl- bladder 12,13-dihydro-2,10-dihydroxy-6-((2-hydroxy-1-(hydroxymethyl)ethyl)amino- [CAS] J-1133971-[(3R,4R)-1-Cyclooctylmethyl-3- Analgesic, other Pain, generalhydroxymethyl-4-piperidyl]-3-ethyl-1,3- dihydro-2H-benzimidazole-2-oneJanex-1 Phenol, 4-[(6,7-dimethoxy-4- 202475-60-3 Anticancer, otherCancer, quinazolinyl)amino]-[CAS] leukaemia, general josamycinLeucomycin V, 3-acetate 4B-(3- 16846-24-5 JP 41021759 Macrolideantibiotic Infection, methylbutanoate) [CAS] general JTV-5191,4-Benzothiazepine, 2,3,4,5-tetrahydro-7- 145903-06-6 WO 9212148Cardiovascular Infarction, methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-myocardial piperidinyl]propyl]-[CAS] K-777 U.S. 6,287,840 ProtozoacideInfection, trypano- somiasis, American Kainic Acid 487-79-6 KalimateKalimate-[CAS] 92354-70-6 Urological Kallidin 342-10-9 KB-130015 Aceticacid (2,6-diodo-4-((2-methyl-3- 147030-48-6 Antiarrhythmic Arrhythmia,benzofuranyl)methyl)phenoxy)-[CAS] general KCB-328 Methanesulfonamide,N-[3-amino-4-[2-[[2- 177596-55-3 WO 9604231 Antiarrhythmic Arrhythmia,(3,4- general dimethoxyphenyl)ethyl]methylamino]ethoxy]- phenyl]-,monohydrochloride [CAS] Kebuzone 853-34-9 ketamine2-(2-Chlorophenyl)-2-(methylamino)- 6740-88-1 Formulation, Pain, post-cyclohexanone hydrochloride transmucosal, nasal operative ketanserin2,4(1H,3H)-Quinazolinedione, 3-[2-[4-(4- 74050-98-9 EP 13612Antihypertensive, Hypertension,fluorobenzoyl)-1-piperidinyl]ethyl]-[CAS] 83846-83-7 other generalketazolam 4H-[1,3]Oxazino[3,2- 27223-35-4 GB 1222294 Anxiolyticd][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b- phenyl-[CAS] Kethoxal 27762-78-3Ketobemidone 469-79-4 ketoconazole Piperazine, 1-acetyl-4-[4-[[2-(2,4-65277-42-1 U.S. 4,335,125 Antifungal Infection,dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)- fungal,1,3-dioxolan-4-yl]methoxy]phenyl]-, cis- general [CAS] ketoprofenmono(3-benzoyl-Alpha- 173011-11-5 EP 502502 Formulation, Pain, generalmethylbenzeneacetate) [CAS] transdermal, systemic ketorolac1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl- 74103-06-3 EP 53021Analgesic, NSAID 2,3-dihydro-, (+/−)-[CAS] 74103-07-4 KetorolacTromethamine ketotifen 10-H-Benzo[4,5]cyclohepta[1,2-b]thiophen-34580-13-7 GB 1355539 Antiasthma Asthma 10-one,4,9-dihydro-4-(1-methyl-4- 34580-14-8 piperidinylidene)-,(E)-2-butenedioate (1:1)- [CAS] Khellin 82-02-0 kinetin 9001-29-0Dermatological Photodamage KNI-272 4-Thiazolidinecarboxamide, N-(1,1-147318-81-8 U.S. 5,466,028 Antiviral, anti-HIV Infection,dimethylethyl)-3-[2-hydroxy-3-[[2-[[(5- HIV/AIDSisoquinolinyloxy)acetyl]amino]-3-(methylthio)-1-oxopropyl]amino]-1-oxo-4- phenylbutyl]-,[4R-[3[2S*,3S*(R*)],4R*]]- [CAS] KP-103(R,R)-2-(2,4-Difluorophenyl)-3-(4- Antifungal Infection,methylenepiperidin-1-yl)-1-(1,2,4-triazol-1- general yl)-2-butanolKP-157 U.S. 6,110,961 Antidepressant Depression, general KP-544 WO9919305 Cognition enhancer Unspecified KRN-5500 L-glycero-β-L-manno-151276-95-8 WO 9015811 Anticancer, Cancer, Heptopyranosylamine,4-deoxy-4- antibiotic colorectal [[[[(2E,4E)-1-oxo-2,4-tetradecadienyl]amino]acetyl]amino]-N-1H- purin-6-yl-[CAS] KT-136Alpha-D-Glucopyranoside, β-D- 121602-88-8 Formulation, dermal, Ulcer,fructofuranosyl, mixt. with 1-ethenyl-2- topical decubitus pyrrolidinonehomopolymer compd. with iodine [CAS] KUL-7211(−)-2-[(2S)-1,2,3,4-tetrahydro-2-[[(2R)-2- Urological Urinaryhydroxy-2-(4- calculus hydroxphenyl)ethyl]amino]naphthalen-7-yloxy]-N,N-dimethylacetamide hydrochloride monohydrate KW-21706H-Pyrazolo[4,5,1-de]acridin-6-one,5-[(3- 207862-44-0 Anticancer,Cancer, lung, aminopropyl)amino]-7,10-dihydroxy-2-[[(2- alkylatingnon-small hydroxyethyl)amino]methyl-, cell dihydrochloride [CAS] KW-60021H-Purine-2,6-dione, 8-(2-(3,4- 155270-99-8 Antiparkinsonian Parkinson'sdimethoxyphenyl)ethenyl)-1,3-diethyl-3,7- diseasedihydro-7-methyl-(E)-[CAS] KW-71583,3,3-Trifluoro-2-hydroxy-2-methyl-N-(10- Urological Incontinenceoxo-4,10-dihydrothieno[3,2-C][1] benzothiepin-9-yl)propanamide 5,5dioxide L-365260 Urea, N-(2,3-dihydro-1-methyl-2-oxo-5- 118101-09-0 EP284256 Anticancer, other Cancer,phenyl-1H-1,4-benzodiazepin-3-yl)-N′-(3- general methylphenyl)-,(R)-[CAS] L-5-hydroxy- L-Tryptophan, 5-hydroxy-[CAS] 4350-09-8 Metabolicand Unspecified tryptophan enzyme disorders L-745337 Methanesulfonamide,N-[6-[(2,4- 158205-05-1 WO 9413635 Analgesic, NSAID Pain, generaldifluorophenyl)thio]-2,3-dihydro-1-oxo-1H- inden-5-yl]-[CAS] L-758298Phosphonic acid, [3-[[(2R,3S)-2-.(.(1R)-1- 172673-20-0 WO 9523798Antimetic Chemotherapy- [3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-induced nausea fluorophenyl)-4-morpholinyl]methyl]-2,5- and vomitingdihydro-5-oxo-1H-1,2,4-triazol-1-yl]-[CAS] L-826141 WO 9722585Antiasthma Unspecified labetalol 5-[1-hydroxy-2-[(1-methyl-3- 32780-64-6U.S. 4,012,444 Antihypertensive, phenylpropyl)amino]ethyl]salicylamideHCl 36894-69-6 adrenergic lacidipine 3,5-Pyridinedicarboxylic acid,4-[2-[3-(1,1- 103890-78-4 GB 2164336 Antihypertensive, Hypertension,dimethylethoxy)-3-oxo-1-propenyl]phenyl]- other general1,4-dihydro-2,6-dimethyl-, diethyl ester, (E) [CAS] Lactic Acid lactitolD-Glucitol, 4-O-β-D-galactopyranosyl- 585-86-4 HepatoprotectiveInfection, [CAS] neurological Lactulose 4618-18-2 lafutidine Acetamide,2-[(2-furanylmethyl)sulfinyl]-N- 118288-08-7 EP 282077 Antiulcer Ulcer,gastric [4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]- 169899-19-82-butenyl]-, (Z)-[CAS] Lamifiban 144412-49-7 lamivudine2(1H)-Pyrimidinone, 4-amino-1-[2- 134678-17-4 EP 51397 Antiviral,anti-HIV Infection, (hydroxymethyl)-1,3-oxathiolan-5-yl]-, (2R- HIV/AIDScis)-[CAS] lamotrigine 1,2,4-Triazine-3,5-diamine, 6-(2,3- 84057-84-1 EP21121 Antiepileptic Epilepsy, partial dichlorophenyl)-[CAS] (focal,local) landiolol Benzenepropanoic acid, 4-[2-hydroxy-3-[[2- 133242-30-5EP 397031 Antiarrhythmic Tachycardia, [(4- generalmorpholinylcarbonyl)amino]ethyl]amino]- propoxy]-,(2,2-dimethyl-1,3-dioxolan-4- yl)methyl ester, [S-(R*,R*)]-HCLlanicemine (S)-Alpha-phenyl-2-pyridine ethanamine 153322-05-5Neurological Unspecified dihydrochloride laniquidar Methyl6,11-dihydro-11-[1-[2-[4-(-2- 197509-46-9 WO 9734897 Radio/ Cancer,general quinolylmethoxy)phenyl]ethyl]-4- chemosensitizerpiperidinylidene]-5H-imidazo[2,1- b][3]benzazepine-3-carboxylatelanoconazole 1H-Imidazole-1-acetonitrile, Alpha-[4-(2- 101530-10-3 U.S.4,738,976 Antifungal Infection, chlorophenyl)-1,3-dithiolan-2-ylidene]-,(E)- fungal, (±)-[CAS] general Lanoteplase 171870-23-8 Lanreotide108736-35-2 lansoprazole 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-103577-45-3 EP 174726 Antiulcer Ulcer,trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]- duodenal [CAS] lanthanumcarbonate Carbonic acid, lanthanum(3+) salt 587-26-8 U.S. 5,968,976Urological Hyperphos- (3:2)[CAS] phataemia lapatinib 4-Quinazolinamine,N-[3-chloro-4-[(3- 388082-78-8 Anticancer, other Cancer, breastfluorobenzyl)methoxy phenyl]-6-[5-[[[2-[methylsulfonyl]ethyl]amino]methyl]furan-2- yl] laquinimod 248281-84-7Multiple sclerosis Multiple treatment sclerosis, general lasofoxifene2-Naphthalenol, 5,6,7,8-tetrahydro-6- 190791-29-8 WO 9716434 MenopausalHormone phenyl-5-(4-(2-(1- disorders replacementpyrrolidinyl)ethoxy)phenyl-(5R-cis)-, (S- therapy(R*,R*))-2,3-dihydroxybutanedioate [CAS] latamoxef5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2- 64952-97-2 GB 1547351 Beta-lactamInfection, carboxylic acid, 7-[[carboxy(4- 64953-12-4 antibiotic generalhydroxyphenyl)acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8- oxo-[CAS] latanoprost5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3- 130209-82-4 WO 9002553Prostaglandin Glaucoma hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R- (1Alpha(Z),2β(R*),3Alpha,5Alpha))-[CAS]Lauroguadine 135-43-3 Laurolinium Acetate 146-37-2 Lawsone 83-72-7LAX-111 1-(Z,Z,Z,Z,Z-eicosa-5,8,11,14,17- Neuroleptic Schizophreniapentaenoyloxy)-3-(Z,Z,Z,Z,Z-eicosa- 5,8,11,14,17-pentaenoyloxy)-propaneLazabemide 103878-84-8 LB-30057 Benzenecarboximidic acid, 4-[(2S)-3- WO9749673 Antithrombotic Thrombosis, (cyclopentylmethylamino)-2-[(2-venous naphthalenylsulfonyl)amino]-3-oxopropyl]-, hydrazide [CAS]L-Cystine Lefetamine 7262-75-1 leflunomide 4-Isoxazolecarboxamide,5-methyl-N-[4- 75706-12-6 EP 13376 Antiarthritic, Arthritis,(trifluoromethyl)phenyl]-[CAS] immunological rheumatoid leflunomide4-Isoxazolecarboxamide, 5-methyl-N-[4- 104981-93-3 U.S. 5,610,173Anticancer, other Cancer, (trifluoromethyl)phenyl]-[CAS] 75706-12-6ovarian Leiopyrrole 5633-16-9 lenampicillin4-Thia-1-azabicyclo[3.2.0]heptane-2- 80734-02-7 carboxylic acid, 6-86273-18-9 EP 61206 Penicillin, oral Infection,[(aminophenylacetyl)amino]-3,3-dimethyl-7- general oxo-,(5-methyl-2-oxo-1,3-dioxol-4- yl)methyl ester, [2S-[2Alpha,5Alpha,6β(S*)]]-[CAS] lentinan Lentinan [CAS] 37339-90-5Anticancer, Cancer, immunological stomach Lepirudin lercanidipine3,5-Pyridinedicarboxylic acid, 1,4-dihydro- 100427-26-7 U.S. 4,705,797Antihypertenzive, Hypertension, 2,6-dimethyl-4-(3-nitrophenyl)-,2-[(3,3- 132866-11-6 other general diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester-, hydrochloride [CAS] lerisetron1H-Benzimidazole, 1-(phenylmethyl)-2-(1- 143257-98-1 U.S. 5,256,665Antimetic Nausea and piperazinyl)-[CAS] vomiting, general Lesopitron132449-46-8 leteprinim Benzoic acid, 4-((3-(1,6-dihydro-6-oxo-9H-138117-50-7 U.S. 6,338,963 Antiparkinsonian Parkinson'spurin-9-yl)-1-oxopropyl)amino)-, disease monopotassium salt [CAS]letosteine 4-Thiazolidinecarboxylic acid, 2-[2-[(2- 53943-88-7 U.S.4,032,534 COPD treatment Bronchitis, ethoxy-2-oxoethyl)thio]ethyl]-[CAS]chronic letrozole Benzonitrile, 4,4′-(1H-1,2,4-triazol-1- 112809-51-5 EP236940 Anticancer, Cancer, breast ylmethylene)bis-[CAS] hormonalLeucocyanidin 480-17-1 Leuprolide 53714-56-0 leuprolide acetateLuteinizing hormone-releasing factor (pig), 53714-56-0 Formulation,Cancer, 6-D-leucine-9-(N-ethyl-L-prolinamide)-10- 74381-53-6 implantprostate deglycinamide-, monoacetate (salt) [CAS] leuprorelinLuteinizing hormone-releasing factor (pig), 53714-56-0 Formulation,Cancer, 6-D-leucine-9-(N-ethyl-L-prolinamide)-10- implant prostatedeglycinamide-, [CAS] Levallorphan 152-02-3 levaminsoleImidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro- 14769-73-4 U.S. 4,584,305Anthelmintic Infection, 6-phenyl-, (S)-[CAS] 16895-80-5 helminth,general Levcromakalim 94535-50-9 levetiracetam 1-Pyrrolidineacetamide,Alpha-ethyl-2-oxo-, 102767-28-2 EP 162036 Antiepileptic Epilepsy,(S)-[CAS] general levobetaxolol 2-Propanol, 1-(4-(2- 116209-55-3Formulation, Glaucoma (cyclopropylmethoxy)ethyl)phenoxy)-3-((1- mucosal,topical methylethyl)amino) hydrochloride [CAS] levobunolol1(2H)-Naphthalenone, 5-[3-[(1,1- 27912-14-7 U.S. 3,641,152 Formulation,Glaucoma dimethylethyl)amino]-2-hydroxypropoxy]- 47141-42-4 mucosal,topical 3,4-dihydro-, (S)-[CAS] levobupivacaine 2-Piperidinecarboxamide,1-butyl-N-(2,6- 27262-47-1 WO 9510276 Anaesthetic, Anaesthesiadimethylphenyl)-, (S)-[CAS] injectable levocabastine4-Piperidinecarboxylic acid, 1-[4-cyano-4- 79449-98-2 U.S. 4,369,184Antiallergic, Rhinitis, allergic,(4-fluorophenyl)cyclohexyl]-3-methyl-4- 79516-68-0 non-asthma generalphenyl-, [3S-[1(cis),3Alpha,4β]]-[CAS] 79547-78-7 levocetirizine Aceticacid, (2-(4-((4- 130018-77-8 WO 9406429 Antiallergic, Allergy, generalchlorophenyl)phenylmethyl)-1- non-asthma piperazinyl)ethoxy)-, (R)-[CAS]Levodopa 59-92-7 levodropropizine 1,2-Propanediol, 3-(4-phenyl-1-99291-25-5 EP 147847 Antitussive Cough piperazinyl)-, (S)-[CAS]levofloxacin 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6- 100986-85-4 EP206283 Quinolone Infection, carboxylic acid, 9-fluoro-2,3-dihydro-3-138199-71-0 antibacterial respiratorymethyl-10-(4-methyl-1-piperazinyl)-7-oxo-, tract, lower (S)-[CAS]Levomethadyl Acetate 1477-40-3 levomoprolol 2-Propanol,1-(2-methoxyphenoxy)-3-[(1- 27058-84-0 EP 15418 Antihypertensive,methylethyl)amino]-, (S)-[CAS] 5741-22-0 adrenergic 77164-20-6levonorgestrel 18,19-Dinopregn-4-en-20-yn-3-one, 13- 797-63-7Formulation, Contraceptive, ethyl-17-hydroxy-, (17Alpha)-[CAS] implantfemale Levophacetoperane 24558-01-8 Levopropoxyphene 2338-37-6Levorphanol 77-07-6 levosimendan Propanedinitrile,[[4-(1,4,5,6-tetrahydro-4- 131741-08-7 EP 383449 Cardiostimulant Heartfailure methyl-6-oxo-3- 141505-33-1 pyridazinyl)phenyl]hydrazono]-,(R)-[CAS] levosulpride Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-23672-07-3 GB 2014990 Antiemetic Dyspepsia2-pyrrolidinyl)methyl]-2-methoxy-, (S)- [CAS] Levothyroxine levovirin1-β-L-ribofuranosyl-1,2,4-triazole-3- Antiviral, other Infection,carboxamide hepatitis- C virus lexipafant L-Leucine,N-methyl-N-[[4-[(2-methyl-1H- 139133-26-9 WO 9203423 NeurologicalDementia, imidazo[4,5-c]pyridin-1- AIDS-relatedyl)methyl]phenyl]sulfonyl]-, ethyl ester- [CAS] LF-15-0195 WO 9624579Immunosuppressant Lupus erythematosus, general LF-16-06872-Pyrrolidinecarboxamide, N-[3-[[4- 209733-45-9 FR 2756562Neuroprotective Head trauma (aminoiminomethyl)benzoyl]amino]propyl]-1-[[2,4-dichloro-3-[[(2,4-dimethyl-8-quinolinyl)oxy]methyl]phenyl]sulfonyl]-, (2S)-[CAS] LGD-15502,4,6-Octatrienoic acid, 7-(3,5-bis(1,1- 178600-20-9 Anticancer, otherCancer, dimethylethyl)phenyl)-3-methyl- cervical (2E,4E,6E)-[CAS] LH902-67-9 LH-RH 934-40-6 liarozote 1H-Benzimidazole,5-[(3-chlorophenyl)-1H- 115575-11-6 Formulation, other Psoriasisimidazol-1-ylmethyl]-[CAS] licofelone 1H-Pyrrolizine-5-acetic acid,6-(4- 156897-06-2 Antiarthritic, other Arthritis,chlorophenyl)-2,3-dihydro-2,2-dimethyl-7- osteo phenyl-[CAS] Licostinel153504-81-5 lidadronate Phosphonic acid, [1-amino-3- 63132-38-7 WO9702827 Urological Unspecified (dimethylamino)propylidene]bis-[CAS]Lidamidine 66871-56-5 lidocaine Acetamide, 2-(diethylamino)-N-(2,6-137-58-6 Formulation, Pain, post- dimethylphenyl)-[CAS] transdermal,patch herpetic Lidofenin 59160-29-1 Lidoflazine 3416-26-0 limaprostProsta-2,13-dien-1-oic acid, 11,15- 74397-12-9 GB 2041368 ProstaglandinBuerger's dihydroxy-17,20-dimethyl-9-oxo-, syndrome(2E,11Alpha,13E,15S,17S)-, [CAS] Lincomycin 154-21-2 Lindan 58-89-9linezolid Acetamide, N-((3-(3-fluoro-4-(4- 165800-03-3 WO 9507271Antibiotic, other Infection, morpholinyl)phenyl)-2-oxo-5- dermatologicaloxazolidinyl)methyl)-, (S)-[CAS] Linoleic Acid 60-33-3 Linolenic Acid463-40-1 Liothyronine 6893023 Lipase 9001-62-1 Lipo-dexamethasonePregna-1,4-diene-3,20-dione, 9-fluoro- 14899-36-6 Formulation,Arthritis, 11,17-dihydroxy-16-methyl-21-[(1- optimized, rheumatoidoxohexadecyl)oxy]-, (11β,16Alpha)-[CAS] microemulsion lipo-flurbiprofen[1,1′-Biphenyl]-4-acetic acid, 2-fluoro- 91503-79-6 JP 60208910Formulation, Pain, cancer Alpha-methyl-, 1-(acetyloxy)ethyl esteroptimized, [CAS] microemulsion Lipogel HA EP 525655 Formulation,Unspecified optimized, liposomes LiquiVent perfluorooctylbromide423-55-2 U.S. 5,437,272 Lung Surfactant Respiratory distress syndrome,adult liranaftate Carbamothioic acid, (6-methoxy-2- 88678-31-3 GB2124617 Antifungal Infection, pyridinyl)methyl-,O-(5,6,7,8-tetrahydro-2- dermatological naphthalenyl) ester [CAS]lisinopril L-Proline, 1-[N2-(1-carboxy-3- 76547-98-3 EP 12401Antihypertensive, Hypertension, phenylpropyl)-L-lysyl]-, (S)-[CAS]83915-83-7 renin system general Lisofyllin 100324-81-0 lisuride Urea,N′-[(8Alpha)-9,10-didehydro-6- 19875-60-8 Antiprolactin Acromegalymethylergolin-8-yl]-N,N-diethyl-, [CAS] 305-13-5 18016-80-3 LithiumCitrate 919-16-4 lithium Carbonic acid, dilithium salt [CAS] 554-13-2Formulation, Depression, modified- bipolar release, <=24 hr lixivaptanBenzamide, N-[3-chloro-4-(5H-pyrrolo[2,1- 168079-32-1 U.S. 5,736,540Cardiovascular Heart failure c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methyl- [CAS] LJP-1082 U.S. 6,207,160Immunosuppressant Thrombosis, venous LLUAlphaS-2,7,8-Trimethyl-6-(β-carboxyethyl)-6- Antihypertensive, Hypertension,hydroxychroman other general LMP-160 U.S. 5,643,893 Antiasthma AsthmaLMP-420 U.S. 5,643,893 Antiarthritic, other Arthritis, lobaplatinPlatinum, (1,2-cyclobutanedimethanamine- 135558-11-1 DE 4115559Anticancer, Cancer, lung, N,N′)[2-hydroxypropanoato(2-)-O1,O2]-,alkylating small cell [SP-4-3-(S),(trans)]-[CAS] Lobeline 90-69-7Lobenzarit 63329-53-3 lodoxamide 2,2′-((2-chloro-5-cyano-1,3- 63610-09-3U.S. 4,439,445 Antiasthma Asthma phenylene)diimino)bis(2-oxoacetate):2-53882-12-5 amino-2-(hydroxymethyl)-1,3-propanediol (1:2) Lofentanil61380-40-3 lofepramine Ethanone, 1-(4-chlorophenyl)-2-[[3-(10,11-23047-25-8 GB 1177525 Antidepressant dihydro-5H-dibenz[b,f]azepin-5-26786-32-3 yl)propyl]methylamino]-[CAS] lofexidine 1H-Imidazole,2-[1-(2,6- 31036-80-3 GB 1181356 Antihypertensive, Hypertension,dichlorophenoxy)ethyl]-4,5-dihydro-[CAS] adrenergic general Loflucarban790-69-2 lomefloxacin 3-Quinolinecarboxylic acid, 1-ethyl-6,8-98079-51-7 EP 140116 Quinolone Infection,difluoro-1,4-dihydro-7-(3-methyl-1- 98079-52-8 antibacterial respiratorypiperazinyl)-4-oxo-[CAS] tract, lower lomerizine Piperazine,1-[bis(4-fluorophenyl)methyl]-4- 101477-54-7 EP 159566 AntimigraineMigraine [(2,3,4-trimethoxyphenyl)methyl]-, [CAS] 101477-55-8lomifylline 7-(5-oxohexyl)theophylline 10226-54-7 DE 2207860Neurological lomustine Urea, N-(2-chloroethyl)-N′-cyclohexyl-N-13010-47-4 JP 48075526 Anticancer, nitroso-[CAS] alkylating lonafarnib1-Piperidinecarboxamide, 4-[2-[4-[(11R)- 193275-84-2 U.S. 5,874,442Anticancer, other Cancer, lung, 3,10-dibromo-8-chloro-6,11-dihydro-5H-non-small cell benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-[CAS] Lonapalene 91431-42-4 Lonazolac53808-88-1 lonidamine 1H-Indazole-3-carboxylic acid, 1-[(2,4- 50264-69-2DE 2310031 Radio/ Cancer, breast dichlorophenyl)methyl]-[CAS]chemosensitizer loperamide 4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-34552-83-5 U.S. 3,714,159 Antidiarrhoeal Diarrhoea,Alpha,Alpha-diphenyl-1-piperidine 53179-11-6 general butyramide HClloperamide oxide 1-Piperidinebutanamide, 4-(4- 106900-12-3 EP 219898Antidiarrhoeal Diarrhoea, chlorophenyl)-4-hydroxy-N,N-dimethyl- generalAlpha,Alpha-diphenyl-, 1-oxide, trans- [CAS] loprazolam1H-Imidazo[1,2-a][1,4]benzodiazepin-1- 61197-73-7 GB 1496426 Hypnotic/one, 6-(2-chlorophenyl)-2,4-dihydro-2-[(4- 61197-93-1 Sedativemethyl-1-piperazinyl)methylene]-8-nitro- 70111-54-5 [CAS] Loprinone106730-54-5 loracarbef 1-Azabicyclo[4.2.0]oct-2-ene-2-carboxylic76470-66-1 EP 14475 Cephalosporin, oral Infection, acid,7-[(aminophenylacetyl)amino]-3- 121961-22-6 respiratory chloro-8-oxo-,[6R-[6Alpha,7β(R*)]]-[CAS] tract, lower Lorajmine 47562-08-3 loratadine1-Piperidinecarboxylic acid, 4-(8-chloro- 79794-75-5 EP 42544Antiallergic, Rhinitis, 5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-non-asthma allergic, b]pyridin-11-ylidene)-, ethyl ester-[CAS] generallorazepam 2H,1,4-Benzodiazepin-2-one, 7-chloro-5- 846-49-1 Formulation,oral, Epilepsy, (2-chlorophenyl)-1,3-dihydro-3-hydroxy-orally-disintegrating general lorcainide Benzeneacetamide,N-(4-chlorophenyl)-N- 58934-46-6 DE 2642856 Antiarrhythmic[1-(1-methylethyl)-4-piperidinyl]-[CAS] 59729-31-6 lormetazepam2H-1,4-Benzodiazepin-2-one, 7-chloro-5- 848-75-9 U.S. 3,296,249Hypnotic/Sedative Insomnia (2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-[CAS] lornoxicam 2H-Thieno[2,3-e]-1,2-thiazine-3- 70374-39-9 EP313935 Analgesic, NSAID Pain, post- carboxamide,6-chloro-4-hydroxy-2-methyl- operative N-2-pyridinyl-, 1,1-dioxide-[CAS]losartan 1H-Imidazole-5-methanol, 2-butyl-4-chloro- 124750-99-8 EP253310 Antihypertensive, Hypertension,1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4- 114798-26-4 renin systemgeneral yl]methyl]-, [CAS] loteprednol Androsta-1,4-diene-17-carboxylicacid, 17- 82034-46-6 GB 2079755 Anti-inflammatory, Uveitis[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, topical chloromethyl ester,(11β,17Alpha)-[CAS] Lotrafiban 171049-14-2 Lovastatin 75330-75-5Loxapine 10/02/1977 loxiglumide Pentanoic acid, 4-[(3,4- 107097-80-3 WO8703869 GI inflammatory/ Pancreatitis dichlorobenzoyl)amino]-[(3- boweldisorders methoxypropyl)pentylamino]-5-oxo-, (±)- [CAS] loxoprofenBenzeneacetic acid, Alpha-methyl-4-[(2- 68767-14-6 EP 55588Antiarthritic, other Arthritis, oxocyclopentyl)methyl]-[CAS] 80382-23-6rheumatoid 87828-36-2 Lu-35-1381-[3[[2-[5-chloro-1-(4-fluorophenyl)-3-1H- WO 9516684 NeurolepticPsychosis, indolyl]ethyl]methylamino)propyl]-2- general imidazolidinonehydrochloride] Lubeluzole 144665-07-6 lubiprostone(−)-7-[(2R,4aR,5R,7aR)-2-(1,1- 136790-76-6 Laxative Constipationdifluoropentyl)-2-hydroxy-6- oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid lucanthone Thioxanthen-9-one, 1-((2- 479-50-5 Radio/Cancer, brain (diethylamino)ethyl)amino-4-methyl-[CAS] chemosensitizerLucanthone 548-57-2 Lumefantrine 82186-77-4 lumiracoxib Benzeneaceticacid, 2-((2-chloro-6- 220991-20-8 Analgesic, NSAID Pain, generalfluorophenyl)amino)-5-methyl-[CAS] lurtotecan 11H-1,4-Dioxino[2,3-155773-58-3 Formulation, Cancer,g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline optimized, lipocomesovarian 9,12-[8H,14H]-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-[[4-methyl-1- piperazinyl]methyl]-, [CAS] lutetium texaphyrinLutetium, bis(acetato-O)[9,10-diethyl- 156436-90-7 WO 9906411 Radio/Athero- 20,21-bis-[2-[2-(2- chemosensitizer sclerosismethoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14- dipropanolatlo-N1,N18,N23,N24,N25]-,(PB 7-11-233′2′4)-[CAS] LV-216Zinc[2-(2,6-dichloroanilino)phenyl]acetate Anti-inflammatory Arthritis,rheumatoid LX-104 Hexadecanamide, N-[4-[[2-[2-[[O-(N- 158792-45-1Cognition enhancer Dementia, acetyl-Alpha-neuraminosyl)-(2-3)-O-β-D-senile, galactopyranosyl-(1-4)-O-[6-deoxy-Alpha- generalL-galactopyranosyl]oxy]ethoxy]ethoxy]ethoxy]-methyl]phenyl]-2-tetradecyl-[CAS] LY-156735 β-methyl-6-chloromelatoninEP 655243 Hypnotic/Sedative Sleep disorder, general LY-293111 Benzoicacid, 2-[3-[3-[(5-ethyl-4′-fluoro-2- 161172-51-6 Anticancer, otherCancer, hydroxy[1,1′-biphenyl]-4-yl)oxy]propoxy]-2- melanomapropylphenoxy]-[CAS] LY-293558 3-Isoquinolinecarboxylic acid,decahydro-6- 154652-83-2 Anticancer, other Pain,[2-(1H-tetrazol-5-yl)ethyl]-, [3S- neuropathic(3Alpha.,4aAlpha,6β,8aAlpha.)]-[CAS] LY-3557031,4-Dioxa-8,11-diazacyclohexadec-13-ene- 18256-67-7 WO 9707798Anticancer, other Cancer, lung, 2,5,9,12-tetrone, 10-[(3-chloro-4-non-small cell methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2S,3R)-3- phenyloxiranyl]ethyl]-,(3S,10R,13E,16S)- [CAS] Lyapolate 25053-27-4 Lymecycline 992-21-2Lynestrenol 52-76-6 Lypressin 50-57-7 Lysine Acetylsalicylate 62952-06-1lysine salicylate L-Lysine, 2-hydroxybenzoate [CAS] 59535-08-9 WO9624331 Analgesic, NSAID lysophospholipids WO 9843093 DiagnosticDiagnostic, cancer M-40403 Dichloro[(4aR,13aR,17aR,21aR)- U.S. 6,180,620Anticancer, other Unspecified 1,2,3,4,4a,5,6,12,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-1,7-nitrilo-7H-dibenzo[b,h][1,4,7,10]tetraazacyclo- heptadecine-kappaN5,kappaN13,kappaN18,kappaN21, kappaN22]manganese mabuprofenBenzeneacetamide, N-(2-hydroxyethyl)- 82821-47-4 DE 3121595Anti-inflammatory Alpha-methyl-4-(2-methylpropyl)-, (+/−)- [CAS]Mabuterol 56341-08-3 Macrophage Colony- 81627-83-0 Stimulating FactorMADU 840-50-6 mafenide Benzenesulfonamide, 4-(aminomethyl)- 13009-99-9Vulnerary Burns monoacetate [CAS] 138-39-6 mafosfamide Ethanesulfonicacid, 2-[[2-[bis(2- 88859-04-5 EP 393575 Anticancer, Cancer, renalchloroethyl)amino]tetrahydro-2H-1,3,2- 98845-64-8 alkylatingoxazaphosphorin-4-yl]thio]-, P-oxide, cis- (±)-[CAS] magaldrate Aluminummagnesium hydroxide sulfate 74978-16-8 U.S. 2,923,660 Antacid/(Al5Mg10(OH)31(SO4)2), hydrate [CAS] Antiflatulent Magenta I 632-99-5Magnesium 132-49-0 Acetylsalicylate Magnesium Carbonate 39409-82-0Hydroxid magnesium chloride Magnesium chloride (MgCl2) [CAS] 7786-30-3Formulation, oral, Nutrition enteric-coated Magnesium Citrate 3344-18-1magnesium gluconate D-Gluconic acid, magnesium salt (2:1) 3632-91-5Formulation, other Hypertension, [CAS] general Magnesium Lactate18917-93-6 Magnesium Salicylate 18917-89-0 Malathion 121-75-5 Malotilate59937-28-9 Mandelic Acid 90-64-2 Mandelic Acid Isoamyl 5421045 EsterMangafodipir 118248-94-5 (free acid); 155319-91-8 (hexa- hydrogen)manidipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro- 89226-50-6 EP94159 Antihypertensive, Hypertension, 2,6-dimethyl-4-(3-nitrophenyl)-,2-[4- 89226-75-5 other general (diphenylmethyl)-1-piperazinyl]ethylmethyl ester [CAS] Mannomustine 551-74-6 mannose-6-phosphatemannose-6-phosphate Vulnerary Wound healing Maprotilline 10262-69-8maribavir 1H-Benzimidazol-2-amine, 5,6-dichloro-N- 176161-24-3Antiviral, other Infection, (1-methylethyl)-1-β-L-ribofuranosyl-[CAS]cytomegalo- virus marimastat N-[2,2-Dimethyl-a(S)-(N- 154039-60-8 WO9402447 Anticancer, other Cancer,methylcarbamoyl)propyl]-N,3(S)-dihydroxy- pancreatic2(R)-isobutylsuccinamide maxacalcitol 1,3-Cyclohexanediol,4-methylene-5-(2- 103909-75-7 U.S. 4,891,364 Hormone Hyperpara-(octahydro-1-(1-(3-hydroxy-3- thyroidismmethylbutoxy)ethyl)-7a-methyl-4H-inden-4- ylidene)ethylidene)-, (1S-(1Alpha(R*),3aβ,4E(1S*,3R*,5Z),7aAlpha))- [CAS] mazindol3H-Imidazo[2,1-a]isoindol-5-ol, 5-(4- 22232-71-9 U.S. 3,763,178Anorectic/ Obesity chlorophenyl)-2,5-dihydro-[CAS] AntiobesityMazipredone 13085-08-0 MC-5723 U.S. 6,043,259 Cardiovascular UnspecifiedMCC-478 (2-amino-6-(4-methoxyphenylthio)-9-[2- Antiviral, otherInfection, (phosphonomethoxy)ethyl]purine bis(2,2,2- hepatitis-Btrifluoroethyl)ester) virus MCI-154 3(2H)-Pyridazinone,4,5-dihydro-6-[4-(4- 98326-32-0 EP 145019 Cardiostimulant Heart failurepyridinylamino)phenyl]-, 98326-33-1 monohydrochloride [CAS] m-CresylAcetate 122-46-3 MDAM Gamma-Methylene-10-deazaaminopterin Anticancer,Cancer, antimetabolite general MDI-101 U.S. 4,885,311 Antiacne AcneMDI-403 403849-94-5 U.S. 4,677,120 Antiacne Acne MDL-1009074-Piperidinemethanol, Alpha-(2,3- 139290-65-6 Hypnotic/Sedative Sleepdisorder, dimethoxyphenyl)-1-(2-(4- general fluorophenyl)ethyl)-,(R)-[CAS] mebendazole methyl-5-benzoylbenzimidazole-2- 31431-39-7 GB1307306 Anthelmintic carbamate mebeverine Benzoic acid, 3,4-dimethoxy-,4-[ethyl[2-(4- 3625-06-7 Antispasmodic Irritable bowelmethoxyphenyl)-1-methylethyl]amino]butyl syndrome ester [CAS]Mebhydroline 524-81-2 Mebrofenin 78266-06-5 Mebutamate 64-55-1mecamylamine Bicyclo(2.2.1)heptan-2-amine, N,2,3,3- 60-40-2 NeurologicalUnspecified tetramethyl-[CAS] Mechlorethamine 51-75-2 Mechlorethamine302-70-5 Oxide mecillinam 4-Thia-1-azabicyclo[3.2.0]heptane-2-32887-01-7 GB 1293590 Penicillin, Infection, carboxylic acid,6-[[(hexahydro-1H-azepin- 32887-03-9 injectable general1-yl)methylene]amino]-3,3-dimethyl-7-oxo-,[2S-(2Alpha,5Alpha,6.beta.)]-[CAS] Meclizine 569-65-3 Meclocycline2013-58-3 meclofenamate Benzoic acid, 2-[(2,6-dichloro-3- 6385-02-0Antiarthritic, other Arthritis, methylphenyl)amino]-, monosodium salt644-62-2 osteo [CAS] Meclofenamic Acid 644-62-2 Meclofenoxate 51-68-3Mecloqualone 340-57-8 Mecysteine 18598-63-5 Medazepam 12/06/2898medifoxamine Ethanamine, N,N-dimethyl-2,2-diphenoxy- 32359-34-5 FR M5498Antidepressant [CAS] Medrogestone 977-79-7 Medronic Acid 1984-15-2medroxyprogesterone Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6- 71-58-9Formulation, fixed- Contraceptive, methyl-,(6Alpha) 520-85-4 dosecombinations female Medrysone 2668-66-8 Mefenamic Acid 61-68-7 Mefenorex17243-57-1 Mefexamide 1227-61-8 mefloquine 4-Quinolinemethanol,Alpha-2-piperidinyl- 51773-92-3 GB 1594282 Antimalarial2,8-bis(trifluoromethyl)-, (R*,S*)-(±)-[CAS] 53230-10-7 69191-18-0Mefruside 7195-27-9 Megestrol 595-33-5 Meglumin 22154-43-4 131-49-7meglutol 2-hydroxy-2-methyl-1,3-propandicarboxylic 503-49-1 U.S.3,629,449 Hypolipaemic/ Hyper- acid Antiatherosclerosis lipidaemia,general melagatran Glycine, N-[(1R)-2-[(2S)-2-[[[[4- 159776-70-2 WO9616671 Antithrombotic Thrombosis,(aminoiminomethyl)phenyl]methyl]amino]- generalcarbonyl]-1-azetidinyl]-1-cyclohexyl-2- oxoethyl]-[CAS] melanocortin-4N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium- Anorectic/ Obesity agonist3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4- Antiobesitycyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine(1) Melarsoprol 494-79-1Melengestrol 5633-18-1 melevodopa Alanine, 3-(3,4-dihydroxyphenyl)-7101-51-1 EP 252290 Antiparkinsonian Parkinson's methylester [CAS]disease Melinamide 14417-88-0 Melitracen 5118-29-6 meloxicam2H-1,2-Benzothiazine-3-carboxamide, 4- 71125-38-7 U.S. 4,233,299Antiarthritic, other Arthritis,hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, rheumatoid 1,1-dioxide-[CAS]melperone 1-Butanone, 1-(4-fluorophenyl)-4-(4- 1622-79-3 BE 651144Neuroleptic methyl-1-piperidinyl)-[CAS] 3575-80-2 Melphalan 148-82-3meluadrine Benzenemethanol, 2-chloro-Alpha-(((1,1- 134865-37-5 EP 420120Labour inhibitor Labour, dimethylethyl)amino)methyl)-4-hydroxy-, preterm(R)-, (R*,R*))-2,3-dihydroxybutanedioate (1:1) (salt) [CAS] memantineTricyclo[3.3.1.13,7]decan-1-amine, 3,5- 41100-52-1 EP 392059 Cognitionenhancer Dementia, dimethyl [CAS] 19982-08-2 AIDS-related MEN-10700Acetamide, 2-[[[(5R,6S)-6-[(1R)-1- 195874-55-6 WO 9406803 Beta-lactamInfection, hydroxyethyl]-2-methyl-7-oxo-4-thia-1- antibiotic generalazabicyclo[3.2.0]hept-2-en-3- yl]methyl]methylamino]-[CAS] MEN-107555,12-Naphthacenedione, 7-[[4-O-(3-amino- 169317-77-5 WO 9509173Anticancer, Cancer, 2,3,6-trideoxy-Alpha-L-lyxo- antibiotic breasthexopyranosyl)-2,6-dideoxy-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, hydrochloride, (7S,9S)-[CAS]Menadiol 481-85-6 Menadione 58-27-5 Menadoxime 573-01-3 Menbutone3562-99-0 Menogaril 71628-96-1 MENT 7Alpha-Methyl-19-nortestosteroneFormulation, Contraceptive, transdermal, systemic male mentholCyclohexanol, 5-methyl-2-(1-methlethyl)- 1490-04-6 Formulation, dermal,Pruritus [CAS] 89-78-1 topical Menthyl Valerate 89-47-4 Meobentine46464-11-3 Meparfynol 77-75-8 mepartricin Partricin, methyl ester [CAS]11121-32-7 U.S. 3,780,173 Antifungal Infection, Candida, generalMepazine 60-89-9 Mepenzolate Bromide 76-90-4 Meperidine 57-42-1Mephenesin 59-47-2 Mephenoxalone 70-07-5 Mephentermine 100-92-5Mephenytoin 50-12-4 Mephobarbital 115-38-8 Mepindolol 23694-81-7Mepitiostane 21362-69-6 mepivacaine N-(2,6-Dimethylphenyl)-1-methyl-2-96-88-8 Formulation, Pain, post- piperidinecarboxamide modified-operative release, >24 hr Mepixanox 17854-59-0 Meprednisone 1247-42-3Meprobamate 57-53-4 meproscillarin Bufa-4,20,22-trienolide,3-[(6-deoxy-4-O- 33396-37-1 DE 1910207 Cardiostimulant Heart failuremethyl-Alpha-L-mannopyranosyl)oxy]-14- hydroxy-, (3β)-[CAS] meptazinolPhenol, 3-(3-ethylhexahydro-1-methyl-1H- 54340-58-8 GB 1285025Analgesic, other Pain, general azepin-3-yl)-[CAS] 59263-76-2 mequitazine10H-Phenothiazine, 10-(1- 29216-28-2 GB 1250534 Antiallergic,azabicyclo[2.2.2]oct-3-ylmethyl)-[CAS] non-asthma Meralein 4386-35-0Meralluride 8069-64-5 Merbromin 129-16-8 Mercaptomerin 21259-76-7Mercumallylic Acid 86-36-2 Mercuric Chloride, 10124-48-8 AmmoniatedMercuric Oleate 1191-80-6 Mercuric Oxycyanide 1335-31-5 merimepodibCarbamic acid, ((3-((((3-methoxy-4-(5- 198821-22-6 U.S. 5,807,878Antiviral, other Infection, oxazolyl)phenyl)amino)carbonyl)amino)-hepatitis- phenyl)methyl)-(3S)-tetrahydro-3-furanyl C virus ester [CAS]meropenem 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic 96036-03-2 EP126587 Beta-lactam Infection, acid, 3-[[5-[(dimethylamino)carbonyl]-3-antibiotic respiratory pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4- tract,lower methyl-7-oxo-, [4R- [3(3S*,5S*),4Alpha,5β,6β(R*)]]-[CAS] Mersalyl492-18-2 Mesalamine 89-57-6 mesalazine Benzoic acid,5-amino-2-hydroxy-[CAS] 89-57-6 WO 5541170 Formulation, oral, Colitis,other ulcerative Mesna 19767-45-4 Mesoridazine 5588-33-0 Mestanolone521-11-9 Mesterolone 1424-00-6 Mestranol 72-33-3 Mesulfen 135-58-0Metaclazepam 84031-17-4 Metampicillin 6489-97-0 Metapramine 21730-16-5Metaproterenol 586-06-1 Metaraminol 54-49-9 Metazocine 3734-52-9metergoline Carbamic acid, [[(8β)-1,6-dimethylergolin- 17692-51-2 GB1401935 Antiprolactin Amenorrhoea 8-yl]methyl]-, phenylmethyl ester[CAS] 21631-37-8 2706-42-5 metformin Imidodicarbonimidic diamide,N,N-dimethyl 657-24-9 Formulation, Diabetes, [CAS] modified- Type IIrelease, <=24 hr Methacholine 62-51-1 Methacycline 914-00-1 Methadone76-99-3 Methafurylene 531-06-6 Methamphetamine 537-46-2 Methandriol521-10-8 Methandrostenolone 72-63-9 Methantheline 53-46-3 Methapyrilene91-80-5 Methaqualone 72-44-6 Metharbital 50-11-3 Methazolamide 554-57-4Methdilazine 1982-37-2 Methenamine 100-97-0 Methenolone 153-00-4Methestrol 130-73-4 Methetoin 5696-06-0 Methicillin 132-92-3 Methimazole60-56-0 Methiodal 126-31-8 Methionic Acid 503-40-2 Methionine 63-68-3Methisazone 1910-68-5 Methitural 467-43-6 Methixene 02/02/4969Methocarbamol 532-03-6 Methohexital 22151-68-4 methotrexate L-Glutamicacid, N-[4-[[(2,4-diamino-6- 59-05-2 U.S. 2,512,572 Anticancer, Cancer,pteridinyl)methyl]methylamino]benzoyl]- antimetabolite general [CAS]Methotrimeprazine 60-99-1 Methoxamine 390-28-3 Methoxsalen 298-81-7Methoxyflurane 76-38-0 Methoxyphenamine 93-30-1 Methoxypromazine 61-01-8Methscopolamine 155-41-9 Methsuximide 77-41-8 Methyclothiazide 135-07-9Methyl Blue 28983-56-4 Methyl Nicotinate 93-60-7 Methyl Propyl Ether557-17-5 Methyl Salicylate 119-36-8 Methyl tert-Butyl Ether 1634-04-4Methylbenzethonium 25155-18-4 Chloride Methylcobalamin 13422-55-4methyldopa L-Tyrosine, 3-hydroxy-Alpha-methyl- 555-30-6 Formulation,Hypertension, [CAS] modified- general release, <=24 hr Methylene Blue61-73-4 Methylergonovine 113-42-8 Methylhexaneamide 105-41-9methylphenidate 2-Piperidineacetic acid, Alpha-phenyl-, 113-45-1Formulation, Attention methyl ester [CAS] 298-59-9 modified- deficitrelease, multi disorder Methylprednisolone 83-43-2 methylprednisolonePregna-1,4-diene-3,20-dione, 21- 86401-95-8 EP 72547 Antipruritic/Pruritus aceponate (acetyloxy)-11-hydroxy-6-methyl-17-(1- inflamm,allergic oxopropoxy)-, (6Alpha,11β)-[CAS] methylprednisolone suleptanatePregna-1,4-diene-3,20-dione, 11,17- 90350-40-6 JP 59137500 AntiasthmaAsthma dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxooctyl]oxy]-, monosodium salt,(6Alpha,11β)-[CAS] Methylthiouracil 56-04-2 Methyltrienolone 965-93-5Methyprylon 125-64-4 Methysergide 361-37-5 Metiazinic Acid 13993-65-2metipranolol Phenol, 4-[2-hydroxy-3-[(1- 22664-55-7 GB 1206148Antihypertensive, methylethyl)amino]propoxy]-2,3,6-trimethyl-,adrenergic 1-acetate [CAS] metoclopramide Benzamide,4-amino-5-chloro-N-[2- 364-62-5 Formulation, Gastro-(diethylamino)ethyl]-2-methoxy-[CAS] modified- oesophageal release, <=24hr reflux Metocurine Iodide 7601-55-0 Metofenazate 388-51-2 metolazone6-Quinazolinesulfonamide, 7-chloro- 17560-51-9 U.S. 4,517,179Antihypertensive, 1,2,3,4-tetrahydro-2-methyl-3-(2- diureticmethylphenyl)-4-oxo-[CAS] Metopimazine 14008-44-7 Metopon 143-52-2metoprolol 2-Propanol, 1-[4-(2- 51384-51-1 Formulation, Hypertension,methoxyethyl)phenoxy]-3-[(1- 56392-17-7 modified- generalmethylethyl)amino]-, (+/−)-[CAS] 37350-58-6 release, other Metralindole54188-38-4 Metrizamide 31112-62-6 Metrizoic Acid 1949-45-7 Metron S13946-02-6 Metyrapone 54-36-4 Metyrosine 672-87-7 Mexazolam 31868-18-5Mexenone 1641-17-4 Mexiletine 31828-71-4 mezlocillin4-Thia-1-azabicyclo[3.2.0]heptane-2- 42057-22-7 GB 1301961 Penicillin,Infection, carboxylic acid, 3,3-dimethyl-6-[[[[[3- 51481-65-3 injectablegeneral (methylsulfonyl)-2-oxo-1- 72539-76-5imidazolidinyl]carbonyl]amino]- phenylacetyl]amino]-7-oxo-, [2S-[2Alpha,5Alpha,6β(S*)]]-[CAS] MFH-244 Benzenecarboximidic acid, 3,4,5-95933-76-9 U.S. 4,623,659 Cardiovascular Reperfusion trihydroxy-, ethylester, hydrochloride injury mianserinDibenzo[c,f]pyrazino[1,2-a]azepine, 21535-47-7 GB 1173783 AntidepressantDepression, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS] 24219-97-4 generalMibefradil 116644-53-2 Miboplatin 103775-75-3 Micafungin 235114-32-6miconazole 1H-Imidazole, 1-(2,4-dichlorophenyl)-2[2,4- 22916-47-8Formulation, Infection, dichlorophenyl)methoxy]ethyl] modified- Candida,release, other general Micronomicin 52093-21-7 midaxifyline1H-Purine-2,6-dione-8-(1- 151159-23-8 U.S. 5,378,844 CardiovascularUnspecified aminocyclopentyl)-3,7-dihydro-1,3-dipropyl- [CAS] midazolam4H-Imidazo[1,5-a][1,4]benzodiazepine, 8- 59467-70-8 U.S. 4,280,957Anaesthetic, chloro-6-(2-fluorophenyl)-1-methyl-[CAS] 59467-94-6injectable midecamycin Leucomycin V, 3,4B-dipropanoate [CAS] 35457-80-8U.S. 3,761,588 Macrolide Infection, antibiotic general midecamycinacetate Leucomycin V, 3B,9-diacetate 3,4B- 55881-07-7 JP 49124087Macrolide Infection, dipropanoate [CAS] antibiotic general midesteine2-Thiophenecarbothioic acid, S-[1-methyl- 94149-41-4 EP 120534 COPDtreatment Emphysema, 2-oxo-2-[(tetrahydro-2-oxo-3- generalthienyl)amino]ethyl] ester [CAS] midodrine Acetamide, 2-amino-N-[2-(2,5-42318-56-0 EP 164571 Urological Incontinencedimethoxyphenyl)-2-hydroxyethyl]-[CAS] 42794-76-3 midostaurin Benzamide,N-(2,3,10,11,12,13-hexahydro- 120685-11-2 EP 296110 Anticancer, otherCancer, 10-methoxy-9-methyl-1-oxo-9,13-epoxy- leukaemia,1H,9H-diindolo[1,2,3-gh:3′,2′,1′- acutelm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)- myelogenous N-methyl-,(9Alpha,10β,11β,13Alpha)- [CAS] mifepristone Estra-4,9-dien-3-one,11-[4- 84371-65-3 EP 57115 Abortifacient Abortion(dimethylamino)phenyl]-17-hydroxy-17-(1- propynyl)-, (11β,17β)-[CAS]miglitol 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2- 72432-03-2 EP55431 Antidiabetic Diabetes, (hydroxymethyl)-, [2R- Type I(2Alpha,3β,4Alpha,5β)]-[CAS] miglustat 3,4,5-Piperidinetriol, 1-butyl-2-72599-27-0 DE 2758025 Metabolic and Gaucher's(hydroxymethyl)-(2R-(2Alpha, 3β, 4Alpha, enzyme disorders disease 5β))[CAS] mildronate Hydrazinium, 2-(2-carboxyethyl)-1,1,1- 76144-81-5 WO8001068 Cardiostimulant Heart failure trimethyl), inner salt-[CAS]milnacipran Cyclopropanecarboxamide, 2- 101152-94-7 U.S. 4,478,836Antidepressant Depression, (aminomethyl)-N,N-diethyl-1-phenyl-, cis-92623-85-3 general (±)-[CAS] Miloxacin 37065-29-5 milrinone[3,4′-Bipyridine]-5-carbonitrile, 1,6-dihydro- 78415-72-2 U.S. 4,313,951Cardiostimulant Heart failure 2-methyl-6-oxo-[CAS] ,iltefosineEthanaminium, 2- 53949-20-5 EP 225608 Anticancer, other Cancer, skin,[[(hexadecyloxy)hydroxyphosphinyl]oxy]- 58066-85-6 generalN,N,N-trimethyl-, hydroxide, inner salt [CAS] minaprine4-Morpholineethanamine, N-(4-methyl-6- 25905-77-5 GB 1345880Antidepressant Depression, phenyl-3-pyridazinyl)-[CAS] 25953-17-7general minocycline 2-Naphthacenecarboxamide, 4,7- 10118-90-8Formulation, Infection, oral bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-optimized, octahydro-3,10,12,12a-tetrahydroxy-1,11- microparticlesdioxo-, [4S- (4Alpha,4aAlpha,5a.alpha.,12aAlpha)]- [CAS] minodronic acidPhosphonic acid, (1-hydroxy-2- 180064-38-4 EP 354806 Anticancer, otherCancer, imidazo(1,2-a)pyridin-3-ylethylidene)bis-, myeloma [CAS]minoxidil 2,4-Pyrimidnediamine, 6-(1-piperidinyl)-, 38304-91-5 U.S.4,139,619 Vasodilator, Hypertension, 3-oxide [CAS] peripheral generalMiokamycin 55881-07-7 mirtazapine Pyrazino[2,1-a]pyrido[2,3- 85650-52-8GB 1543171 Antidepressant Depression, c][2]benzazepine, 1,2,3,4,10,14b-61337-67-5 general hexahydro-2-methyl-[CAS] misoprostolProst-13-en-1-oic acid, 11,16-dihydroxy-16 59122-46-2 U.S. 4,301,146Prostaglandin Ulcer, gastric methyl-9-oxo-, methyl ester, 59122-48-4(11Alpha,13E)-(±)-[CAS] mitemcinal Erythromycin,8,9-didehydro-N-demethyl-9- 154802-96-7 WO 9324509 GastroprokineticGastro- deoxo-6,11-dideoxy-6,9-epoxy-12-O- oesophagealmethyl-N-(1-methylethyl)-11-oxo-, (2E)-2- reflux butenedioate (2:1)[CAS] mitiglinide Calcium (2S)-2-benzyl-3-(cis-hexahydro-2- 145525-41-3EP 507534 Antidiabetic Diabetes, isoindolinylcarbonyl)propionate,dihydrate- Type II [CAS] Mitobronitol 488-41-5 Mitoguazone 459-86-9mitolactol Galactitol, 1,6-dibromo-1,6-dideoxy-[CAS] 10318-26-0 U.S.3,993,781 Anticancer, Cancer, alkylating cervical mitomycinAzino[2′,3′:3,4]pyrrolo[1,2-a]indole-4,7- 50-07-7 Formulation, Cancer,dione, 5-amino-8- parenteral, other stomach[[(aminocarbonyl)oxy]methyl]- 1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS- (1aAlpha,8β,8aAlpha,8bAlpha)]-[CAS] Mitotane 53-19-0mitoxantrone 9,10-Anthracenedione, 1,4-dihydroxy-5,8- 65271-80-9 U.S.4,197,249 Anticancer, other Cancer,bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- 70476-82-3 breast [CAS]mitoxantrone 9,10-Anthracenedione, 1,4-dihydroxy-5,8- 65271-80-9Formulation, Cancer, bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-70476-82-9 optimized, liposomes general [CAS] MIV-210(3′-Fluoro-2′,3′-dideoxy guanosine) Antiviral, other Infection,hepatitis- B virus mivacurium Isoquinolinium, 2,2′-[(1,8-dioxo-4-octene-106861-44-3 EP 181055 Muscle relaxant Anaesthesia,1,8-diyl)bis(oxy-3,1-] adjunct propanediyl)bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5- trimethoxyphenyl)methyl]-, dichloride, [R-[R*,R*-(E)]]]-[CAS] Mivazerol 125472-02-8 mizolastine4(1H)-Pyrimidinone, 2-[[1-[1-[(4- 108612-45-9 EP 217700 Antiallergic,Rhinitis, fluorophenyl)methyl]-1H-benzimidazol-2- non-asthma allergic,yl]-4-piperidinyl]methylamino]-[CAS] general Mizoribine 50924-49-7MKC-733 (R)-N-(3-quinuclidinyl)-7-oxo-4,7- 194093-42-0 JP 09216888Gastroprokinetic Gastro- dihydrothieno[3,2-b]pyridine-6- oesophagealcarboxamide hydrochloride reflux MLN-5196-Oxa-2-azabicyclo[3.2.0]heptane-3,7- 211866-70-5 WO 9915183Neuroprotective Ischaemia, dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-cerebral propyl-, (1R,4R,5S)-[CAS] MLN-5764-Methoxy-benzo[a]phenazine-11- Anticancer, other Cancer, carboxylicacid (2-dimethylamino)-1-(R)- general methylethyl)-amide moclobemideBenzamide, 4-chloro-N-[2-(4- 71320-77-9 EP 326023 AntidepressantDepression, morpholinyl)ethyl]-[CAS] general modafinil Acetamide,2-[(diphenylmethyl)sulfinyl]- 68693-11-8 DE 2809625 PsychostimulantNarcolepsy [CAS] moexipril 3-Isoquinolinecarboxylic acid, 2-[2-[[1-103775-10-6 U.S. 4,344,949 Antihypertensive, Hypertension,(ethoxycarbonyl)-3-phenylpropyl]amino]-1- 103775-14-0 renin systemgeneral oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-(3S-(2(R*(R*)),3R*))-[CAS] Mofarotene 125533-88-2 Mofebutazone2210-63-1 Mofegiline 119386-96-8 mofezolac 5-Isoxazoleacetic acid,3,4-bis(4- 78967-07-4 EP 26928 Analgesic, NSAID Pain,methoxyphenyl)-[CAS] post-operative MOL-6131N-[4-(aminomethyl)benzyl]-8(S)-[1-[4-[2-(4- Antiasthma Asthmaaminophenyl)-acetamido]butyryl]piperidin-4-yl]-2-(naphthalen-1-ylmethyl)-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]-pyridazine-5(R)-carboxamide Molindone 7416-34-4 molsidomine Sydnoneimine, N-(ethoxycarbonyl)-3-(4- 25717-80-0 U.S. 3,769,283 Vasodilator,morpholinyl)-[CAS] coronary mometasone Pregna-1,4-diene-3,20-dione,9,21- 105102-22-5 EP 57401 Antipruritic/inflamm, Psoriasisdichloro-11,17-dihydroxy-16-methyl-, 83919-23-7 allergic(11β,16Alpha)-[CAS] Monatepil 103377-41-9 Monobenzone 103-16-2monolaurin Dodecanoic acid, monoester with 1,2,3- 27215-38-9 U.S.4,885,282 Dermatological Ichthyosis propanetriol [CAS] montelukastCyclopropaneacetic acid, 1-[[[1-[3-[2-(7- 151767-02-1 Antiasthma AsthmaChloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1- 158966-92-8 hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, [CAS] Monteplase 122007-85-6Moperone 1050-79-9 Mopidamol 13665-88-8 Moprolol 5741-22-0 moracizineCarbamic acid, [10-[3-(4-morpholinyl)-1- 29560-58-5 U.S. 3,864,487Antiarrhythmic Tachycardia, oxopropyl]-10H-phenothiazin-2-yl]-, ethyl31883-05-3 ventricular ester [CAS] Morazone 6536-18-1 Moricizine31883-05-3 Moroxydine 3731-59-7 Morphazinamide 952-54-5 morphineMorphine-3,6-diol, 7,8-didehydro-4,5- 57-27-2 Formulation, Pain, cancerepoxy-17-methyl-(5Alpha,6Alpha)-, [CAS] 6055-06-7 parenteral, other64-31-3 morphine-6- morphine-6-glucuronide Formulation, Pain, generalglucuronide inhalable, systemic mosapramineSpiro[imidazo[1,2-a]pyridine-3(2H),4′- 89419-40-9 U.S. 4,337,260Neuroleptic piperidin]-2-one, 1′-[3-(3-chloro-10,11- 98043-60-8dihydro-5H-dibenz[b,f]azepin-5- yl)propyl]hexahydro-, (+/−)-[CAS]mosapride Benzamide, 4-amino-5-chloro-2-ethoxy-N- 112885-41-3 EP 243959GI inflammatory/ Gastritis ((4-((4-fluorophenyl)methyl)-2- 112885-42-4bowel disorders morpholinyl)methyl)-[CAS] motexafin Gadolinium,bis(acetetato-kappaO)(9,10- 246252-06-2 Radio/ Cancer, gadoliniumdiethyl-20,21-bis(2-(2-(2- chemosensitizer brainmethoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16:16,13-dinitrilo-1,18- benzodiazacycloeicosine-5,14-dipropanalato-kappaN1,kappaN18, kappaN23, kappaN24, kappaN25), (PB-7-11-233′2′4) [CAS] Motretinide 56281-36-8 Moveltipril 85856-54-8Moxalactam 64952-97-2 Moxastine 3572-74-5 Moxaverine 10539-19-2Moxestrol 34816-55-2 moxifloxacin 3-Quinolinecarboxylic acid,1-cyclopropyl-6- 186826-86-8 DE 19546249 Quinolone Infection,fluoro-1,4-dihydro-8-methoxy-7-(octahydro- 151096-09-2 antibacterialrespiratory 6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-, tract, generalhydrochloride (4aS-cis)-[CAS] moxisylyte Phenol,4-[2-(dimethylamino)ethoxy]-2- 964-52-3 Male sexual Impotencemethyl-5-(1-methylethyl)-, acetate (ester), 54-32-0 dysfunction [CAS]moxonidine 5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro- 75438-57-2 DE2849537 Antihypertensive, Hypertension,1H-imidazol-2-yl)-6-methoxy-2-methyl- other general [CAS] M-PGA(−)-(S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H- U.S. 5,712,291 Anticancer,other Cancer, isoindol-2-yl)pentanedioic acid general MPI-5010 Platinumdiamminedichloro-, (SP-4-2) + U.S. 6,224,883 Formulation, Cancer, head(R)-4-[1-hydroxy-2-(methylamino)-ethyl]- parenteral, other and neck1,2-benzenediol MPI-5020 2,4(1H,3H)-Pyrimidinedione, 5-fluoro- 51-21-8U.S. 5,750,146 Formulation, Cancer, breast [CAS] parenteral, other MPL198076-81-2 Immunostimulant, Vaccine other adjunct MRS-1754 U.S.6,060,481 Antiasthma Asthma MS-209 1-Piperazineethanol,4-(diphenylacetyl)- 158681-49-3 Radio/ Cancer,Alpha-[(5-quinolinyloxy)methyl]-, (2E)-2- chemosensitizer breastbutenedioate(2:3) (salt) [CAS] MS-275N-(2-Aminophenyl)-4-[N-(pyridin-3-yl- Anticancer, Cancer, lung,methoxycarbonyl)aminomethyl]benzamide antimetabolite general MS-325201688-00-8 MS-377 EP 839805 Neuroleptic Schizophrenia Mupirocin12650-69-0 Muscarin 300-54-9 Muzolimine 55294-15-0 MX-1013 U.S.6,153,591 Hepatoprotective Unspecified mycophenolate 4-Hexenoic acid,6-(1,3-dihydro-4-hydroxy- 116680-01-4 WO 9119498 ImmunosuppressantTransplant mofetil 6-methoxy-7-methyl-3-oxo-5- 128794-94-5 rejection,isobenzofuranyl)-4-methyl-, 2-(4- general morpholinyl)ethyl ester,(E)-[CAS] mycophenolic acid 4-hexanoic acid, 6-(1,3-dihydro-4-hydroxy-37415-62-6 Formulation, oral, Transplant 6-methoxy-7-methyl-3-oxo-5-24280-93-1 enteric-coated rejection, isobenzofuranyl)-4-methyl-, generalMyrophine 467-18-5 N-(Hydroxymethyl)- 3569-99-1 nicotinamide N,N,N′,N′-83-81-8 Tetraethylphthalamide N₂-Formyl- 795-13-1 sulfisomidineN₄-β-_(D)- 53274-53-6 Glucosylsulfanilamide N₄- 547-52-4 Sulfanilylsulf-anilamide Nabilone 51022-71-0 nabumetone 2-Butanone,4-(6-methoxy-2-naphthalenyl)- 42924-53-8 GB 1476721 Anti-inflammatoryArthritis, [CAS] osteo N-acetylcysteine L-Cysteine, N-acetyl-[CAS]616-91-1 Anticancer, other Cancer, general N-Acetylmethionine 65-82-7nadifloxacin 1H,5H-Benzo[ij]quinolizine-2-carboxylic 124858-35-1 U.S.4,399,134 Quinolone Acne acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-antibacterial piperidinyl)-5-methyl-1-oxo-, (+/−)-[CAS] nadolol2,3-Naphthalenediol, 5-[3-[(1,1- 42200-33-9 U.S. 4,346,106Antihypertensive, dimethylethyl)amino]-2-hydroxypropoxy]- adrenergic1,2,3,4-tetrahydro-[CAS] Nadoxolol 54063-51-3 nafamostat Benzoic acid,4- 80251-32-7 EP 450232 GI inflammatory/ Pancreatitis[(aminoiminomethyl)amino]-, 6- 81525-10-2 bowel disorders(aminoiminomethyl)-2-naphthalenyl ester- 82956-11-4 [CAS] nafarelinLuteinizing hormone-releasing factor (pig), 76932-56-4 EP 21234Releasing Endometriosis 6-[3-(2-naphthalenyl)-D-alanine]-[CAS]86220-42-0 hormones Nafcillin 147-52-4 Nafronyl 31329-57-4 naftidofuryl2-Furanpropanoic acid, tetrahydro-Alpha- 31329-57-4 Formulation,Unspecified (1-naphthalenylmethyl)-, 2- modified- (diethylamino)ethylester release, other naftifine 1-Naphthalenemethanamine, N-methyl-N-65472-88-0 U.S. 4,282,251 Antifungal Infection, (3-phenyl-2-propenyl)-,(E)-[CAS] 65473-14-5 dermatological naftopidil 1-Piperazineethanol,4-(2-methoxyphenyl)- 57149-07-2 U.S. 3,997,666 Antihypertensive,Hypertension, Alpha-[(1-naphthalenyoxy)methyl]-[CAS] adrenergic generalnalbuphine Morphinan-3,6,14-triol, 17- 20594-83-6 U.S. 3,393,197Analgesic, other Pain, general (cyclobutylmethyl)-4,5-epoxy-, 23277-43-2(5Alpha,6Alpha)-[CAS] Nalidixic Acid 389-08-2 nalmefeneMorphinan-3,14-diol, 17- 55096-26-9 JP 56167687 Dependence Poisoning,drug (cyclopropylmethyl)-4,5-epoxy-6- treatmentmethylene-,(5Alpha)-[CAS] Nalorphine 62-67-9 naloxone Morphinan-6-one,17-allyl-4,5Alpha-epoxy- 357-08-4 Septic shock 3,14-dihydroxy-,hydrochloride [CAS] 465-65-6 treatment naltrexone Morphinan-6-one,17-(cyclopropylmethyl)- 16590-41-3 U.S. 3,332,950 Dependence Addiction,4,5-epoxy-3,14-dihydroxy-, (5Alpha)-[CAS] 16676-29-2 treatmentnarcotic/opiate NAMI Imidazolium Anticancer, other Cancer, generaltrans(imidazole)(dimethylsulfoxide)- tetrachlororuthenate (III)naminidil Guanidine, N-cyano-N′-(4-cyanophenyl)- 220641-11-2Dermatological Alopecia, N″-[(1R)-1,2,2-trimethylpropyl]-[CAS] generalNandrolone 434-22-0 Naphazoline 835-31-4 Naphthalene 91-20-3 naproxenbetainate Methanaminium, 1-carboxy-N,N,N- 104124-26-7 U.S.. 4,672,077Antiarthritic, Arthritis, trimethyl-salt with (R)-6-methoxy-Alpha- otherrheumatoid methyl-2-naphthaleneacetic acid (1:1), sodium salt [CAS]naproxen 2-Naphthaleneacetic acid, 6-methoxy- 26159-34-2 GB 1211134Analgesic, NSAID Pain, general Alpha-methyl-, [CAS] 22204-53-1naratriptan 1H-Indole-5-ethanesulfonamide, N-methyl- 121679-13-8 EP303507 Antimigraine Migraine 3-(1-methyl-4-piperidinyl)-[CAS] Narceine131-28-2 Narcobarbital 125-55-3 Natamycin 7681-93-8 nateglinideD-phenylalanine, N-((4-(1- 105816-04-4 EP 196222 Antidiabetic Diabetes,methylethyl)cyclohexyl)carbonyl)-, trans- Type II [CAS] N-Butyldeoxy-72599-27-0 nojirimycin N-Butylscopol- 149-64-4 ammonium Bromide NC-503U.S. 5,643,562 Anti-inflammatory Amyloidosis NC-531 U.S. 5,643,562Cognition enhancer Alzheimer's disease NCX-1000 WO 0061604Hepatoprotective Cirrhosis, hepatic NCX-4016 Benzoic acid,2-(acetyloxy)-, 2- 175033-36-0 WO 9716405 Symptomatic Insulin-related((nitrooxy)methyl)phenyl ester [CAS] antidiabetic metabolic syndromeNCX-456 Benzoic acid, 5-amino-2-hydroxy-, 4- 256499-26-0 GIinflammatory/ Inflammatory (nitrooxy)butyl ester [CAS] bowel disordersbowel disease NCX-950 Alpha′-[[(1,1-dimethylethyl)amino]methyl]-4Antiasthma Asthma hydroxy-1,3-benzenedimethanol nitrate n-Docosanol661-19-8 NE-100 Benzeneethanamine, 4-methoxy-3-(2- 149409-57-4 WO9307113 Neuroleptic Schizophrenia phenylethoxy)-N,N-dipropyl-,hydrochloride [CAS] Nealbarbital 561-83-1 nebivolol2H-1-Benzopyran-2-methanol, 118457-14-0 EP 145067 Antihypertensive,Hypertension, Alpha,Alpha′-[iminobis(methylene)]bis[6- 99200-09-6adrenergic general fluoro-3,4-dihydro]-, (2R*(R*(R*(S*))))-(1+)- [CAS]nebostinel N1-(4,4-Dimethylcyclohexyl)-L- 163000-63-3 EP 0688312Cognition Unspecified isoglutamine enhancer Nebracetam 97205-34-0nedaplatin Platinum, diammine[hydroxyacetato(2-)- 95734-82-0 EP 216362Anticancer, O1,O2]-, (SP-4-3)-[CAS] alkylating nedocromil4H-Pyrano[3,2-g]quinoline-2,8-dicarboxylic 69049-73-6 EP 555718Antiasthma, Rhinitis, allergic, acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-69049-74-7 Ophthalmological general, Ocular propyl-[CAS] disorder,general nefazodone 3H-1,2,4-Triazol-3-one, 2-[3-[4-(3- 82752-99-6 U.S.4,338,317 Antidepressant Depression,chlorophenyl)-1-piperazinyl]propyl]-5-ethyl- 83366-66-9 general2,4-dihydro-4-(2-phenoxyethyl)-, [CAS] nefiracetam1-Pyrrolidineacetamide, N-(2,6- 77191-36-7 U.S. 4,341,790 CognitionDementia, dimethylphenyl)-2-oxo-[CAS] enhancer senile, general nefopam1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro- 13669-70-0 U.S. 3,487,153Analgesic, NSAID 5-methyl-1-phenyl-[CAS] 23327-57-3 Negamycin 33404-78-3nelfinavir 3-Isoquinolinecarboxamide, N-(1,1- 159989-65-8 Antiviral,anti-HIV Infection, dimethylethyl)decahydro-2-(2-hydroxy-3- 159989-64-7HIV/AIDS ((3-hydroxy-2-methylbenzoyl)amino)-4- (phenylthio)butyl)-, (3S-(2(2S*,3S*),3Alpha,4aβ,8aβ))-, [CAS] Nemonapride 75272-39-8 Neostigmine59-99-4 nepadutant Cyclo[3-amino-L-alanyl-L-leucyl-N-[2- 183747-35-5 WO9628467 Antiasthma Asthma (acetylamino)-2-deoxy-β-D-glucopyranosyl]-L-asparaginyl-L-Alpha-aspartyl-L-tryptophyl-L-phenylalanyl], (4-1)- lactam [CAS] neramexane1,3,3,5,5-pentamethylcyclohexylamine 202807-80-5 Dependence Addiction,219810-59-0 treatment alcohol neridronic acid Phosphonic acid,(6-amino-1- 79778-41-9 Musculoskeletal Osteogenesishydroxyhexylidene)bis-[CAS] imperfecta Neriifolin 466-07-9N-Ethylamphetamine 457-87-4 neticonazole 1H-Imidazole,1-[2-(methylthio)-1-[2- 130773-02-3 EP 445540 Antifungal Infection,(pentyloxy)phenyl]ethenyl]-, 130726-68-0 Candida, monohydrochloride,(E)-[CAS] general netilmicin D-Streptamine, O-3-deoxy-4-C-methyl-3-56391-56-1 GB 1473733 Aminoglycoside Infection,(methylamino)-β-L-arabinopyranosyl-(1-6)- 56391-57-2 antibiotic generalO-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-Dglycero-hex-4-enopyranosyl-(1-4)]-2-deoxy- N1-ethyl-[CAS] nevirapine6H-Dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6- 129618-40-2 EP 429987Antiviral, Infection, one, 11-cyclopropyl-5,11-dihtdro-4-methyl-anti-HIV HIV/AIDS [CAS] NGD-98-2 WO 9635689 Anxiolytic Anxiety, generalNialamide 51-12-7 Niaprazine 27367-90-4 Nicametate 3099-52-3 nicaraven3-Pyridinecarboxamide, N,N′-(1-methyl-1,2- 79455-30-4 EP 29602Neuroprotective Haemorrhage, ethanediyl)bis-[CAS] subarachnoidnicardipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro- 54527-84-3 U.S.3,985,758 Neuroprotective Hypertension, 2,6-dimethyl-4-(3-nitrophenyl)-,methyl 2- 55985-32-5 general [methyl(phenylmethyl)amino]ethyl ester[CAS] nicergoline Ergoline-8-methanol, 10-methoxy-1,6- 27848-84-6Formulation, Unspecified dimethyl-, (8/b)-, 5-bromo-3- modified-pyridinecarboxylate(ester) release, other Niceritrol 5868053 Niclosamide50-65-7 Nicoclonate 10571-59-2 Nicofuranose 15351-13-0 Nicomol27959-26-8 Nicomorphine 639-48-5 nicorandil 3-Pyridinecarboxamide, N-[2-65141-46-0 U.S. 4,792,564 Vasodilator, Hypertension,(nitrooxy)ethyl]-[CAS] coronary general Nicotinamide 98-92-0 nicotinePyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- 54-11-5 Formulation,Addiction, [CAS] inhalable, other nicotine Nicotinic Acid 59-67-6Nicotinic Acid Benzyl 94-44-0 Ester Nicotinyl Alcohol 100-55-0nifedipine 4-(2′-nitrophenyl)-2,6-dimethyl-3,5- 21829-25-4 GB 1173862Vasodilator, Hypertension, dicarbomethoxy-1,4-dihydropyridine coronarygeneral nifekalant 2,4(1H,3H)-Pyrimidinedione, 6-[[2-[(2- 130636-43-0 EP369627 Antiarrhythmic Arrhythmia, hydroxyethyl)[3-(4- 130656-51-8general nitrophenyl)propyl]amino]ethyl]amino]-1,3- dimethyl-, [CAS]Nifenalol 7413-36-7 Niflumic Acid 4394-00-7 Nifuratel 4936-47-4Nifurfoline 3363-58-4 Nifuroxazide 965-52-6 Nifuroxime 6236051Nifurpirinol 13411-16-0 Nifurprazine 1614-20-6 Nifurtimox 23256-30-6Nifurtoinol 1088-92-2 nifurzide 2-Thiophenecarboxylic acid, 5-nitro-,[3-(5- 39978-42-2 U.S. 3,847,911 Antidiarrhoeal Infection,nitro-2-furanyl)-2-propenylidene]hydrazide GI tract [CAS] NIK-254Gentamicin, sulfate (salt) [CAS] 1405-41-0 Formulation, other Infection,general Nikethamide 59-26-7 nilutamide 2,4-Imidazolidinedione,5,5-dimethyl-3-[4- 63612-50-0 U.S. 4,472,382 Anticancer, Cancer,nitro-3-(trifluoromethyl)phenyl]-[CAS] hormonal prostate nilvadipine3,5-Pyridinedicarboxylic acid, 2-cyano-1,4- 75530-68-6 U.S. 4,338,322Antihypertensive, Hypertension, dihydro-6-methyl-4-(3-nitrophenyl)-, 3-other general methyl 5-(1-methylethyl) ester [CAS] nimesulideMethanesulfonamide, N-(4-nitro-2- 51803-78-2 U.S. 3,840,597Anti-inflammatory Pain, general phenoxyphenyl)-[CAS] Nimetazepam2011-67-8 nimodipine 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-66085-59-4 EP 533014 Neuroprotective 2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS] Nimorazole 6506-37-2 nimustineUrea, N′-[(4-amino-2-methyl-5- 103745-00-2 GB 1374344 Anticancer,Cancer, brain pyrimidinyl)methyl]-N-(2-chloroethyl)-N- 42471-28-3alkylating nitroso-[CAS] 55661-38-6 Ninopterin 2179-16-0 NIP-142N-[4(S)-(Cyclopropylamino)-3-(R)-hydroxy- WO 9804542 AntiarrhythmicFibrillation, 2,2-dimethyl-7-nitro-3,4-dihydro-2H-1- atrialbenzopyran-6-yl]-4- methoxybenzeneacetamide NIP-531N′-[3,5-Bis(trifluoromethyl)benzyl]-N-[3-[N- Antipruritic/inflamm,Eczema, [1-(4-fluorobenzyl)benzimidazol-2-yl]- allergic atopicamino]propyl-N-methylurea hydrochloride niperotidine N-[2-[[5-84845-75-0 GB 2104071 Antiulcer Ulcer, GI,[(dimethylamino)methyl]furfuryl]thio]ethyl]- general2-nitro-N′-piperonyl-1,1-ethenediamine nipradilol 2H-1-Benzopyran-3-ol,3,4-dihydro-8-[2- 81486-22-8 EP 42299 Formulation, Glaucomahydroxy-3-[(1-methylethyl)amino]propoxy]-, 86247-86-1 mucosal, topical3-nitrate [CAS] Niridazole 61-57-4 nisoldipine 3,5-Pyridinedicarboxylicacid, 1,4-dihydro- 63675-72-9 GB 1516793 Antihypertensive, Hypertension,2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2- other general methylpropylester-[CAS] nitazoxanide Benzamide, 2-(acetyloxy)-N-(5-nitro-2-55981-09-4 U.S. 5,387,598 Protozoacide Infection, GI thiazolyl)-[CAS]tract nitisinone 1,3-Cyclohexanedione, 2-[2-nitro-4- 104206-65-7 EP186118 Metabolic and Cirrhosis, (trifluoromethyl)benzoyl]-[CAS] enzymedisorders hepatic nitracrine 1,3-Propanediamine, N,N-dimethyl-N′-(1-4533-39-5 FR 1458183 Anticancer, other Cancer, nitro-9-acridinyl)-[CAS]6514-85-8 ovarian Nitrazepam 146-22-5 nitrendipine3,5-Pyridinedicarboxylic acid, 1,4-dihydro- 39562-70-4 GB 1358951Antihypertensive, Hypertension, 2,6-dimethyl-4-(3-nitrophenyl)-, ethylother general methyl ester-[CAS] nitroflurbiprofen(1,1′-Biphenyl)-4-acetic acid, 2-fluoro- 158836-71-6 EP 670825Urological Incontinence Alpha-methyl-, 4-(nitrooxy)butyl ester [CAS]Nitrofurantoin 67-20-9 Nitrofurazone 59-87-0 nitroglycerin1,2,3-Propanetriol, trinitrate [CAS] 55-63-0 Formulation, Angina,transdermal, patch general Nitromersol 133-58-4 nitronaproxen2-Naphthaleneacetic acid, 6-methoxy-Alpha- 163133-43-5 WO 9509831Analgesic, NSAID Pain, post- methyl 4-(nitrooxy)butyl ester (AlphaS)-operative [CAS] nitroxazepine Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-16398-39-3 NL 6608671 Antidepressant [3-(dimethylamino)propyl]-2-nitro-,monohydrochloride [CAS] Nitroxoline 4008-48-4 nizatidine1,1-Ethenediamine, N-[2-[[[2- 76963-41-2 EP 49618 Antiulcer Ulcer,[(dimethylamino)methyl]-4- duodenalthiazolyl]methyl]thio]ethyl]-N′-methyl-2- nitro-[CAS] Nizofenone54533-85-6 NM-3 3-(2-methylcarboxymethyl)-6-methoxy-8- JP 08176138Anticancer, other Cancer, hydroxy-isocoumarin general NM-7024-Bromo-5-(3-pyridylmethylamino)-6-[3-(4- Antithrombotic Peripheralchlorophenyl)propoxy]-3(2H)pyridazinone vascular hydrochloride diseaseN-Methylephedrine 552-79-4 N-Methylepinephrine 554-99-4N-Methylglucamine 6284-40-8 NN-4146-chloro-3-(1-methylcyclopropylamino)-4H- Antidiabetic Diabetes,thieno[3,2-e]-[1,2,4]thiadiazine-1,1-dioxide Type II NNC-05-1869(R)-1-(3-(10,11-dihydro-5H- Symptomatic Neuropathy,dibenzo[a,d]cyclohepten-5-ylidene)-1- antidiabetic diabeticpropyl)-3-piperidine carboxylic acid Nogalamycin 1404-15-5 nolatrexed4(1H)-Quinazolinone, 2-amino-6-methyl-5- 152946-68-4 WO 9320055Anticancer, (4-pyridinylthio)-, [CAS] 147149-76-6 antimetabolite Cancer,liver nolomirole Propanoic acid, 2-methyl-, 5,6,7,8- 138531-51-8 WO9529147 Cardiostimulant Heart failure tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (+/−)- [CAS] nolpitantium1-Azoniabicyclo[2.2.2]octane, 1-[2-[3-(3,4- 153050-21-6 EP 591040 GIinflammatory/ Inflammatory dichlorophenyl)-1-[[3-(1- bowel disordersbowel methylethoxy)phenyl]acetyl]-3- diseasepiperidinyl]ethyl]-4-phenyl-, chloride, (S)- [CAS] nomegestrol19-Norpregna-4,6-diene-3,20-dione, 17- 58652-20-3 DE 2522533Menstruation Menstrual (acetyloxy)-6-methyl-[CAS] disorders disorder,general Nomifensine 24526-64-5 Noprylsulfamide 576-97-6 Norbolethone1235-15-0 Nordazepam 1088-11-5 Nordefrin 6539-57-7 (unspecified);74812-63-8 (R*,S*)-(±)- form Nordihydroguaiaretic 27686-84-6 Acid(meso-form); 500-38-9 (unspecified) Norelgestromin, Ethinyl EstradiolNorepinephrine 51-41-2 Norethandrolone 52-78-8 Norethindrone 68-22-4Norethynodrel 68-23-5 Norfenefrine 536-21-0 norfloxacin3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro- 68077-27-0 U.S. 4,146,719Quinolone Infection, 1,4-dihydro-4-oxo-7-(1-piperazinyl)-[CAS]70458-96-7 antibacterial general Norgesterone 13563-60-5 Norgestimate35189-28-7 Norgestrel 6533-00-2 Norgestrienone 848-21-5 Norlevorphanol1531-12-0 Normethadone 467-85-6 Normethandrone 514-61-4 Normorphine466-97-7 Norphenazone 89-25-8 Norpipanone 561-48-8 Norpseudoephedrine492-39-7 Nortriptyline 72-69-5 Norvinisterone 6795-60-4 Noscapine128-62-1 Novembichin 1936-40-9 Novobiocin 303-81-1 Noxiptillin 3362-45-6Noxythiolin 15599-39-0 NS-1209 Butanoic acid, 2-[[[5-[4- 254751-28-5 WO9426747 Antiepileptic Epilepsy, [(dimethylamino)sulfonyl]phenyl]-general 1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3- ylidene]amino]oxy]-3-hydroxy-[CAS] NS-12315-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H- Neuroprotective Ischaemia,pyrolo-(3,2-h)naphthalene-2,3-dione-3- cerebral oxime NS-126 U.S.5,063,222 Antiallergic, Rhinitis, non-asthma allergic, general NS-2202-Methyl-c-5-[4-[5-methyl-2-(4- Hypolipaemic/ Athero-methylphenyl)-4-oxazolyl]butyl]-1,3- Antiatherosclerosis sclerosisdioxane-r-2-carboxylic acid NS-2330 NS 2330 [CAS] 402856-42-2 Cognitionenhancer Alzheimer's disease NS5A inhibitors U.S. 6,030,785 Antiviral,other Infection, hepatitis- C virus NS-7 Pyrimidine,4-(4-fluorophenyl)-2-methyl-6- 178429-67-9 WO 9607641 NeuroprotectiveIschaemia, [[5-(1-piperidinyl)pentyl]oxy]-, cerebral monohydrochloride[CAS] NS-8 2-Amino-5-(2-fluorophenyl)-4-methyl-1H- UrologicalIncontinence pyrrole-3-carbonitrile NSC-330507 17-AllylaminogeldanamycinAnticancer, Cancer, antibiotic general NSC-619534 2-chloroethyl phenylselenone Anticancer, Cancer, alkylating general NSC-6977262,5-diazinidinyl-3-[hydroxymethyl]6-methyl- Anticancer, Cancer,1,4-benzoquinone antibiotic general N-Sulfanilyl-3,4- 120-34-3 xylamideNU-6027 2,4-Pyrimidinediamine, 6- 220036-08-8 Anticancer, other Cancer,(cyclohexylmethoxy)-5-nitroso-[CAS] general NV-072,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl- 53745-16-7 U.S. 6,455,032Antipruritic/inflamm, Keratosis 5-sec-pentyl-, 2-oxime [CAS]non-allergic NVP-SRA880 ([3R,4aR,10aR]-1,2,3,4,4a,5,10,10a- NeurologicalUnspecified Octahydro-6-methoxy-1-methyl- benz[g]quinoline-3-carboxylicacid-4-(4- nitrophenyl)piperazine amide, hydrogen maleate NW-1029(S)-(+)-2-[4-(2- Analgesic, other Pain, generalfluorobenzyloxy)benzylamino]propanamide methansulfonate NXY-059 CPI 22[CAS] 168021-79-2 U.S. 5,780,510 Neuroprotective Ischaemia, cerebralNylidrin 447-41-6 NZ-314 1-Imidazolidineacetic acid, 3-[(3- 128043-99-2EP 353198 Symptomatic Neuropathy, nitrophenyl)methyl]-2,4,5-trioxo-[CAS]antidiabetic diabetic NZ-419 5-hydroxy-1-methylimidazolidine-2,4-dioneEP 412940 Urological Renal failure Obidoxime Chloride 114-90-9 OC-108 OC108 [CAS] 162602-62-2 Vasoprotective, Venous topical insufficiencyocinaplon Methanone, 2-pyridinyl[7-(4- 96604-21-6 EP 129847 AnxiolyticGeneralized pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]- anxiety [CAS]disorder Octabenzone 1843-05-6 Octacaine 13912-77-1 Octamoxin 4684-87-1Octaverine 549-68-8 octenidine 1-Octanamine, N,N′-(1,10-decanediyldi-70775-75-6 WO 8705501 Stomatological Periodontitis1(4H)-pyridinyl-4-ylidene)bis-[CAS] 71251-02-0 86767-75-1 Octodrine543-82-8 Octopamine 104-14-3 Octotiamine 137-86-0 octreotideL-Cysteinamide, D-phenylalanyl-L- 83150-76-9 Formulation, Cancer,cysteinyl-L-phenylalanyl-D-tryptophy-L- fixed-dose generallysyl-L-threonyl-N-[2-hydroxy-1- combinations (hydroxymethyl)propyl]-,cyclic (2-7)- disulfide, [R-(R*,R*)]-[CAS] Octyl 5466-77-3Methoxycinnamate ofloxacin 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-82419-36-1 EP 47005 Quinolone carboxylic acid, 9-fluoro-2,3-dihydro-3-antibacterial methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+/−)-[CAS]o-lodohippurate 133-17-5 loanzapine10H-Thieno(2,3-b)(1,5)benzodiazepine, 2- 132539-06-1 EP 454436Neuroleptic Schizophrenia methyl-4-(4-methyl-1-piperazinyl)-[CAS]Oleandrin 465-16-7 Oleic Acid 112-80-1 olmesartan -1H-Imidazole-5-carboxylic acid, 4-(1- 144689-63-4 EP 503785Antihypertensive, Hypertension, medoxomilhydroxy-1-methylethyl)-2-propyl-1-((2′-(1H- renin system generaltetrazol-5-yl)(1,1′-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS] olopatadine11-[(Z)-3-(Dimethylamino)propylidene]- 113806-05-6 EP 235796Ophthalmological Conjunctivitis 6,11-dihydrodibenz[b,e]oxepin-2-acetic140462-76-6 acid, monohydrochloride olpadronic acid Monosodium3-dimethylamino-1- 63132-39-8 WO 9619998 Osteoporosis Osteoporosis(hydroxypropylidene)-1,1-bisphosphonate treatment olsalazine Benzoicacid, 3,3′-azobis[6-hydroxy-[CAS] 15722-48-2 U.S. 4,559,330 GIinflammatory/ Colitis, 53200-51-4 bowel disorders ulcerative oltipraz3H-1,2-Dithiole-3-thione, 4-methyl-5- 64224-21-1 DE 2705641 Anticancer,other Cancer, general pyrazinyl-[CAS] OM-294DP2-[3(R)-(Dodecanoyloxy)tetradecanamido]- Anticancer, UnspecifiedN-[4-[3(R)-hydroxytetradecanamido]-5- immunological(phosphonooxy)pentyl]-4- (phosphonooxy)butyramide Omacor ethyl(5Z,8Z,11Z,14Z,17Z)-eicosa- 81926-94-5 Hypolipaemic/ Hypertrigly-5,8,11,14,17-pentaenoate + ethyl 86227-47-6 Antiatherosclerosisceridaemia (4Z,7Z,10Z,13Z,16Z,19Z)-docosa- 4,7,10,13,16,19-hexaenoateomapatrilat 7H-Pyrido(2,1-b)(1,3)thiazepine-7- 167305-00-2 U.S.5,508,272 Antihypertensive, Hypertension, carboxylic acid,octahydro-4-((2-mercapto- renin system general1-oxo-3-phenylpropyl)amino)-5-oxo, (4S- (4Alpha(R*),7Alpha,10aβ))-[CAS]omeprazole 1H-Benzimidazole, 5-methoxy-2-[[(4- 73590-58-6 U.S. 4,255,431Antiulcer Ulcer, GI, methoxy-3,5-dimethyl-2- generalpyridinyl)methyl]sulfinyl]-[CAS] omiloxetine Ethanone,2-[(3R,4S)-3-[(1,3-benzodioxol- 176894-09-0 Antidepressant Depression,5-yloxy)methyl]-4-(4-fluorophenyl)-1- generalpiperidinyl]-1-(4-fluorophenyl)-, rel-[CAS] omoconazole 1H-Imidazole,1-[2-[2-(4- 74512-12-2 EP 8804 Antifungal Infection,chlorophenoxy)ethoxy]-2-(2,4- dermatologicaldichlorophenyl)-1-methylethenyl]-, (Z)- [CAS] Onapristone 96346-61-1ondansetron 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9- 99614-01-4 U.S.4,847,281 Antiemetic Chemotherapy- methyl-3-[(2-methyl-1H-imidazol-1-99614-02-5 induced nausea yl)methyl]-[CAS] and vomiting ONO-3403 Benzoicacid, 4-[(1E)-3-[(2-ethoxy-2- 181586-07-2 GI inflammatory/ Unspecifiedoxoethyl)-2-propenylamino]-2-methyl-3- bowel disorders oxo-1-propenyl]-,4- (aminoiminomethyl)phenyl ester, monomethanesulfonate [CAS] ONO-41281,4,9-Triazaspiro(5.5)undecane-2,5-dione, 342394-93-8 Antiviral,anti-HIV Infection, 1-butyl-3-(cyclohexylmethyl)-9-((2,3- HIV/AIDSdihydro-1,4-benzodioxin-6-yl)methyl- [CAS] ONO-8815 Ly L-lysine(Z)-7-[(1R,2R,3R,5R)-5-chloro-3- Labour inhibitor Labour,hydroxy-2-[(E)-(S)-4-(1-ethylcyclobutyl)-4- pretermhydroxy-1-butenyl]cyclopentyl]-5- heptenoate ONT-093 U.S. 5,756,527Radio/ Cancer, chemosensitizer general OPC-14523 2(1H)-Quinolinone,1-[3-[4-(3- 145969-30-8 EP 512525 Antidepressant Depression,chlorophenyl)-1-piperazinyl]propyl]-3,4- general dihydro-5-methoxy-[CAS]OPC-31260 Benzamide, N-[4-[[5-(dimethylamino)- 137975-06-5 WO 9105549Urological Unspecified 2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl- OPC-51803 (5R)-2-[1-(2-chloro-4-(1-Antidiabetic Diabetes, pyrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-insipidus 1-benzazepin-5-yl]-N-isopropylacetamide OPC-65352-Pyridinecarboxylic acid, 6-[2-(3,4- 145739-56-6 WO 9209586 GIinflammatory/ Inflammatory diethoxyphenyl)-4-thiazolyl]-[CAS] boweldisorders bowel disease Opiniazide 2779-55-7 opioid analgesics2-(4-trifluoromethylphenyl)-N-methyl-[1- Analgesic, other Pain, generalphenyl-2-(1-pyrolidinyl)ethylacetamide] Opipramol 315-72-0 Orazamide2574-78-9 orazipone 2,4-Pentanedione, 3-((4- 137109-78-5 EP 440324Antiasthma Unspecified methylsulfonyl)phenyl)methylene)-[CAS] Org-12962Piperazine, 1-[6-chloro-5-(trifluoromethyl)- 210821-63-9 AntidepressantDepression, 2-pyridinyl]-, monohydrochloride [CAS] general Org-24448U.S. 6,166,008 Neuroleptic Schizophrenia oritavancin Vancomycin,22-O-(3-amino-2,3,6-trideoxy- 171099-57-3 U.S. 5,840,684 Peptideantibiotic Infection, 3-C-methyl-Alpha-L-arabino- dermatologicalhexopyranosyl)-N3″-[(4′-chloro[1,1′- biphenyl]-4-yl)methyl]-,(4″R)-[CAS]orlistat L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2- 96829-58-2 EP 129748Anorectic/ Obesity oxetanyl)methyl]dodecyl ester, [2S- Antiobesity[2Alpha(R*),3β]]-[CAS] ormeloxifene Pyrrolidine, 1-[2-(p-(7-methoxy-2,2-31477-60-8 DE 2329201 Female Contraceptive, dimethyl-3-phenyl-4-contraceptive female chromanyl)phenoxy)ethyl]-, trans-[CAS] Ornidazole16773-42-5 Ornipressin 3397-23-7 Ornithine 70-26-8 ornoprostilProst-13-en-1-oic acid, 11,15-dihydroxy- 70667-26-4 U.S. 4,278,688Prostaglandin Ulcer, gastric 17,20-dimethyl-6,9-dioxo-, methyl ester,(11Alpha,13E,15S,17S)-[CAS] Orotic Acid 65-86-1 Orphenadrine 83-98-7Orthocaine 536-25-4 Osalmid 526-18-1 osanetant Acetamide,N-[1-[3-[(3R)-1-benzoyl-3-(3,4- 160492-56-8 EP 673928 NeurolepticSchizophrenia dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl]-N-methyl-[CAS] osaterone2-Oxapregna-4,6-diene-3,20-dione, 17- 105149-00-6 EP 193871 ProstateBenign prostatic (acetyloxy)-6-chloro-[CAS] disorders hyperplasiaoseltamivir 1-Cyclohexene-1-carboxylic acid, 4- 196618-13-0 WO 9626933Antiviral, other Infection, (acetylamino)5-amino-3-(1-ethylpropoxy)-,influenza virus ethyl ester, (3R-(3Alpha,(4β,5Alpha))- [CAS] OSI-78364′-Thio-β-D-arabinofuranosylcytosine Anticancer, Cancer, antimetabolitegeneral OSI-7904 Pentanedioic acid, 2-[5-[[(1,2-dihydro-3- 139987-54-5WO 9119700 Formulation, Cancer, methyl-1-oxobenzo[f]quinazolin-9-optimized, liposomes general yl)methyl]amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-, (S)-[CAS] ospemifene Ethanol,2-[4-[(1Z)-4-chloro-1,2-diphenyl-1- 128607-22-7 WO 9607402 MenopausalOsteoporosis butenyl]phenoxy]-[CAS] disorders otilonium bromideEthanaminium, N,N-diethyl-N-methyl-2-[[4- 26095-59-0 GB 1181406Antispasmodic Irritable bowel [[2-(octyloxy)benzoyl]amino]benzoyl]oxy]-,syndrome bromide [CAS] Ouabain 630-60-4 Oxaceprol 33966-33-7 Oxacillin66-79-5 Oxaflozane 26629-87-8 oxaliplatin Platinum,(1,2-cyclohexanediamine- 61825-94-3 EP 393575 Anticancer, Cancer,N,N′)[ethanedioato(2-)-O,O′]-, [SP-4-2-(1R- alkylating colorectaltrans)]-[CAS] Oxalyt-C 1,2,3-Propanetricarboxylic acid, 2-hydroxy-,28060-67-5 DE 2249274 Urological potassium sodium salt [CAS] Oxamarin15301-80-1 Oxametacine 27035-30-9 Oxamniquine 21738-42-1 oxandrolone2-Oxaandrostan-3-one, 17-hydroxy-17- 53-39-4 U.S. 3,128,283Reproductive/ Sex- methyl-, (5Alpha,17β)-[CAS] gonadal, generalchromosome abnormality, Turner's syndrome Oxantel 36531-26-7Oxapropanium 541-66-2 oxaprozin 2-Oxazolepropanoic acid, 4,5-diphenyl-21256-18-8 GB 1206403 Antiarthritic, other Arthritis, [CAS] osteooxatomide 2H-Benzimidazol-2-one, 1-[3-[4- 60607-34-3 GB 1579365Antiallergic, Rhinitis, (diphenylmethyl)-1-piperazinyl]propyl]-1,3-non-asthma allergic, dihydro-[CAS] general oxazepam7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl- 604-75-1 Formulation, oral,Anxiety, 2H-1,4-benzodiazepin-2-one orally-disintegrating generaloxazolam Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)- 27167-30-2 U.S.3,772,371 Anxiolytic one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl-[CAS] oxcarbazepine5H-Dibenz[b,f]azepine-5-carboxamide, 28721-07-5 DE 2011087 AntiepilepticEpilepsy, 10,11-dihydro-10-oxo-[CAS] 29331-92-8 general Oxeladin468-61-1 Oxendolone 33765-68-3 Oxethazaine 126-27-2 Oxetoron 26020-55-3oxiconazole Ethanone, 1-(2,4-dichlorophenyl)-2-(1H- 64211-45-6 GB1514870 Antifungal Infection, imidazol-1-yl)-, O-[(2,4- fungal,dichlorophenyl)methyl]oxime, (Z)-[CAS] general Oxidronic Acid 15468-10-7Oxiniacic Acid 2398-81-4 Oxiracetam 62613-82-5 oxitropium3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 30286-75-0 GB 1178305Antiasthma 9-ethyl-7-(3-hydroxy-1-oxo-2- phenylpropoxy)-9-methyl-,bromide, [7(S)- (1Alpha,2β,4β,5Alpha,7β)]-[CAS] Oxolamin 959-14-8Oxolinix Acid 14698-29-4 Oxophenarsine 538-03-4 Oxprenolol 6452-71-7Oxybenzone 131-57-7 oxybutynin Benzeneacetic acid, Alpha-cyclohexyl-5633-20-5 Formulation, Incontinence Alpha-hydroxy-,4-(diethylamino)-2-butynyl modified- ester-[CAS] release, otherOxycinchophen 485-89-2 oxycodone Morphinan-6-one,4,5-epoxy-14-hydroxy-3- 76-42-6 Formulation, Pain, generalmethoxy-17-methyl-, (5Alpha)- transmucosal, nasal Oxytedrine 15687-41-9Oxygent Octane, 1-bromo- 423-55-2 Haematological Surgery1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8- adjunct heptadecfluoro-[CAS]Oxymesterone 145-12-0 Oxymetazoline 1491-59-4 oxymetholoneAndrostan-3-one, 17-hydroxy-2- 434-07-1 Hormone Anaemia,(hydroxymethylene)-17-methyl-, general (5Alpha,17β)-[CAS] Oxymethurea140-95-4 oxymorphone (5Alpha)-4,5-Epoxy-3,14-dihydroxy-17- 76-41-5Formulation, Pain, general methylmorphinan-6-one [CAS] modified-release, immediate Oxypendyl 5585-93-3 Oxypertine 153-87-7Oxyphenbutazone 129-20-4 Oxyphencyclimine 125-53-1 Oxyphenisatin115-33-3 Oxyphenonium 50-10-2 Oxypinocamphone 10136-65-9 oxypurinol1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)- 2465-59-0 Antigout Hyper- dione[CAS] uricaemia Oxytetracycline 79-57-2 ozagrel 2-Propenoic acid,3-[4-(1H-imidazol-1- 78712-43-3 GB 2025946 Antithrombotic Vasospasm,ylmethyl)phenyl]-, (E)-[CAS] 82571-53-7 cerebral p-(Benzyl- 536-95-8sulfonamido)- benzoic Acid P-100 U.S. 6,313,777 Antiviral, anti-HIVInfection, HIV/AIDS P-1202 Pentanoic acid, 5-amino-4-oxo, methyl79416-27-6 U.S. 6,034,267 Dermatological Keratosis ester, hydrochloride[CAS] P32/98 Di-(3N-[(2S,3S)-2-amino-3-methyl- Antidiabetic Diabetes,pentanoyl]-1,3-thiazolidine)fumarate Type II PA-824 WO 9701562Antimycobacterial Infection, tuberculosis PACAP 38 Pituitary adenylatecyclase-activating 128606-20-2 U.S. 5,128,242 Neuroprotective Nerveinjury, peptide-38 [CAS] general pactitaxel5β,20-Epoxy-1,2Alpha,4,7β,10β,13Alpha- 33069-62-4 Formulation, Cancer,hexahydroxytax-11-en-9-one-4,10- optimized, breastdiacetate-2-benzoate-13-(Alpha- nanoparticles phenylhippurate) PADREU.S. 6,413,935 Immunostimulant, Vaccine other adjunct pagoclone1H-Isoindol-1-one, 2-(7-chloro-1,8- 133737-32-3 U.S. 4,960,779Anxiolytic Panic naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl- disorder2-oxohexyl)-(R)-[CAS] PAI inhibs WO 9404512 Antithrombotic Thrombosis,venous palindore 8H-1,4-dioxino[2,3-e]indol-8-one,2,3,7,9- 189681-71-8Neuroleptic Schizophrenia tetrahydro-2-[(phenylmethyl)amino]methyl]-,2(S)-, (2E)-2-butendioate (1:1) Palivizumab 188039-54-5 palonosetron3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]- 135729-62-3 U.S. 5,202,333Antiemetic Chemotherapy- 2,3,3a,4,5,6-hexahydro-1-oxo-1H- inducedbenz[de]isoquinoline hydrochloride nausea and vomiting Pamabrom 606-04-2Pamaquine 491-92-9 pamicogral 1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-101001-34-7 EP 159677 Antithrombotic Thrombosis,methoxyphenyl)-2-thiazolyl]-, ethyl ester cerebral [CAS] pamidronate(3-Amino-1- 40391-99-9 Formulation, Hyper-hydroxypropylidene)diphosphonic acid- implant calcaemia [CAS] ofmalignancy p-Aminobenzoic Acid 150-13-0 p-Aminohippuric Acid 61-78-9p-Amino- 70-69-9 propiophenone p-Aminosalicylic 65-49-6 Acid Panavir4,4′-isopropylidenedithiobis-2,6-di-t- Neuroprotective Vasospasm,butylphenol cerebral Pancuronium 15500-66-0 Panipenem 87726-17-8Pantethine 16816-67-4 pantoprazole 1H-Benzimidazole,5-(difluoromethoxy)-2- 102625-70-7 EP 166287 Antiulcer Ulcer,[[(3,4-dimethyloxy-2-pyridinyl)methyl]- duodenal sulfinyl]-[CAS]Pantothenic Acid 79-83-4 Papain Papaverine 58-74-2 paracetamolAcetamide, N-(4-hydroxyphenyl)-[CAS] 103-90-2 Formulation, oral, Pain,general other, modified- release Paraflutizide 1580-83-2 Paraldehyde123-63-7 Paramethadione 115-67-3 Paramethasone 53-33-8 Paranyline1729-61-9 Parathyroid Hormone 9002-64-6 parecoxib Propanamide,N-((4-(5-methyl-3-phenyl-4- 198470-85-8 WO 9738986 Analgesic, NSAIDPain, post- isoxazolyl)phenyl)sulfonyl)-, sodium salt operative [CAS]Parethoxycaine 94-23-5 Pargyline 555-57-7 paricalcitol19-Nor-9,10-secoergosta-5,7,22-triene- 131918-61-1 EP 387077 HormoneHyperparathy- 1,3,25-triol, (1Alpha,3β,7E,22E)-[CAS] roidsm paromomycinO-2-Amino-2-deoxy-Alpha-D- 7542-37-2 Protozoacide Infection,glucopyranosyl-(1-4)-O-[O-2,6-diamino-2,6- leishmaniasisdideoxy-β-L-idopyranosyl-(1-3)-β-D-ribofuranosyl-(1-5)]-2-deoxy-D-streptamine paroxetine Piperidine,3-[(1,3-benzodioxol-5- 61869-08-7 EP 223403 Antidepressant, Depression,yloxy)methyl]-4-(4-fluorophenyl)-, (3S- formulation, oral, generaltrans)-[CAS] orally- disintegrating Paroxypropione 70-70-2 Parsalmide30653-83-9 PaTrin-2 4-Bromothenylguanine Radio/ Cancer, chemosensitizermelanoma Pazinaclone 103255-66-9 pazufloxacin7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6- 127045-41-4 DE 3913245 QuinoloneInfection, carboxylic acid, 10-(1-aminocyclopropyl)-9- 127046-45-1antibacterial general fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-136905-87-8 [CAS] p-Bromoacetanilide 103-88-8 PC-NSAIDs U.S. 4,918,063Formulation, other Arthritis, general PD-01662856-(2,6-Dichlorophenyl)-2-[4-(diethylamino- Anticancer, other Cancer,ethoxy)-phenylamino]-8-pyrido[2,3- general D]pyrimidine-7-one Pecilocin19504-77-9 pefloxacin 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-70458-92-3 GB 1598915 Quinolone Infection,1,4-dihydro-7-(4-methyl-1-piperazinyl)-4- antibacterial urinary tractoxo-[CAS] pegvisomant Somatotropin (18-aspartic acid, 21- 218620-50-9Somatostatin Acromegaly asparagine, 120-lysine, 167-asparagine,168-alanine, 171-serine, 172-arginine, 174- serine, 179-threonine(human), pegylated [CAS] Pelletierine 4396-1-4 pemetrexed L-Glutamicacid, N-[4-[2-(2-amino-4,7- 137281-23-3 U.S. 5,248,775 Anticancer,Cancer, dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5- 150399-23-8antimetabolite mesothel- yl)ethyl]benzoyl]-, disodium salt [CAS] iomapemirolast 4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl- 100299-08-9 U.S.4,457,932 Antiasthma Asthma 3-(1H-tetrazol-5-yl)-[CAS] 69372-19-6Pemoline 2152-34-3 Pempidine 79-55-0 PEN-203 U.S. 5,955,446 Antiviral,other Infection, human papilloma virus Penamecillin 983-85-7 penbutolol2-Propanol, 1-(2-cyclopentylphenoxy)-3- 38363-32-5 GB 1215751Antihypertensive, [(1,1-dimethylethyl)amino]-, (S)-, sulfate 38363-40-5adrenergic (2:1) (salt) [CAS] penciclovir 6H-Purin-6-one,2-amino-1,9-dihydro-9-[4- 39809-25-1 JP 60058982 Antiviral, otherInfection, hydroxy-3-(hydroxymethyl)butyl]-[CAS] herpes simplex virusPenethamate 808-71-9 penfluridol 4-Piperidinol, 1-[4,4-bis(4- 26864-56-2DE 2040231 Neuroleptic fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-[CAS] Penicillamine 52-67-5 Penicillin G61-33-6 Penicillin G 1538-09-6 Benzathine Penicillin G Procaine6130-64-9 Penicillin N 525-94-0 Penicillin O 87-09-2 Penicillin V87-08-1 Penimepicycline 4599-60-4 Penntuss U.S. 4,221,778 Formulation,Rhinitis, modified- allergic, release, other general PentaerythritolChloral 78-12-6 Pentaerythritol 2209-86-1 Dichlorohydrin Pentaerythritol597-71-7 Pentagastrin 5534-95-2 Pentagestrone 7001-56-1 PentaLyteStarch, 2-hydroxyethyl ether [CAS] 9005-27-0 U.S. 5,407,428 Plasmasubstitute Surgery adjunct Pentam thonium 541-20-8 pentamidineBenzenecarboximidamide, 4,4′-[1,5- 100-33-4 Formulation, Infection,pentanediylbis(oxy)]bis-[CAS] inhalable, systemic Pneumocystis jiroveciprophylaxis Pentazocine 359-83-1 Pentetate 12111-24-9 Pentetic Acid67-43-6 Pentetreotide 138661-02-6 Penthienate 60-44-6 Pentifyllin1028-33-7 Pentigetide 62087-72-3 Pentisomide 78833-03-1 Pentobarbital76-74-4 Pentolinium 52-62-0 Pentorex 434-43-5 pentosan Xylan, [CAS]37319-17-8 U.S. 5,180,715 Urological Inflammation, urinary tractpentostatin Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2- 53910-25-1 U.S.3,923,785 Anticancer, Cancer, deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-antimetabolite leukaemia, tetrahydro-, (R)-[CAS] hairy cellpentoxifylline 1H-Purine-2,6-dione, 3,7-dihydro-3,7- NeuroprotectiveAmyotrophic dimethyl-1-(5-oxohexyl)-[CAS] lateral sclerosis Pentoxyl147-61-5 Pentrinitrol 1607-17-6 Pentylenetetrazole 54-95-5 peplomycinBieomycinamide, N1-[3-[(1- 68247-85-8 U.S. 4,195,018 Anticancer,phenylethyl)amino]propyl]-, (S)-[CAS] antibiotic Perazine 84-97-9Perflubron 423-55-2 Perfosfamide 62435-42-1; 39800-16-3 (unspecified)pergolide Ergoline, 8-[(methylthio)methyl]-6-propyl-, 66104-22-1 U.S.4,797,405 Antiparkinsonian Parkinson's (8β)-, monomethanesulfonate-[CAS]66104-23-2 disease Perhexiline 6621-47-2 Pericyazine 2622-26-6perifosine Piperidinium, 4- 157716-52-4 EP 594999 Anticancer, otherCancer, [[hydroxy(octadecyloxy)phosphinyl]oxy]- prostate 1,1-dimethyl-,inner salt [CAS] perillyl alcohol 1-Cyclohexene-1-methanol, 4-(1-536-59-4 U.S. 5,110,832 Anticancer, other Cancer, methylethenyl)-[CAS]breast Perimethazine 13093-88-4 perindopril 1H-Indole-2-carboxylic acid,1-[2-[[1- 107133-36-8 EP 49658 Antihypertensive, Hypertension,(ethoxycarbonyl)butyl],amino]-1- 82834-16-0 renin system generaloxopropyl]octahydro-, [2S- 95153-31-4 [1-[R*(R*)],2Alpha,3aβ,7aβ]]-,compd. with 2-methyl-2-propanamine (1:1) [CAS] Periodyl 53586-99-5perisoxal 1-Piperidineethanol, Alpha-(5-phenyl-3- 2139-25-5 JP 04217925Anti-inflammatory isoxazolyl)-, 2-hydroxy-1,2,3- 2055-44-9propanetricarboxylate (2:1) (salt) [CAS] Perlapine 1977-11-3 Permethrin52645-53-1 perospirone 1H-Isoindole-1,3(2H)-dione, 2-[4-[4-(1,2-129273-38-7 CA 2167004 Neuroleptic Schizophrenia benzisothiazol-3-yl)-1-150915-41-6 piperazinyl]butyl]hexahydro-, cis-[CAS] Perphenazine 58-39-9Petroleum Benzin 8030-30-6 PH-10 U.S. 6,331,286 Antipsoriasis PsoriasisPhanquinone 84-12-8 Pharmaprojects No. WO 9638482 ImmunologicalUnspecified 4994 Pharmaprojects No. WO 9703986 Neuroleptic Schizophrenia5325 Pharmaprojects No. WO 0204426 Antiasthma Asthma 5972 PharmaprojectsNo. U.S. 6,057,346 Antiviral, anti-HIV Infection, 6362 HIV/AIDSPharmaprojects No. (R)-N-[4-[2-[[2-Hydroxy-2-(3- Anorectic/ Obesity 6446pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4- Antiobesity(trifluoromethyl)phenyl]thiazo-2-yl]- benzenesulfonamide PharmaprojectsNo. WO 0206223 Psychostimulant Attention 6590 deficit disorderPharmaprojects No. U.S. 6,455,026 Genomics-based Cancer, brain 6656 drugdiscovery Pharmaprojects No. U.S. 6,299,900 Formulation, other Pain,general 6691 Pharmaprojects No. 3-(6-Aminopyridin-3-yl)-N-methyl-N-[(1-Antibacterial, other Infection, 6743methyl-1H-indol-2-yl)methyl]acrylamide general Pharmaprojects No.1,2,3,4,10,14b-Hexahydro-6-methoxy-2- Antidepressant Depression, 6748methyldibenzo[c,f]pyrazino[1,2-a]azepin general Phenacaine 620-99-5Phenacemide 63-98-9 Phenacetin 62-44-2 Phenadoxone 467-84-5 Phenallymal115-43-5 Phenamet 3819-34-9 Phenazocine 127-35-5 Phenazopyridine136-40-3 Phenbutamide 3149-00-6 Phencyclidine 77-10-1 Phendimetrazine634-03-7 Phenelzine 51-71-8 Phenesterine 3546-10-9 Phenetharbital357-67-5 Phenethicillin 132-93-4 Pheneturide 90-49-3 Phenformin 114-86-3Phenglutarimide 1156-05-4 Phenindamine 82-88-2 Phenindione 83-12-5Pheniprazine 55-52-7 Pheniramine 86-21-5 Phenmetrazine 134-49-6Phenobarbital 50-06-6 Phenobutiodil 554-24-5 Phenocoll 103-97-9Phenoctide 78-05-7 Phenolphthalein 77-09-8 Phenolphthalol 81-92-5Phenolsulfonphthalein 143-74-8 Phenol- 639-44-1 tetrachlorophthaleinPhenoperidine 562-26-5 Phenosulfazole 515-54-8 Phenoxybenzamine 59-96-1Phenoxypropazine 3818-37-9 Phenprobamate 673-31-4 Phenprocoumon 435-97-2phenserine Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a- 101246-66-6Cognition enhancer Alzheimer's hexahydro-1,3a,8-trimethyl-, diseasephenylcarbamate (ester), (3aS-cis)-[CAS] Phensuximide 86-34-0Phentermine 122-09-8 Phentetiothalein 18265-54-8 phentolamine Phenol,3-(((4,5-dihydro-1H-imidazol-2- 65-28-1 Formulation, Impotenceyl)methyl)(4-methylphenyl)amino)-, 50-60-2 oral, othermonomethanesulfonate (salt) [CAS] Phenyl Acetylsalicylate 134-55-4Phenyl Aminosalicylate 133-11-9 Phenyl Salicylate 118-55-8Phenylbutazone 50-33-9 Phenylephrine 61-76-7 Phenylethanolamine7568-93-6 Phenylmercury 102-98-7 Phenylmethylbarbituric 76-94-8 Acidphenylpropanolamine Benzenemethanol, Alpha-(1-aminoethyl)-, 14838-15-4Anorectic/ (R*,S*)-(+/−)-[CAS] Antiobesity, formulation, optimized,microparticles Phenylpropyl- 93-88-9 methylamine Phenyltoloxamine92-12-6 Phenyramidol 553-69-5 phenytoin 2,4-Imidazolidinedione,5,5-diphenyl- 57-41-0 Formulation, Epilepsy, [CAS] oral, other generalPhethenylate 510-34-9 Phloroglucinol 108-73-6 Pholcodine 509-67-1Pholedrine 370-14-9 Phosphocreatine 67-07-2 Phosphocysteamine 5746-40-7Phosphorylcholine 107-73-3 Phthalysulfacetamide 131-69-1Phthalylsulfathiazole 85-73-4 p-Hydroxyephedrine 365-26-4 Phylloquinone84-80-0 Physostigmine 57-47-6 Phytic Acid 83-86-3 PI-88 D-Mannose,O-6-O-phosphono-Alpha-D- 185077-23-0 Anticancer, other Cancer,mannopyranosyl-(1-3)-O-Alpha-D- melanoma mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D- mannopyranosyl-(1-2)-hydrogen sulphate[CAS] Piberaline 39640-15-8 piboserod 2H-(1,3)Oxazino(3,2-a)indole-10-152811-62-6 WO 9318036 Antiarrhythmic Fibrillation, carboxamide,N-((1-butyl-4- atrial piperidinyl)methyl)-3,4-dihydro-[CAS] Picilorex62510-56-9 Picloxydine 5636-92-0 Picoperine 21755-66-8 Picosulfate10040-45-6 Picotamide 32828-81-2 Picumast 39577-19-0 pidotimod4-Thiazolidinecarboxylic acid, 3-[(5-oxo-2- 121808-62-6 EP 276752Immunomo Infection, pyrrolidinyl)carbonyl]-[CAS] dulator, respiratoryanti-infective tract, lower Pifarnine 56208-01-6 piketoprofenBenzeneacetamide, 3-benzoyl-Alpha- 60576-13-8 GB 1436502Anti-inflammatory, methyl-N-(4-methyl-2-pyridinyl)-[CAS] topicalPildralazine 64000-73-3 pilocarpine 2(3H)-Furanone,3-ethyldihydro-4-[(1- 92-13-7 Formulation,methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- implant, [CAS]Stomatological Piloplex 2-Propenoic acid, 2-methyl-, dodecyl 62783-28-2DE 2636559 Formulation, Glaucome ester, polymer with 2-propenoicacid,mucosal, topical compd. with (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)- furanone [CAS] pilsicainide1H-Pyrrolizine-7a(5H)-acetamide, N-(2,6- 88069-49-2 U.S. 4,564,624Antiarrhythmic Arrhythmia, dimethylphenyl)tetrahydro-, 88069-67-4general monohydrochloride [CAS] Pimeclone 534-84-9 pimecrolimus15,19-Epoxy-3H-pyrido(2,1- 137071-32-0 EP 626385 Antipruritic/ Eczema,c)(1,4)oxaazacyclotricosine- inflamm, allergic atopic1,7,20,21(4H,23H)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methyletheny)-8- ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3S- (3R*E(1S*,3S*,4R*)),4S*,5R*,8S*,9E*,12R*,14R*,5S*,16R*,18S 8,19S*,26aR*))-[CAS] Pimefylline10001-43-1 pimilprost Acetic acid, [2-[octahydro-5-hydroxy-6-(3-139403-31-9 Dermatological Ulcer, hydroxy-5-methyl-1-nonenyl)-2- generalpentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha(1E,3S*,5S*),5β,6a Alpha]]-[CAS] Piminodine13495-09-5 Pimobendan 74150-27-9 pimozide 2H-Benzimidazol-2-one,1-[1-[4,4-bis(4- 2062-78-4 FR M3695 Neurolepticfluorophenyl)butyl]-4-piperidinyl]-1,3- dihydro-[CAS] Pinacidil85371-64-8 pinaverium Morpholinium, 4-[(2-bromo-4,5- 53251-94-8 EP406743 Antispasmodic Irritable dimethoxyphenyl)methyl]-4-[2-[2-(6,6-59995-65-2 bowel dimethylbicyclo[3.1.1]hept-2- syndromeyl)ethoxy]ethyl]-, [CAS] pinazepam 2H-1,4-Benzodiazepin-2-one,7-chloro-1,3- 52463-83-9 DE 2339790 Anxiolyticdihydro-5-phenyl-1-(2-propynyl)-[CAS] Pindolol 13523-86-9 pioglitazone2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2- 111025-46-8 EP 193256Antidiabetic Diabetes, pyridinyl)ethoxy]phenyl]methyl]-, 112529-15-4Type II monohydrochloride (+/−)-[CAS] Pipacycline 1110-80-1 Pipamazine84-04-8 Pipamperone 1893-33-0 Pipazethate 2167-85-3 Pipebuzone27315-91-9 Pipecurium 52212-02-9 pipecuronium Piperazinium, 4,4′-52212-02-9 GB 1398050 Muscle relaxant Anaesthesia,[(2β,3Alpha,5Alpha,16β,17β)-3,17- 68399-57-5 adjunctbis(acetyloxy)androstane-2,16-diyl]bis[1,1]- dimethyl-, [CAS] pipemidicacid Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 51940-44-4 GB 1451911Antibacterial, Infection, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)-other urinary tract [CAS] Pipenzolate Bromide 125-51-9 Piperacetazine3819-00-9 piperacillin 4-Thia-1-azabicyclo[3.2.0]heptane-2- 59703-84-3GB 1508062 Penicillin, Infection, carboxylic acid,6-[[[[(4-ethyl-2,3-dioxo-1- 61477-96-1 injectable generalpiperazinyl)carbonyl]amino]phenylacetyl]-amino]-3,3-dimethyl-7-oxo-,[2S- [2Alpha,5Alpha,6β(S*)]]-[CAS] PiperazineAdipate 142-88-1 Piperidione 77-03-2 Piperidolate 82-98-4 Piperilate4546-39-8 piperine analogues WO 002544 Dermatological VitiligoPiperocaine 136-82-3 Piperonal 120-57-0 Piperoxan 59-39-2 Piperylone 2531-4-6 Pipobroman 54-91-1 Piposulfan 2608-24-4 pipotiazine Hexadecanoicacid, 2-[1-[3-[2- 37517-26-3 U.S. 4,782,077 Neuroleptic[(dimethylamino)sulfonyl]-10H- 39860-99-6 phenothiazin-10-yl]propyl]-4-piperidinyl]ethyl ester [CAS] Pipoxolan 18174-58-8 Pipradrol 467-60-7piprozolin Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)- 17243-64-0U.S. 3,971,794 GI inflammatory/ Motility 2-thiazolidinylidene]-, ethylester [CAS] bowel disorders dysfunction, GI, general Piracetam 7491-74-9pirarubicin 5,12-Naphthacenedione, 10-[[3-amino- 72496-41-4 U.S.4,303,785 Anticancer, Cancer, breast2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2- antibioticyl)-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8- (hydroxyacetyl)-1-methoxy-,[8S- [8Alpha,10Alpha(S*)]]-[CAS] Pirazolac 71002-09-0 pirbuterol2,6-Pyridinedimethanol, Alpha6-[[(1,1- 38029-10-6 U.S. 3,786,160Antiasthma Asthma dimethylethyl)amino]methyl]-3-hydroxy-, 38677-81-5monoacetate (salt) [CAS] 65652-44-0 Pirenoxine 1043-21-6 pirenzepine6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 28797-61-7 FR 1505795Antiulcer 5,11-dihydro-11-[(4-methyl-1- 29868-97-1piperazinyl)acetyl]-[CAS] piretanide Benzoic acid,3-(aminosulfonyl)-4-phenoxy- 55837-27-9 U.S. 4,010,273 Antihypertensive,Hypertension, 5-(1-pyrrolidinyl)-[CAS] diuretic general pirfenidone2(1H)-Pyridnone, 5-methyl-1-phenyl- 53179-13-8 Respiratory Fibrosis,[CAS] pulmonary piribedil Pyrimidine, 2-[4-(1,3-benzodioxol-5- 3605-01-4U.S. 3,299,067 Vasodilator, Parkinson's ylmethyl)-1-piperazinyl]-[CAS]peripheral disease Piridocaine 87-21-8 Pirifibrate 55285-45-5Piritramide 302-41-0 Piritrexim 72732-56-0 pirlindole1H-Pyrazine[3,2,1-jk]carbazole, 16154-78-2 SU 276060 AntidepressantDepression, 2,3,3a,4,5,6-hexahydro-8-methyl-[CAS] 60762-57-4 generalpirmenol (2-Pyridinemethanol, Alpha-[3-(2,6- 61477-94-9 U.S. 4,112,103Antiarrhythmic Tachycardia, dimethyl-1-piperidinyl)propyl]- 68252-19-7supra- Alpha.phenyl-, cis-(+)-[CAS] ventricular Piroctone 50650-76-5Piroheptine 16378-21-5 Piromidic Acid 19562-30-2 piroxicam2H-1,2-Benzothiazine-3-carboxamide, 4- 36322-90-4 U.S. 3,862,319Anti-inflammatory hydroxy-2-methyl-N-2-pyridinyl-, 1,1- dioxide [CAS]piroxicam betadex β-Cyclodextrin, compd. with 4-hydroxy-2- 121696-62-6EP 153998 Formulation, other Pain,methyl-N-2-pyridinyl-2H-1,2-benzothiazine- 96684-39-8 musculo-3-carboxamide 1,1-dioxide-[CAS] skeletal piroxicam cinnamate 2-Propenoicacid, 3-phenyl-, 2-methyl-3- 87234-24-0 EP 79639 Antiarthritic, otherInflammation, [(2-pyridinylamino)carbonyl]-2H-1,2- generalbenzothiazin-4-yl ester, S,S-dioxide [CAS] Pirozadil 54110-25-7Pirprofen 31793-07-4 pitavastatin 6-Heptenoic acid,7-[2-cyclopropyl-4-(4- 147526-32-7 EP 304063 Hypolipaemic/ Hyper-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, Antiatherosclerosislipidaemia, calcium salt (2:1), [S-[R*,S*-(E)]]-[CAS] general pivagabineN-trimethylacetyl-4-aminobutyric acid 69542-93-4 Neurological Anxiety,general pivaloyloxymethyl Butanoic acid, (2,2-dimethyl-1- 122110-53-6 EP302349 Anticancer, other Cancer, lung, oxopropoxy)methyl ester [CAS]non-small cell Pivalylbenzhydrazine 306-19-4 Pivampicillin 33817-20-8pivampicillin/ 98445-47-7 Penicillin, oral Infection, pivmecillinamgeneral Pivcefalexin 63836-75-9 pivmecillinam4-Thia-1-azabicyclo[3.2.0]heptane-2- 32886-97-8 GB 1293590 Penicillin,oral Infection, carboxylic acid, 6-[[(hexahydro-1H-azepin-1- generalyl)methylene]amino]-3,3-dimethyl-7-oxo-,(2,2-dimethyl-1-oxopropoxy)methyl ester, [2S-(2Alpha,5Alpha,6β)]-[CAS]pixantrone Benz[g]isoquinoline-5,10-dione, 6,9-bis[(2- 144675-97-8 EP503537 Anticancer, other Cancer, aminoethyl)amino]-, (2Z)-2- lymphoma,butenedioate(1:2) [CAS] non-Hodgkin's pizotifen 4-(9,10-dihydro-4H-15574-96-6 DE 2346747 Antimigraine benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine Pizotyline 15574-96-6 PKI-166 Phenol,4-(4-(((1R)-1-phenylethyl)amino)- 187724-61-4 Anticancer, other Cancer,1H-pyrrolo(2,3-d)pyrimidin-6-yl)-[CAS] general p-Lactophenetide 539-08-2Plafibride 63394-05-8 plasminogen activator Plasminogen activator [CAS]105913-11-9 EP 151996 Fibrinolytic Infarction, myocardial Plasmocid551-01-9 Platonin 3571-88-8 Plaunotol 64218-02-6 PLD-118Cyclopentanecarboxylic acid, 2-amino-4- 198022-65-0 EP 805145 AntifungalInfection, methylene-, (1R,2S)-[CAS] Candida, general PLD-147(OC-6-43)-Bis(acetato)(1- Anticancer, Cancer,adamantylamine)ammine-dichloro- alkylating general platinum (IV)pleconaril 1,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3- 153168-05-9 U.S.5,464,848 Antiviral, other Infection,methyl-5-isoxazolyl)propoxy)phenyl)-5- respiratory(trifluoromethyl)-[CAS] tract, general Plicamycin 18379-89-7p-Methyldiphen- 19804-27-4 hydramine PMS-601 WO 0001677 Antiviral,Anti-HIV Infection, HIV/AIDS Pneumococcal Vaccine, Diphtheria ConjugatePneumococcal Vaccine, Polyvalent PNU-288034 N-[[(5s)-3[4[(1,1-dioxido-4-Antibiotic, other Infection, thiomorpholinyl)3,5-difluorophenyl]-2-oxo-general 5-oxazolidinyl]methyl]acetamide] Podophyllotoxin 518-28-5polaprezinc Zinc, bis(N-β-alanyl-L-histidinato- 107667-60-7 EP 303380Antiulcer Ulcer, N3,OAlpha)-, (T-4)-[CAS] duodenal Poldine Methylsulfate545-80-2 Policresulen 9011-2-3 Polidexide 9064-92-0 polidocanolPolyethylene glycol monododecyl ether 3055-99-0 Vasoprotective, Venous9002-92-0 systemic insufficiency Poliovirus Vaccine Inactivatedpoly-ADPRT inhibitors WO 9845253 Anticancer, other Cancer, generalPolyestradiol 28014-46-2 Phosphate Polyphenon E Polyphenon E [CAS]188265-33-0 Antiviral, other Infection, human papilloma virusPolythiazide 346-18-9 porfimer Photofrin [CAS] 87806-31-3 U.S. 4,882,234Anticancer, other Cancer, lung, non-small cell Perfiromycin 801-52-5posaconazole D-threo-Pentitol, 2,5-anhydro-1,3,4- 171228-49-2 U.S.5,714,490 Antifungal Infection,trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4- fungal,(4-(1(1S,2S)-1-ethyl-2-hydroxypropyl)-1,5- generaldihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4- triazol-1-yl)-[CAS]Posatirelin 7866473-0 potassium chloride Potassium chloride (KCl) [CAS]7447-40-7 Formulation, oral, enteric-coated Potassium Gluconate 299-27-4Potassium 1321-14-8 Gualacolsulfonate Potassium p- 138-84-1Aminobenzoate Potassium 7722-64-7 Permanganate Povidone 9003-39-8Povidone-Iodine 25655-41-8 PP-117 3-Pyridinemethanol, hydrofluoride[CAS] 62756-44-9 DE 2633028 Formulation, oral, Unspecified other PR-2699(−)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan- Antifungal Infection,2-ylidene]-1-imidazolylacetonitrile fungal, general PR-608(S)-(−)-1-[4,4-bis(4-fluorophenyl)butyl]-4-(2- AntiparkinsonianParkinson's hydroxy-3-phenylaminopropyl)piperazine diseasetrihydrochloride Practolol 6673-35-4 Prajmaline 35080-11-6 Pralidoxime51-15-0 pralnacasan 6H-Pyridazino(1,2-a)(1,2)diazepine-1- 192755-52-5Antiarthritic, Arthritis, carboxamide, N-((2R,3S)-2- immunologicalrheumatoid ethoxytetrahydro-5-oxo-3- furanyl)octahydro-9-((1-isoquinolinylcarbonyl)amino)-6,10-dioxo-, (1S,9S)-[CAS] pramipexole2,6-Benzothiazolediamine, 4,5,6,7- 104632-26-0 EP 186087Antiparkinsonian Parkinson's tetrahydro-N6-propyl-, (S)-[CAS] diseasepramiracetam 1-Pyrrolidineacetamide, N-[2-[bis(1- 68497-62-1 U.S.4,145,347 Cognition enhancer Amnesia methylethyl)amino]ethyl]-2-oxo-,72869-16-0 monohydrochloride [CAS] 75733-50-5 Pramiverin 14334-40-8pramlintide 1,2-Dithia-5,8,11,14,17- 151126-32-8 U.S. 5,124,314Antidiabetic Diabetes, pentaazacycloeicosane, cyclic peptide Type Ideriv. [CAS] Pramoxine 140-65-8 pranidipine 3,5-Pyridinedicarboxylicacid, 1,4-dihydro- 99522-79-9 EP 173126 Antihypertensive, Hypertension,2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3- other generalphenyl-2-propenyl ester, (E)-[CAS] Pranlukast 103177-37-3 pranoprofen5H-[1]Benzopyrano[2,3-b]pyridine-7-acetic 52549-17-4 Formulation, Oculardisorder, acid, Alpha-methyl-[CAS] mucosal, topical general prasteroneAndrost-5-en-17-one, 3-hydroxy-, (3β)- 53-43-0 Labour inducer [CAS]pratosartan 4(3H)-Cycloheptimidazolone, 5,6,7,8- 153804-05-8 U.S.5,409,947 Antihypertensive, Hypertension,tetrahydro-2-propyl-3-[[2′-(1H-tetrazol-5- renin system generalyl)[1,1′-biphenyl]-4-yl]methyl]-[CAS] pravastatin 1-Naphthaleneheptanoicacid, 1,2,6,7,8,8a- 81093-37-0 U.S. 4,346,227 Hypolipaemic/Atherosclerosis hexahydro-β,delta,6-trihydroxy-2-methyl-8- 81131-70-6Antiatherosclerosis (2-methyl-1-oxobutoxy)-, monosodium salt, [1S-[1Alpha(βS*,deltaS*),2Alpha,6Alpha,8β(R*), 8aAlpha]]-[CAS] Prazepam2955-38-6 praziquantel 4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-55268-74-1 U.S. 4,001,411 Schistosomicide(cyclohexylcarbonyl)-1,2,3,6,7,11b- hexahydro-[CAS] prazosin Piperazine,1-(4-amino-6,7-dimethoxy-2- 19216-56-9 U.S. 4,092,315 Antihypertensive,Hypertension, quinazolinyl)-4-(2-furanylcarbonyl)-[CAS] 19237-84-4adrenergic general Prednicarbate 73771-04-7 prednimustinePregna-1,4-diene-3,20-dione, 21-[4-[4- 29069-24-7 GB 1272841 Anticancer,[bis(2-chloroethyl)amino]phenyl]-1- alkylatingoxobutoxy]-11,17-dihydroxy-, (11β)-[CAS] Prednisolone 50-24-8Prednisolone 21- 5626-34-6 Diethylaminoacetate prednisolone farnesilPregna-1,4-diene-3,20-dione, 11,17- 118244-44-3 EP 332143 Antiarthritic,other Arthritis, dihydroxy-21-[(3,7,11-trimethyl-1-oxo- rheumatoid2,6,10-dodecatrienyl)oxy]-, [11β,21(2E,6E)]-[CAS] Prednisolone Sodium125-02-0 Phosphate Prednisone 53-03-2 Prednival 15180-00-4 Prednylidene599-33-7 pregabalin Hexanoic acid, 3-(aminomethyl)-5-methyl, 148553-50-8Antiepileptic Epilepsy, (S)-[CAS] general Pregnan-3α-ol-20-one 128-20-1Premarin + Estra-4,9-dien-3-one, 17-(2-hydroxy-1- 74513-62-5 MenopausalHormone trimegestone oxopropyl)-17-methyl-, [17β(S)]-[CAS] disordersreplacement therapy prenalterol Phenol, 4-[2-hydroxy-3-[(1- 57526-81-5GB 1470039 Cardiostimulant methylethyl)amino]propoxy]-, 61260-05-7hydrochloride, (S)-[CAS] Prenoxdiazine 982-43-4 Prenylamine 390-64-7prezatide Cuprate(1-), (N2-(N-glycyl-L-histidyl)-L- 130120-57-9Vulnerary Wound lysinato)(N2-(N-glycyl-L-histidyl)-L- healinglysinato(2-))-, hydrogen, [CAS] Pridinol 511-45-5 Prifinium 4630-95-9Prilocaine 721-50-6 Primaquine 90-34-6 Primidone 125-33-7 Prinomastat192329-42-3 PRO-2000 U.S. 5,614,599 Antiviral, anti-HIV Infection, HIVprophylaxis Probenecid 57-66-9 Probucol 23288-49-5 procainamideBenzamide, 4-amino-N-[2- 51-06-9 Formulation, other Arrhythmia,(diethylamino)ethyl]-[CAS] 614-39-1 general Procaine 59-46-1Procarbazine 671-16-9 procaterol 2(1H)-Quinolinone,8-hydroxy-5-[1-hydroxy- 59828-07-8 GB 1496766 Antiasthma2-[(1-methylethyl)amino]butyl]- 60443-17-6 monohydrochloride [CAS]72332-33-3 prochlorperazine 10H-Phenothiazine,2-chloro-10-[3-(4- 58-38-8Formulation, oral, Nausea and methyl-1-piperazinyl)propyl]-, (Z)-2-84-02-6 other vomiting, butenedioate general procodazol1H-Benzimidazole-2-propanoic acid [CAS] 23249-97-0 ES 407882 Anticancer,Cancer, immunological general Procyclidine 77-37-2 Procymate 13931-64-1Prodipine 31314-38-2 Proflavine 92-62-6 Progabide 62666-20-0progesterone Prefn-4-ene-3,20-dione [CAS] 57-83-0 Formulation,Amenorrhoea transmucosal, systemic proglumetacin 1H-Indole-3-aceticacid, 1-(4- 57132-53-3 GB 1467568 Anti-inflammatory Inflammation,chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4- 59209-40-4 general(3-((4-(benzoylamino)-5-(dipropylamino)- 1,5-dioxopentyl)oxy)propyl)-1-piperazinyl)ethylester, (+/−)-[CAS] proglumide Pentanoic acid,4-(benzoylamino)-5- 6620-60-6 DE 1518125 Antiulcer Ulcer, gastric(dipropylamino)-5-oxo-, (+/−)-[CAS] Proheptazine 77-14-5 Prolactin9002-62-4 Prolintane 493-92-5 Prolonium 123-47-7 Promazine 58-40-2Promedol 64-39-1 Promegestone 34184-77-5 promestrieneEstra-1,3,5(10)-triene, 17-methoxy-3- 39219-28-8 GB 1337198Reproductive/ Acne propoxy-, (17β)-[CAS] gonadal, general Promethazine60-87-7 Pronethalol 54-80-8 propacetamol Glycine, N,N-diethyl-, 4-66532-85-2 U.S. 4,127,671 Formulation, (acetylamino)phenyl ester [CAS]66532-86-3 parenteral, other propafenone 1-Propanone, 1-[2-[2-hydroxy-3-54063-53-5 GB 1307455 Antiarrhythmic Fibrillation,(propylamino)propoxy]phenyl]-3-phenyl- ventricular [CAS] Propagermanium12758-40-6 Propallylonal 545-93-7 Propamidine 104-32-5 propane-1,2-diol1,2-propanediol 57-55-6 Formulation, Infection, fungal, dermal, topicalgeneral Propanidid 1421-14-3 Propantheline 50-34-0 Proparacaine 499-67-2Propatyl 2921-92-8 propenidazole ethyl trans-Alpha-acetyl-1-methyl-5-76448-31-2 Antifungal Infection, nitroimidazole-2-acrylatetrichomoniasis propentofylline 1H-Purine-2,6-dione,3,7-dihydro-3-methyl- 55242-55-2 GB 1470220 Neuroprotective Ischaemia,1-(5-oxohexyl)-7-propyl-[CAS] cerebral Propicillin 551-27-9 Propiomazine362-29-8 Propionic Acid 79-09-4 propionyl L-carnitine 1-Propanaminium,3-carboxy-N,N,N- 119793-66-7 GB 2008578 Vasodilator, Peripheraltrimethyl-2-(1-oxopropoxy)-, chloride, (R)- 20084-19-1 peripheralvascular disease [CAS] Propipocaine 3670-68-6 Propiram 15686-91-6propiverine 2,2-diphenyl-2-(1-propoxy)acetic acid (1- 54556-98-8Urological Incontinence methylpiperid-4-yl) ester hydrochloride60569-19-9 Propizepine 10321-12-7 propofol Phenol,2,6-bis(1-methylethyl)-[CAS] 2078-54-8 U.S. 4,056,635 Anaesthetic,Anaesthesia injectable Propoxycaine 550-83-4 Propoxyphene 469-62-5propranolol 2-Propanol, 1-[(1-methylethyl)amino]-3-(1- 318-98-9Formulation, Hypertension, naphthalenyloxy)-[CAS] 525-66-6 modified-general release, <=24 hr Propylhexedrine 101-40-6 Propyliodone 587-61-1Propylthiouracil 51-25-5 Propyphenazone 479-92-5 Proquazone 22760-18-5Proscillaridin 466-06-8 Prostacyclin 35121-78-9 Prostaglandin E₁745-65-3 Prostaglandin E₂ 363-24-6 Prostaglandin F_(2α) 551-11-1Prosultiamine 59-58-5 Protein C 60202-16-6 Protheobromine 50-39-5Prothipendyl 303-69-5 Protiofate 58416-00-5 Protionamide 14222-60-7protizinic acid 10H-Phenothiazine-2-acetic acid, 7- 13799-03-6 U.S.3,450,698 Anti- methoxy-Alpha,10-dimethyl-, (+/−)-[CAS] inflammatoryProtoanemonin 108-28-1 Protoklol 136-70-9 Protoporphyrin IX 553-12-8Protriptyline 438-60-8 Pro-Urokinase 82657-92-9 Proxazole 5696-9-3Proxibarbal 2537-29-3 proxigermanium Propanoic acid,3,3′-(1,3-dioxo-1,3- 12758-40-6 FR 2005110 Antiviral, other Infection,digermoxanediyl)bis-[CAS] hepatitis- B virus Proxyphylline 603-00-9Prozapine 3426-8-2 Prucalopride 179474-81-8 prulifloxacin1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3- 123447-62-1 EP 315828 QuinoloneInfection, carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5- antibacterialrespiratory methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1- tract, generalpiperazinyl]-4-oxo-[CAS] Pseudococaine 478-73-9 pseudoephedrine +Benzenemethanol, Alpha-[1- Formulation, Rhinitis, triprolidine(methylamino)ethyl]-, hydrochloride, [S- modified- allergic, (R*,R*)]-,mixt. with (E)-2-[1-(4- release, other generalmethylphenyl)-3-(1-pyrrolidinyl)-1- propenyl]pyridine monohydrochloride[CAS] pseudoephedrine Benzenemethanol, Alpha-[1- 90-82-4, Formulation,oral, Infection, (methylamino)ethyl]-, [S-(R*,R*)]-[CAS] 8054-27-1,other respiratory 345-78-8 tract, general Psilocybin 520-52-5 PSK-3841Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4- 154992-24-2 DermatologicalAlopecia, dimethyl-2,5-dioxo-1-imidazolidinyl]-2- general(trifluoromethyl)-[CAS] p-Sulfanilyl- 4393-19-5 benzylamine PT-141 U.S.6,051,555 Male sexual Impotence dysfunction Pteropterin 89-38-3Puromycin 53-79-2 PX-12 1-Methylpropyl 2-mercaptoimidazolyl Anticancer,other Cancer, disulfide general Pyrantel 15686-83-6 Pyrazinamide 98-96-4Pyridinol Carbamate 1882-26-4 Pyridostigmine 101-26-8 Bromide Pyridoxal5-Phosphate 54-47-7 Pyridoxine 58-56-0 Pyrilamine 91-84-9 Pyrimethamine58-14-0 Pyrinoline 1740-22-3 Pyrisuccideanol 33605-94-6 Pyrithione1121-30-8 Pyrithyldione 77-04-3 Pyritinol 1098-97-1 Pyrocatechol120-80-9 Pyrogallol 87-66-1 Pyronaridine 74847-35-1 Pyrovalerone3563-49-3 Pyroxylin 9004-70-0 Pyrrobutamine 91-82-7 Pyrrocaine 2210-77-7Pyrrolntrin 1018-71-9 Pyrvinium Pamoate 3546-41-6 quazepam2H-1,4-Benzodiazepine-2-thione, 7-chloro- 36735-22-5 U.S. 3,845,039Hypnotic/Sedative Insomnia 5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-[CAS] Quercetin 117-39-5 quetiapine Ethanol,2-[2-(4-dibenzo[b,f][1,4]thiazepin- 111974-69-7 EP 240228 NeurolepticSchizophrenia 11-yl-1-piperazinyl)ethoxy]-, (E)-2- 111974-72-2butenedioate (2:1) (salt) [CAS] Quinacillin 1596-63-0 quinacrineN-(6-Chloro-2-methoxy-9-acridinyl)-N,N- 83-89-6 NeurologicalCreutzfeldt- diethyl-1,4-pentanediamine + 10H- Jakob diseasePhenothiazine-10-propanamine, 2-chloro- N,N-dimethyl quinagolideSulfamide, N,N-diethyl-N′- 87056-78-8 EP 77754 AntiprolactinHyperprolactin- (1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy- 94424-50-7aemia 1-propylbenzo[g]quinolin-3-yl)-, 97805-49-7(3Alpha,4aAlpha,10aβ)-(+/−)-[CAS] quinapril 3-Isoquinolinecarboxylicacid, 2-[2-[[1- 82586-55-8 EP 49605 Antihypertensive, Hypertension,(ethoxycarbonyl)-3-phenylpropyl]amino]-1- 85441-61-8 renin systemgeneral oxopropyl]-1,2,3,4-tetrahydro-, [3S- 90243-99-5[2[R*(R*)],3R*]]-[CAS] quinaprilat 3-Isoquinolinecarboxylic acid,2-[2-[(1- 82768-85-2 EP 46953 Antihypertensive, Hypertension,carboxy-3-phenylpropyl)amino]-1- renin system generaloxopropyl]-1,2,3,4-tetrahydro-, [3S- [2[R*(R*)],3R*]]-[CAS]Quinapyramine 20493-41-8 Quinbolone 2487-63-0 Quinestradiol 1169-79-5Quinestrol 152-43-2 Quinethazone 73-49-4 quinfamide 2-Furancarboxylicacid, 1-(dichloroacetyl)- 62265-68-3 U.S. 3,997,542 Amoebicide1,2,3,4-tetrahydro-6-quinolinyl ester [CAS] quinidine Cinchonan-9-ol,6′-methoxy-, (9S)-, sulfate 747-45-5 Formulation, Arrhythmia, (1:1)(salt) [CAS] 56-54-2 modified- general release, other Quinine 130-95-0Quinocide 525-61-1 Quinupramine 31721-17-2 Quinupristin 120138-50-3R-107500 cis-2,3,3a,8-tetrahydro-N,N- WO 9614320 Anxiolytic Anxiety,dimethyldibenz[c,f]isoxazolo[2,3-a]azepine- general 2-methanamine R-667WO 0204439 COPD treatment Emphysema, general rabeprazole1H-Benzimidazole, 2-[[[4-(3- 117976-89-3 EP 268956 Antiulcer Ulcer,methoxypropoxy)-3-methyl-2- 117976-90-6 gastricpyridinyl]methyl]sulfinyl]-, sodium salt- [CAS] racecadotril Glycine,N-[2-[(acetylthio)methyl]-1-oxo-3- 112573-72-5 EP 38758 AntidiarrhoealDiarrhoea, phenylpropyl]-, phenylmethyl ester, (+/−)- 81110-73-8 general[CAS] Racemethorphan 510-53-2 raloxifene Methanone, [6-hydroxy-2-(4-82640-04-8 EP 62503 Osteoporosis Osteoporosishydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1- 84449-90-1 treatmentpiperidinyl)ethoxy]phenyl]-, hydrochloride [CAS] raltitrexed L-glutamicacid, N-[[5-[[(1,4-dihydro-2- 112887-68-0 EP 239362 Anticancer, Cancer,methyl-4-oxo-6- antimetabolite colorectalquinazolinyl)methyl]methylamino]-2- thienyl]carbonyl]-[CAS] ramatroban9H-Carbazole-9-propanoic acid, 3-[[(4- 116649-85-5 EP 242518Antiallergic, Rhinitis, fluorophenyl)sulfonyl]amino]-1,2,3,4- non-asthmaallergic, tetrahydro-, (R)-[CAS] perennial Ramifenazone 3615-24-5ramipril Cyclopenta[b]pyrrole-2-carboxylic acid, 1- 87269-97-4 EP 79022Antihypertensive, Heart failure [2-[[1-(ethoxycarbonyl)-3- 87333-19-5renin system phenylpropyl]amino]-1- oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aβ,6aβ]]-[CAS] ramosetron Methanone,(1-methyl-1H-indol-3- 132907-72-3 EP 381422 Antiemetic Nausea andyl)(4,5,6,7-tetrahydro-1H-benzimidazol-5- 132036-88-5 vomitting, yl)-,monohydrochloride, (R)-[CAS] general Ramot project No. U.S. 5,730,992Dermatological Unspecified 1097 Ranimustine 58994-96-0 ranitidine1,1-Ethenediamine, N-[2-[[[5- 66357-35-5 U.S. 4,128,658 Antiulcer Ulcer,[(dimethylamino)methyl]-2- duodenalfuranyl]methyl]thio]ethyl]-N′-methyl-2-nitro- [CAS] ranitidine bismuth1,2,3-Propanetricarboxylic acid, 2-hydroxy- 128345-62-0 EP 533281Antiulcer Ulcer, citrate bismuth(3+) salt (1:1), compd. with N-(2-duodenal (((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N′-methyl-2-ni1- ethenediamine (1:1)-[CAS]ranolazine 1-Piperazineacetamide, N-(2,6- 95635-55-5 EP 126449Antianginal Angina, dimethylphenyl)-4-[2-hydroxy-3-(2- 95635-56-6general methoxyphenoxy)propyl]-, (+/−)-[CAS] Ranpirnase 133737-96-9Rapacuronium 156137-99-4 rasagiline 1H-Inden-1-amine, 2,3-dihydro-N-2-161735-79-1 U.S. 5,457,133 Antiparkinsonian Parkinson's propynyl-, (R)-,[CAS] disease Raubasine 483-04-5 ravuconazole Benzonitrile,4-[2-[(1R,2R)-2-(2,4- 182760-06-1 Antifungal Infection,difluorophenyl)-2-hydroxy-1-methyl-3-(1H- meningitis,1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-[CAS] general raxofelast2-Benzofuranacetic acid, 5-(acetyloxy)-2,3- 128232-14-4 U.S. 4,999,350Symptomatic Nephropathy, dihydro-4,6,7-trimethyl-, (+)-[CAS]antidiabetic diabetic razoxane 2,6-Piperazinedione, 4,4′-(1-methyl-1,2-21416-67-1, GB 1234935 Anticancer, other Cancer, ethanediyl)bis-[CAS]21416-87-5 general RC-529 Tetradecanoic acid (1R)-1-(2-((2-((2-deoxy216014-46-9 Immunostimulant, Vaccine 3-O-((3R)-1-oxo-3-((1- otheradjunct oxotetradecyl)oxy)tetradecyl)amino-4-O- phosphono-β-D-glucopyranosyl)oxy)ethyl)amino)-2- oxoethyl)dodecyl ester, compd. withN,N- diethylethanamine (1:1) [CAS] rebamipide 4-Quinolinepropanoic acid,Alpha-[(4- 90098-04-7 DE 3324034 Antiulcerchlorobenzoyl)amino]-1,2-dihydro-2-oxo- [CAS] rebimastat L-Valinamide,N-((2S)-2-mercapto-1-oxo-4- 259188-38-0 Anticancer, other Cancer, lung,(3,4,4-trimethyl-2,5-dioxo-1- non-small cellimidazolidinyl)butyl)-L-leucyl-N,3-dimethyl- [CAS] reboxetimeMorpholine, 2-[(2- 71620-89-8, U.S. 4,229,449 Antidepressant Depression,ethoxyphenoxy)phenylmethyl]-, (R*,S*)- 98769-81-4 general [CAS]Remacemide 128298-28-2 remifentanil 1-Piperidinepropanoic acid, 4-132539-07-2, EP 383579 Analgesic, other Pain, general(methoxycarbonyl)-4-((1- 132875-61-7 oxopropyl)phenylamino)-methylester- [CAS] reminetant Tricyclo[3.3.1.13,7]decane-2-carboxylic146362-70-1 EP 699438 Neuroleptic Schizophrenia acid,2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6- dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]-[CAS] Remoxipride 80125-14-0 renzapride Benzamide,4-amino-N-1- 109872-41-5 JP 58188885 Gastroprokinetic Irritable bowelazabicyclo[3.3.1]non-4-yl-5-chloro-2- 88721-77-1 syndrome methoxy-[CAS]repaglinide Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2- 135062-02-1 WO9300337 Antidiabetic Diabetes, (1-piperidinyl)phenyl]butyl]amino]-2-Type II oxoethyl]-, (S)-[CAS] repertaxin L-lysine salt2(R)-4-Isobutylphenylpropionyl WO 0024710 Cardiovascular Reperfusionmethanesulfonamide L-lysine salt injury repinotan1,2-Benzisothiazol-3(2H)-one, 2-(4-(((3,4- 144980-29-0 U.S. 5,137,901Neuroprotective Ischaemia, dihydro-2H-1-benzopyran-2- 144980-77-8cerebral yl)methyl)amino)butyl)-, 1,1-dioxide, monohydrochloride [CAS]repirinast 4H-Pyrano[3,2-c]quinoline-2-carboxylic 73080-51-0 U.S.4,298,610 Antiasthma acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-,3-methylbutyl ester [CAS] Reposal 3625-25-0 reproterol1H-Purine-2,6-dione, 7-[3-[[2-(3,5- 13055-82-8 FR M5969 AntiasthmaAsthma dihydroxyethyl]amino]propyl]-3,7-dihydro- 54063-54-61,3-dimethyl-[CAS] Rescimetol 73573-42-9 Rescinnamine 24815-24-5Reserpiline 131-02-2 Reserpine 50-55-5 Resibufogenin 465-39-4 resiquimod1H-Imidazo(4,5-c)quinoline-1- 144875-48-9 U.S. 5,389,640 Antiviral,other Infection, ethanol(ethoxymethyl)-Alpha, Alpha- hepatitis-dimethyl-[CAS] C virus Resorcinol 108-46-3 Reteplase 133652-38-7retigabine Carbamic acid, (2-amino-4-(((4- 150812-12-7 DE 4200259Antiepileptic Epilepsy, fluorophenyl)methyl)amino)phenyl)-, ethylgeneral ester [CAS] retinoic acid Retinoic acid [CAS] 302-79-4Formulation, Cancer, parenteral, leukaemia, other acute myelogenousRevimid U.S. 6,281,230 Anticancer, other Cancer, myelome R-flurbiprofen[1,1′-Biphenyl]-4-acetic acid, 2-fluoro- 5104-49-4 Anticancer, otherCancer, Alpha-methyl prostate Rho (D) Immune Globulin (Human) Rho-kinaseinhibitors WO 0156988 Antiasthma Unspcified ribavirin1H-1,2,4-Triazole-3-carboxamide, 1-β-D- 36791-04-5 U.S. 4,122,771Antiviral, other Infection, ribofuranosyl-[CAS] haemorrhagic feverRiboflavin 146-17-8 ribostamycin D-Streptamine,O-2,6-diamono-2,6-dideoxy- 25546-65-0 GB 1254883 AminoglycosideInfection, Alpha-D-glucopyranosyl-(1-4)-O-[β-D- antibiotic generalribofuranosyl-(1-5)]-2-deoxy-[CAS] Ricinoleic Acid 141-22-0 Ridogrel110140-89-1 rifabutin Rifamycin XIV, 1′,4-didehydro-1-deoxy-1,4-72559-06-9 U.S. 4,219,478 Antimycobacterial Infection,dihydro-5′-(2-methylpropyl)-1-oxo-[CAS] Mycobacterium avium complexrifalazil Rifamycin VIII, 1′,4-didehydro-1-deoxy-1,4- 129791-92-0 EP366914 Antimycobacterial Infection,dihydro-3′-hydroxy-5′-[4-(2-methylpropyl)- 129791-94-2 tuberculosis1-piperazinyl]-1-oxo-[CAS] 133633-12-2 rifametane Rifamycin, 3-[[[1-94168-98-6 EP 119571 Antimycobacterial Infection,(diethylamino)ethylidene]hydrazono]methyl]- general [CAS] RifamideRifamycin, 3-[[(4-methyl-1- 2750-76-7 rifampicin +piperazinyl)imino]methyl]-, mixt. with 5- 61498-94-0 Formulation,Infection, trimethoprim [(3,4,5-trimethoxyphenyl)methyl]-2,4- fixed-dosegeneral pyrimidinediamine [CAS] combinations Rifampin 13292-46-1Rifamycin SV 6998-60-3 rifapentine Rifamycin, 3-[[(4-cyclopentyl-1-61379-65-5 DE 2608218 Antibiotic, other Infection,piperazinyl)imino]methyl]-[CAS] tuberculosis rifaximinEpoxypentadeca[1,11,13]trienimino)benzo 80621-81-4 GB 2079270Antibiotic, other Infection, GI furo[4,5-e]-pyrido[1,2-a]benzimidazole-tract 1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23- tetrahydroxy-27-methoxy-2,4,11,16,20,22,25,26-octamethyl-, [2S-(2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*, 26S*,27R*,28E)] rifaximine cream4-deoxy-4′-methylpyrido[1′,2′- 80621-81-4 BE 888895 Formulation,Infection, 1,2]imidoazo[5,4-c]rifamycin SV dermal, topicaldermatological Rilmazafone 99593-25-6 rilmenidine 2-Oxazolamine,N-(dicyclopropylmethyl)- 54187-04-1 DE 2362754 Antihypertensive,Hypertension, 4,5-dihydro-[CAS] 54249-57-9 adrenergic general riluzole2-Benzothiazolamine, 6-(trifluoromethoxy)- 1744-22-5 EP 50551Neuroprotective Amyotrophic [CAS] lateral sclerosis Rimantadine13392-28-4 rimazolium 4H-Pyrido[1,2-a]pyrimidinium, 3- 28610-84-6 DE2461349 Analgesic, NSAID (ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6-35615-72-6 dimethyl-4-oxo-, [CAS] rimexolone Androsta-1,4-dien-3-one,11-hydroxy-16,17- 49697-38-3 DE 2301317 Ophthalmological Inflammation,dimethyl-17-(1-oxopropyl)-, ocular (11β,16Alpha,17β)-[CAS] Rimiterol32953-89-2 rimonabant 1H-Pyrazole-3-carboxamide, 5-(4- 158681-13-1 U.S.5,624,941 Anorectic/ Obesity chlorophenyl)-1-(2,4-dichlorophenyl)-4-Antiobesity methyl-N-1-piperidinyl-, monohydrochloride [CAS] riodoxol1,3-Benzenediol, 2,4,6-triiodo-[CAS] 19403-92-0 U.S. 3,755,251Antiviral, other Rioprostil 77287-05-9 risedronate Phosphonic acid,(1-hydroxy-2-(3- 115436-72-1 EP 304961 Osteoporosis Pagets diseasepyridinyl)ethylidene)bis-, monosodium salt treatment Risedronic Acid105492-24-6 risperidone 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-106266-06-2 EP 196132 Neuroleptic, Schizophreniafluoro-1,2-benzisoxazol-3-yl)-1- formulation,piperidinyl]ethyl]-6,7,8,9-tetrahydro-2- optimized, methyl-[CAS]microencapsulate Ritanserin 87051-43-2 Ritipenem 84845-57-8 ritodrineBenzenemethanol, 4-hydroxy-Alpha-[1-[[2- 23239-51-2 U.S. 3,410,944Labour inhibitor Labour, preterm (4-hydroxyphenyl)ethyl]amino]ethyl]-,26652-09-5 (R*,S*)-[CAS] ritonavir 2,4,7,12-Tetraazatridecan-13-oicacid, 10- 155213-67-5 WO 9414436 Antiviral, anti-HIV Infection, HIV/hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1- AIDSmethylethyl)-4-thiazolyl)-3,6-dioxo-8,11- bis(phenylmethyl)-,5-thiazolyl-methyl ester, (5S-(5R*,8R*,10R*,11R*))-[CAS] Rituximab174722-31-7 rivastigmine Carbamic acid, ethylmethyl-, 3[1- 123441-03-2DE 3805744 Cognition enhancer Alzheimer's (dimethylamino)ethyl]phenylester, (S)- 129101-54-8 disease [CAS] rizatriptan1H-Indole-3-ethanamine, N,N-dimethyl-5- 145202-66-0 EP 497512Antimigraine Migraine (1H-1,2,4-triazol-1-ylmethyl)-, [CAS] 159776-67-7144034-80-0 RJR-2403 3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-,183288-99-5 Cognition enhancer Alzheimer's (3E)-, (2E)-2-butenedioate(1:1) [CAS] disease RNA Stealth 5-Formyluridine Antiviral, otherInfection, Nucleosides hepatitis- C virus Ro-00948892′,3′-Di-O-acetyl-5′-vinylcytidine Anticancer, Cancer, antimetabolitegeneral Ro-61-1790 2-Pyridinesulfonamide, N-[6-(2- 180384-56-9 WO9619459 Cardiovascular Haemorrhage,hydroxyethoxy)-5-(2-methoxyphenoxy)-2- subarachnoid[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4- pyrimidinyl]-5-methyl-[CAS]Rociverine 53716-44-2 rocuronium Pyrrolidinium, 1- 104855-17-6 EP 287150Muscle relaxant Muscle [(2β,3Alpha,5Alpha,16β,17β)-17- 104884-91-5spasm, (acetyloxy)-3-hydroxy-2-(4- 119302-91-9 generalmorphonlinyl)androstan-16-yl]-1-(2- 143558-00-3 propenyl)-,bromide-[CAS] rofecoxib 2(5H)-Furanone, 4-(4- 162011-90-7 U.S. 5,474,995Analgesic, NSAID Arthritis, (methylsulfonyl)phenyl)-3-phenyl-[CAS] osteoroflumilast Benzamide, 3-(cyclopropylmethoxy)-N- 162401-32-3 WO 9501338COPD treatment Chronic (3,5-dichloro-4-pyridinyl)-4- obstructive(difluoromethoxy)-[CAS] pulmonary disease rokitamycin Leucomycin V,4B-butanoate 3B- 74014-51-0 U.S. 4,242,504 Macrolide antibioticInfection, propanoate [CAS] general Rolipram 61413-54-5 Rolitetracycline751-97-3 Romurtide 78113-36-7 Ronifibrate 42597-57-9 ropinirole2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]- 91374-20-8 EP 266033Antiparkinsonian Parkinson's 1,3-dihydro-, monohydrochloride-[CAS]91374-21-9 disease ropivacaine 2-Piperidinecarboxamide, N-(2,6-84057-95-4 EP 239710 Anaesthetic, local Anaesthesiadimethylphenyl)-1-propyl-, (S)-[CAS] 98717-15-8 Roquinimex 84088-42-6rosaprostol Cyclopentaneheptanoic acid, 2-hexyl-5- 56695-65-9 GB 1523355Prostaglandin hydroxy-[CAS] Rosaramicin 35834-26-5 Rose Bengal 632-68-8rosiglitazone 2,4-Thiazolidinedione, 5-((4-(2-methyl-2- 122320-73-4 U.S.5,002,953 Antidiabetic Diabetes, pyridinylamino)ethoxy)phenyl)methyl)-,(Z)- 155141-29-0 Type II 2-butenedioate (1:1) [CAS] rosoxacin3-Quinolinecarboxylic acid, 1-ethyl-1,4- 40034-42-2 U.S. 3,753,993Quinolone Infection, dihydro-4-oxo-7-(4-pyridinyl)-[CAS] antibacterialgonorrhoea rostaporfin Tin, dichloro[ethyl 3,4,10,21-tetrahydro-114494-17-6 Ophthalmological Macular 4,9,14,19-tetraethyl-18.19-dihydro-degeneration 3,8,13,18-tetramethyl-20- phorbinecarboxylato(2-)-kappaN23,kappaN24,kappaN25,kappaN26]-, (OC-6-13)-[CAS] rosuvastatin6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6- 147098-20-2 JP 2648897Hypolipaemic/ Hyper- (1-methylethyl)-2- Antitherosclerosis lipidaemia,(methyl(methylsulfonyl)amino)-5- general pyrimdinyl)-3,5-dihydroxy-(S-(R*,S*-(E))) [CAS] rotigotine 1-Naphthalenol, 5,6,7,8-tetrahydro-6-99755-59-6 U.S. 4,564,628 Antiparkinsonian Parkinson's[propyl[2-(2-thienyl)ethyl]amino]-, (S)- disease [CAS] Rotraxate92071-51-7 Roxarsone 121-19-7 roxatidine Acetamide,2-(acetyloxy)-N-[3-[3-(1- 78628-28-1 EP 24510 Antiulcer Ulcer, gastricpiperidinylmethyl)phenoxy]propyl]-, [CAS] 93793-83-0 roxifibanL-Alanine, 3-(((3-(4- 176022-59-6 U.S. 5,849,736 AntithromboticThrombosis, (aminoiminomethyl)phenyl)-4,5-dihydro-5- generalisoxazolyl)acetyl)amino)-N- (butoxycarbonyl)-, methyl ester, (R)-, [CAS]Roxindol 112192-04-8 roxithromycin Erythromycin, 9-[O-[(2- 80214-83-1 EP33255 Macrolide Infection, methoxyethoxy)methyl]oxime][CAS] 80214-86-4antibiotic general RPR-109881A Benzenepropanoic acid, β-(((1,1-192573-38-9 Anticancer, other Cancer, lung,dimethylethoxy)carbonyl)amino)-Alpha- general hydroxy-(1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acetyloxy)-1-(benzoyloxy)- 1,3,47,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca(3,4) cyclopropa (4,5) benz (1,2-b)oxet-4-yl ester, dihydrate Alpha R, betaS [CAS] RPR-1304014,9-Ethano-3aH-benz[f]isoindole-3a- 210282-69-2 WO 9829390 Anticancer,other Cancer, carboxylicacid, 1,2,3,4,9,9a-hexahydro-2- general[2-(2-methoxyphenyl)-1-oxo-2-propenyl]-9- (4-methylphenyl)-,(3aR,4S,9S,9aR)-rel- [CAS] R-roscovitine U.S. 6,316,456 Anticancer,other Cancer, lung, non-small cell RS-0406N′N′-bis(3-hydroxyphenyl)pyridazine-3,6- Neuroprotective Alzheimer'sdiamine disease RSR-13 131179-95-8 Rubijervine 79-58-3 rubitecan1H-Pyrano(3′,4′:6,7)indolizino(1,2- 91421-42-0 U.S. 6,485,514Anticancer, other Cancer, b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-pancreatic hydroxy-10-nitro-, (S)-[CAS] ruboxistaurin 9H,18H-5,21:12,17-169939-94-0 Symptomatic Retinopathy, Dimethenodibenzo(e,k)pyrrolo(3,4-antidiabetic diabetic h)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione,9- ((dimethylamino)methyl)-6,7,10,11- tetrahydro-,(S)-[CAS] Rufinamide 106308-44-5 rufloxacin7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6- 101363-10-4 EP 165375 QuinoloneInfection, carboxylic acid, 9-fluoro-2,3-dihydro-10-(4- 102052-47-1antibacterial general methyl-1-piperazinyl)-7-oxo-[CAS] 106017-08-7rupatadine 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8- 156611-76-6 EP0577957 Antiallergic, Rhinitis, chloro-6,11-dihydro-11-[1-[(5-methyl-3-non-asthma allergic, pyridinyl)methyl]-4-piperidinylidene]-, seasonaltrihydrochloride-[CAS] Rutin 153-18-4 RWJ-544285-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- 189448-35-9 WO 3713772Cephalosporin, Infection, carboxylic acid, 7-[[(2Z)-(2-amino-5-chloro-injectable beta- 4-thiazolyl)(hydroxyimino)acetyl]amino]-3- lactamase[(3-[[(2-aminoethyl)thio]methyl]-4- resistant pyridinyl]thio]methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)-[CAS] S-0139 Olean-12-en-28-oic acid,27-[[3-[5-hydroxy- 193969-54-9 WO 9727314 Cardiovascular Ischaemia,2-[(4-methoxy-1,4-dioxo-2- cerebral butenyl)]amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo-[CAS] S-15535 Piperazine,1-(2,3-dihydro-1,4-benzodioxin- 146998-34-7 Cognition Cognitive5-yl)-4-(2,3-dihydro-1H-inden-2-yl)-[CAS] enhancer disorder, generalS-18886 1-Naphthalenepropanoic acid, 6-(((4- 165537-73-5 AntithromboticThrombosis, chlorophenyl)sulfonyl)amino)-5,6,7,8- generaltetrahydro-2-methyl [CAS] S-347307-chloro-6-sulfamoyl-2-(1H)-quinoleinone- Neuroprotective Unspecified3-phosphonic acid S-3578 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-Cephalosporin, Infection, ethoxyiminoacetamido]-3-(1-(N- injectablegeneral methylaminopropyl)-1H-imidazo[4,5-b]pyridinium-4-methyl-3-cephem-4- carboxylate monosulfate S-364962-[N-[4-(4- Antiasthma Asthma Chlorophenylsulfonylamino)butyl]-N-[3-[(4-isopropylthiazol-2- yl)methyloxy]benzyl]sulfamoyl]benzoic acid S-365272-[N-[4-(4- Antiasthma Asthma Chlorophenylsulfonylamino)butyl]-N-[3-[(4-(4-cyclobutylthiazol-2- yl)ethyl]benzyl]sulfamoyl]benzoic acid S-5751(1R,2R,3S,5S)-7-[2-(5- Antiallergic, Allergy,Hydroxybenzothiophen-3-ylcarboxamido)- non-asthma general6,6-dimethylbicyclo[3.1.1]hept-3yl]-5(Z)- heptenoic acid S-8510Imidazo[4,5-d]pyrano[4,3-b]pyridine, 151466-23-8 EP 556008 CognitionAlzheimer's 1,6,7,9-tetrahydro-2-(3-isoxazolyl)-, enhancer diseasephosphate (1:1) [CAS] S-8921 2-Naphthalenecarboxylis acid, 1-(3,4-151165-96-7 WO 9308155 Hypolipaemic/ Hypercholest-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)- Antiatherosclerosis erolaemia4-hydroxy-6,7,8-trimethoxy-, methyl ester [CAS] Sabcomeline 159912-53-5Sabeluzole 104383-17-7 S-Adenosylmethionine 29908-03-0 safinamide(S)-(+)-2-[4-(3- 133865-89-1 AU 711309 Antiepileptic Epilepsy,fluorobenzyloxy)benzylamino]propanamide general methansulfonateSalacetamide 487-48-9 Salazosulfadimidine 2315-8-4 salbutamol1,3-Benzenedimethanol,Alpha1-[[(1,1- 18559-94-9 EP 451745 Formulation,Asthma dimethylethyl)amino]methyl]-4-hydroxy- inhalable, [CAS] topical,dry powder Salicin 138-52-3 Salicyl Alcohol 90-01-7 Salicylamide 65-45-2Salicylamide O-Acetic 25395-22-6 Acid Salicylanilide 87-17-2 SalicylicAcid 69-72-7 Salicylsilfuric Acid 89-45-2 Salinazid 495-84-1 salmeterol1,3-Benzenedimethanol, 4-hydroxy-Alpha1- 89365-50-4 WO 9006775Antiasthma Asthma [[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, 94749-08-3(±)-1-hydroxy-2-naphthalenecarboxylate [CAS] Salsalate 552-94-3Salverine 6376-26-7 Samarium ₁₅₃Sm 154427-83-5 Lexidronam sampatrilatL-Tyrosine, N2-(methylsulfonyl)-L-lysyl-1- 129981-36-8 EP 358398Antihypertensive, Hypertension, [(2S)-3-amino-2- renin system generalcarboxypropyl]cyclopentanecarbonyl- [CAS] Sancycline 808-26-4Saperconazole 110588-57-3 sapropterin 4(1H)-Pteridinone, 2-amino-6-(1,2-69056-38-8 EP 191335 Antidepressant Hyperphenyl-dihydroxypropyl)-5,6,7,8-tetrahydro-, 62989-33-7 alaninaemiadihydrochloride, [6R-[6R*(1R*,2S)]]- [CAS] saquinavir Butanediamide,N1-[3-[3-[[(1,1- 127779-20-8 EP 432695 Antiviral, anti-HIV Infection,dimethylethyl)amino]carbonyl]octahydro- HIV/AIDS2(1H)-isoquinolinyl]-2-hydroxy-1- (phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [3S- [2[1R*(R*),2S*],3Alpha,4aβ,8aβ]]-[CAS]Saralasin 34273-10-4 saredutant Benzamide, N-[4-[4-(acetylamino)-4-142001-63-6 EP 474561 Antiasthma Asthma phenyl-1-piperidinyl]-2-(3,4-dichloropenyl)butyl]-N-methyl-, (S)-[CAS] sarizotan3-Pyridinemethanamine, N-((3,4-dihydro- 177975-08-5 AntiparkinsonianParkinson's 2H-1-benzopyran-2-yl)methyl)-5-(4- diseasefluorophenyl)-[CAS] sarpogrelate Butanedioic acid,mono[2-(dimethylamino)- 125926-17-2 EP 398326 Antithrombotic1-[[2-[2-(3- methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester [CAS]Satigrel 111753-73-2 satraplatin Platinum, bis(acetato- 129580-63-8 EP328274 Anticancer, Cancer, O)amminedichloro(cyclohexanamine)-,alkylating prostate (OC-6-43)-[CAS] Satumomab 144058-40-2 SB-237376N-[3-[[2-(3,4- Antiarrhythmic Fibrillation,dimethoxyphenyl)ethyl]amino]propyl]-4- atrial nitrobenzamide, HClSB-238039 (5-(-2-phenylamino-4-pyrimidinyl)-4-)(4- Anticancer, otherCancer, fluorophenyl)-1-(4-piperidinyl)imidazole general SB-277011trans-N-[4-[2-(Cyano-1,2,3,4- Neuroleptic Schizophreniatetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]- 4-quinolinecarboxamideScarlet Red 85-83-6 SCH-00013 Benzonitrile,4-[2-[3,6-dihydro-4-(1,4,5,6- 217963-18-3 EP 618204 CardiostimulantHeart failure tetrahydro-6-oxo-3-pyridazinyl)-1(2H)-pyridinyl]-1-hydroxyethyl]-[CAS] Sch-23863(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo Immunosuppressant Inflammation,[a,d] cyclohepten-S-yl]-N,N-dimethyl- general ethanamine saredutantBenzamide, N-[4-[4-(acetylamino)-4- 142001-63-6 EP 474561 AntiasthmaAsthma phenyl-1-piperidinyl]-2-(3,4- dichlorophenyl)butyl]-N-methyl-,(S)-[CAS] sarizotan 3-Pyridinemethanamine, N-((3,4-dihydro- 177975-08-5Antiparkinsonian Parkinson's 2H-1-benzopyran-2-yl)methyl)-5-(4- diseasefluorophenyl)-[CAS] sarpogrelate Butanedioic acid,mono[2-(dimethylamino)- 125926-17-2 EP 398326 Antithrombotic1-[[2-[2-(3- methoxyphenyl)ethyl]phenoxy]methyl]- ethyl] ester [CAS]Satigrel 111753-73-2 satraplatin Platinum, bis(acetato- 129580-63-8 EP328274 Anticancer, Cancer, O)amminedichloro(cyclohexanamine)-,alkylating prostate (OC-6-43)-[CAS] Satumomab 144058-40-2 SB-237376N-[3-[[2-(3,4- Antiarrhythmic Fibrillation,dimethoxyphenyl)ethyl]amino]propyl]-4- atrial nitrobenzamide, HClSB-238039 (5-(-2-phenylamino-4-pyrimidinyl)-4-)(4- Anticancer, otherCancer, fluorophenyl)-1-(4-piperidinyl)imidazole general SB-277011trans-N-[4-[2-(6-Cyano-1,2,3,4- Neuroleptic Schizophreniatetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]- 4-quinolinecarboxamideScarlet Red 85-83-6 SCH-00013 Benzonitrile,4-[2-[3,6-dihydro-4-(1,4,5,6- 217963-18-3 EP 618204 CardiostimulantHeart failure tetrahydro-6-oxo-3-pyridazinyl)-1(2H)-pyridinyl]-1-hydroxyethyl]-[CAS] Sch-23863(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo Immunosuppressant Inflammation,[a,d]cyclohepten-S-yl]-N,N-dimethyl- general ethanamine sertaconazole1H-Imidazole, 1-[2-[(7-chlorobenzo[b]thien- 99592-32-2 EP 151477Antifungal Infection, 3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-dermatological [CAS] sertindole 2-Imidazolidinone,1-[2-[4-[5-chloro-1-(4- 106516-24-9 EP 392959 Neuroleptic Schizophreniafluorophenyl)-1H-indol-3-yl]-1- piperidinyl]ethyl]-[CAS] sertraline1-Naphthalenamine, 4-(3,4- 79559-97-0 EP 30081 AntidepressantDepression, dichlorophenyl)-1,2,3,4-tetrahydro-N- 79617-96-2 generalmethyl-, (1S-cis)-[CAS] 79617-97-3 Setastine 64294-95-7 sevelamer2-Propen-1-amine polymer with 152751-57-0 U.S. 5,496,545 UrologicalRenal failure (chloromethyl)oxirane, hydrochloride 52757-95-6 [CAS]sevoflurane Propane, 1,1,1,3,3,3-hexafluoro-2- 28523-86-6 DE 1954268Anaesthetic, Anaesthesia (fluoromethoxy)-[CAS] inhalation SG-2102H-1,4-Benzothiazine-2-acetic acid, 3,4- 143162-65-6 SymptomaticNeuropathy, dihydro-3-oxo-4-((4,5,7-trifluoro-2- antidiabetic diabeticbenzothiazolyl)methyl)-[CAS] sibutramine Cyclobutanemethanamine, 1-(4-106650-56-0 GB 2098602 Anorectic/ Obesitychlorophenyl)-N,N-dimethyl-Alpha-(2- 84485-00-7 Antiobesitymethylpropyl)-[CAS] siccanin (4aS- 22733-60-4 JP 37003548 Antifungal(4aAlpha,6aAlpha,11bAlpha,13aR*, 13bAlpha))-1,2,3,4,4a,5,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H- benzo[a]furo[2,3,4-mn]xanthen-11-olsildenafil Piperazine, 1-((3-(4,7-dihydro-1-methyl-7- 171599-83-0 WO9428902 Male sexual Impotence oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-139755-83-2 dysfunction 5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl, 2-hydroxy-1,2,3-propanetricarboxylate-(1:1) [CAS] silodosin1H-Indole-7-carboxamide, 2,3-dihydro-1- 160970-54-7 EP 600675 UrologicalDysuria (3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]- propyl]-[CAS] Silver Lactate128-00-7 Sch-57790 1-Piperazineacetonitrile, 4-cyclohexyl- 221660-80-6Cognition enhancer Alzheimer's alpha-[4-[(S)-(4- diseasemethoxyphenyl)sulfinyl]phenyl]-[CAS] Sch-633907H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5- 174648-45-4 AntiparkinsonianParkinson's c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3- diseasephenylpropyl)-[CAS] Scillarenin 465-22-5 Scopolamine 51-34-3 ScopolamineN-Oxide 97-75-6 scopolamine Benzeneacetic acid, Alpha- 51-34-3 U.S.4,262,003 Formulation, Nausea and (hydroxymethyl)-, 9-methyl-3-oxa-9-transdermal, other vomitting, azatricyclo[3.3.1.02,4]non-7-yl ester,general [7(S)-(1Alpha,2β,4β,5Alpha,7β)]-[CAS] SCS technology U.S.6,046,188 Antiasthma Unspecified secalciferol9,10-Secocholesta-5,7,10(19)-triene- 55721-11-4 EP 301167 OsteoporosisOsteo- 3,24,25-triol, (3β,5Z,7E,24R)-[CAS] treatment dystrophysecnidazole 1H-Imidazole-1-ethanol, Alpha,2-dimethyl 3366-95-8 FR M3270Protozoacide Infection, 5-nitro-[CAS] trichomoniasis Secobarbital309-43-3 selegiline Benzeneethanamine, N,Alpha-dimethyl-N- 14611-51-9 GB1153578 Antiparkinsonian 2-propynyl, (R)-[CAS] Selenomethionine1464-42-2 Sematilide 101526-83-4 Semotiadil 116476-13-2 seocalcitol1,3-Cyclohexanediol, 5-((1-(6-ethyl-6- 134404-52-7 WO 9100855Anticancer, other Cancer, hydroxy-1-methyl-2,4-octadienyl)octahydro-liver 7a-methyl-4H-inden-4-ylidene)ethylidene)- 4-methylene-, (1R-(1Alpha(1R*,2E,4E),3aβ,4E(1R*,3S*,5Z), 7aAlpha))-[CAS] Sepimostat103926-64-3 seratrodast Benzeneheptanoic acid, zeta-(2,4,5- 103187-07-1EP 232089 Antiasthma Asthmatrimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, 112665-43-7 (+/−)-[CAS]sertaconazole 1H-Imidazole, 1-[2-[(7-chlorobenzo[b]thien- 99592-32-2 EP151477 Antifungal Infection, 3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-derma- [CAS] tological sertindole 2-Imidazolidinone,1-[2-[4-[5-chloro-1-(4- 106516-24-9 EP 392959 Neuroleptic Schizophreniafluorophenyl)-1H-indol-3-yl]-1- piperidinyl]ethyl]-[CAS] sertraline1-Naphthalenamine, 4-(3,4- 79559-97-0 EP 30081 AntidepressantDepression, dichlorophenyl)-1,2,3,4-tetrahydro-N- 79617-96-2 generalmethyl-, (1S-cis)-[CAS] 79617-97-3 Setastine 64294-95-7 sevelamer2-Propen-1-amine polymer with 152751-57-0 U.S. 5,496,545 UrologicalRenal failure (chloromethyl)oxirane, hydrochloride 52757-95-6 [CAS]sevoflurane Propane, 1,1,1,3,3,3-hexafluoro-2- 28523-86-6 DE 1954268Anaesthetic, Anaesthesia (fluoromethoxy)-[CAS] inhalation SG-2102H-1,4-Benzothiazine-2-acetic acid, 3,4- 143162-65-6 SymptomaticNeuropathy, dihydro-3-oxo-4-((4,5,7-trifluoro-2- antidiabetic diabeticbenzothiazolyl)methyl)-[CAS] sibutramine Cyclobutanemethanamine, 1-(4-106650-56-0 GB 2098602 Anorectic/ Obesitychlorophenyl)-N,N-dimethyl-Alpha-(2- 84485-00-7 Antiobesitymethylpropyl)-[CAS] siccanin (4aS- 22733-60-4 JP 37003548 Antifungal(4aAlpha,6aAlpha,11bAlpha,13aR*, 13bAlpha))-1,2,3,4,4a,5,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H- benzo[a]furo[2,3,4-mn]xanthen-11-olsildenafil Piperazine, 1-((3-(4,7-dihydro-1-methyl-7- 171599-83-0 WO9428902 Male sexual Impotence oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-139755-83-2 dysfunction 5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl, 2-hydroxy-1,2,3-propanetricarboxylate-(1:1) [CAS] silodosin1H-Indole-7-carboxamide, 2,3-dihydro-1- 160970-54-7 EP 600675 UrologicalDysuria (3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]- propyl]-[CAS] Silver Lactate128-00-7 Silver Picrate 146-84-9 silver sulfadiazineN′-2-pyrimidinylsulfanilamide 22199-08-2 Anti-infective, otherInfection, monosilver salt 68-35-9 general Simetride 154-82-5 Simfibrate14929-11-4 simvastatin Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-79902-63-9 U.S. 4,444,784 Hypolipaemic/ Hyper-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4- Antiatherosclerosislipidaemia, hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1- general naphthalenylester, [1S- [1Alpha,3Alpha,7β,8β(2S*,4S*),8aβ]]- [CAS] Sincalide25126-32-3 Sintropium Bromide 79467-19-9 Sisomicin 32385-11-8sitafloxacin 3-Quinolinecarboxylic acid, 7-(7-amino-5- 127254-12-0 EP341493 Quinolone Infection, azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-antibacterial general (2-fluorocyclopropyl)-1,4-dihydro-4-oxo-,[1R-[1Alpha(S*),2Alpha]]-, hydrate sitamaquine 1,6-Hexanediamine,N,N-diethyl-N′-(6- 5330-29-0 methoxy-4-methyl-8-quinolinyl)-[CAS]57695-04-2 Protozoacide Infection, leishmaniasis sitaxsentanN-(4-Chloro-3-methyl-5-isoxazolyl)-2-[[4,5- 184036-34-8 U.S. 5,464,853Antihypertensive, Hypertension, (methylenedioxy)-o-toly]acetyl]-3- otherpulmonary thiophenesulfonamide sivelestat Glycine,N-[2-[[[4-(2,2-dimethyl-1- 127373-66-4 EP 347168 Respiratory Systemicoxopropoxy)phenyl]sulfonyl]amino]benzoyl]- inflammatory [CAS] responsesyndrome SJA-6017 Butanamide, 2-[[(4- 190274-53-4 EP 771565Ophthalmological Cataract fluorophenyl)sulfonyl]amino]-N-[(1S)-1-formyl-3-methylbutyl,),-3-methyl-, (2S)- [CAS] SL-65-14986-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1- EP 607076 Anxiolytic Anxiety,ylcarbonyl)-2,9-dihydro-1H-pyrido[3,4- general b]indole-1-one SLV-306(3S,2′R)-3-[1-[2′-(Ethoxycarbonyl)-4′- Antihypertensive, Hypertension,phenyl-butyl-]cyclopentan-1- diuretic generalcarbonylamino]-2,3,4,5-tetra-hydro-2-oxo- 1H-benzapin-1-acetic acidSLV-308 2(3H)-Benzoxazolone, 7-(4-methyl-1- 269718-83-4 AntiparkinsonianParkinson's piperazinyl)-, monohydrochloride disease Sm153 lexidronamSamarate(5-)-153Sm, (((1,2- 160369-78-8 Analgesic, other Pain, cancerethanediylbis(nitrilobis(methylene)))- tetrakis(phosphonato))(8-)-N,N′,OP,OP′,OP′′′,OP′′′′)-, pentasodium, (OC-6-21)-[CAS]S-Methylmethionine 4727-40-6 SMP-300N-(Aminoiminomethyl)-11-chloro-5,6,7,8- Antianginal Angina,tetrahydro-8-oxo-4H-pyrrolo[3,2,1- generalk][1]benzazocine-2-carboxamide monomethanesulfonate monohydrate SN-38(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro- 100286-90-6 Formulation,Cancer, 4,10-dihydroxy-3,14-dioxo-1H- optimized, colorectalpyrano[3′,4′:6,7]indolizino[1,2-b]quindin-9- liposomes yl SNAP-7941((+)-methyl (4S)-3-[[(3-(4-[3- Anxiolytic Anxiety,(acetylamino)phenyl]-1- generalpiperidinyl)propyl)amino]carbonyl]-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate hydrochloride) SOA-1322-Naphthalenecarboxamide, N-[2-[4- 143964-80-1 Formulation, Asthma(diphenylmethoxy)-1-piperidinyl]ethyl]-3- inhalable, topicalhydroxy-5-(3-pyridinylmethoxy)-[CAS] soblidotin L-valinamide,N,N-dimethyl-L-valyl-N-[2- 149606-27-0 WO 9303054 Anticancer, Cancer,lung, methoxy-4-[2-[1-methoxy-2-methyl-2-oxo- other non-small3-((2-phenylethyl)amino]proply]-1- cellpyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]- N-methyl-, [2S-[1[1R*(R*),2S*],2R*(1S*,2S*)]]-[CAS] Sobrerol 498-71-5 sobuzoxaneCarbonic acid, 1,2-ethanediylbis[(2,6-dioxo 98631-95-9 EP 140327Anticancer, other Cancer, 4,1-piperazinediyl)methylene]bis(2- lymphoma,methylpropyl) ester [CAS] T-cell Sodium Arsanilate 127-85-5 SodiumArsphenamine 1936-28-3 Sodium Chloride Sodium Dibunate 14992-59-7 SodiumFolate 6484-89-5 Sodium 149-44-0 Formaldehy desulfoxylate Sodium1334-74-3 Glycerophosphate Sodium Hyaluronate Sodium Iodomethamate519-26-6 Sodium Nitrite 7632-00-0 Sodium Nitroprusside 14402-89-2 sodiumoxybate Butyric acid, 4-hydroxy monosodium salt 502-85-2 PsychostimulantNarcolepsy [CAS] Sodium Phenol- 1300-51-2 sulfonate sodiumphenylbutyrate Butyric acid, 4-phenyl-, sodium salt-[CAS] 1716-12-7Formulation, other Hyper- ammonaemia sodium phosphate Sodium phosphatemonobasic U.S. 6,162,464 Formulation, Surgery monohydrate + sodiumphosphate dibasic oral, other adjunct anhydrous sodium prasterone3β-hydroxy-5-androsten-17-one(sodium EP 380036 Formulation, Labour,sulfate sulfate dihydrate) mucosal, topical induction Sodium Propionate137-40-6 sodium salicylate Benzoic acid, 2-hydroxy-, monosodium 54-21-7Formulation, oral, Pain, general salt [CAS] solubility-enhanced SodiumTetradecyl 139-88-8 Sulfate sofalcone Acetic acid,[5-[(3-methyl-2-butenyl)oxy]-2- 64506-49-6 GB 1523241 Antiulcer[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1- oxo-2-propenyl]phenoxy]-[CAS]Solasulfone 133-65-3 solifenacin Butanedioic acid compd with(1S)-(3R)-1- 242478-38-2 Urological Overactive azabicyclo(2.2.2)oct-3-yl3,4-dihydro-1- bladder phenyl-2(1H)-isoquinolinecarboxylate (1:1) [CAS]Sorbinicate D-Glucitol, hexa-3-ptridinecarboxylate 6184-06-1 BE 883352Hypolipaemic/ [CAS] Antiatherosclerosis Sorbitol 50-70-4 Sorivudine77181-69-2 sotalol Methanesulfonamide, N-[4-[1-hydroxy-2- 3930-20-9Antiarrhythmic [(1-methylethyl)amino]ethyl]phenyl]-[CAS] 959-24-0Soterenol 13642-52-9 Sozoiodolic Acid 554-71-2 spaglumic acid L-Glutamicacid, N-(N-acetyl-L-Alpha- 3106-85-2 Formulation, Conjunctivitisaspartyl)-[CAS] 80619-64-3 mucosal, topical sparfloxacin3-Quinolinecarboxylic acid, 5-amino-1- 110871-86-8 EP 221463 QuinoloneInfection, cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)- antibacterialrespiratory 6,8-difluoro-1,4-dihydro-4-oxo-, cis-[CAS] tract, generalSparteine 90-39-1 SPA-S-843 Candicin D, 18-decarboxy-40-demethyl-202748-83-2 U.S. 5,298,495 Antifungal Infection,3,7-dideoxo-N3′-((dimethylamino)acetyl)- fungal, 18-(((2- general(dimethylamino)ethyl)amino)carbonyl)-3,7- dihydroxy-N47-methyl-5-oxocyclic 15,19- hemiacetal, comp with L-ascorbic acid (1:2) [CAS]Spasmolytol 25333-96-4 SPD-754 2(1H)-Pyrimidinone, 4-amino-1-(2-160707-69-7 U.S. 6,228,860 Antiviral, anti-HIV Infection,(hydroxymethyl)-1,3-oxathiolan-4-yl-(2R- HIV/AIDS cis)- Spectinomycin1695-77-8 SPI-339 4-[3-(4-Oxo-4,5,6,7-tetrahydroindol- CognitionAlzheimer's yl)propionylamino]benzoic acid ethyl ester enhancer diseaseSpiperone 749-02-0 spirapril 1,4-Dithia-7-azaspiro[4.4]nonane-8-83647-97-6 EP 50800 Antihypertensive, Hypertension, carboxylic acid,7-[2-[[1-(ethoxycarbonyl)-3- renin system generalphenylpropyl]amino]-1-oxopropyl]-, [8S- [7[R*(R*)],8R*]]-[CAS]Spirogermanium 41992-23-8 spironolactone Pregn-4-ene-21-carboxylic acid,7- 52-01-7 EP 124147 Formulation, Acne (acetylthio)-17-hydroxy-3-oxo-,Gamma- dermal, topical lactone,(7Alpha,17Alpha)-[CAS] SR-121463Benzamide, N-(1,1-dimethylethyl)-4-[[cis-5′- 185913-78-4 WO 9715556Cardiostimulant Heart ethoxy-4-[2-(4-morpholinyl)ethoxy]-2′- failureoxospiro[cyclohexane-1,3′-[3H]indol]-1′(2′H)-yl]sulfonyl]-3-methoxy-[CAS] SR-144190 Morpholine,4-benzoyl-2-(3,4- 201152-86-5 WO 9623787 Anxiolytic Anxiety,difluorophenyl)-2-[2-[4- general[[(dimethylamino)carbonyl]amino]-4-phenyl- 1-piperidinyl]ethyl]-,(2R)-[CAS] SR-146131 1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-221671-61-0 WO 9915525 Anorectic/ Obesity 2,5-dimethoxyphenyl)-5-(2-Antiobesity cyclohexylethyl)-2- thiazolyl]amino]carbonyl]-5,7-dimethyl-[CAS] SR-271425 N-[1-[2-(diethylamino)ethylamino]-7- Anticancer, Cancer,methoxy-9-oxo-9H-thioxanthen-4- alkylating general ylmethyl]formamideSR-27897 1H-Indole-1-acetic acid, 2-[[[4-(2- 136381-85-6 EP 432040Anticancer, other Cancer, chlorophenyl)-2-thiazolyl]amino]carbonyl]-pancreatic [CAS] SR-31747 Cyclohexanamine, N-(3-(3-chloro-4- 132173-07-0EP 376850 Anticancer, other Cancer,cyclohexylphenyl)-2-propenyl)-N-ethyl-, myeloma hydrochloride, (Z)-[CAS]SR-58611 Acetic acid, [[(7S)-7-[[(2R)-2-(3- 121524-09-2 EP 303546 GIinflammatory/ Irritable chlorophenyl)-2-hydroxyethyl]amino]- boweldisorders bowel 5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, syndrome ethylester, hydrochloride [CAS] SS732 U.S. 5,385,900 Formulation, Infection,mucosal, topical ocular SS-750 (R)-(−)-2-(2,4-difluorophenyl)-1- U.S.6,083,968 Antifungal Infection,(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4- fungal,triazol-1-yl)-2-propanol general β-alethine Propanamide,N,N′(dithiodi-2,1- 646-08-2 Anticancer, Cancer,ethanediyl)bis(3-amino)-[CAS] immunological myeloma SSR-149415(2S,4R)-1-[5-chloro-1-[(2,4- WO 0155130 Antidepressant Depression,dimethoxyphenyl)sulfonyl]-3-(2-methoxy- generalphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidone carboxamide SSR-1805752-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5- Neuroprotective Unspecifieddihydro-3H-pyridazino[4,5-6]indol-1-yl)- N,N-dimethylacetamideSSR-181507 (3-Exo)-8-benzoyl-N-[[(2S)-7-chloro-2,3- U.S. 6,221,879Neuroleptic Schizophrenia dihydro-1,4-benzodioxin-2-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine HCl SSR-591813(5aS,8S,10aR)-5a,6,9,10-tetrahydro, Dependence Addiction, 7H,11H-8,10a-treatment nicotine methanopyrido[2′,3′:5,6]pyrano[2,3- d]azepine SST-101D-Glucitol, 1,4:3,6-dianhydro-, dinitrate 87-33-2 Formulation, Angina,[CAS] transdermal, other general SSY-726(−)-(R)-3-Methyl-3-(methylsulfonyl)-1- U.S. 5,147,886 AntifungalInfection, (1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)- fungal,phenyl]-2-butanol general ST-200 1-Propanaminium,2-(acetyloxy)-3-carboxy- 5080-50-2 DE 3015635 Cognition Dementia,N,N,N-trimethyl-, chloride, (R)-[CAS] enhancer senile, generalstachyfilin WO 9711947 Antiviral, other Infection, influenza virusStallimycin 636-47-5 Stampidine U.S. 6,350,736 Antiviral, anti-HIVInfection, HIV/AIDS Stannous 15578-26-4 Pyrophosphate stannsoporfin(OC-6-13)-Dihydrogen dichloro[7,12- 106344-20-1 HepatoprotectiveHyperbiliru- diethyl-3,8,13,17-tetramethyl-21H,23H- binaemiaporphine-2,18-dipropanoato(4-)- N21,N22,N23,N24]stannate(2-) Stanolone521-18-6 Stanozolol 10418-03-8 (2′H form); 302-96-5 (1′H form) Staphaureus ther U.S. 6,376,652 Genomics-based Infection, drug discovery MRSASTAT4 inhibitors WO 9629341 Immunosuppressant Unspecified stavudineThymidine, 2′,3′-didehydro-3′-deoxy-[CAS] 3056-17-5 EP 501511 Antiviral,anti-HIV Infection, HIV/AIDS Stenbolone 5197-58-0 stepronim Glycine,N-[1-oxo-2-[(2- 72324-18-6 U.S. 4,242,354 Antitussive Coughthienylcarbonyl)thio]propyl]-[CAS] Stibocaptate 27279-76-1 Stibophen15489-16-4 Stilbamidine 122-06-5 stiripentol 1-Penten-3-ol,1-(1,3-benzodioxol-5-yl)-4,4- 49763-96-4 Antiepileptic Epilepsy,dimethyl-[CAS] general Streptodornase 37340-82-2 Streptomycin 57-92-1Streptonicozid 5667-71-0 Streptonigrin 3930-19-6 Streptozocin 18883-66-4strontium ranelate 3-Thiopheneacetic acid, 5- 135459-87-9 EP 415850Osteoporosis Osteoporosis [bis(carboxymethyl)amino]-2-carboxy-4-treatment cyano-, strontium salt (1:2)-[CAS] strontium-89 chlorideStrontium chloride (89SrCl2) [CAS] 38270-90-5 Analgesic, other Pain,cancer Succimer 304-55-2 Succinimide 123-56-8 Succinylcholine 55-94-7Succinylcholine 71-27-2 Succinylsulfathiazole 116-43-8 Succisulfone5934-14-5 Suclofenide 30279-49-3 sucralfate Aluminium, hexadeca-μ-54182-58-0 JP 58208233 Antiulcer, Ulcer, generalhydroxytetracosahydroxy(μ8-(1,3,4,6-tetra- Formulation,O-sulfo-β-D-fructofuranosyl-Alpha-D- oral, other glucopyranosidetetrakis(hydrogen sulfato)(8-)))hexadeca-[CAS] sufentanil Propanamide,N-[4-(methoxymethyl)-1-[2- 56030-54-7 U.S. 3,998,834 Analgesic, other,Pain, general (2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- formulationimplant [CAS] sulbactam 4-Thia-1-azabicyclo[3.2.0]heptane-2- 68373-14-8GB 2000138 Antibiotic, other Infection, carboxylic acid,3,3-dimethyl-7-oxo-, 4,4- general dioxide, (2S-cis)-[CAS] sulbactam +ampicillin 117060-71-6 U.S. 4,234,579 Antibiotic, other Infection,general sulbenicillin 4-Thia-1-azabicyclo[3.2.0]heptane-2- 28002-18-8 GB1289358 Penicillin, Infection, carboxylic acid, 3,3-dimethyl-7-oxo-6-41744-40-5 injectable pseudomonal [(phenylsulfoacetyl)amino]-, [2S-[2Alpha,5Alpha,6β(S*)]]-[CAS] Sulbentine 350-12-9 sulbutiamine Propanoicacid, 2-methyl-, dithiobis[3-[1- 3286-46-2 Neurological Unspecified[[(4-amino-2-methyl-5- 67-16-3 pyrimidinyl)methyl]formylamino]-ethylidene]-3,1-propanediyl] ester [CAS] sulconazole 1H-Imidazole,1-[2-[[(4- 61318-90-9 U.S. 4,055,652 Antifungal Infection,chlorophenyl)methyl]thio]-2-(2,4- 61318-91-0 fungal,dichlorophenyl)ethyl]-, (+/−)-[CAS] general Sulesomab 167747-19-5Sulfabenzamide 127-71-9 Sulfacetamide 144-80-9 Sulfachlorpyridazine80-32-0 Sulfachrysoidine 485-41-6 Sulfacytine 17784-12-2 Sulfadiazine68-35-9 Sulfadicramide 115-68-4 Sulfadimethoxine 122-11-2 Sulfadoxine2447-57-6 Sulfaethidole 94-19-9 Sulfaguanidine 57-67-0 Sulfaguanole27031-08-9 Sulfalene 152-47-6 Sulfaloxic Acid 14376-16-0 Sulfamerazine127-79-7 Sulfameter 651-06-9 Sulfamethazine 57-68-1 Sulfamethizole144-82-1 Sulfamethomidine 3772-76-7 Sulfamethoxazole 723-46-6Sulfamethoxy- 80-35-3 pyridazine Sulfametrole 32909-92-5Sulfamidochrysoidine 103-12-8 Sulfamoxole 729-99-7 Sulfanilamide 63-74-1Sulfanilic Acid 121-57-3 Sulfanilylurea 547-44-4 Sulfaperine 599-88-2Sulfaphenazole 526-08-9 Sulfaproxyline 116-42-7 Sulfapyrazine 116-44-9Sulfapyridine 144-83-2 Sulfarside 1134-98-1 Sulfarsphenamine 618-82-6sulfasalazine Benzoic acid, 2-hydroxy-5-[[4-[(2- 599-79-1 Formulation,oral, Arthritis, pyridinylamino)sulfonyl]phenyl]azo]-[CAS]enteric-coated rheumatoid Sulfasomizole 632-00-8 Sulfasymazine 1984-94-7Sulfathiazole 72-14-0 Sulfathiourea 515-49-1 Sulfinalol 66264-77-5Sulfinpyrazone 57-96-5 Sulfiram 95-05-6 Sulfisomidine 515-64-0Sulfisoxazole 127-69-5 Sulfobromophthalein 71-67-0 Sulfonethylmethane76-20-0 Sulfoniazide 3691-81-4 Sulfonmethane 115-24-2 Sulforidazine14759-06-9 Sulfoxone 144-75-2 sulindac cis-5-fluoro-2-methyl-1-[(p-38194-50-2 U.S. 3,725,548 Anti-inflammatory In-methylsulfinyl)benzylidene]indene-3-acetic flammation, acid generalSulisatin 54935-03-4 Sulisobenzone 4065-45-6 Sulmarin 29334-07-4Sulmazole 73384-60-8 Suloctidil 54063-56-8 Sulphan Blue 129-17-9sulpiride Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl- 15676-16-1Alimentary/ 2-pyrrolidinyl)methyl]-2-methoxy-[CAS] Metabolic, othersilprostone 5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy- 60325-46-4 U.S.4,024,179 Prostaglandin Abortion4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N- (methylsulfonyl)-, [1R-[1Alpha(Z),2β(1E,3R*),3Alpha]]-[CAS] sultamicillin4-Thia-1-azabicyclo(3.2.0)heptane-2- 117060-71-6 GB 2044255 Penicillin,oral Infection, carboxylic acid, 6- 76497-13-7 general((aminophenylacetyl)amino)-3,3-dimethyl- 7-oxo-,(((3,3-dimethyl-7-oxo-4-thia-1- azabicyclo(3.2.0)hept-2-yl)carbonyl)oxy)methyl ester, S, S-dioxide, (2S-(2.alpha.(2R*,5S*),5,alpha.,6.beta.(S*)))- [CAS] Sulthiame 61-56-3sultopride Benzamide, N-[(1-ethyl-2- 53583-79-2 FR M5916 NeurolepticPsychosis, pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2- generalmethoxy-[CAS] Sultosilic Acid 57775-26-5 sumanirole4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6- 179386-44-8 WO 9514020Antiparkinsonian Parkinson's dihydro-5-(methylamino)-, (5R)-, (2Z)-2-disease butenedioate (1:1) [CAS] sumatriptan1H-Indole-5-methanesulfonamide, 3-[2- 103628-46-2 EP 147107 AntimigraineMigraine (dimethylamino)ethyl]-N-methyl-, 103628-48-4 butanedioate(1:1)-[CAS] SUN-N8075 1-(4-amino-2,3,5-trimethylphenoxy)-3-(4-[4-Neuroprotective Infarction, (4-fluorobenzyl)phenyl]piperazin-1- cerebralyl)propan-2(s)-ol dimethanesulfonate suplatast Sulfonium,[3-[[4-(3-ethoxy-2- 94055-76-2 JP 59167564 Antiasthma Asthmahydroxypropoxy)phenyl]amino]-3- oxopropyl]dimethyl-, [CAS] Suprofen40828-46-4 Suramin 129-46-4 surfactant TA Beractant [CAS] 108778-82-1 WO9117766 Lung Surfactant Respiratory distress syndrome, general Suriclone53813-83-5 Suxibuzone 27470-51-5 SYM-1010 U.S. 5,830,998 AntiapilepticEpilepsy, general SYM-2081 L-Glutamic acid, 4-methyl-, (4R)-[CAS]31137-74-3 Analgesic, other Pain, general SYM-22074-(Aminophenyl)-1-methyl-6,7- Neuroprotective Ischaemia,(methylenedioxy)-N-butyl-1,2- cerebral dihydrophthalazine-2-carboxamideSymclosene 87-90-1 Syn-1253 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-Quinolone Infection, methyl-1,2,3-triazol-1-yl)pyrrolidin-1-yl]-4-antibacterial peritoneum oxo-1,4-dihydroquinoline 3-carboxylic acidSyn-2190 1-Azetidinesulfonic acid, 3-[[(2E)-[[(1,4- 214963-75-4 WO9847895 Antibacterial, Infection, dihydro-1,5-dihydroxy-4-oxo-2- othergeneral pyridinyl)methoxy]imino]-2- thienylacetyl]amino]-2-methyl-4-oxo,(2S,3S)-[CAS] Syn-2869 3H-1,2,4-Triazol-3-one, 4-(4-(4-((1R,2R)-2-210562-98-4 U.S. 6,153,616 Antifungal Infection,(2,4-difluorophenyl)-2-hydroxy-1-methyl-3- Aspergillus(1H-1,2,4-triazol-1-yl)propyl)-1- piperazinyl)phenyl)-2,4-dihydro-2((4-(trifluoromethoxy)phenyl)methyl)-[CAS] Synephrine 94-07-5 Syrosingopine84-36-6 T-1095 1-Propanone, 3-(5-benzofuranyl)-1-(2- 209746-59-8 EP850948 Antidiabetic Diabetes, hydroxy-6-((6-O-methoxycarbonyl)-β-D-general glucopyranosyl)oxy)-4-methylphenyl- [CAS] T-1249L-Phenylalaninamide, N-acetyl-L- 251562-00-2 WO 9959615 Antiviral,Infection, tryptophyl-L-glutaminyl-L-Alpha-glutamyl- anti-HIV HIV/AIDSL-tryptophyl-L-Alpha-glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha- glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl- L-glutaminyl-L-glutaminyl-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginyl-L-tyrosyl-L-Alpha-glutanyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-l-trytophyl-L-ananyl-L-seryl-L-leucyl-L-trytophyl-L-Alpha- glutamyl-L-tryptophyl-[CAS] T-39121-cyclopropyl-8-methyl-7-[5-methyl-6- Quinolone Infection,(methylamino)-3-pyridinyl]-4-oxo-1,4- antibacterial derma-dihydro-3-quinolinecarboxylic acid tological T-588Benzo(b)thiophene-5-methanol, Alpha-((2- 142935-03-3 EP 565965 CognitionAlzheimer's (diethylamino)ethoxy)methyl)-, enhancer diseasehydrochloride, (R)-[CAS] T-67 Benzenesulfonamide, 2,3,4,5,6- 195533-53-0Anticancer, other Cancer, pentafluoro-N-(3-fluoro-4-methoxyphenyl)-liver [CAS] T-82 U.S. 5,190,951 Cognition enhancer Alzheimer's diseaseTA-2005 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy 137888-11-0 U.S.4,579,854 Antiasthma Asthma 2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]-[CAS] TA-20052(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy WO 189480 Formulation, Asthma2-[[2-(4-methoxyphenyl)-1- inhalable, methylethyl]amino]ethyl]-,solution monohydrochloride, [R-(R*,R*)]-[CAS] TA-9931,5-Benzothiazepin-4(5H)-one, 3- 122024-98-0 JP 01045376 AntithromboticPeripheral (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- vasculardihydro-8-methyl-2-(4-methylphenyl)-, disease (2R,3R)-rel-(−)-,(2Z)-2-butenedioate [CAS] tabimorelin(R)-Alpha-[(E)-5-Amino-N,5-dimethyl-2- 170851-70-4 Releasing Growthhexenamido]-N-methyl-N-[(R)-Alpha- 193079-69-5 hormones hormone(methylcarbamoyl)phenethyl]-2- deficiency napthalenepropionamidetacalcitol 9,10-Secocholesta-5,7,10(19)-triene- 57333-96-7 EP 129003Antipsoriasis Keratosis 1,3,24-triol, (1Alpha,3β,5Z,7E,24R)-[CAS]93129-94-3 tacedinaline Benzamide, 4-(acetylamino)-N-(2- 112522-64-2 DE3613571 Anticancer, other Cancer, aminophenyl)-[CAS] pancreatic tacrine9-Acridinamine, 1,2,3,4-tetrahydro-[CAS] 1684-40-8 EP 332147 CognitionAlzheimer's 321-64-2 enhancer disease Tacrolimus 104987-11-3 tadalafilPyrazino(1′,2′:1,6)pyrido(3,4-b)indole 1,4- 171596-29-5 U.S. 6,143,746Male sexual Impotence dione, 6-(1,3-benzodioxol-5-yl)- dysfunction2,3,6,7,12,12a-hexahydro-2-methyl-, (6R- trans) [CAS] tafenoquine1,4-Pentanediamine, N4-[2,6-dimethoxy-4- 106635-80-7 U.S. 4,617,394Antimalarial Infection, methyl-5-[3-(trifluoromethyl)phenoxy]-8-106635-81-8 malaria quinolinyl]-[CAS] 80065-55-0 tafluposide 179067-42-6WO 9612727 Anticancer, other Cancer, general TAK-375(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno- Hypnotic/ Insomnia[5,4-b]furan-8-yl)]propionamide Sedative TAK-4272-[6-[[3-[4-(Diphenylmethoxy)- Antipruritic/ Eczema,piperidino]imidazo[1,2-b]pyridazin-2-yl-2- allergic atopicmethylpropionic acid dihydrate TAK-559(E)-4-[4-[5-Methyl-2-phenyl-1,3-oxazol-4- Antidiabetic Diabetes,yl)methoxy]benzyloxyimino]-4- general phenylbutyric acid Taka-Diastase9001-19-8 talampanel 7H-1,3-Dioxolo[4,5- 161832-65-1 U.S. 5,639,751Antiepileptic Epilepsy, h][2,3]benzodiazepine,7-acetyl-5-(4- generalaminophenyl)-8,9-dihydro-8-methyl-,(8R)- [CAS] Talampicillin 47747-56-8talaporfin N-[(2S,3S)-18-Carboxy-2-(2-carboxy- 220201-34-3 Radio/Cancer, lung, ethyl)-13-ethyl-2,3-dihydro-3,7,12,17- chemosensitizergeneral tetramethyl-8-vinyl porphyrin-20-yl]acetyl]- L-aspartic acidTalastine 16188-61-7 Talbutal 115-44-6 Talinolol 57460-41-0 talipexole4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8- 101626-70-4 DE 3503963Antiparkinsonian Schizophrenia tetrahydro-6-(2-propenyl)-[CAS]36085-73-1 talnetant 4-Quinolinecarboxamide, 3-hydroxy-2- 174636-32-9 WO9532948 GI inflammatory/ Irritable bowelphenyl-N-[(1S)-1-phenylpropyl]-[CAS] bowel disorders syndrometalniflumate 3-Pyridinecarboxylic acid, 2-[[3- 66898-62-2 BE 858864Anti-inflammatory Inflammation, (trifluoromethyl)phenyl]amino]-, 1,3-ocular dihydro-3-oxo-1-isobenzofuranyl ester [CAS] taltirelinL-Prolinamide, N-[(hexahydro-1-methyl-2,6- 103300-74-9 JP 61033197Neurological Dyskinesia, dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-,general (S)-[CAS] tamoxifen Ethanamine, 2-[4-(1,2-diphenyl-1- 10540-29-1U.S. 4,536,516 Anticancer, butenyl)phenoxy]-N,N-dimethyl-, (Z)- hormonal[CAS] tamsulosin Benzenesulfonamide, 5-[2-[[2-(2- 106133-20-4 EP 34432Prostate disorders Benign ethoxyphenoxy)ethyl]amino]propyl]-2-80223-99-0 prostatic methoxy-, (R)-[CAS] hyperplasia tandospirone4,7-Methano-1H-isoindole-1,3(2H)-dione, 112457-95-1 EP 82402 AnxiolyticAnxiety, hexahydro-2-[4-[4-(2-pyrimidinyl)-1- 87760-53-0 generalpiperazinyl]butyl]-, (3aAlpha,4β,7β,7aAlpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS] Tannoform 9010-29-1 Taprostene108945-35-3 tariquidar 3-Quinolinecarboxamide, N-[2-[[[4-[2-(3,4-206873-63-4 WO 9817648 Radio/ Cancer, lung, dihydro-6,7-dimethoxy-2(1H)-chemosensitizer non-small cellisoquinolinyl)ethyl]phenyl]amino]carbonyl]- 4,5-dimethoxyphenyl]-[CAS]TAS-103 6-[[2-(Dimethyl-amino)ethyl]amino]-3- 174634-09-4 WO 9532187Anticancer, other Cancer, lung, hydroxy-7H-indeno[2,1-c]quinolin-7-onenon-small dihydrochloride cell Tasosartan 145733-36-4 Taurocholic Acid81-24-3 Taurolidine 19388-87-5 tazanolast Acetic acid,oxo[[3-(1H-tetrazol-5- 82989-25-1 U.S. 4,778,816 Antiasthmayl)phenyl]amino]-, butyl ester [CAS] tazarotene 3-Pyridinecarboxylicacid, 6-[(3,4-dihydro- 118292-40-3 EP 284288 Antipsoriasis Psoriasis4,4-dimethyl-2H-1-benzothiopyran-6- yl)ethynyl]-, ethyl ester [CAS]Tazobactam 89786-04-9 tazobactam + JP 58225091 Antibiotic, otherInfection, piperacillin general TBC-3711 374680-51-0 CardiovascularHeart failure TCH-346 N-Methyl-N-propargyl-10-aminomethyl-Neuroprotective Amyotrophic dibenzo(b,f)oxepin lateral sclerosistebipenem 5-Hexenoic acid, 4-hydroxy-, polymer with 82200-24-6Beta-lactam Infection, 4-ethenyl-1H-imidazole [CAS] antibioticstreptococcal tecadenoson Adenosine, N-[(3R)-tetrahydro-3-furanyl]-204512-90-3 WO 9808855 Antiarrhythmic Tachycardia, [CAS] supra-ventricular tecastemizole 1H-Benzimidazol-2-amine, 1-((4- 75970-99-9U.S. 4,219,559 Antiallergic, Rhinitis,fluorophenyl)methyl)-N-4-piperidinyl- non-asthma allergic, [CAS]seasonal Technetium _(99m)Tc 121281-41-2 Bicisate Technetium _(99m)Tc125224-05-7; Mertiatide 104348-91-6 Technetium _(99m)Tc 109581-73-9Sestamibi Technetium _(99m)Tc 104716-22-5 Teboroxime Teclothiazide4267-5-4 Teclozan 5560-78-1 tedisamil Spiro[cyclopentane-1,9′-90961-53-8 EP 102833 Antiarrhythmic Fibrillation,[3,7]diazabicyclo[3.3.1]nonane], 3′,7′- atrialbis(cyclopropylmethyl)-[CAS] Teflurane 124-72-1 tegafur2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1- 17902-23-7 GB 1168391Anticancer, Cancer, (tetrahydro-2-furanyl)-[CAS] antimetabolite generaltegafur + uracil 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1- 74578-38-4 EP224885 Anticancer, Cancer, (tetrahydro-2-furanyl)-, mixt. withantimetabolite breast 2,4(1H,3H)-pyrimidinedione-[CAS] tegaserodHydrazinecarboximidamine, 2-((5-methoxy- 189188-57-6 GI inflammatory/Irritable 1H-indol-3-yl)methylene)-N-pentyl-, (Z)-2- 145158-71-0 boweldisorders bowel butenedioate [CAS] syndrome Teicoplanin 61036-64-4telbivudine β-L-2′-deoxythymidine 3424-98-4 Antiviral, other Infection,hepatitis- B virus Telenzepine 80880-90-6 telithromycin3-De((2,6-dideoxy-3-C-methyl-3-O-methyl- 191114-48-4 EP 680967 MacrolideInfection, Alpha-L-ribo-hexopyranosyl)oxy)-11,12- antibiotic respiratorydideoxy-6-O-methyl-3-oxo-12,11- tract,(oxycarbonyl((4-(4-(3-pyridinyl)-1H- generalimidazol-1-yl)butyl)imino))-[CAS] telmesteine3,4-Thiazolidinedicarboxylic acid, 3-ethyl 122946-43-4 COPD treatmentBronchitis, ester, (R)-[CAS] chronic telmisartan(1,1′-Biphenyl)-2-carboxylic acid, 4′-((1,4- 144701-48-4 EP 502314Antihypertensive, Hypertension, dimethyl-2′-propyl(2,6′-bi-1H- reninsystem general benzimidazol)-1′-yl)methyl)-[CAS] telomerase inhibs WO9941261 Anticancer, other Cancer, general temazepam7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5- 846-50-4 U.S. 3,197,467Hypnotic/ Insomnia phenyl-2H-1,4-benzodiazepin-2-one Sedative temiverineBenzeneacetic acid, Alpha-cyclohexyl- 129927-33-9 GB 2222828 UrologicalPollakisuria Alpha-hydroxy-, 4-(diethylamino)-1,1- dimethyl-2-butynyester, [CAS] temocapril 1,4-Thiazepine-4(5H)-acetic acid, 6-[[1-102090-90-4 U.S. 4,495,188 Antihypertensive, Hypertension,(ethoxycarbonyl)-3- 110221-44-8 renin system generalphenylpropyl]amino]tetrahydro-5-oxo-2-(2- 111902-57-9 thienyl)-,[2S-[2Alpha,6β(R*)]]-[CAS] Temocillin 66148-78-5 temoporfin Phenol,3,3′,3″,3′′′-(2,3-dihydro-21H,23H- 122341-38-2 EP 337601 Radio/ Cancer,head porphine-5,10,15,20-tetrayl)tetrakis-[CAS] chemosensitizer and necktemozolomide Imidazo[5,1-d]-1,2,3,5-tetrazine-8- 85622-93-1 DE 3231255Anticancer, Cancer, brain, carboxamide, 3,4-dihydro-3-methyl-4-oxo-alkylating general [CAS] tenatoprazole 1H-Imidazo(4,5-b)pyridine,5-methoxy-2- 113712-98-4 U.S. 4,808,596 Antiulcer Ulcer, gastric(((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-[CAS]Tenecteplase 191588-94-0 Tenidap 120210-48-2 teniposideFuro[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol- 29767-20-2 U.S. 3,524,844Anticancer, other Cancer, 6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-lymphoma, hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2- non-thienylmethylene)-β-D-glucopyranosyl]oxy]-, Hodgkin's[5R-[5Alpha,5aβ,8aAlpha,9β(R*)]]-[CAS] tenofovir Phosphonic acid,(((1R)-2-(6-amino-9H- 147127-20-6 Antiviral, anti-HIV Infection,purin-9-yl)-1-methylethoxy)methyl)-[CAS] HIV/AIDS tenofovir disoproxil2,4,6,8-tetraoxa-5-phosphanonanedioic 202138-50-9 Antiviral, anti-HIVInfection, acid, 5-(2-(6-amino-9H-purin-9-yl)-1- HIV/AIDSmethylethoxymethyl) bis(1- methylethyl)ester, 5-oxide (R)-, (E)-2-butenedioate Tenonitrozole 3810-35-3 tenoxicam2H-Thieno[2,3-e]-1,2-thiazine-3- 59804-37-4 GB 1519811 Antiarthritic,other carboxamide, 4-hydroxy-2-methyl-N-2- pyridinyl-, 1,1-dioxide [CAS]Tenuazonic Acid 610-88-8 teprenone 5,9,13,17-Nonadecatetraen-2-one,3796-63-2 Antiulcer 6,10,14,18-tetramethyl-[CAS] 6809-52-5 terazosinPiperazine, 1-(4-amino-6,7-dimethoxy-2- 63074-08-8 U.S. 4,112,097Antihypertensive, Hypertension, quinazolinyl)-4-[(tetrahydro-2-63590-64-7 adrenergic general furanyl)carbonyl]-[CAS] 70024-40-7terbinafine 1-Naphthalenemethanamine, N-(6,6- 78628-80-5 EP 24587Antifungal Infection, dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)-91191-71-6 derma- [CAS] tological terbutaline 1,3-Benzenediol,5-[2-[(1,1- 23031-25-6 Formulation, Dysmen-dimethylethyl)amino]-1-hydroxyethyl]- mucosal, topical orrhoea [CAS]terconazole Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2- 67915-31-5 U.S.4,358,449 Antifungal Vaginitis(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, cis-[CAS] terfenadine1-Piperidinebutanol, Alpha-[4-(1,1- 50679-08-8 U.S. 3,878,217Antiallergic, dimethylethyl)phenyl]-4- non-asthma(hydroxydiphenylmethyl)-[CAS] terguride Urea,N,N-diethyl-N′-[(8Alpha)-6- 37686-84-3 EP 159522 Antiprolactin Hyperpro-methylergolin-8-yl]-[CAS] lactinaemia Terlipressin 14636-12-5 Terodiline15793-40-5 Terofenamate 29098-15-5 Terpin 80-53-5 tertalolol 2-Propanol,1-[(3,4-dihydro-2H-1- 33580-30-2 GB 1308191 Antihypertensive,Hypertension, benzothiopyran-8-yl)oxy]-3-[(1,1- 83688-84-0 adrenergicgeneral dimethylethyl)amino]-, hydrochloride, 34784-64-0 (+/−)-[CAS]tert-Pentyl Alcohol 75-85-4 tesaglitazar (2S)-2-ethoxy-3-[4-[2-[4-Antidiabetic Diabetes, [(methylsulfonyl)oxy]phenyl]ethoxy]phenyl] TypeII propanoic acid tesmilifene Ethanamine, N,N-Diethyl-2-(4- 92981-78-7Radio/ Cancer, (phenylmethyl)phenoxy)-[CAS] chemosensitizer breastTestolactone 968-93-4 Testosterone androst-4-en-3-one, 17-hydroxy-,58-22-0 Formulation, Hormone (17β)-[CAS] 5949-44-0 transdermal,replacement systemic therapy tetrabamate 60763-47-5 DE 2748794Anxiolytic Addiction, alcohol Tetrabarbital 76-23-3 Tetrabenazine58-46-8 Tetracaine 136-47-0 Tetrachloroethylene 127-18-4 tetracineBenzoic acid, 4-(butylamino)-, 2- 94-24-6 Formulation, Pain, general(dimethylamino)ethyl ester [CAS] transdermal, systemic tetracycline2-Naphthacenecarboxamide, 4- 60-54-8 Formulation, oral, Infection,(dimethylamino)-1,4,4a,5,5a,6,11,12a- other oraloctahydro-3,6,10,112,12a-pentahydroxy-6- methyl-1,11-dioxo-, [4S-(4Alpha,4aAlpha,5aAlpha,6β,12aAlpha)]- [CAS] Tetrahydrozoline 84-22-0Tetrandrine 518-34-3 Tetrantoin 52094-70-9 Tetrazepam 10379-14-3Tetrofosmin 127502-06-1 tetroxoprim 2,4-Pyrimidinediamine,5-[[3,5-dimethoxy- 53808-87-0 U.S. 3,992,379 Trimethoprim and Infection,4-(2-methoxyethoxy)phenyl]methyl]-[CAS] 74515-38-1 analogues generalTevenel ® 4302-95-8 tezacitabine Cylidine,2′-deoxy-2′-(fluoromethylene)-, 130306-02-4 U.S. 5,616,702 Anticancer,Cancer, (2E)-[CAS] antimetabolite colorectal tezosentan2-Pyridinesulfonamide, N-(6-(2- 180384-57-0 Cardiostimulant Oedema,hydroxyethanoxy)-5-(2-methoxyphenoxy)-2- general(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)-[CAS] thalidomide1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3- 50-35-1 DermatologicalInfection, piperidinyl)-[CAS] derma- tological Thenaldine 86-12-4Thenyldiamine 91-79-2 Theobromine 83-67-0 Theofibrate 54504-70-0theophylline 1H-Purine-2,6-dione, 3,7-dihydro-1,3- 58-55-9 Formulation,Asthma dimethyl-[CAS] 5967-84-0 modified- release, other Thiabendazole148-79-8 Thiacetazone 104-06-3 thiacymserine Carbamic acid,[4-(1-methylethyl)phenyl]-, 145209-51-4 Cognition enhancer Alzheimer's(3aS,8aS)-3,3a,8,8a-tetrahydro-3a,8- diseasedimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS] Thialbarbital 467-36-7Thiamine 59-43-8 Thiamine 154-87-0 Thiamine 67-16-3 Thiamiprine5581-52-2 Thiamphenicol 15318-45-3 Thiamylal 77-27-0 Thiazesim 5845-26-1Thiazinamium 58-34-4 Thiazolinobutazone 54749-86-9 Thiazolsulfone473-30-3 Thibenzazoline 6028-35-9 Thiethylperazine 1420-55-9Thimerfonate 5964-24-9 Thimerosal 54-64-8 Thiobarbital 77-32-7Thiobutabarbital 2095-57-0 Thiocarbamizine 91-71-4 Thiocarbarsone120-02-5 Thiocolchicine 2730-71-4 Thiocresol 26445-03-4 Thioctic Acid62-46-4 Thioglycerol 96-27-5 Thioguanine 154-42-7 ThioimragL-Thiolyrosinyl-glycinyl-glycine Anticancer, Cancer, immunologicalgeneral Thiopental 71-73-8 Thiopropazate 84-06-0 Thioproperazine316-81-4 Thioridazine 50-52-2 Thiothixene 5591-45-7 ThiovirThiophosphonoformic acid Antiviral, anti-HIV Infection, HIV/AIDSThiphenamil 82-99-5 Thiram 137-26-8 Thonzylamine 63-56-9 Thozalinone655-05-0 Thromboplastin 9035-58-9 Thurfyl Nicotinate 70-19-9 thymectacinU.S. 6,245,750 Anticancer, other Cancer, colorectal Thymol 89-83-8Thymopentin 69558-55-0 Thymyl N- 578-20-1 Isoamylcarbamate ThyropropicAcid 51-26-3 Thyroxine 51-48-9 Tiadenol 6964-20-1 tiagabine3-Piperidinecarboxylic acid, 1-[4,4-bis(3- 115103-54-3 WO 8700171Antiepileptic Epilepsy, methyl-2-thienyl)-3-butenyl]-, (R)-[CAS] generalTiamenidine 31428-61-2 tianeptine Heptanoic acid,7-[(3-chloro-6,11-dihydro- 72797-41-2 GB 1269551 AntidepressantDepression, 6-methyldibenzo[c,f][1,2]thiazepin-11- 66981-73-5 generalyl)amino]-, S,S-dioxide [CAS] tiapride Benzamide,N-[2-(diethylamino)ethyl]-2- 51012-32-9 GB 1394563 Neurolepticmethoxy-5-(methylsulfonyl)-[CAS] tiaprofenic acid 2-Thiopheneaceticacid, 5-benzoyl-Alpha- 33005-95-7 GB 1331505 Antiarthritic, othermethyl-[CAS] Tiaramide 32527-55-2 tiazofurin 4-Thiazolecarboxamide,2-β-D- 60084-10-8 EP 54432 Anticancer, Cancer, ribofuranosyl-[CAS]antimetabolite leukaemia, chronic myelogenous Tibezonium 54663-47-7tibolone 19-Norpregn-5(10)-en-20-yn-3-one, 17- 5630-53-5 EP 389035Menopausal Hormone hydroxy-7-methyl-, (7Alpha,17Alpha)- disordersreplacement [CAS] therapy Ticarcillin 34787-01-4 ticlopidineThieno[3,2-c]pyridine, 5-[(2- 53885-35-1 GB 1554424 Antithromboticchlorophenyl)methyl]-4,5,6,7-tetrahydro- 55142-85-3 [CAS] Ticrynafen40180-04-9 tiemonium 4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)-6252-92-2 Antispasmodic 4-methylmorpholinium 144-12-7 tigecycline2-Naphthacenecarboxamide, 4,7- 220620-09-7 EP 582829 TetracyclineInfection, bis(dimethylamino)-9-[[[(1,1- generaldimethylethyl)amino]acetyl]amino]- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-[CAS] Tigemonam102507-71-1 Tigloidine 495-83-0 Tilidine 20380-58-9 Tilisolol 85136-71-6tilmacoxib Benzenesulfonamide, 4-(4-cyclohexyl-2- 180200-68-4 WO 9619463Alimentary/ Polyp methyl-5-oxazolyl)-2-fluoro-[CAS] Metabolic, othertiludronic acid Phosphonic acid, [[(4- 89987-06-4 EP 100718 OsteoporosisPaget's chlorophenyl)thio]methylene]bis-[CAS] treatment disease Timentin86482-18-0 Antibiotic, other Infection, general timepidium Piperidinium,3-(di-2-thienylmethylene)-5- 35035-05-3 GB 1358446 Antispasmodicmethoxy-1,1-dimethyl-, [CAS] Timiperone 57648-21-2 timolol(−)-1-(t-butylamino)-3-[(4-morpholino-1,2,5- 26839-75-8 GB 1253709Antihypertensive, thiadiazol-3-yl)oxy]-2-propanolmaleate 26921-17-5adrenergic, (1:1) salt antiglaucoma Timonacic 444-27-9 Tin EthylEtiopurpurin 113471-15-1 tinazoline 1H-Indole,3-[(4,5-dihydro-1H-imidazol-2- 62882-99-9 U.S. 3,376,311 Vasodilator,yl)thio]-[CAS] peripheral Tinidazole 19387-91-8 Tinoridine 24237-54-5Tiocarlide 910-86-1 Tioclomarol 22619-35-8 tioconazole 1H-Imidazole,1-[2-[(2-chloro-3- 61675-64-7 U.S. 4,062,966 Antifungal Infection,thienyl)methoxy]-2-(2,4- 65899-73-2 fungal, dichlorophenyl)ethyl]-[CAS]general tiopronin Glycine, N-(2-mercapto-1-oxopropyl)- 1953-02-2 U.S.3,246,025 Urological Homo- [CAS] cystinuria tiotropium3-Oxa-9-azoniatricyclo(3.3.1.02,4)nonane, 136310-93-5 EP 418716 COPDtreatment Chronic 7-((hydroxydi-2-thienylacetyl)oxy)-9,9- obstructivedimethyl-, [CAS] pulmonary disease Tioxolone 4991-65-5 Tipepidine5169-78-8 tipifarnib 2(1H)-Quinolone, 6-(amino(4- 192185-68-5 WO 9716443Anticancer, other Cancer, chlorophenyl)(1-methyl-1H-imidazol-5-192185-72-1 breast yl)methyl)-4-(3-chlorophenyl)-1-methyl [CAS]tipranavir N-[3-[1(R)-[4-Hydroxy-2-oxo-6(R)-(2- 174484-41-4 Antiviral,anti-HIV Infection, phenylethyl)-6-propyl-5,6-dihydro-2H- HIV/AIDSpyran-3-yl]propyl]phenyl]-5- (trifluoromethyl)pyridine-2-sulfonamidetiquizium 2H-Quinolizinium, 3-(di-2- 71731-58-3 U.S. 4,205,074Antispasmodic thienylmethylene)octahydro-5-methyl-, [CAS] tirapazamine1,2,4-Benzotriazin-3-amine, 1,4-dioxide- 20028-80-2 DE 2204574 Radio/Cancer, lung, [CAS] 27314-97-2 chemosensitizer non-small 5424-06-6 cellTiratricol 51-24-1 tirilazad Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-110101-65-0 WO 8701706 Neuroprotective Haemorrhage,(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1- 110101-67-2 subarachnoidpiperazinyl]-16-methyl-, (16Alpha)-, [CAS] 110101-66-1 tirofibanL-Tyrosine, N-(butylsulfonyl)-O-[4-(4- 142373-60-2 EP 478363Antithrombotic Infarction, piperidinyl)butyl]-, [CAS] 144494-65-5myocardial tiropramide Benzenepropanamide, Alpha- 55837-29-1 DE 2503992Antispasmodic Muscle spasm, (benzoylamino)-4-[2-(diethylamino)ethoxy]-general N,N-dipropyl-, (+/−)-[CAS] Titanium Sulfate 13825-74-6tixocortol Pregn-4-ene-3,20-dione, 21-[(2,2-dimethyl- 55560-96-81-oxopropyl)thio]-11,17-dihydroxy-, (11β)- 61951-99-3 GB 1475795Antiallergic, non- Rhinitis, [CAS] asthma, mucosal, allergic, topicalgeneral tizanidine 2,1,3-Benzothiadiazol-4-amine, 5-chloro-N- 51322-75-9GB 1429926 Muscle relaxant Spastic (4,5-dihydro-1H-imidazol-2-yl)-[CAS]paralysis TLK-199 Glycine, L-Gamma-glutamyl-S- 168682-53-9 U.S.5,679,643 Immunostimulant, Myelo- (phenylmethyl)-L-cysteinyl-2-phenyl-,other dysplastic diethyl ester, (2R)-[CAS] syndrome TLK-286 Glycine,L-Gamma-glutamyl-3-[[2- 158382-37-7 U.S. 5,545,621 Anticancer, otherCancer, ([bis[bis(2- ovarian chloroethyl)amino]phosphinyl]oxy)ethyl]-sulfonyl]-L-alanyl-2-phenyl-, (2R)-[CAS] TNF-β analogue RU 2035185Anticancer, Cancer, immunological general TNP-470 129298-91-5 TO-186Pregna-1,4-diene-3,20-dione, 9-fluoro- 5534-02-1 Antipruritic/inflamm,11β,17,21-trihydroxy-16.beta.-methyl-, 17- allergic butyrate21-propionate [CAS] tobramycin O-3-amino-3-deoxy-Alpha-D- 32986-56-4Formulation, Infection, glucopyranosyl-(1,6)-O-(2,6-diamino-2,3,6-inhalable, respiratory trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4)-topical tract, general 2-deoxy-[CAS] tocainide Propanamide,2-amino-N-(2,6- 41708-72-9 U.S. 4,218,477 Antiarrhythmic Fibrilation,dimethylphenyl)-[CAS] ventricular Tocamphyl 5634-42-4 tocladesine8-Chloroadenosine 3′5′-cyclic phosphate 41941-56-4 Anticancer, otherCancer, colorectal Tocoretinate 40516-48-1 Todralazine 14679-73-3Tofenacin 15301-93-6 tofimilast 5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-185954-27-2 Antiasthma Asthma a]pyridine,9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)- tofisopam 5H-2,3-Benzodiazepine, 1-(3,4-22345-47-7 GB 1334271 Anxiolytic Anxiety,dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4- general methyl-[CAS] Tolazamid1156-19-0 Tolazolin 59-98-3 Tolbutamide 64-77-7 tolcapone Methanone,(3,4-dihydroxy-5- 134308-13-7 EP 237929 Antiparkinsonian Parkinson'snitrophenyl)(4-methylphenyl)-[CAS] disease tolciclate Carbamothioicacid, methyl(3- 50838-36-3 GB 1364407 Antifungal Infection,methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4- derma-methanonaphthalen-6-yl) ester [CAS] tological Tolcyclamide 664-95-9tolevamer Benzenesulfonic acid, 4-ethenyl-, 28038-50-8 Antibacterial,Infection, homopolymer. other Clostridium, general tolfenamic acidBenzoic acid, 2[(3-chloro-2- 13710-19-5 DE 1543295 Anti-inflammatoryInflammation, methylphenyl)amino]-[CAS] general Tolindate 27877-51-6Toliprolol 2933-94-0 Tolmetin 26171-23-3 Tolnaftate 2398-96-1 Tolonidine4201-22-3 Tolonium 92-31-9 toloxatone 2-Oxazolidinone,5-(hydroxymethyl)-3-(3- 29218-27-7 GB 1250538 Antidepressantmethylphenyl)-[CAS] Tolperisone 728-88-1 Tolpropamine 5632-44-0Tolrestat 82964-04-3 tolserine Carbamic acid, (2-methylphenyl)-,145209-30-9 Cognition Alzheimer's(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8- enhancer diseasetrimethylpyrrolo[2,3-b]indol-5-yl ester [CAS] tolterodine Phenol,2-(3-(bis(1-methylethyl)amino)-1- 124937-51-5 EP 325571 UrologicalIncontinence phenylpropyl)-4-methyl-, (R)-[CAS] tolvaptan Benzamide,N-[4-[(7-chloro-2,3,4,5- 150683-30-0 EP 450097 Cardiovascular Heartfailure tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methyl]phenyl]-2-methyl- [CAS] Tolycaine 3686-58-6Topiramate Beta-D-Fructopyranose, 2,3:4,5- 97240-79-4 EP 533483Antiepileptic Epilepsy, bis-O-(1-methylethylidene)-, generalized,sulfamate [CAS] tonic-clonic topoisomerase U.S. 5,733,880 Anticancer,other Cancer, inhibitors general topotecan1H-Pyrano[3′,4′:6,7]indolizino[1,2- 123948-87-8 EP 231122 Anticancer,Cancer, b]quinoline-3,14(4H,12H)-dione, 9- other ovarian[(dimethylamino)methyl]-4-ethyl-4,10- dihydroxy-, (S)-[CAS] torasemide3-Pyridinesulfonamide, N-[[(1- 56211-40-6 U.S. 4,018,929Antihypertensive, Hypertension, methylethyl)amino]carbonyl]-4-[(3-diuretic general methylphenyl)amino]-[CAS] torcetapib ethyl(2R,4S)-4-[[3,5-bis(trifluoromethyl) 262352-17-0 Hypolipaemic/ Athero-benzyl](methoxycarbonyl)amino]-2-ethyl-6- Antiatherosclerosis sclerosis(trifluoromethyl)-3,4-dihydroquinoline- 1(2H)-carboxylate torcitabineβ-L-2′Deoxycytidine Antiviral, other Infection, hepatitis- B virustoremifene Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1- 89778-26-7 EP95875 Anticancer, Cancer, butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]89778-27-8 hormonal breast Torsemide 56211-40-6 Tositumomab 208921-02-2tosulfloxacin 1,8-Naphthyridine-3-carboxylic acid, 7-(3- 100490-36-6U.S. 4,704,459 Quinolone Infection,amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)- 115964-29-9 antibacterialurinary tract 6-fluoro-1,4-dihydro-4-oxo-, [CAS] tramadol Cyclohexanol,2-[(dimethylamino)methyl]-1- 27203-92-5 Analgesic, other Pain, general(3-methoxyphenyl)-, cis-(+/−)-[CAS] 36282-47-0 Tramazoline 1082-57-1trandolapril 1H-Indole-2-carboxylic acid, 1-[2-[(1- 87679-71-8 DE3151690 Antihypertensive, Hypertension, carboxy-3-phenylpropyl)amino]-1-87679-37-6 renin system general oxopropyl]octahydro-, [2S- 52-53-9[1[R*(R*)],2Alpha,3aAlpha,7aβ]]-[CAS] tranexamic acidCyclohexanecarboxylic acid, 4- 1197-18-8 U.S. 3,950,405 AntifibrinolyticMenstrual (aminomethyl)-, trans-[CAS] disorder, general tranilastBenzoic acid, 2-[[3-(3,4-dimethoxyphenyl)- 53902-12-8 U.S. 3,940,422Vulnerary Wound 1-oxo-2-propenyl]amino]-[CAS] healing trans-retinoicacid Retinoic acid [CAS] 302-79-4 Anticancer, other Cancer, generalTranylcypromine 155-09-9 trapidil[1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 15421-84-8 DD 55956Vasodilator, N,N-diethyl-5-methyl-[CAS] coronary Trastuzumab 180288-69-1travoprost 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3- 157283-68-6Formulation, Glaucoma hydroxy-4-(3-(trifluoromethyl)phenoxy)-1- mucosal,topical butenyl)cyclopentyl)-, 1-methylethylester(1R(1Alpha(Z),2β(1E,3R*),3Alpha,5Alpha) [CAS] Traxanox 58712-69-9traxoprodil 1-Piperidineethanol, 4-hydroxy-Alpha-(4- 134234-12-1Analgesic, other Pain, hydroxyphenyl)-β-methyl-4-phenyl-, 188591-67-5general (AlphaS,βS)-[CAS] trazodone1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2- 19794-93-5 U.S. 4,215,104Antidepressant [3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- 25332-39-2[CAS] Tremacamra 155576-45-7 Trenbolone 10161-33-8 Trengestone 5192-84-7treosulfan 1,2,3,4-Butanetetrol, 1,4- 299-75-2 WO 8401506 Anticancer,dimethanesulfonate, [S-(R*,R*)]-[CAS] alkylating trepibutoneBenzenebutanoic acid, 2,4,5-triethoxy- 41826-92-0 GB 1387733Antispasmodic Gamma-oxo-[CAS] treprostinol Prosta-5,13-dien-1-oic acid,6,9-epoxy- 35121-78-9 U.S. 6,054,486 Formulation, Hypertension,11,15-dihydroxy-, 61849-14-7 parenteral, other pulmonary[5Z,9Alpha,11Alpha,13E,15S]-[CAS] tretinoin Retinoic acid [CAS] 302-79-4Formulation, Acne dermal, topical tretoquinol 6,7-Isoquinolinediol,1,2,3,4-tetrahydro-1- 18559-59-8 ZA 6802416 Antiasthma[(3,4,5-trimethoxyphenyl)methyl]-, (S)- 30418-38-3 [CAS] 21650-42-0 TRH24305-27-9 TRI-50b TRI 50b [CAS] 226214-49-9 Antithrombotic Thrombosis,general Triacetin 102-76-1 Triamcinolone 76-25-5 Acetonide Triamcinolone31002-79-6 Benetonide Triamcinolone 5611-51-8 Hexacetonide triamcinolonePregna-1,4-diene-3,20-dione, 9-fluoro- 76-25-5 Formulation, Asthma11,21-dihydroxy-16,17-[(1- 124-94-7 inhalable, topicalmethylethylidene)bis(oxy)]-, (11β,16Alpha)- [CAS] Triamterene 396-01-0triapine Triapine [CAS] 236392-56-5 U.S. 6,458,816 Anticancer, Cancer,antimetabolite leukaemia, general Triaziquone 68-76-8 triazolam8-chloro-6-(2-chlorophenyl)-1-methyl-4H- 28911-01-5 U.S. 3,980,790Hypnotic/ Insomnia [1,2,4]-triazolo[4,3-a][1,4]benzodiazepine SedativeTribenoside 10310-32-4 Trichlorfon 52-68-6 Trichlormethiazide 133-67-5Trichlormethine 555-77-1 Trichloroethylene 79-01-6 Triclobisonium79-90-3 Triclocarban 101-20-2 Triclofenol Piperazine 5714-82-9 Triclofos306-52-5 Triclosan 3380-34-5 Tricromyl 85-90-5 Tridihexethyl Iodide125-99-5 trientine 1,2-Ethanediamine, N,N2-bis(2aminoethyl)-, 38260-01-4Metabolic and Wilson's [CAS] 112-24-3 enzyme disorders diseaseTriethanolamine 102-71-6 Triethylenemelamine 51-18-3 Triethylenephos-545-55-1 phoramide Triethylene- 52-24-4 thiophosphoramideTrifluoperazine 117-89-5 Trifluperidol 749-13-3 Triflupromazine 146-54-3trifluridine Thymidine, Alpha,Alpha,Alpha-trifluoro- 70-00-8 U.S.3,201,387 Antiviral, other Infection, [CAS] herpes virus, generaltriflusal Benzoic acid, 2-(acetyloxy)-4- 322-79-2 U.S. 4,096,252Antithrombotic Thrombosis, (trifluoromethyl)-[CAS] generalTrihexyphenidyl 52-49-3 triolstane Androst-2-ene-2-carbonitrile,4,5-epoxy- 13647-35-3 U.S. 3,296,255 Anticancer, Cancer,3,17-dihydroxy-, (4Alpha,5Alpha,17β)- hormonal breast [CAS] Trimazosin35795-16-5 trimebutine Benzoic acid, 3,4,5-trimethoxy-, 2- 34140-59-5 DE2151716 Antispasmodic (dimethylamino)-2-phenylbutyl ester, (Z)-2-39133-31-8 butenedioate (1:1) [CAS] Trimecaine 616-68-2 Trimeprazine84-96-8 Trimetazidine 5011-34-7 Trimethadione 127-48-0 Trimethaphan68-91-7 Trimethobenzamide 138-56-7 Trimethoprim 738-70-5 Trimetozine635-41-6 trimetrexate 2,4-Quinazolinediamine, 5-methyl-6- 52128-35-5U.S. 4,391,809 Antifungal Infection,[[(3,4,5-trimethoxyphenyl)amino]methyl]- 82952-64-5 Pneumocystis [CAS]jiroveci trimipramine 5H-Dibenz[b,f]azepine-5-propanamine, 521-78-8Antidepressant 10,11-dihydro-N,N,β-trimethyl-, (Z)-2- 739-71-9butenedioate (1:1) [CAS] Trimoprostil 69900-72-7 Trioxsalen 3902-71-4tripamide Benzamide, 3-(aminosulfonyl)-4-chloro-N- 73803-48-2 JP 7305585Antihypertensive, Hypertension,(octahydro-4,7-methano-2H-isoindol-2-yl)-, diuretic general(3aAlpha,4Alpha,7Alpha,7aAlpha)-[CAS] Triparanol 78-41-1 Tripelennamine91-81-6 Triprolidine 486-12-4 triptorelin Luteinizing hormone-releasingfactor (pig), 124508-66-3 U.S. 4,010,125 Releasing hormones Cancer,6-D-tryptophan-[CAS] 57773-63-4 prostate tritiozine Morpholine,4-[thioxo(3,4,5- 35619-65-9 U.S. 3,862,138 Antiulcertrimethoxyphenyl)methyl]-[CAS] Tritoqualine 14504-73-5 TRK-530Phosphonic acid, [[[4- 151425-92-2 WO 9410181 Antiarthritic, Arthritis,(methylthio)phenyl]thio]methylene]bis-, other rheumatoid disodium salt[CAS] TRK-820 2-Propenamide, N-[(5Alpha,6β)-17- 152658-17-8 WO 9315081Antipruritic/ Pruritus (cyclopropylmethyl)-4,5-epoxy-3,14- inflamm,dihydroxymorphinan-6-yl]-3-(3-furanyl)-N- non-allergic methyl-,monohydrochloride, (2E)-[CAS] Troclosene 2244-21-5 trofosfamide3-2-(chloroethyl)-2-[bis(2- 22089-22-1 GB 1188159 Anticancer,chloroethyl)amino]tetrahydro-2H-1,3,2- alkylating oxazaphosphorin2-oxide Troglitazone 97322-87-7 Troleandomycin 2751-9-9 Trolnitrate588-42-1 tromantadine N-(1-adamantyl)-2-(2-dimethylamine 53783-83-8 DE1941218 Antiviral, other Infection, ethoxy)acetamide herpes simplexvirus Tromethamine 77-86-1 Tropacine 6878-98-4 Tropesin 65189-78-8Tropicamide 1508-75-4 tropine 1H-Indole-3-acetic acid, 1-(4- 65189-78-8Antiarthritic, other chlorobenzoyl)-5-methoxy-2-methyl-, 2-carboxy-2-phenylethyl ester, (+/−)-[CAS] tropisetron1H-Indole-3-carboxylic acid, 8-methyl-8- 89565-68-4 GB 2125398Antiemetic Chemotherapy- azabicyclo[3.2.1]oct-3-yl ester, endo-[CAS]induced nausea and vomiting Trospectomycin 88669-04-9 trospium3Alpha-Hydroxyspiro[1AlphaH,5AlphaH- 10405-02-4 Urological Pollakisurianortropane-8,1′-pyrrolidinium] benzilate trovafloxacin1,8-Naphthyridine-3-carboxylic acid, 7-(6- 147059-72-1 U.S. 5,164,402Quinolone Infection, amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-147059-75-4 antibacterial respiratorydifluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, tract, general(1Alpha,5Alpha,6Alpha)-, [CAS] troxacitabine 2(1H)-Pyrimidinone,4-amino-1-(2- 145918-75-8 Anticancer, Cancer,(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2S- other leukaemia, cis)-[CAS]acute myelogenous Troxerutin 7085-55-4 troxipide Benzamde,3,4,5-trimethoxy-N-3- 30751-05-4 U.S. 3,647,805 Antiulcer Ulcer, gastricpiperidinyl-, (+/−)-[CAS] 99777-81-8 Trypan Red 574-64-1 Tryparsamide554-72-3 Tryptophan 73-22-3 TSH 9002-71-5 TSN-096,14-Ethenomorphinan-7-methanol, 17- 52485-79-7 Formulation, Pain,cancer (cyclopropylmethyl)-Alpha-(1,1- transdermal, patchdimethylethyl)-, 5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha,(S)]-[CAS] TU-2100Nonanedioic acid, bis[(2- U.S. 6,180,669 Antiacne Acne(ethoxycarbonyl)phenyl] ester Tuaminoheptane 123-82-0 Tubercidin 69-33-0Tubocurarine Chloride 57-94-3 tulobuterol Benzenemethanol,2-chloro-Alpha-[[(1,1- 41570-61-0 DE 2244737 Antiasthma Asthmadimethylethyl)amino]methyl]-[CAS] TV-3326N-(Propargyl-(3R)aminoindan-5-yl)-ethyl Cognition Alzheimer's methylcarbamate enhancer disease TY-11223 Acetic acid,[2-[2,3,3a,6,7,7a-hexahydro-2- 140694-43-5 U.S. 4,837,342 AntithromboticUnspecified hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadiynyl)-1H-inden-5-yl]ethoxy]-, [1S-[1Alpha(R*),2β,3aAlpha,7aAlpha]]-[CAS] TY-125336,7,8,9-Tetrahydro-2-methyl-5H- U.S. 6,258,829 AntiarrhythmicUnspecified cyclohepta[b]pyridine-3-carbonylguanidine maleate TYB-3215D-Glucitol, 1,4:3,6-dianhydro-, dinitrate 87-33-2 Formulation, Angina,[CAS] modified- general release, other Tybamate 4268-36-4 tyloxapol4-(1,1,3,3-Tetramethylbutyl)phenol 25301-02-4 Formulation, Cysticfibrosis polymer with formaldehyde and oxirane inhalable, topical [CAS]Tymazoline 24243-97-8 Tyramine 51-67-2 Tyropanoate 7246-21-1 Ubenimex58970-76-6 ufenamate Benzoic acid, 2-[[3- 67330-25-0 BE 861852Antipruritic/ (trifluoromethyl)phenyl]amino]-, butyl ester inflamm,[CAS] non-allergic Undecylenic Acid 112-38-9 Unoprostone 12037-36-6UR-8880 4-[4-Chloro-5-(3-fluoro-4- Anti-inflammatory Inflammation,methoxyphenyl)imidazol-1-imidazol-1- general yl]benzenesulfonamide-[CAS]Uracil Mustard 66-75-1 Uralyt-U 1,2,3-Propanetricarboxylic acid,2-hydroxy-, 55049-48-4 U.S. 4,400,535 Urological potassium sodium salt(5:6,6), hydrate [CAS] urapidil 2,4(1H,3H)-Pyrimidinedione, 6-[[3-[4-(2-34661-75-1 GB 1309324 Antihypertensive, Hypertension, methoxyphenyl)-1-adreergic general piperazinyl]propyl]amino]-1,3-dimethyl- [CAS] ureaUrea [CAS] 57-13-6 Antipsoriasis Uredepa 302-49-8 Urethan 51-79-6Uridine 5′- 63-39-8 Triphosphate Urinastatin 80449-31-6 ursodeoxycholicacid 3Alpha,7β-dihydroxy-5β-cholan-24-oic 128-13-2 Formulation, other,Cirrhosis, acid [CAS] Cirrhosis, primary primary biliary, hepaticbiliary dysfunction, biliary calcalus Ursodiol 128-13-2 Ushercell U.S.6,063,773 Formulation, Contraceptive, mucosal, topical female Uzarin20231-81-6 valaciclovir L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-124832-26-4 EP 308065 Antiviral, other Infection,9H-purin-9-yl)methoxy]ethyl ester [CAS] herpes simplex virusValacyclovir 124832-26-4 valdecoxib Benzenesulfonamide, 4-(5-methyl-3-181695-72-7 U.S. 5,859,257 Antiarthritic, other Arthritis,phenyl-4-isoxazolyl)-[CAS] rheumatoid Valdetamide 512-48-1 Valethamate90-22-2 valganciclovir L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-175865-59-5 EP 694547 Antiviral, other Infection,9H-purin-9-yl)methoxy)-3-hydroxypropyl 175865-60-8 cytomegalo- ester[CAS] virus Valnoctamide 4171-13-5 valomaciclovir L-Valine(3R)-3-((2-amino-1,6-dihydro-6- 195156-77-5 Antiviral, other Infection,oxo-9H-purin-9-yl)methyl)-4-((1- herpes oxooctadecyl)oxy)butyl ester[CAS] simplex virus valproate Pentanoic acid, 2-propyl-, [CAS]76584-70-8 U.S. 4,988,731 Antiepileptic Epilepsy, 1069-66-5 generalized,tonic-clonic Valproic Acid 99-66-1 Valpromide 2430-27-5 valrocemidePentanamide, N-(2-amino-2-oxoethyl)-2- 92262-58-3 U.S. 5,585,358Antiepileptic Epilepsy, propyl-[CAS] general valrubicin Pentanoic acid,2-(1,2,3,4,6,11-hexahydro- 56124-62-0 U.S. 4,035,566 Anticancer, Cancer,2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4- antibiotic bladder((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-Alpha-L-lyxo-hexopyranosyl)oxy)-2- naphthacenyl)-2-oxoethyl ester(2S-cis)- [CAS] valsartan L-Valine, N-(1-oxopentyl)-N-[[2′-(1H-137862-53-4 EP 443983 Antihypertensive, Hypertension,tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]- renin system general [CAS]Valspodar 121584-18-7 vardenafil Piperazine,1-(3-(1,4-dihydro-5-methyl(-4- 224785-90-4 Male sexual Sexualoxo-7-propylimidazo(5,1-f)(1,2,4)-triazin-2- dysfunction dysfunction,yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl-[CAS] male, general varespladibAcetic acid, ((3-(aminooxoacetyl)-2-ethyl-1- 172732-68-2 EP 675110Septic shock Sepsis (phenylmethyl)-1H-indol-4-yl)oxy)-[CAS] 172733-42-5treatment Varicella Virus Vaccine vatanidipine 3,5-Pyridinedicarboxylicacid, 1,4-dihydro- 116308-55-5 EP 257616 Neuroprotective Hypertension,2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-[4- 133743-71-2 general(diphenylmethyl)-1-piperazinyl]phenyl]ethyl methyl ester, [CAS] VEA U.S.6,007,817 Radio/ Cancer, chemosensitizer general vecuroniumPiperidinium, 1- 50700-72-6 U.S. 4,237,126 Muscle Anaesthesia,[(2β,3Alpha,5Alpha,16β,17β)-3,17- relaxant adjunctbis(acetyloxy)-2-(1-piperidinyl)androstan- 16-yl]-1-methyl-, [CAS]Velnacrine 104675-29-8 venlafaxine Cyclohexanol,1-[2-(dimethylamino)-1-(4- 93413-69-5 GB 2227743 AntidepressantDepression, methoxyphenyl)ethyl]-, [CAS] 99300-78-4 general Veralipride66644-81-3 verapamil Benzeneacetonitrile, Alpha-[3-[[2-(3,4- 52-53-9Formulation, Hypertension, dimethoxyphenyl)ethyl]methylamino]propyl]-modified- general 3,4-dimethoxy-Alpha-(1-methylethyl)- release, other[CAS] verteporfin 23H,25H-Benzo[b]porphine-9,13- 129497-78-5 U.S.5,238,940 Ophthalmological Macular dipropanoic acid,18-ethenyl-4,4a-dihydro- degeneration3,4-bis(methoxycarbonyl)-4a,8,14,19- tetramethyl-, monomethyl ester,trans- [CAS] vesnarinone Piperazine, 1-(3,4-dimethoxybenzoyl)-4-81840-15-5 GB 2086896 Cardiostimulant Heart failure(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)- [CAS] Vetrabutine 3735-45-3VF-233 Benzene carboximidamide, N,3,4,5- 95933-74-7 U.S. 4,623,659Cardiovascular Reperfusion, tetrahydroxy-[CAS] injury VI-0134 U.S.6,403,597 Male sexual Premature dysfunction ejaculation vidarabine9H-Purin-6-amine, 9-β-D-arabinofuranosyl- 24356-66-9 GB 1159290Antiviral, other Infection, [CAS] 5536-17-4 herpes virus, generalvigabatrin 5-Hexenoic acid, 4-amino-[CAS] 68506-86-5 GB 1472525Antiepileptic Epilepsy, 60643-86-9 partial (focal, local) vilazodone2-Benzofurancarboxamide, 5-[4-[4-(5- 163521-12-8 EP 648767Antidepressant Depression, cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-general [CAS] Viloxazine 46817-91-8 Viminol 21363-18-8 Vinbarbital125-44-0 Vinblastine 865-21-4 vinburnine Eburnamenin-14(15H)-one,474-00-0 DE 1932245 Cognition (3Alpha,16Alpha)-[CAS] 4880-88-0 enhancerVincamine 1617-90-9 Vinconate 70704-03-9 vincristine Vincaleukoblastine,22-oxo-, sulfate (1:1) 2068-78-2 EP 207831 Formulation, Cancer,(salt)[CAS] 57-22-7 parenteral, other general vindesineVincaleukoblastine, 3-(aminocarbonyl)-O4- 53643-48-4 GB 1463575Anticancer, other Cancer, deacetyl-3-de(methoxycarbonyl)-[CAS]59917-39-4 leulaemia, acute lymphocytic vinflunineAspidospermidine-3-carboxylic acid, 4- 162652-95-1 FR 2707988Anticancer, other Cancer, (acetyloxy)-6,7-didehydro-15- general[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)- 1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16- methoxy-1-methyl-, methyl ester,(2β,3β,4β,5Alpha,12β,19Alpha)-[CAS] vinorelbineC′-Norvincaleukoblastine, 3′,4′-didehydro- 71486-22-1 EP 10458Anticancer, other Cancer, lung, 4′-deoxy-[CAS] non-small cellvinpocetine Eburnamenine-14-carboxylic acid, ethyl 42971-09-5 GB 1405127Cognition Cognitive ester, (3Alpha,16Alpha)-[CAS] enhancer disorder,general Vinyl Ether 109-93-3 Vinylbital 2430-49-1 Viquidil 84-55-9Viridin 3306-52-3 Visnadine 477-32-7 Vitamin A 68-26-8 vitamin B12Vitamin B12 [CAS] 68-19-9 Formulation, Anaemia, transmucosal, nasalgeneral vitamin C L-Ascorbic acid [CAS] 50-81-7 Formulation, Nutritionmodified- release, <=24 hr Vitamin D₂ 50-14-6 Vitamin D₃ 67-97-0 VitaminK₅ 83-70-5 Vitamins, Prenatal VLA-4 antagonists((R,S)-4-(4-(Amino-imino-methyl)-phenyl)- EP 842943 Antiasthma Asthma3-((4-biphenylyl)-methyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)-acetyl-L-N-methyl- aspartyl-L-phenylglycineVNP-4010M 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2- U.S. 6,040,338Anticancer, Cancer, (methylamino)carbonylhydrazine alkylating generalvoglibose D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1- 83480-29-9 EP56194 Antidiabetic Diabetes, (hydroxymethyl)ethyl]amino]-2-C- Type II(hydroxymethyl)-[CAS] voriconazole 4-Pyrimidineethanol, Alpha-(2,4-137234-62-9 EP 440372 Antifungal Infection,difluorophenyl)-5-fluoro-β-methyl-Alpha- fungal,(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))- general [CAS] Vorozole129731-10-8 VUF-K-8788 7-[3-[4-(2-Quinolinylmethyl)-1- Antiasthma Asthmapiperazinyl]propoxy]-3,4-dihydro-2H-1,4- benzothiazine-3-one Warfarin81-81-2 WF-10 Tetrachlorodecaoxide [CAS] 92047-76-2 Radio/ Chemotherapy-chemoprotective induced injury, bone marrow, general WMC-792-(3-[4-[3-(6-oxo-6H-2, 10b-diaza- Anticancer, other Cancer,aceanthrenylen-5-ylamino)propyl]- colorectalpiperazin-1-yl]propyl)-5-nitro-2-aza- phenalene-1,3-dione wound healingmatrix U.S. 5,897,880 Formulation, Ulcer, diabetic transdermal, patchWP-170 U.S. 6,531,121 Cytokine Unspecified xaliproden Pyridine,1,2,3,6-tetrahydro-1-[2-(2- 90494-79-4 naphthalenyl)ethyl]-4-[3-135354-020-8 EP 101381 Neuroprotective Amyotrophic(trifluoromethyl)phenyl]-, [CAS] lateral sclerosis xamoterol4-Morpholinecarboxamide, N-[2-[[2- 73210-73-8 GB 2002748 CardiostimulantHeart failure hydroxy-3-(4- 81801-12-9hydroxyphenoxy)propyl]amino]ethyl]-, (+/−)- [CAS] Xanomeline 131986-45-3Xanthinol Niacinate 437-74-1 Xemilofiban 149820-74-6 Xenbucin 959-10-4Xibenolol 81584-06-7 xibornol Phenol, 4,5-dimethyl-2-(1,7,7- 13741-18-9GB 1206774 Antibacterial, other Infection,trimethylbicyclo[2.2.1]hept-2-yl)-, exo- general [CAS] ximelagatranGlycine, N-((R)-cyclohexyl-2-((2S)-2-((((4- 192939-46-1 AntithromboticThrombosis, (hydroxyamino)iminomethyl)phenyl)methyl)- venousamino)carbonyl)-1-azetidinyl)2-oxoethyl ethyl ester [CAS] Ximoprofen56187-89-4 xipamide Benzamide, 5-(aminosulfonyl)-4-chloro-N- 14293-44-8U.S. 3,567,777 Antihypertensive, (2,6-dimethylphenyl)-2-hydroxy-[CAS]diuretic xorphanol Morphinan-3-ol, 17-(cyclobutylmethyl)-8- 77287-89-9Analgesic, other Pain, cancer methyl-6-methylene-, (8β)-[CAS] XR-51182,5-Piperazinedione, 3-[[5-[[2- 174766-49-5 WO 9532190 Anticancer, otherCancer, (dimethylamino)ethyl]thio]-2- generalthienyl]methylene]-6-(phenylmethylene)-, monohydrochloride,(3Z,6Z)-[CAS] XR-5944 N,N′-(1,2-Ethanediyl)bis(imino-2,1- EP 934278Anticancer, other Cancer, ethanediyl)bis(9-methylphenazine-1- generalcarboxamide) Xylometazoline 526-36-3 Xylose 58-86-6 YH-18852-Pyrimidinamine, 4-(3,4-dihydro-1-methyl- 178307-42-1 WO 9605177Antiulcer Ulcer, GI, 2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-general dimethyl-, monohydrochloride [CAS] YM-511 Benzonitrile,4-[[(4-bromophenyl)methyl]- 148869-05-0 WO 9305027 Anticancer, Cancer,4H-1,2,4-triazol-4-ylamino]-[CAS] hormonal breast YM-598potassium(E)-N-[6-methoxy-5-(2- Anticancer, other Cancer,methoxyphenoxy)-2-(pyrimidin-2- prostate yl)pyrimidin-4-yl]-2-phenylethenesulfonamidate Yohimbine 146-48-5 YT-146 Adenosine,2-(1-octynyl)-[CAS] 90596-75-1 U.S. 5,270,304 Anti-inflammatoryInflammation, general Z-321 Thiazolidine, 3-((2,3-dihydro-1H-inden-2-130849-58-0 EP 372484 Cognition Dementia,yl)acetyl)-4-(1-pyrrolidinylcarbonyl)-, (R)- enhancer senile, [CAS]general Z-335 (1H-Indene-5-acetic acid, 2[[[(4- 146731-14-8 JP 92506077Antithrombotic Peripheral chlorophenyl)sulfonyl]amino]methyl]-2,3-vascular dihydro, monosodium salt) [CAS] disease zafirlukast Carbaminacid, [3-[[2-methoxy-4-[[[(2- 107753-78-6 EP 199543 Antiasthma Asthmamethylphenyl)sulfonyl]amino]carbonyl]-phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester [CAS]zalcitabine Cytidine, 2′,3′-dideoxy-[CAS] 7481-89-2 U.S. 4,879,277Antiviral, anti-HIV Infection, HIV/AIDS Zaldaride 109826-26-8 zaleplonAcetamide, N-[3-(3-cyanopyrazolo[1,5- 151319-34-5 EP 776898 Hypnotic/Insomnia a]pyrimidin-7-yl)phenyl]-N-ethyl-[CAS] Sedative zaltoprofenDibenzo[b,f]thiepin-2-acetic acid, 10,11- 74711-43-6 JP 55053282 Anti-dihydro-Alpha-methyl-10-oxo-[CAS] inflammatory zanamivir5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4- 139110-80-8 WO 9116320Antiviral, other Infection, guanidino-D-glycero-D-galacto-non-2-influenza enonic acid [CAS] virus zanapezil 1-Propanone,3-(1-(phenylmethyl)-4- 142852-50-4 EP 487071 Cognition Alzheimer'spiperidinyl)-1-(2,3,4,5-tetrahydro-1H-1- enhancer diseasebenzazepin-8-yl)-[CAS] Zatebradine 85175-67-3 ZD-0473 Platinum,amminedichloro(2- 181630-15-9 EP 727430 Anticancer, Cancer,methylpyridine)-(SP-4-3)-[CAS] alkylating ovarian ZD-0947 WO 9528388Urological Overactive bladder ZD-6126 N-acetylcolchinol-O-phosphateAnticancer, other Cancer, general ZD-9331 1H-Tetrazole-5-butanoic acid,Alpha-((4- 153537-73-6 GB 2264946 Anticancer, Cancer,(((1,4-dihydro-2,7-dimethyl-4-oxo-6- antimetabolite pancreaticquinazolinyl)methyl)-2-propynylamino)-2- fluorobenzoyl)amino) (S)-[CAS]zebularine 2(1H)-Pyrimidinone, 1-β-D-ribofuranosyl- 3690-10-6Anticancer, other Cancer, [CAS] general zelandopam 7,8-Isoquinolinediol,4-(3,4- 138086-00-7 JP 03190818 Vasodilator, Hypertension,dihydroxyphenyl)-1,2,3,4-tetrahydro-, renal general [CAS] Zenarestat112733-06-9 Ziconotide 107452-89-1 zidovudine Thymidine,3′-azido-3′-deoxy-[CAS] 30516-87-1 U.S. 4,724,232 Antiviral, Infection,anti-HIV HIV/AIDS zileuton Urea, N-(1-benzo[b]thien-2-ylethyl)-N-111406-87-2 EP 279263 Antiasthma Asthma hydroxy-[CAS] Zimeldine56775-88-3 zinc acetate hexakis(\m-acetato)-\m4-oxotetrazinc 12129-82-7Antiviral, other Infection, herpes simplex virus prophylaxis zincacexamate Hexanoic acid, 6-(acetylamino)-, zinc salt 70020-71-2 EP369088 Antiulcer Ulcer, (2:1)-[CAS] duodenal zinc ibuprofenate78416-80-5 Anti-inflammatory, Inflammation, topical dermal Zincp-Phenolsulfonate 127-82-2 Zinc Salicylate 16283-36-6 Zinostatin9014-2-2 zinostatin stimalamer 123760-07-6 EP 136791 Anticancer, Cancer,antibiotic liver Zipeprol 34758-83-3 ziprasidone 2H-Indol-2-one,5-(2-(4-(1,2- 122883-93-6 EP 281309 Neuroleptic Schizophreniabenzisothiazol-3-yl)-1-piperazinyl)ethyl)-6- 146939-27-7chloro-1,3-dihydro-[CAS] zofenopril L-Proline,1-[3-(benzoylthio)-2-methyl-1- 75176-37-3 oxopropyl]-4-(phenylthio)-,81872-10-8 GB 2028327 Antihypertensive, Hypertension,[1(R*),2Alpha,4Alpha]-[CAS] 81972-10-8 renin system general 81938-43-4zofenpril + HCTZ L-Proline, 1-[3-(benzoylthio)-2-methyl-1- Formulation,fixed-dose Hypertension, oxopropyl]-4-(phenylthio)-, combinationsgeneral [1(R*),2Alpha,4Alpha]- + 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiazide-7- sulfonamide 1,1-dioxide [CAS]zoledronic acid Phosphonic acid, [1-hydroxy-2-(1H- 118072-93-8 EP 531253Osteoporosis Hyper- imidazol-1-yl)ethylidene]bis-[CAS] 165800-06-6treatment calcaemia of malignancy zolimidine2-(p-methylsulfonylphenyl)imidazo[1,2- 1222-57-7 U.S. 3,318,880Antiulcer Gastritis a]pyridine zolmitriptan 2-Oxazokidinone, 4-((3-(2-139264-17-8 WO 9118897 Antimigraine Migraine(dimethylamino)ethyl)-1H-indol-5- yl)methyl)-, (S)-[CAS] zolpidemImidazol[1,2-a]pyridine-3-acetamide, N,N,6- 99294-93-6 EP 50563Hypnotic/ Insomnia trimethyl-2-(4-methylphenyl)-(R-(R*,R*))- 82626-48-0Sedative 2,3-dihydroxybutanediotade (2:1) [CAS] Zomepirac 33369-31-2zonampanel 1(2H)-Quinoxalineacetic acid, 3,4-dihydro- 210245-80-0Neuroprotective Ischaemia, 7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-cerebral [CAS] zoniporide 1H-pyrazole-4-carboxamide,N- 249296-45-5Cardiovascular Unspecified (aminoimino methyl)-5-cyclopropyl-1-(5-quinolinyl)-, zonisamide 1,2-Benzisoxazole-3-methanesulfonamide68291-97-4 GB 2025931 Antiepileptic Epilepsy, [CAS] 68291-98-5generalized, tonic-clonic zopiclone 1-Piperazinecarboxylic acid,4-methyl-, 6- 43200-80-2 GB 1358680 Hypnotic/ Insomnia(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H- Sedativepyrrolo[3,4-b]pyrazin-5-yl ester [CAS] Zopolrestat 110703-94-1 Zorubicin54083-22-6 zosuquidar 1-Piperazineethanol, 4-(1,1-difluoro- 167465-36-3Radio/ Cancer, 1,1a,6,10b- chemosensitizer leukaemia,tetrahydrodibenzo[a,e]cyclopropa[c]cyclo- acutehepten-6-yl)-Alpha-[(5-quinolinyloxy)methyl]-, myelogenous[6(R)-(1aAlpha,6Alpha,10bAlpha)]-[CAS] zotepine Ethanamine, 2-[(8-26615-21-4 GB 1247067 Neuroleptic Schizophreniachlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N- dimethyl-[CAS] ZP-123 WO0162775 Antiarrhythmic Arrhythmia, general Z-tamoxifen Ethanamine,2-[4-(1,2-diphenyl-1- 10540-29-1 Anticancer, Cancer,butenyl)phenoxy]-N,N-dimethyl-, (Z)- hormonal colorectal [CAS]zuclopenthixol 1-Piperazineethanol, 4-[3-(2-chloro-9H- 53772-83-1 EP27082 Neuroleptic Psychosis, thioxanthen-9-ylidene)propyl]-, (Z)-[CAS]982-24-1 general 85721-05-7 64053-00-5

1. A co-crystal comprising an API and a co-crystal former selected from:(a) carbamazepine and saccharin; (b) carbamazepine and nicotinamide; (c)carbamazepine and trimesic acid; (d) celecoxib and nicotinamide; (e)celecoxib and 18-crown-6; (f) 5-fluorouracil and urea; (g) acetaminophenand 4,4′-bipyridine; (h) phenytoin and pyridone; (i) aspirin and4,4′-bipyridine; (j) ibuprofen and 4,4′-bipyridine; (k) flurbiprofen and4,4′-bipyridine; (l) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene;(m) carbamazepine and p-phthalaldehyde; (n) carbamazepine and2,6-pyridinecarboxylic acid; (o) carbamazepine and 5-nitroisoplithalicacid; (p) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; or(q) carbamazepine and benzoquinone, wherein the API and co-crystalformer are hydrogen bonded to each other.
 2. The co-crystal according toclaim 1, wherein said co-crystal comprises carbamazepine and saccharin.3. The co-crystal according to claim 1, wherein said co-crystalcomprises carbamazepine and nicotinamide.
 4. The co-crystal according toclaim 1, wherein said co-crystal comprises carbamazepine and trimesicacid.
 5. The co-crystal according to claim 1, wherein said co-crystalcomprises celecoxib and nicotinamide.
 6. The co-crystal according toclaim 1, wherein said co-crystal comprises celecoxib and 18-crown-6. 7.The co-crystal according to claim 1, wherein said co-crystal comprises5-fluorouracil and urea.
 8. The co-crystal according to claim 1, whereinsaid co-crystal comprises acetaminophen and 4,4′-bipyridine.
 9. Theco-crystal according to claim 1, wherein said co-crystal comprisesphenytoin and pyridine.
 10. The co-crystal according to claim 1, whereinsaid co-crystal comprises aspirin and 4,4′-bipyridine.
 11. Theco-crystal according to claim 1, wherein said co-crystal comprisesibuprofen and 4,4′-bipyridine.
 12. The co-crystal according to claim 1,wherein said co-crystal comprises flurbiprofen and 4,4′-bipyridine. 13.The co-crystal according to claim 1, wherein said co-crystal comprisesflurbiprofen and trans-1,2-bis(4-pyridyl)ethylene.
 14. The co-crystalaccording to claim 1, wherein said co-crystal comprises carbamazepineand p-phthalaldehyde.
 15. The co-crystal according to claim 1, whereinsaid co-crystal comprises carbamazepine and 2,6-pyridinecarboxylic acid.16. The co-crystal according to claim 1, wherein said co-crystalcomprises carbamazepine and 5-nitroisophthalic acid.
 17. The co-crystalaccording to claim 1, wherein said co-crystal comprises carbamazepineand 1,3,5,7-adamantane tetracarboxylic acid.
 18. The co-crystalaccording to claim 1, wherein said co-crystal comprises carbamazepineand benzoquinone.
 19. A pharmaceutical composition comprising apharmaceutically acceptable diluent, excipient, or carrier and aco-crystal comprising an API and a co-crystal former selected from: (a)carbamazepine and saccharin; (b) carbamazepine and nicotinamide; (c)carbamazepine and trimesic acid; (d) celecoxib and nicotinamide; (e)celecoxib and 18-crown-6; (f) 5-fluorouracil and urea; (g) acetaminophenand 4,4′-bipyridine; (h) phenytoin and pyridone; (i) aspirin and4,4′-bipyridine; (j) ibuprofen and 4,4′-bipyridine; (k) flurbiprofen and4,4′-bipyridine; (l) flurbiprofen and trans-1,2-bis(4-pyridyl)ethylene;(m) carbamazepine and p-phthalaldehyde; (n) carbamazepine and2,6-pyridinecarboxylic acid; (o) carbamazepine and 5-nitroisophthalicacid; (p) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; or(q) carbamazepine and benzoquinone, wherein the API and co-crystalformer hydrogen bonded to each other.
 20. The pharmaceutical compositionaccording to claim 19, wherein said co-crystal comprises carbamazepineand saccharin.
 21. The pharmaceutical composition according to claim 19,wherein said co-crystal comprises carbamazepine and nicotinamide. 22.The pharmaceutical composition according to claim 19, wherein saidco-crystal comprises carbamazepine and trimesic acid.
 23. Thepharmaceutical composition according to claim 19, wherein saidco-crystal comprises celecoxib and nicotinamide.
 24. The pharmaceuticalcomposition according to claim 19, wherein said co-crystal comprisescelecoxib and 18-crown-6.
 25. The pharmaceutical composition accordingto claim 19, wherein said co-crystal comprises 5-fluorouracil and urea.26. The pharmaceutical composition according to claim 19, wherein saidco-crystal comprises acetaminophen and 4,4′-bipyridine.
 27. Thepharmaceutical composition according to claim 19, wherein saidco-crystal comprises phenytoin and pyridine.
 28. The pharmaceuticalcomposition according to claim 19, wherein said co-crystal comprisesaspirin and 4,4′-bipyridine.
 29. The pharmaceutical compositionaccording to claim 19, wherein said co-crystal comprises ibuprofen and4,4′-bipyridine.
 30. The pharmaceutical composition according to claim19, wherein said co-crystal comprises flurbiprofen and 4,4′-bipyridine.31. The pharmaceutical composition according to claim 19, wherein saidco-crystal comprises flurbiprofen and trans-1,2-bis(4-pyridyl)ethylene.32. The pharmaceutical composition according to claim 19, wherein saidco-crystal comprises carbamazepine and p-phthalaldehyde.
 33. Thepharmaceutical composition according to claim 19, wherein saidco-crystal comprises carbamazepine and 2,6-pyridinecarboxylic acid. 34.The pharmaceutical composition according to claim 19, wherein saidco-crystal comprises carbamazepine and 5-nitroisophthalic acid.
 35. Thepharmaceutical composition according to claim 19, wherein saidco-crystal comprises carbamazepine and 1,3,5,7-adamantanetetracarboxylic acid.
 36. The pharmaceutical composition according toclaim 19, wherein said co-crystal comprises carbamazepine andbenzoquinone.